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Abstracts 
Introduction 
We know that translating new knowledge from research into change in health care delivery is not a 
simple process. This thesis examines this process for a new technology applied to primary health care 
in tropical countries:  including RDTs in clinical guidelines for treating fever in children  
 
Method  
The thesis examines the question: ―does implementing policy of using RDTs to target treatment 
instead of presumptive treatment of fever result in better quality patient care under experimental 
conditions as well as in routine practice?‖ Three methodological approaches are used to delineate 
translation to change in the field. A Cochrane review of randomised trials examines effects on quality 
of care in a trial, where delivery conditions are usually optimal. An analysis of a dataset from an 
effectiveness trial from Uganda examines effects of the policy on quality of care delivered within the 
context of a trial through routine health services. And third, a survey of current practice assesses 
implementation of an RDT-based guideline when it is introduced into the health system for routine 
use in selected districts. Across all three components, the thesis examines implementation of the 
guideline. In addition, both the systematic review and the effectiveness trial measure effects of the 
intervention on prescribing of antimalarials and antibiotics, and clinical outcomes (primary 
outcomes).The effectiveness trial evaluates effects of the policy on incremental cost, and  the survey of 
current practice also assesses adequacy of essential health systems inputs and support services.   
 
Results  
The systematic review showed that HWs prescribed antimalarials to as many as 40% to 80% of cases 
with negative RDTs under experimental conditions. Use of RDTs was associated with 29% decline in 
prescribing of antimalarial drugs. Prescribing of antibiotics did not change in one trial but increased by 
19% in another. Data from the effectiveness trial show that HWs used RDTs and adhered to RDT 
results almost all the time. This reduced antimalarials usage by 60.2% (high), 48.9% (medium) and by 
22.1% (low). The data show no significant change in usage of antibiotics. Both the review and the 
pragmatic trial detected no significant difference in clinical outcomes between RDT and clinical 
diagnosis arms. 
Data from the effectiveness trial shows that use of RDTs is associated with a cost-saving of US$ 0.50 
per case of fever (24.5% decline) in low transmission setting, and a cost-saving of US$ 0.33 per case of 
fever (17.7% decline) in medium transmission. Use of RDTs did not lead to a significant change in 
cost in high transmission settings: US$ +0.02 (95% CI: US$ -0.97 to US$+1.06). Cost-savings were 
accrued exclusively in older children and adults.  
The survey found inadequate implementation of all components of the guideline in both districts. 
Essential supplies, equipment and in-service training were inadequate in both districts.  
 
Discussion and conclusion 
Antimalarial use is lower when RDTs are used to guide treatment of fever instead of presumptive 
treatment. This results in savings from drugs costs in older children and adults with fever in low and 
medium transmission areas. This research does not confirm whether or not use of RDT-based 
guidelines has any effects on usage of antibiotics or clinical outcomes. A case study of Uganda shows 
that when delivered through routine services, none of the components of an RDT-based guideline is 
implemented to acceptable standards. There is insufficient evidence to suggest that the policy is 
superior to presumptive treatment of fever in terms of clinical outcomes. However, it can save money 
for medicines in low and medium transmission settings if its use is restricted to older children and 
adults.
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Chapter 1 Introduction 
1.1 Background 
1.1.1 Burden of malaria in Africa 
Malaria is one of the leading causes of morbidity and mortality in the world. It causes 
189 to 327 million clinical cases and more than 800 thousand deaths each year [1]. More 
than 80% of cases and more than 90% of deaths occur in sub-Saharan Africa [1]. Eighty 
five percent (85%) of all deaths occur in children under 5 years [1]. Limited evidence 
from countries in sub-Sahara Africa shows that, in the late 1990‘s, both poor and better-
off households spent approximately $19 for malaria treatment annually [2, 3], and that 
the annual per capita growth of the GDP in the countries intensely affected by malaria 
was reduced by 1.3%1 [5]. 
In Uganda, malaria accounts for 30% to 50% of outpatient visits at health facilities, 15% 
to 20% of all hospital admissions, and 9% to 14% of all hospital deaths [1]. In 2006, the 
reported number of fever episodes suspected of being malaria was 0.94 (0.47 – 1.4) per 
capita per year, with the prevalence among children younger than 5 years of age being 
2.9 episodes (0.54 to 5.5) per child per year [1].  About one third of them , which 
equates to  between 10 and 12 million clinical cases, were treated in the public health 
sector [3, 6]. Nearly half of hospital in-patient deaths among children less than five years 
of age were attributed to clinical malaria [3, 6, 7]. In addition, malaria is responsible for 
up to 22% of low birth weight in newborns in high transmission areas, and a major 
cause of spontaneous abortions in low endemicity areas [3]. A significant percentage of 
illnesses and deaths due to malaria occur at home and are not captured by the facility-
based Health Management Information System (HMIS). It is estimated that the current 
morbidity due to malaria reduces economic output in Uganda by 26.3% [8].   
1.1.2 Malaria policies in the last 10 years 
Prompt diagnosis and effective treatment is the mainstay of the WHO malaria control 
strategy[1]. However, the diagnosis and treatment of malaria has been problematic. Until 
recently, WHO guidelines have stressed treating all cases of fever as malaria in endemic 
                                                          
1
 the GDP per capita for Uganda in 1990 was US$ 700 (adjusted for purchasing power parity)4.
 World Bank/UN Common database, Globalis, Uganda. 
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areas irrespective of the cause of fever[9]. Symptoms-based treatment was intended to 
simplify the management of malaria in settings without the capacity for microscopy [10]. 
Although a poor predictor of malaria [11-14], symptoms-based diagnosis has been 
accepted on the ground that it is better to treat all febrile cases as malaria than to miss 
one potentially fatal infection due to malaria, especially in a child younger than 5 years 
old [15]. Further, for several decades, health workers in malaria endemic areas have 
treated uncomplicated malaria using mono-therapies which were cheap and easy to 
administer [15]. 
Owing to the emergence of P. falciparum parasites which are resistant to the anti-
malarials previously used, the WHO revised the guidelines for treating malaria in 2001, 
recommending the use of artemisinin-based drugs as the first line drugs for treating 
uncomplicated malaria [16]. By 2001, most of artemisinin-based drugs were in the form 
of mono-therapies [16]. In 2006, a new guideline was developed, which recommended 
the use of Artemisinin-based Combination Therapies (ACTs) for treating uncomplicated 
malaria instead of artemisinin-based mono-therapies. ACTs have a more complex 
dosing regimen than all the antimalarials previously used [17]. In addition, ACTs are 
nearly 10 times more costly than the antimalarials previously used for treating 
uncomplicated malaria [15, 18].2 For this reason, the 2006 guidelines also stressed 
parasitological confirmation of malaria prior to prescribing ACTs, wherever possible, 
except in children in high transmission areas [9]. In 2010, the malaria policy was revised 
further, recommending parasitological confirmation in all age groups, including children, 
and in all transmission settings [19].  
Both the 2006 and 2010 malaria treatment guidelines recommend light microscopy as 
the gold standard diagnostic tool for malaria. Microscopy has several advantages, 
including parasite quantification, species differentiation and staging of parasites, all of 
which are useful indicators in selection and evaluation of treatment [20-22]. However, 
the health system in malaria endemic countries cannot widely deploy microscopes in 
rural health centres, the first contact points for most febrile patients, in the near future 
because of the high investment and operational costs, and the technical capacity 
                                                          
2 For example, in Uganda, the estimated cost of an adult fixed-dose of artemether-lumefantrine is US$ 2.4 
in a public facility. The cost of an adult dose of CQ/SP, the combination of antimalarials previously used 
for treating uncomplicated malaria, is US$ 0.2 in the same type of facility. The cost of the same drugs in 
the private sector is US$ 10.0 and US$ 1.10 respectively (Obua, 2007) 
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building required [23, 24]. For these reasons, antigen-based Rapid Diagnostic Tests 
(RDTs) are proposed for use in settings without capacity for microscopy [9, 19]. 
Guidelines based on RDTs are now operational in many malaria endemic countries to 
support the diagnosis and treatment of febrile patients in settings without microscopy 
[25]. 
Therefore, over the past 10 years, the policy for treating fever in malaria endemic areas 
has changed from a symptom-based policy using cheap, easy-to-administer mono-
therapies, to parasite-based policies using expensive ACTs with complex dosing 
regimens. In addition, the current policy introduces a new diagnostic technique into the 
health system in resource-poor settings with limited supervision. Implementing this 
policy requires a significant shift in mindset and practice [15, 26].  
1.2 Problem statement 
Clinical guidelines are intended to systematically introduce scientific evidence into 
practice in order to improve practitioners‘ performance and the quality of patient care 
[27-29]. Effectiveness and efficiency can only be achieved if there is a change in clinical 
practice—that is if guidelines are sufficiently implemented [27-29]. Non-adherence to 
clinical guidelines is common place the world-over [28, 30-39]. In Africa, evidence from 
routine practice shows wide variability in Health Worker (HW) adherence to parasite-
based guidelines for treating patients with fever [32-37]. Presently, it is uncertain if 
RDT-based guidelines can be implemented sufficiently, and if their use can lead to 
improved outcomes or cost-savings, especially in routine practice [14, 26, 33, 34].  
Further, the health systems capacity to support implementation of the policy has not 
been demonstrated [26]. It is generally accepted that it is unethical to disseminate and 
implement an intervention whose benefits are not known for certain [40]. If guidelines 
are disseminated for wide-scale use without sufficient evaluation, the decision may result 
in more harm than good being done [26, 40, 41]. Before adopting an RDT-based 
guideline for routine implementation in settings where the conventional treatment of 
fever is currently based on clinical judgement, there is need to demonstrate that its 
application can lead to better quality of patient care.  
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1.3 Framework for assessing new technologies 
New ideas, knowledge, practices, products, guidelines, services are referred to as 
innovations [41, 42]. The process by which innovations spread and get adopted for 
routine use is called diffusion [41, 42]. Diffusion of innovations is slow, complex and 
unpredictable [43, 44]. Several diffusion models based on behaviour change, social 
change and organisational change theories have identified numerous barriers which 
must be overcome in order to move innovations from providers to users in routine 
practice [25, 28, 31, 45-48]. All the models have identified the lack of or inadequate 
information about the technical and operational attributes of an innovation as a 
significant barrier to its effective dissemination into the real world [28, 30, 31, 41, 46]. 
Accordingly, all diffusion of innovation models consider assessment of the value of an 
innovation and of its applicability in routine practice as a critical step in the diffusion 
process [41, 47]. Therefore, innovations should be considered ready for application in 
real-world settings only if they have undergone sufficient evaluation to assess their 
values and applicability in routine practice [40, 41].  
Assessment of new technologies involves several well-recognised level and types of 
research. Figure 1 depicts the common phases identified by several models which an 
innovation must pass through during the assessment stage of the diffusion process [27, 
40, 41, 49], namely: hypothesis development (phase 1), methods development (phase 2), 
smaller-scale efficacy trials (phase 3), larger-scale effectiveness trial (phase 4), and 
demonstration or implementation studies (phase 5).  
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Sources: [27, 40, 41] 
Phase 1 and phase 2 correspond with the development stage of the innovation where by 
hypotheses are conceptualised, tested and then transformed into the technology (e.g. 
devices, protocol, methods, drugs). Assessment of the value of the innovation consists 
of phase 3 through 5. Phase 3 consists of smaller-scale efficacy trials which use 
Randomised Controlled Trials (RCTs) to determine whether use of the innovation does 
more good than harm under optimum conditions [40, 41, 50]. Phase 4 consists of larger-
scale effectiveness trials which use pragmatic trials to determine whether use of the 
innovation does more good than harm when delivered under real-world conditions (e.g. 
larger population in routine practice) [40, 50].  
Phase 5 consists of demonstration or implementation studies to test the quality of 
delivery of the innovation in real-world settings [40]. It assesses whether all components 
of the intervention can be delivered to acceptable standards in routine practice. 
Additionally, demonstration studies may assess operational attributes of the innovation 
such as ease-of-use, timeliness, acceptability, compatibility and adaptability[40]. Further, 
demonstrations are useful for identifying potential barriers within the user system that 
may hinder effective implementation of the innovation in real-world settings—for 
which interventions may need to be identified and implemented to ensure effective 
implementation of the guideline [40].  
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Figure 1: Phases in assessment of a new technology 
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Economic evaluation of the intervention may be undertaken as part of phase 3, phase 4, 
or phase 5 [47, 51, 52].  
Innovations should be considered ready for application in real-world settings only if 
they have passed through phases 3 through 5 [40, 41].  A new technology may be 
ineffective in real-world settings either because it is not efficacious or because of poor 
implementation of an efficacious intervention [40].  
1.4 The thesis 
This thesis examines evidence for this evaluation process for a relatively new 
technology: policy for treating fever, based on the use and results of RDTs in settings 
without capacity for microscopy. RDT-based policies for treating fever are expected to 
improve the quality of practice, and thereby reduce usage of antimalarials, lower 
treatment cost and improve clinical outcomes in settings where presumptive treatment 
is currently the norm [14, 32-35, 53]. This thesis examines the extent to which these 
objectives can be achieved when the policy is delivered under carefully controlled 
conditions and when delivered in routine practice. Further, it assesses the quality of 
current practice in a sample of districts in Uganda where an RDT-based guideline has 
been rolled-out for small-scale implementation. This assessment is carried out to 
determine whether all components of the guideline can be delivered to acceptable 
standards in routine practice where there is relatively limited supervision and resources 
compared to implementation in a research setting; and whether essential health system 
inputs and support services which are required for effective implementation of the 
guideline are adequate.  
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1.5 Conceptual map of the thesis 
The thesis consists of 3 studies which reflect the sequence of movement from phase 3 
(efficacy trial) to phase 5 (demonstration) of the assessment process (Figure 2).  
 
 
A systematic review of evidence from randomised trials in Africa is undertaken to 
evaluate the effect of RDT-based policies on the amount of antimalarials and antibiotics 
prescribed and on clinical outcomes under relatively optimal conditions. In addition, the 
review assesses the extent to which HWs prescribe antimalarials according to RDT 
results, which is an indicator of HW adherence to RDT-based guidelines. Other aspects 
of guideline implementation, such as the quality of clinical assessment, use of RDTs, 
Research 
questions 
Do carefully controlled 
trials show that this 
policy leads to 
improved prescribing 
and improved clinical 
outcomes under 
optimal conditions? 
Does the evidence from 
a pragmatic trial in 
Uganda show improved 
prescribing, improved 
clinical outcomes and 
reduced cost when the 
policy is applied in 
routine practice? 
Is the RDT-based policy 
being implemented 
sufficiently in the districts 
where it has been rolled-
out in Uganda? 
 
Sequence 
of studies 
Systems readiness 
-Essential inputs (drugs, 
staff, and equipment 
-Support services 
(training, supervision) 
Implementation 
-Adherence to RDT results 
Implementation 
-Use of RDTs 
-Adherence to RDT results 
Implementation  
-Clinical assessment  
-Use of RDTS 
- Patient classification 
-Treatment prescribed  
-Advice on medications Consequences 
-Cases prescribed AM* 
-Cases prescribed AB** 
-Clinical outcomes 
 -Malarial fevers missed 
 -Non-malarial fevers 
prescribed AM* 
Consequences 
-Cases prescribed AM* 
-Cases prescribed AB** 
-Clinical outcomes 
-Malarial fevers missed 
-Non-malarial fevers 
prescribed AM* 
 -Cost 
CHAPTER 3 
Systematic review of 
Randomised Controlled 
Trials (RCTs) to assess 
quality of care under 
optimal conditions 
CHAPTER 4 
Effectiveness trial from 
Uganda to assess quality 
of care in routine 
practice 
CHAPTER 5 
Survey of current practice to 
evaluate the quality of 
implementation of an RDT-
based guideline in routine 
practice and adequacy of 
health systems support 
inputs and support services 
 
Indicators 
assessed  
*AM: antimalarials; **AB: antibiotics 
Figure 2: Conceptual map of the thesis 
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patient classification (diagnosis given by the HW) and advice on medications are not 
evaluated in this review due to data limitation.  
An analysis of existing dataset from a pragmatic trial from Uganda is used to evaluate 
the effect of RDT-based policies on the amount of antimalarials and antibiotics 
prescribed. Additionally, the analysis examines the effect of the policy on clinical 
outcomes and incremental cost in routine practice in Uganda. Further, it describes HW‘s 
use of RDTs and response to RDT results in routine practice. Because of data 
limitations, it does not assess the quality of implementation of other components of the 
guideline such as clinical assessment, patient classification and advice on medications. 
A survey of current practice was carried out in Uganda to evaluate the quality of actual 
practice and adequacy of inputs and support services in the districts where RDT-based 
guidelines have been rolled out for small-scale implementation. 
1.6 Research question 
Does implementing an RDT-based guideline instead of presumptive treatment of fever 
result in better quality of patient care under optimal conditions as well as in routine 
practice?  
1.7 Aim  
To establish if the use of RDT-supported guidelines in treating fever leads to better 
quality of patient care relative to presumptive treatment when delivered under optimal 
conditions and through routine clinical practice.  
1.8 Objectives  
1) To review evidence from RCTs to determine if RDT-based policies for fever 
lead to better quality of patient care than presumptive treatment under optimal 
conditions 
2) To analyse data from a pragmatic trial to determine if RDT-based policies for 
fever lead to better quality of patient care than presumptive treatment in routine 
practice 
3) To assess the quality of actual practice when an RDT-based guideline is rolled 
out to health services in a district as a whole. 
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1.9 Overview of the thesis 
The thesis is structured into 6 chapters. 
Chapter 1 Introduction 
Chapter 1 describes the evolution of the policies for treating fever in malaria endemic 
countries over the past 10 year, including the reasons for the shift to parasite-based 
policies. It outlines the unanswered questions regarding the utility of RDT-based 
policies in routine practice, which this thesis attempts to answer. In addition, it describes 
an evaluation framework which guided the structure of this thesis and the selection of 
variables assessed. It provides a conceptual map showing the different studies 
undertaken by the thesis, outlining the questions each study attempted to answer and 
the common variables examined across studies as well as the specific ones examined by 
each study. Further, the chapter gives a brief description of the Uganda health system 
including an outline of the RDT-based guideline for Uganda.  
 
Chapter 2 Literature review 
This chapter summarises the theories and models which describes the process of 
introducing a new technology into a user system, and which offers a comprehensive 
framework for evaluating a new technology. It describes relevant concepts and methods 
used in evaluating health technologies or quality of care and it justifies the methods used 
in the thesis. It highlights the technical and operational attributes of different types of 
malaria RDTs. In addition, it gives an account of the performance of various types of 
RDTs in different epidemiological contexts. Further, it reviews evidence from Africa on 
the quality of guideline implementation and effectiveness of interventions aimed at 
improving the quality of guideline implementation. Finally, it describes the principles of 
the Lot Quality Assurance Sampling (LQAS) method and how the method can be 
applied in healthcare to monitor the quality of health care. 
Chapter 3 A systematic review 
Chapter 3 consists of a systematic review of RCTs from Africa which have examined 
effects of RDT-supported treatment of fever relative to presumptive treatment on 
prescribing and clinical outcomes. Further, it shows the extent to which HWs prescribed 
antimalarials according to results of RDTs under carefully controlled conditions. The 
findings of this review show the quality of practice and ―efficacy‖ of using RDT-based 
guidelines under relatively optimal conditions.   
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Chapter 4 Analysis of data from an effectiveness trial 
Chapter 4 analyses an existing set of data from an effectiveness trial from Uganda to 
determine the effects of using RDT-supported guidelines in routine practice. It assesses 
whether introducing an RDT-based guideline for fever leads to improvement in 
prescribing, clinical outcomes and healthcare cost. Additionally, it assesses whether 
HWs requested RDTs and responded to RDT results as expected. Further, the analysis 
evaluates how local malaria prevalence and age profile of the target population all 
combine to impact the quality of prescribing, clinical outcomes and incremental cost in 
routine practice. The findings of this analysis show the quality of practice, effectiveness 
and cost implications of implementing an RDT-based guideline in routine practice.  
Chapter 5 Survey of current practice 
Chapter 5 consists of a survey of current practice to evaluate the quality of actual 
practice and adequacy of support services in the districts where RDT-based guidelines 
have been rolled out for small-scale implementation. The study uses Health Facility 
Assessment (HFA) tools based on the Lot Quality Assurance Sampling (LQAS) 
method, which provides a rapid comprehensive assessment of key diagnosis and 
treatment subsystems stipulated in the guideline. In addition, the HFA tools allow for an 
assessment of key health systems inputs and support activities (e.g. training, 
supervision). The survey uses the LQAS method to classify implementation of the 
guideline in the selected districts as adequate or inadequate, basing on a pre-defined 
performance benchmark.  
Chapter 6 General discussion 
Chapter 6 discusses the main findings in Chapters 3 to 5, comparing and contrasting 
outcomes which were assessed across studies.  
 
 
 
  
13 
 
 
 
 
 
Chapter 2 
Literature Review  
 
 
 
14 
 
  
15 
 
Chapter 2 Literature Review 
2.1 Introduction 
This chapter is organised into eleven sections. Section 2.3 describes the process of 
knowledge translation based on diffusion of innovation theory and the implication of 
the diffusion theory for the transfer of RDT-based policies into the health system. 
Section 2.4 defines the focus of the thesis and justifies the choice of a 3 chapter 
approach. Section 2.5 consists of definitions of relevant concepts and methods which 
are used in evaluation of new technologies and quality of care; and which have been 
applied in this thesis. Section 2.6 describes the basic principle of Lot Quality Assurance 
Sampling (LQAS) method and its application in healthcare for monitoring interventions 
in developing countries. LQAS method is used in Chapter 5 to assess the adequacy of 
adherence to RDT-based guidelines. Section 2.7, provides an overview of several 
biologic malaria diagnostics that have emerged over the last 100 years. Section 2.8 
provides an overview of malaria RDT technology. It outlines the factors affecting 
performance of RDTs, an overview of the WHO product testing initiative, and 
performance of various RDT assays under experimental conditions, in different 
epidemiological settings. Section 2.9 consists of a synthesis of evidence from Africa on 
the quality of implementation of various clinical guidelines. Section 2.10 synthesises 
evidence from Africa on the effectiveness of various interventions aimed at improving 
the quality of implementation of various clinical guidelines in Africa. Section 2.11 
consists of a summary of the literature review, which brings together all the main topics 
discussed in the chapter, and describes their relevance to the questions the thesis 
attempts to answer, methods used in the thesis, and how they have informed the 
discussions in chapters 3, 4, 5 and 6.  
2.2 Search strategy 
Searches of electronic databases were conducted mainly through EBSCO interface 
hosted at the University of Liverpool Library. Searches were conducted in the following 
databases: Medline, CINHAL, PsychINFO, and the Cochrane Database for Systematic 
Reviews. Search terms were applied using Boolean operators as shown in Appendix 3. 
Searches were restricted to articles published between January 1990 and December 
2011. The hits retrieved were refined using MeSH (Medical Subject Headings) terms. 
Titles of articles retrieved were scanned, and abstracts of the articles considered relevant 
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to the objectives of the thesis were reviewed. Full texts of relevant articles were 
retrieved from the University of Liverpool Library database. Articles which were not 
available electronically were obtained through the University of Liverpool Library 
Holdings. The results of the searches, the papers retrieved and papers reviewed are 
summarised in Table 34 below.  
Table 1: Number of articles retrieved and reviewed from electronic databases 
Section 
Number of hits retrieved after 
applying MeSH terms 
Number of 
full texts 
retrieved 
Number 
reviewed 
Before 
removing 
duplicates 
After 
removing 
duplicates 
2.3 Theory of diffusion of 
innovations  
236 124 25 22 
2.5 Concepts and methods 27 27 27 23 
2.6 LQAS technique 1324 115 47 13 
2.7, 2.8 Overview of malaria 
diagnostics and malaria rapid 
diagnostic tests 
1324 835 25 18 
2.9 Implementation of clinical 
guidelines in Africa 
392 297 20 15 
2.10 Effects of intervention on 
quality of implementation of 
guidelines (Africa) 
392 297 20 9 
 
Citations of electronically selected articles were downloaded and managed using 
EndNote X4. Searches were performed throughout the thesis writing and citation 
library updated regularly.  
Additional searches were conducted from the websites of the WHO and the Ministry of 
Health (Uganda)3. Further, I checked the reference lists of all the selected full texts, and 
searched for relevant articles or reports in the databases and websites described above 
or in Google scholar. 
  
                                                          
3 The website of the Uganda Ministry of Health was search for policy documents and/or guidelines 
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2.3 Theory of diffusion of innovations 
2.3.1 Classical diffusion model 
According to classical diffusion models, innovations originate from some expert 
resource system (e.g. research organisation), which then diffuses it to potential users. 
Traditionally, the process consists of a series of steps which can be grouped into 3 main 
phases (Figure 3): (a) development and assessment, (b) adoption, and (c) utilisation 
(routine implementation) [47].  
At least five types of assessment may be required before an innovation is considered 
ready for adoption and wide-scale use: assessment of safety, assessment of efficacy, 
assessment of effectiveness, assessment of cost, and assessment of applicability in real-
world settings [41, 42]. Upon completion of assessment of the attributes of the 
innovation and its applicability in the real-world, it is then deemed ready for 
introduction into the user system [40, 41]. Dissemination into the user system is 
undertaken either by the developer or an external agent [41, 46, 54].   
Introduction of an innovation into a user system sparks off an adoption process. 
Adoption refers to the decision to accept or reject an innovation [28] or whether to 
accept it now or to defer the decision to a later date [47]. Adoption decision may be 
taken at a central (policy level) and/or by individual users [47]. A vital component of the 
adoption process consists of dissemination of innovations into the user system, by 
means of which potential adopters and users are made aware of availability and 
attributes of innovations, and by means of which they may be persuaded to adopt them 
[31, 46].  
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Figure 3: Diffusion of innovation model 
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Implementation consists of usage activities that follow the adoption decision [46]. More specifically 
implementation refers to the extent to which the technology is made available to the target audience 
in a manner that is acceptable to them [40]. Therefore, implementation studies assess whether all 
components of the technology are being delivered to the target audience to acceptable standards, 
and the extent to which the target audience are receptive to, participant in, comply with or adhere to 
all the components [40, 47]. Additionally, implementation studies seek to identify barriers to 
adoption and implementation of innovations and to test the effectiveness of interventions intended 
to address them [29, 43, 54]. Implementation studies may be undertaken as part of technology 
assessment (phase 5) [40, 41].  
The classical diffusion model just described depicts a centralised, hierarchical (top-down) model 
whereby innovations are transferred from the provider system to the users system as a matter of 
policy [41]. Users have no control over which innovations are considered. Centralised models depict 
what typically happens in a government system [41]. Diffusion of innovations in the private sector is 
generally decentralised:  innovations arise from multiple sources and users exercise control over 
which innovations to adopt [41, 46]. Innovation whose diffusion follows a centralised model (e.g. 
the policy under evaluation) are more likely to be adopted than those for which adoption decisions 
are decentralised [41]. 
The classical diffusion model also portrays a linear transfer pathway of innovations from 
development to implementation. In practice, the process may be iterative or cyclical and some steps 
may be skipped. For example, innovations may be adopted without prior assessment or assessment 
may be undertaken after adoption [40]. 
2.3.2 Drivers of diffusion of innovation 
Each step in the diffusion process is associated with barriers which must be overcome in order to 
move the innovation from assessment stage (provider system) to routine use in the real world (user 
system) [41]. Several models based on behaviour change, social change organisational change 
theories have identified 6 main levels and types of factors which might affect the adoption and 
implementation of innovations. They are summarised in Table 2 below. 
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Table 2: Factors which determine the rate of diffusion of innovations 
System  Factors Examples  
Provider 
system 
Attributes of innovation Relative advantage, simplicity, and compatibility 
User 
system 
Attributes of individual 
professional (user) 
Knowledge, attitude, motivation to change, 
behavioural routine 
Attributes of patients Expectations,  knowledge, attitude, compliance  
Social context Opinion of colleagues, culture of the network, 
collaboration, leadership 
Organisational context Organisation of care processes, staff, capacities, 
resources, structures 
Economic and political 
influences 
Financial arrangements, regulations, policies 
Adopted from Grol and Wensing[38] 
a) Attributes of the innovation 
Attributes of an innovation have repeatedly been identified as a key determinant of whether or not, 
or how fast it is adopted for use in routine practice [28, 30, 31, 38, 41, 46]. Attributes of innovations 
are claimed to impact on the ability to effectively disseminate them into the user system [41]. 
Therefore, assessing attributes of an innovation is essential, not only for ethical reasons, but also 
because it has implications for effective dissemination of the innovation. Attributes of an innovation 
may be technical or operational in nature, all of which need to be assessed prior to dissemination 
[20-22]. Technical characteristics include properties such as efficacy, effectiveness, efficiency and 
safety. Operational characteristics consist of features that affect the application of innovations, e.g. 
simplicity (ease-of-use), timeliness, compatibility and adaptability [28, 30, 31, 38, 41, 46].  
Technical attributes of an innovation appear to have the most powerful influence on the behaviour 
of potential users and policy makers [28, 30, 31, 41, 46]. Innovations that are perceived to be more 
beneficial than the methods previously or currently in use are more likely to be adopted [41, 55]. 
Therefore, the more uncertainty is reduced by providing sufficient evidence on the efficacy, 
effectiveness, cost and safety of innovations, the more likely that potential users will adopt them [41, 
55].  
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Simple innovations are understood and therefore diffuse more rapidly than complex ones [28, 31, 
42, 55]. Complex innovations consists of many different components [30]. An RDT-based guideline 
is a typical example of a complex innovation as it consists of many inter-related components and its 
diffusion and effective implementation could be problematic [41, 46]. 
Further, an innovation is more likely to be adopted if its use is compatible with the norms, values, 
and perceived needs of the potential users, patients and policy makers [28, 31, 42, 55]. An 
innovation which requires change in existing routine and habits is less likely to be adopted. In 
addition, an innovation which invokes negative reactions in patients or other key players because it 
does not fit in their expectations is less likely to be adopted [28, 31, 42, 55].  
b) Attribute of the individual professional 
Knowledge  
According to behaviour change theories, individual health workers are more likely to accept and use 
a new technology if they have good understanding of the aims, content, scientific merit and how to 
use it. An innovation is less likely to be adopted if its use demands the acquisition of new 
competence (skills). Effective communication of the technical characteristics of an innovation is a 
prerequisite for change in attitude and practice [28, 31, 46].   
Importance of training and experience 
According to human capital theory, the knowledge required to effectively use an innovation is 
accumulated through pre-service and in-service training (induced knowledge) [46, 56], or though 
learning-by-doing (experience) [28, 31, 42, 55, 57].  
Experiential knowledge is accumulated by performing the same tasks repetitively and consistently 
[57-59]. The knowledge acquired from a previous experience is carried forward to the next task [59] 
resulting in sequential and incremental accumulation of knowledge [57-59]. Thus, the stock of 
knowledge accumulated through learning-by-doing is proportional to the volume of the task 
performed [56-59]. 
Experiential knowledge has greater impact on the health worker‘s ability to correctly use or apply a 
new technology than induced knowledge [56]. Consistent practice serves to ‗top up‘ the knowledge 
base acquired through training, until an optimum or maximum level is reached. Experiential 
knowledge usually accounts for the bulk of the knowledge stock accumulated by a user and 
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consistent practice serves to maintain an optimum knowledge base and clinical proficiency over time 
[56]. On the other hand, lack of or inadequate practice results in deterioration in knowledge and 
skills over time (forgetting). The rate of forgetting is directly related to the length of interruption in 
practice [59, 60]. Therefore, users of a given technology need to perform a minimum volume of 
tasks with the technology in order to maintain an optimal level of proficiency [59]. Furthermore, 
experience is thought to result in the development of more finely developed skills, which in turn 
leads to better performance—the notion of practice makes perfect—for example being able to 
execute relevant procedures more appropriately and more quickly [56, 61].  
Although regular refresher courses or continuing medical education can reduce the rate of forgetting 
[59], their effects are short-term [62]. Consistent use of a technology is essential in maintaining an 
optimum level of knowledge and clinical proficiency over time [59].  
c) Peer influence and leadership   
Social change theory suggests that adoption and correct use of an innovation can be brought about 
through peer influence and through leadership. Peer influence is exercised through individual 
interactions or professional networks, while leadership normally takes the form of advice from 
senior and respected professionals on task issues (e.g. support supervision) [38, 46]. 
d) Patients’ expectations 
Patients‘ expectations influence prescribing practices. Clinical recommendations that do not fit 
patients‘ expectations may invoke a conflict of interest between patients and doctors [30]. The 
evidence on this theory is equivocal [63] and few studies have included it in the models for analysing 
the determinants of adherence to guidelines [38, 64]. 
e) Organisational factors 
Organisational change theories suggest that, irrespective of the inclination of individual clinicians, 
the process of change in practice can be facilitated or impeded by organisational factors; such as 
staffing, financial resources, availability of required inputs, organisation of activities, and 
organisational policies, [28, 31, 38, 41, 46, 48, 55].   
f) External policy environment 
According to classical diffusion models, innovations whose diffusion follows hierarchical (top-
down) pathways (e.g. the RDT guideline) are more likely to be adopted than when adoption decision 
is decentralised [41]. 
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2.3.3 Implications for introducing RDT-based policies  
The diffusion model depicts the type and sequence of research required in assessing the value and 
applicability of a new healthcare technology before dissemination for routine use. Phase 1 and phase 
2 concern product developments. In the case of the policy under evaluation, this process includes 
evaluation of the intrinsic properties of various RDTs through laboratory-based product testing and 
field trials: diagnostic accuracy, thermal stability and ease-of use. These assessments aim to drive the 
quality of the products to an acceptable level before they are recommended for use in clinical 
settings[65]. An overview of RDT field trials and WHO product testing and is provided in sections 
2.8.3 and 2.8.5 respectively. 
This thesis is concerned with phase 3 through 5 of technology assessment process. Phase 3 and 
phase 4 studies provide information on efficacy, effectiveness and efficiency. Phase 5 study assesses 
whether the guideline can be implemented sufficiently in routine practice. Additionally, it identifies 
key factors within the user system which can affect implementation of the policy in routine 
practice—which may need to be investigated, or which may need to be addressed prior to or during 
wide-scale implementation. These may include the knowledge and skills required to use RDTs and 
to apply all the components of the guideline; and effective communication strategies to impart the 
required knowledge. It also implies that is vital to maintain adequate supply of essential logistics 
(RDTs, drugs, equipment). Otherwise, inconsistent application of the policy could lead to forgetting 
and deterioration in performance. Technical support from senior professionals is equally necessary 
in facilitating the process of change.    
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2.4 Choice of a 3 chapter approach 
The diffusion of innovation model outlines the sequence and type of research required in assessing a 
new technology before dissemination for routine use. Phases 1 and 2 correspond to the 
development phase of the technology and involve evaluating the intrinsic properties of the 
technology [40, 41, 50]. Phases 3 and 5 involve evaluating the usefulness of the technology while 
phase 5 assesses its potential applicability in routine practice. 
Since their introduction in the 1990s, malaria RDTs have been characterised by inconsistency in 
manufacturing standards, product modification, withdrawal, insufficient quality control and 
variability in product stability [24, 66, 67].  
Several field evaluations have been carried out to assess assay performance characteristics, especially 
diagnostic accuracy. Limited laboratory-based evaluations of malaria RDTs have also been 
conducted by manufacturers by testing assays against panels of blood infected with malaria parasites 
[20, 22, 65]. However, comparability of the results of these studies has been limited by errors 
associated with trial designs, variation in reference standards, insufficient quality control and 
epidemiology of malaria [20, 22, 65].  
Because of these limitations, guidelines have been introduced to assist diagnostic assay development 
and manufacture, regulatory approval processes, and to support malaria control programmes [65, 68, 
69].  Additionally, WHO has introduced product testing imitative that assesses assay performance 
characteristics in a standardised way. The WHO product-testing initiative has been running since 
2006. Three rounds of product-testing have been completed, and a 4th round is on-going. These 
assessments aim to drive the quality of RDT products to an acceptable level before they can be 
recommended for use in clinical settings[65].  An overview of RDT field trials and WHO product 
testing is provided in sections 2.8.3 and 2.8.5 respectively.  
Therefore, extensive phase 1 and phase 2-level evaluations have already taken place with regard to 
RDTs. The major debate regarding RDTs currently is whether using them in clinical settings to 
guide treatment in fever patients can lead to improved quality of healthcare. It is presumed that 
RDT-supported management of fever could avert irrational use of ACTs, thereby resulting in cost-
saving [14, 32-35, 53]; improve diagnosis and treatment of parasite-negative individuals [19, 70-72]; 
limit the risk of resistance and adverse reactions [72]; and thus lead to better clinical outcomes in 
25 
 
fever patients, compared to presumptive treatment. Before wide-scale implementation, there is need 
to demonstrate that RDT-based guidelines can be implemented sufficiently and that implementing 
them instead of guidelines based on clinical diagnosis can lead to better outcomes [14, 26, 33, 34].  
According to diffusion of innovation model, in order to determine if a new technology is effective in 
routine practice, it is important to know if it is efficacious first. 
Accordingly, the first level of research undertaken consists of an assessment of the efficacy of the 
intervention. Assessment of efficacy is considered a necessary step in the development and diffusion 
of a new technology or intervention [40]. Knowledge of efficacy is necessary to inform the decision 
as to whether or not it is necessary to carry out an effectiveness study and to aid interpretation of 
evidence from effectiveness trials. Once an intervention is shown to be efficacious, it is then useful 
to carry out an effectiveness trial to investigate if it can work in real-life settings; and implementation 
research to assess if all components can be delivered to acceptable standards in routine practice in a 
manner that is acceptable to the target audience [40]. 
The second level of study chosen is an effectiveness study, which assesses if the intervention works 
for the general population. The third level of research chosen is a demonstration or implementation 
study. Demonstration studies can show the extent to which various elements of a multi-component 
intervention are actually implemented [73, 74]. In addition, it enables the identification of facilitating 
and inhibiting contextual factor.   
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2.5 Concepts and methods 
2.5.1. Malaria endemicity and classification 
Malaria transmission levels vary significantly between different geographic regions [75-77]. Grading 
of malaria transmission is important for targeting control interventions.  
Malaria endemicity is typically classified into 4 levels, based on a variety of quantification methods 
[77, 78]. 
(a) Holoendemic, which is characterized by very intense, year-round transmission, resulting in 
severe anemia during early childhood but considerable degree of immunity outside early 
childhood. 
(b) Hyperendemic, characterized by intense but seasonal transmission. Immunity is insufficient 
in all age groups, and cerebral malaria is common in older children. 
(c) Mesoendemic, characterized by regular seasonal transmission under normal rainfall 
conditions. Transmission is low in dry seasons. Cerebral malaria is a common feature. 
Mesoendemicity is typical in communities in subtropical zones.  
(d) Hypoendemic, where transmission is low and intermittent and the effect on the general 
population is unimportant. However, outbreaks of severe malaria and mortality are common 
in both children and adults. 
Four main methods for grading the magnitude of malaria in the population are described in the 
literature, none of which appears completely satisfactory. They consist of (a) 2 host-based methods 
which involve estimating the prevalence of palpable splenomegaly (spleen rates) and/or parasitaemia 
(parasite rates) in the population [77-79], (b) a vector-based method which estimates malaria 
prevalence in terms of transmission intensity [77, 79], and (c) a vector-based mathematical model 
which measures endemicity in terms of stability of transmission[77-79]. The descriptions and the 
relationship between these indices are shown in Table 3 below. 
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Table 3: Criteria for classifying malaria endemicity 
Criterion  
Endemicity 
Source Hypoendemic Mesoendemic Hyperendemic Holoendemic 
Description  Low Moderate High High [77] 
Spleen rate in children 2 – 9 years 0 – 10% 11 – 50% >51 – 75%  
Also high in 
adults (> 25%) 
>75% 
Low in adults 
[77, 
78] 
Parasite rate in children 2 – 9 years 0 – 10% 11 – 50% 
 
>51 – 75% >75% (among 
infants aged 0 – 11 
months) 
[77, 
78] 
Annual Entomological Inoculation Rate (AEIR) <0.25 0.25 – 10  11 – 140  >140 [77] 
Stability   Unstable  Intermediate  Stable  Stable  [79] 
Source: Adapted from Mendis (2009), Hay (2008) and Roll Back Malaria (undated) [77-79]
28 
 
a) Spleen rate 
Spleen rate or spleen index is the method used in most malaria metric surveys to define 
malaria endemicity[77-79]. It is defined as the proportion of a selected age-group of the 
population with palpable enlargement of the spleen. It is measured per 100 individuals 
of similar ages; typically in children aged 2 to 5 years [77, 78]. This method was the first 
used to quantify malaria disease in the population, having been introduced in India in 
1948 [79]. It is determined through a survey of a selected age-group of randomly 
sampled population. The quantity measured is a point prevalence of splenomegaly, 
although the term ―rate‖ is often used [79]. 
b) Parasite rate 
Parasite rate is another method that has been used in malaria metric surveys because of 
its higher specifity than the spleen index [77]. It is defined as the proportion of the 
population of similar ages with parasitamia [77, 78]. It is also measured per 100 
individuals of similar ages; typically in children aged 2 to 5 years [77, 78]. It is 
determined through a survey of a selected age-group of randomly sampled population. 
It involves assessing the presence of asexual malaria parasite in peripheral blood by slide 
microscopy [79].  It represents the point prevalence of parasitaemia in the selected 
group of the population [78]. Its usefulness in malaria epidemiology remains 
questionable [79]. 
c) Transmission intensity 
This measure depends on the capacity of the vector (Anopheles mosquito) to transmit 
malaria parasite during its life time. The measure of transmission intensity is 
Entomological Inoculation Rate (EIR), which refers to the average number of infective 
bites by Anopheles mosquito per person per unit time, usually one year (i.e. Annual EIR 
= AEIR). EIR is normally measured through sentinel surveillance, using various 
methods [77, 79]. 
d) Stability of transmission 
This is a mathematical model based on EIR. The classical mathematical model is the 
Ross-Macdonald model which can be used to predict the relationship between 
endemicity as measured by P falciparum parasite rate (PfPR) and transmission intensity 
measured by P falciparum EIR (PfEIR) [79]. The Ross-Macdonald model shows that 
PfPR is very sensitive to small changes in PfEIR at low transmission intensity, but it is 
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insensitive to small changes in PfEIR at high transmission intensity [79]. The Ross-
Macdonald model classifies malaria endemicity into stable malaria and unstable malaria 
[79]. Stable malaria implies an overall balanced or constant presence of malaria, with 
persistently high prevalence of infection, which is insensitive to environmental changes. 
Transmission is year-round although there may be seasonal fluctuation. Unstable malaria 
implies irregular transmission of malaria in space and time. The background immunity in 
the population is low and therefore the risk of malaria epidemic is high [78]. 
Intermediate stability is designated between these two extremes. Thus unstable malaria 
settings consist of hypoendemic areas, intermediate stability corresponds to meso-
endemic areas, while stable malaria settings comprise hyper and holoendemic areas. 
e) Classification method adopted in this thesis 
In this thesis, malaria prevalence in Uganda is described as low, medium and high. This 
classification has been used in previous studies, including the trial analysed in chapter 4 
[80, 81]. It is based on AEIR indices derived from a recent 1-year long entomological 
surveillance data obtained from 7 ecologically different sentinel sites throughout the 
country, including the study locations mentioned in this thesis [75]. The values of EIR 
and endemicity classification attributed to the locations studied as part of this thesis 
correspond to the grading presented in Table 3. 
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2.5.2. Measuring quality of care 
a) Definitions  
Definitions of quality vary widely, and so are approaches to measurement [82]. A 
unifying conceptual framework for assessing the quality of healthcare is the Donabedian 
model which was developed over 30 years ago [83, 84]. The Donabedian model 
describes a systemic approach to assessing quality of care. It considers quality on the 
basis of structure, process and outcomes [84, 85]. Figure 4 below shows the causal 
relationship between structure, process and outcomes sub-systems. 
 
 
Adapted from Donabedian (1980) and Coyle 1999 [83, 84] 
Structure describes the setting in which healthcare is provided [83, 85].  It consists of 
institutional factors such as inputs (human, financial, equipment), policies and 
regulations, amenities, and provider characteristics (ownership) [83, 85, 86]. Structural 
attributes measure the presumed capacity of the provider to offer quality health care 
[86].  
Process consists of components of an encounter between a HW and a patient, or what 
is done to patients (e.g. consultations and laboratory tests) [83, 85, 86]. Measurement of 
quality in terms of process data is today commonly referred to as performance 
measurement [86]. The Donebanian model distinguishes quality of process into 
technical quality and inter-personal (service) quality [83, 87]. Technical quality in 
healthcare is the extent to which clinical aspects of care meets pre-defined standards of 
acceptable or good care [87]. It measures disease-oriented aspects of care and deals with 
what the patient receives relative to what is known to be effective [86, 88]. Interpersonal 
(service) quality includes aspects such as patient advice, answering questions from 
patients and taking into account patients‘ preferences in decision-making [83, 86, 89]. 
PROCESS Outcome  
Structure  
Antecedent conditions 
Figure 4: The Donabedian model of health system performance 
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Outcomes attributes consist of clinical endpoints (laboratory values, morbidity and 
mortality), functional status (physical, mental, social), general well-being (perception, 
vitality, fatique) and satisfaction with healthcare [83, 85, 86].  
The structure-process-outcome model does not operate in a vacuum, but in an 
environment referred to as antecedents. Antecedents are factors that affect the 
structure, process and outcomes of medical care, but may not be within the influence of 
the health provider. Antecedents consist of the environmental context of individuals 
(policies, culture, beliefs, sanitation) and individual personal characteristics (genetics, 
socio-demographics). Antecedent factors are known to have the strongest influence on 
outcomes [83]. Analysis of antecedent factors can help explain whether outcomes are 
due to interventions or patient factors or environmental factors [83]. 
For quality of care derived from structural data to be valid, variation in attributes of 
structure assessed should lead to differences in process and outcomes quality indicators. 
Further, for quality of care derived from process data to be valid, variations in the 
process of care attributes measured must lead to a change in outcomes that are 
important to patients. Similarly, outcomes measures are valid indicators of quality only 
to the extent that differences in outcomes can be linked to changes in the process of 
care [83, 86]. Linking outcomes data to process data can inform health managers of the 
kind of actions they should take when health outcomes are poor [86].  
The relationship between structural standards and either process or outcomes attributes 
is questionable [86]. It is acknowledged that compliance with structural standards does 
not mean that high quality care is being provided; nor does their use in quality 
assessment imply that high quality care cannot be provided unless these standards are 
complied with[86]. Nevertheless, structural standards are often combined with measures 
of performance and outcomes in assessing quality of healthcare [86, 90-93]. On the 
other hand, process data are widely considered to be a sensitive predictor of outcomes 
[94-96]. Therefore, both process and outcomes data are considered to provide valid 
information about the overall quality of care. However, outcomes data are usually less 
sensitive in predicting quality of care. This is due to the fact that differences in 
outcomes may not be related to factors under the control of the HW. For example, 
patients receiving the same treatment may experience different outcomes due to factors 
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such as differences in personal characteristics (antecedents). Therefore, a good outcome 
does not imply adequate quality of the process of care, and vice versa [85]. 
b) Methods of assessing technical quality of care 
Methods of assessing quality of care may either be implicit or explicit. In implicit 
methods, standards for judging quality of care are not defined a priori. Therefore, there 
is no basis for judging adequacy of quality. On the other hand, explicit approaches 
involve the use of standards which are set a priori, on the basis of which quality can be 
judged as either adequate or inadequate [85]. The assessor then compares what was 
done against what should have been done and the result is expressed as the proportion 
of the criteria that were met. Additionally, or alternatively, various levels of quality of 
care which have been defined on the basis of explicit a priori criteria can be used to 
predict future outcomes by means of valid models [85]. 
Results of quality assessments vary with the methods used. Explicit process methods are 
the most strict, while implicit outcomes-based methods are the least strict. For example, 
explicit process indicators may show that two population groups have received care that 
is starkly different in quality. However, implicit (subjective) outcomes indicators of the 
same care may show a small difference in quality between the two groups. For this 
reason, it has been proposed that action-oriented assessments of quality of care should 
focus on process data rather than on outcomes data, especially in assessment of HW 
performance [85]. 
c) Implications for RDT-based guideline 
The RDT-based policy is aimed at improving the quality of the process of care for 
patients with fever. Improvement in outcomes is expected to accrue as a consequence 
of improvement in the quality of practice. Therefore, change in the quality of clinical 
practice is a more direct outcome of the intervention rather than change in clinical 
outcomes. Further, it can be construed from the foregoing that change in clinical 
outcomes may not be a sensitive indicator of whether improvement in the overall 
quality of care has taken place. On the other hand, indicators of HW performance may 
be a more valid measure of whether introduction of the policy has led to a change in the 
overall quality of care. However, we know that the main objective of introducing the 
new policy is an expected improvement in outcomes and efficiency (cost-saving). 
Therefore, while indicators of HW performance may be used to demonstrate if change 
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in the overall quality of care has taken place, it is also vital to show that implementing 
the new policy does not do more harm than good, relative to the existing symptoms-
based guidelines. Ultimately, adoption decisions are supposed to be based on outcomes 
indicators. However, lack of improvement in clinical outcomes should not be 
considered to reflect a lack of improvement in the overall quality of care. 
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2.5.3. Difference between efficacy and effectiveness trials 
Table 4 outlines the differences between efficacy and effectiveness trials which, 
respectively, correspond to phase 3 and phase of technology assessment. 
Table 4: Characteristics of efficacy and effectiveness trials 
CRITERIA EFFICACY TRIAL EFFECTIVENESS TRIAL 
Question  Can it work in ideal or optimal 
conditions 
Does it work under routine or ―real 
life‖ conditions? 
   
Purpose  Explanatory: what works? How does 
it work 
Pragmatic: should the service be 
provided to a wide variety of the 
population in a wide variety of 
settings? 
   
Participants  Smaller scale Larger scale 
   
 More homogenous; typically includes 
subgroup analysis 
More heterogeneous; reflective of 
the general population or real life. 
Subgroup analysis is not critical 
   
Intervention  Strictly defined or standardised Strictly defined or standardised 
   
Implementation optimised/tightly controlled may vary—at discretion of 
clinicians 
 provided by ―experts‖ or 
―enthusiasts‖ 
provided by normal staff 
Acceptance optimised Acceptance: variable  
   
Control  Usually a placebo Usually routine practice 
   
Outcomes  Usually intermediate, clinical or 
laboratory or biological measures 
Patient-centred, may include 
broader health-related quality of life 
measures 
   
Analysis  Measures effect of actually receiving 
treatment as per protocol 
Intention-to-treat, according to the 
treatment allocated to rather than to 
treatment received 
   
 Analyse participants according to 
treatment actually received; i.e. for 
those who comply/complete 
Measures effect of making 
treatment available rather than 
actually receiving them 
   
Settings  Well resourced Variable resource levels 
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2.5.4. Measuring efficacy 
a) Definition  
The first level of research which this thesis undertakes consists of an assessment of the 
efficacy of the intervention. Efficacy refers to the effects of an intervention when 
delivered under ideal or experimental conditions. Efficacy studies are concerned with 
assessing if an intervention can work—i.e. whether it can do more good than harm—
under ideal conditions [40, 97]. Further, efficacy trials aim to investigate how and how 
an intervention works. For this reason, they are also referred to as explanatory trials [40, 
97]. Assessment of efficacy is considered a necessary step in the development and 
diffusion of a new technology or intervention [40]. If an intervention is shown to have 
no or negative effect under ideal conditions then it is unlikely to be effective in routine 
practice [40, 50]. On the other hand, once an intervention is shown to be efficacious, it 
is then useful to carry out an effectiveness trial to investigate if it can work in real-life 
settings; and implementation research to assess if all components can be delivered to 
acceptable standards in routine practice in a manner that is acceptable to the target 
audience [40]. 
b) Design of efficacy trials 
Efficacy studies are designed to optimise performance or effects of an intervention.  
Therefore, an efficacy trial is characterised by (a) a well defined or standardised 
intervention that (b) is made available in a uniform fashion (c) within standardised and 
well-resourced settings (d) to specific target audience which (d) completely accepts, 
participates in, complies with or adheres to the intervention delivered [40, 98]. In 
addition, efficacy trials usually apply strict exclusion criteria so as to recruit participants 
with similar characteristics. Further, efficacy trials closely monitor the frequency with 
which interventions are applied and carefully measure outcomes of participants at 
various points in time [40, 98]. A typical study design for assessing efficacy consists of a 
randomised controlled trial (RCT) which involves (a) random assignment of participants 
to comparison arms, (b) conceal of allocation of study participants and (c) blinding of 
study participants and study teams to the interventions provided as well as blinding of 
outcomes assessment. Typically the comparison intervention consists of a placebo. 
However, for most public health interventions, the comparison intervention often 
consists of the best known or the current intervention. The assessment is then 
concerned with whether or not the new intervention does more good than harm when 
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compared with the intervention currently or previously in use. For practical reasons, test 
of efficacy is sometimes carried out using non- or quasi-experimental clinical trials 
which may not involve randomisation or blinding and may use historical controls, 
although they result in weaker causal inferences [40, 98]. 
c) Strength of RCTs 
RCTs are considered the best design for attributing outcomes to an intervention. If well 
conducted, randomisation ensures that, on average, all potential confounders are equally 
distributed between comparison arms. Thus any significant difference between the study 
arms in the outcome assessed can be attributed to the intervention and not to a 
systematic difference between the two groups [50, 98-100]. 
d) Major limitations to RCTs 
Threats to external validity 
A typical RCT takes place under atypical (ideal) conditions characterised by 
standardised, well resourced settings, motivated research staff and participants, 
homogeneous population, and intense application and monitoring of the intervention 
[40, 98]. As such evidence from RCTs may not be generalisable to the general 
population in routine practice [98]. However, threats to external validity would be an 
issue if adoption decisions were based on results of efficacy trials only. According to 
diffusion of innovation model described above, adoption decisions are meant to be 
informed by evidence from effectiveness and demonstration trials. Efficacy trials are 
necessary but not sufficient for adoption decision-making [40]. Knowledge of efficacy is 
necessary to inform the decision as to whether or not it is necessary to carry out an 
effectiveness study and to aid interpretation of evidence from effectiveness trials. 
Therefore, in the context of this study, this limitation is irrelevant. Further, generalisable 
conclusions may be gained from systematic reviews and meta-analysis that identify 
similar effects in various populations [98] 
Sample size, design effect and cost 
The sample size required to detect a difference in effect between two groups is inversely 
proportional to the treatment effect squared [101]. Therefore, in order to detect small 
differences in effects, randomised trials require large sample sizes. 
Many trials of public health interventions use cluster Randomised Controlled Trials 
(cRCTs) because individual randomisation is not feasible [98, 99]. If analysis is 
undertaken at individual level, sample size calculations for cRCTs need to take into 
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account the correlations among the individuals within the clusters (design effect) [98, 
102, 103]. Randomisation can be effective in addressing baseline imbalance in cRCT if 
the number of clusters randomised in large. With fewer clusters, as is the case in most 
cRCTs, randomisation has less statistical power. The general rule of thumb is that more 
clusters with fewer individuals per cluster help to minimise the design effect [98]. 
Although use of stratified or pair-matched methods may minimise design effect in 
cRCTs, these methods also require large numbers of clusters that are similar enough to 
be paired or grouped [98].    
Because RCTs require large samples, they are very costly to conduct—irrespective of 
whether they are individual or cluster randomised. 
In assessing HW performance and guideline implementation, a common approach is to 
observe HW making observation at a few clusters (health facilities) [62, 90-92, 104-118]. 
Data on HW performance tend to be correlated because of the similarity in case 
management as all patients are often seen by only one or two HWs [102]. 
Randomisation of patients does not address the correlation in data on HW 
performance. Therefore, sample size calculation in such surveys need to account for 
potential design effect in the data on HW performance [102]. 
Contamination  
Allocation and blinding is usually not practical or necessary in many public health 
interventions. Therefore, control conditions cannot be guaranteed: aspects of the 
intervention may be implemented in control settings. For example, in one cRCT 
designed to compare effects of implementation of an RDT-based guideline versus a 
conventional symptom-based guideline, some control facilities were later noted to have 
received and used RDTs provided through other supply chains [35]. Such 
contaminations can reduce the statistical power of the trial to detect effects of the 
intervention [98].   
Ethics 
Ethical challenges may arise by withholding potentially beneficial intervention from 
control population units, particularly if the intervention is associated with large positive 
effects [98]. 
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Complex interventions 
Many public health interventions are complex, consisting of several components [73, 
74]. When interventions are associated with significant effects, it is important to identify 
which components of the intervention contributed to the outcomes. RCTs are 
unsuitable for attributing effects to components of interventions: it is difficult to 
identify the components of the intervention which is responsible for an observed effect 
[74]. If linked to outcomes assessment, implementation evaluation (demonstration 
studies) can be more useful in explaining positive, modest and insignificant results [73, 
74]. 
e) Choice of a systematic review of RCTs to assess efficacy 
A systematic review is a method of systematically collating all empirical evidence that 
fits pre-specified eligibility criteria in order to answer a specific research question. It uses 
explicit inclusion criteria that are selected to minimise bias and increase internal validity 
of the findings [119].  
A systematic review was chosen because it was not feasible to undertake an RCT in the 
context of this thesis due to financial and time constraints. Secondly, a systematic review 
pools together all possible evidence from a broader context. Therefore, it represents the 
best evidence for decision making at a broader level. Although RCTs are criticised for 
its limited external validity, systematic reviews can lead to generalisable conclusions by 
identifying similar effects in various populations [98]. 
Evidence from non-randomised trials was excluded from the review. Selection biases 
(confounding) are likely to be greater for non-randomised studies than for RCTs [119]. 
Inclusion of evidence from non-randomised trials in a meta-analysis can lead to a shift 
in the estimate of the effect of an intervention (systematic bias) and excessive 
heterogeneity among studies [119]. 
Potential limitations  
The research quality criteria used to select studies for inclusion in a systematic review of 
effects of interventions has been criticised for being overly biased against studies that 
may show large effects of an intervention, but whose designs are deemed to be sub-
optimal as per the selection criteria [73]. On the hand, it may be biased towards 
interventions with marginal effects because the designs of the studies used in evaluating 
effects meet the selection criteria.  
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Many studies used in evaluating public health interventions employ cluster randomised 
trials in which analysis is done at the level of the individual patients, leading to unit of 
analysis error which may lead to over-precise results.  If included in a meta-analysis 
without correcting for clustering, estimates of effects from cluster randomised trials may 
carry more weight on the pooled result of the meta-analysis and lead to a biased 
estimate [73]. 
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2.5.5. Measuring effectiveness 
a) Definition  
The second level of study applied in this thesis is an effectiveness trial. Effectiveness 
refers to the effect of an intervention under routine or ―real-life‖ conditions. 
Effectiveness trials aim to demonstrate whether an intervention does more good than 
harm in routine or ―real life‖ circumstances. For this reason, effectiveness trials are also 
called ―pragmatic‖ trials because the focus is assessing if the intervention does work in 
the real world [40, 97].   
b) Design of an effectiveness (pragmatic) trial 
A typical design of an effectiveness trial would incorporate situations the clinicians are 
likely to encounter in usual practice [40, 97]. For example participants‘ selection would 
be broad in order to assess if the intervention works for the general population. The 
intervention would be provided by normal program staff, who may not receive any 
special incentives to deliver the intervention as defined. Delivery of the intervention is 
normally at the discretion of the program staff and may vary within and between sites. 
Therefore the magnitude of effects of the intervention may vary between sites due to 
variability in delivery and quality of the intervention to the target audience, and/or 
variability in acceptance of (participation in, compliance with, or adherence to) the 
intervention by the target audience [40]. Control interventions usually consist of current 
or previous interventions or treatment.  
It follows that a good effectiveness study would include an assessment of 
implementation (availability, quality, and acceptance) as well as measuring of effects of 
the intervention. Without assessment of implementation, and especially without prior 
knowledge of the level of efficacy, it is difficult to determine whether a lack of 
intervention effects is due to inefficacious intervention or inadequate programme 
implementation [40].  
Randomisation, allocation concealment and double blinding are usually much more 
difficult to implement in less-controlled, real-world settings [40, 98]. Quasi- or non-
experimental designs are used more often in assessing effectiveness of public health 
interventions than the traditional RCTs described above [120, 121]. Examples of quasi-
experimental designs recommended for effectiveness trials include:  
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(a) basic pretest-posttest design: this involves comparing estimates of effects of the 
intervention in several populations before the intervention, with estimates of 
effects in the same population after they have received the intervention. 
Maturation and history are major threats to internal validity of this design [122, 
123]. Maturation refers to internal changes in the population over time while 
history refers to exposure of the population to external events (external to the 
intervention) that may affect their post-test estimates of effects [122, 123]. 
(b) Control-group pretest-posttest design: this design consists of an intervention arm which 
essentially involves pre-post comparison as described in (a) above, and a parallel 
control arm, which also involves a pre-post comparison at the same time points 
but without application of the intervention. Introducing a control arm is useful 
in assessing the role of maturation and history. Populations may be assigned to 
the two arms through random allocation (and unit of allocation are usually 
clusters) [98, 122, 123]. Additionally the comparison groups may be matched or 
unmatched [98, 122, 123]. Control-group pretest-posttest is the design used in 
the trial analysed in chapter 4 of this thesis. 
(c) Intervention versus control group comparison, without a baseline survey, which may be 
randomised, or non-radomised, matched or un-matched. Baseline imbalance and 
confounding would be the major threats to this design in the absence of 
randomisation and/or matching. 
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2.5.6. Measuring implementation  
a) Definition  
The third level of research proposed in this thesis consists of a demonstration or 
implementation study. A demonstration study consists of routine implementation of an 
intervention of proven efficacy and effectiveness in whole communities (e.g. a district, 
region or state), and monitoring the implementation [40]. The focus of a demonstration 
study is on implementation of the intervention (what components, what quality), 
acceptability (participation or adherence) and context (by whom, under what conditions) 
[73]. However, demonstration studies may include an assessment of outcomes in the 
population (morbidity, mortality, behaviour change, cost, etc) [40]. 
During demonstration, delivery of interventions may vary between settings, or can be 
varied deliberately between sites in order to determine which model is more effective in 
delivering the intervention, or has a better reach. Therefore, demonstration studies can 
show the extent to which various elements of a multi-component intervention are 
actually implemented [73, 74]. In addition, it enables the identification of facilitating and 
inhibiting contextual factor [73]. If linked to outcomes assessment, demonstration 
studies can be useful in interpreting effects of a complex or multi-component 
intervention. Collection of process and context variables helps to explain how and why 
an observed change has occurred [40]. Although it may be difficult to attribute effects 
directly to single and specific element of a multi-component intervention [40, 73], 
detailed implementation evaluation can be used to generate hypothesis about causal 
relationship between intervention components and specific outcomes [40, 73, 74].  
b) Design and methods 
Studies evaluating the quality of clinical practice or guideline implementation usually 
employ one or a combination of the following methods (a) observing a HW perform a 
set of clinical tasks which are specified in the guideline [5-23], (b) ―gold standard 
examination‖ of study participants by a more qualified research staff [8, 13, 16, 18, 24], 
(c) interviewing the HW (e.g. about training, knowledge, attitude, experiences) [6, 8, 10, 
16, 18, 25-27], (d) exit interview of participants (e.g. to evaluate clinical notes, diagnosis 
and prescriptions made) [6, 8, 10, 13, 16-18, 27], and (e) assessing the adequacy of 
essential  health systems inputs and support services that are required for effective 
implementation of the guideline [6, 8, 10, 26].  
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For guidelines originating from international organizations and networks—such as the 
WHO, UNICEF, INRUD—studies typically use standardized and field-tested indicators 
derived from these organisations [28-30]. These indicators are normally adopted whole-
some or are adapted slightly to suite the context of the studies. In a few instances, 
indicators have been developed by the researchers themselves, especially where 
guidelines were developed locally [13, 17]. Studies normally vary in the scope of items 
assessed or how indicators are measured, even when common tools have been used.   
c) Measures of HW performance  
Measures of HW adherence to guideline have commonly taken the form of point 
estimates (with associated estimates of errors) [6, 7, 9, 15, 16, 18, 24, 26] or categorical 
(qualitative) descriptions [20-23], or both [8, 10, 13]. Where both point estimates and 
categorical outcomes are provided, the latter tends to refer to the quality of prescribing 
(type of medications and regimen). When indicators are measured in the form of point 
estimates, they are frequently expressed as adherence or performance scores, which 
represent the percent of expected tasks (i.e. those specified in the guidelines) which are 
performed by the HWs [8, 10, 13, 15-18, 26].  Usually, this process involves counting 
the number of expected tasks performed by the HW, without taking into account the 
quality of execution. Occasionally, or additionally, point estimate measures have been 
expressed in the form of average values (±standard deviation), representing the number 
of expected tasks performed by the HW per consultation. This form of measure has 
commonly been used in evaluation of guidelines focusing on rational drug use [7, 31-
34]. Occasionally, they have also been used in assessing IMCI-related guidelines [19].  
The major limitation of using point estimates as measures of HW adherence to 
guidelines is that frequently standards for judging adequacy of HW performance are not 
provided. In the absence of a standard, it is difficult to judge if a given level of 
performance (percentage point or average value) represents acceptable quality or poor 
quality. Notable exceptions are studies assessing implementation of guidelines on 
rational drug use, for which standards are normally provided. These standards are based 
on surveys carried out in developing countries in the 1990‘s (INRUD). Therefore, most 
of these standards have become obsolete because many clinical guidelines in developing 
countries have evolved since the 1990s, especially those in malaria and HIV endemic 
countries [9, 19, 124]. 
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Much more recently, LQAS-based methods have been widely used in assessing HW 
performance descriptions [20-23]. LQAS-based methods often apply the same data 
collection techniques and indicators described in (b) above. However, the LQAS-
method is a triage system which allows judgement to be made about the adequacy of 
HW performance against pre-set performance standards.  The outcomes in an LQAS-
based survey are dichotomous; e.g. either acceptable or unacceptable, low or high, 
adequate or inadequate, etc. The LQAS-method allows the identification of poorly 
performing HWs or areas that require urgent action. Therefore, the LQAS method uses 
an explicit approach in assessing HW performance, and is action oriented. LQAS 
principle and its application in healthcare are described further below. 
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2.6 Use of LQAS method to assess quality of care 
Chapter 5 of this thesis uses Lot Quality Assurance Sampling (LQAS) method to assess 
whether districts are adequately embracing the RDT guidelines in routine clinical care of 
febrile children.  
2.6.1 Basic principles 
a) Description  
LQAS is a quality control method that originated in industry in the 1920‘s, adapted to 
the health sector in the 1980‘s. LQAS was developed to classify the quality of a 
particular batch, or lot, of goods as acceptable, or not, according to a specified 
performance standard. This is done by counting the number of ‗defects‘ in a small 
sample of a batch. The entire lot, or batch, is then rejected or accepted depending on 
the number of defects in the sample. The maximum number of defects permitted in a 
sample considered to be of good quality is referred as the decision rule (d). The 
outcome in LQAS-based assessments is binary; e.g. either ―acceptable‖ or 
―unacceptable‖. Hence the LQAS is a classification method and is typically not used to 
calculate point estimates.   
LQAS appears sensitive to detecting poorly performing parts of the system being 
sampled. The aim is to help local managers to identify components of the system that 
require urgent action and to prioritise resources [104, 125]. 
The main advantages of LQAS method are that it requires a small sample size, is rapid 
and therefore it is not resource-intensive [105-107, 126]. The trade off in using small 
sample sizes is that some lots may be rejected even if they are in reality acceptable, while 
others with higher than acceptable levels of defects may escape detection [125]. Further, 
because LQAS samples are small, the 95% confidence intervals for point estimates are 
wide.  However, by aggregating data across different lots, a point estimate for a given 
indicator can be calculated due to the large total sample size [107]. 
The LQAS-based methods have recently been applied extensively in developing 
countries to assess child survival and maternal and child health interventions [104, 106, 
127-129], to detect malaria epidemics [130], to assess communities for Schistosoma [126, 
131] and to identify strategies for control of yaws[132]. It is potentially useful for malaria 
programme management [125, 133].  
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b) Standards  
To classify a performance as either acceptable or unacceptable, four parameters are set 
beforehand. The first is the level of the desired performance which defines acceptable 
quality, also referred to as a performance threshold.  The second is the level of 
performance that is considered to be seriously below the performance threshold and is 
deemed ―unacceptable‖, at which point managerial attention is a priority. The third is 
the level of risk one is willing to take in judging a lot as having achieved the 
performance benchmark when in fact it has not (β-error). The fourth is the level of risk 
one is willing to take for judging a lot as having failed to achieve the performance 
benchmark when in fact it has (α-error) [104-107]. The typical decision rule as used in 
public health programme assessments is one in which both α and β  <0.10 and their 
sum is <0.20[104]. 
These benchmarks are usually set in consultation with programme managers [104]. For 
example, in a previous LQAS-based survey of immunisation coverage, the managers 
chose a target of 80% to define adequate immunisation coverage. This target is called 
the upper threshold.  Further, they chose coverage level of 50% to denote a highly 
―unacceptable‖ coverage level which the LQAS was designed to detected with low error 
[106].  
c) Sample size and decision rules 
LQAS is a statistical method that uses cumulative probabilities to calculate an 
appropriate sample size and a decision rule to reliably identify production units (e.g. 
health facilities in a district) that are performing at a desired level of quality [104]. The 
standard approach is to use the binomial formula when dealing with a large population 
size, e.g. when calculating the number of observations (patients) required to judge the 
adequacy of clinician adherence to guidelines [104, 106]. The formula for the binomial 
distribution is shown in Appendix 1. When dealing with a small and finite population, a 
hyper-geometric formula is applied [104]. For example, in calculating the number of 
facilities to sample in a LQAS-based study in a given district, a hyper-geometric formula 
is more appropriate since the total number of facilities (universe) is known and is small. 
The binomial and hypergeometic probabilities approximate each other in large 
populations but differ in small ones.  
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The binomial or hyper-geometric formula calculates the probability of selecting a certain 
number of defects ―d‖ (e.g. unvaccinated children) from a sample ―n‖ drawn from a lot 
of a certain quality ―P‖ (e.g. health area with a given immunisation coverage). 
Conversely, the binomial or hyper-geometric formula calculates the probability of 
correctly identifying a lot of quality ―P‖ given a level of ―d‖ defects in a sample ―n‖ 
drawn from the lot [104].  
The following example from Valadez (1991) illustrates how LQAS and decision rules 
work [104].  In assessing adequacy of immunisation coverage among children in a given 
community, assume 80% and 50% are chosen to denote adequate coverage and 
unacceptable coverage respectively. Assume the calculation yields a sample of 19 
children and a decision rule of 6 (i.e. 19:6). The decision rule 19:6 means that when 6 or 
fewer unvaccinated children are detected in a sample of 19 children, the sample, and the 
community from which it is drawn, is classified as having achieved adequate 
immunisation coverage. This decision is associated with an error (β-error), which 
represents the risk of classifying the coverage in the community as adequate when in 
fact it is not (i.e. when the actual coverage is less than 80%).  
The binomial and hyper-geometric formulas calculate the exact risks associated with 
applying the decision rules. When applied to the binomial formula, the 19:6 rule shows 
that a community with 80% coverage will be classified as adequate 93% of the time 
[104]. That is, 93% of the time the number of unvaccinated children (defects) in a 
sample of 19 children will be 6 or fewer; 7% of the time, the number of unvaccinated 
children in the sample will be more than 6, and the sample—and the community from 
which it is drawn —will be misclassified as having achieved inadequate coverage. If the 
same rule is applied to a community with 50% coverage, it will be incorrectly identified 
as having achieved adequate coverage—that is, the samples will contain 6 or fewer 
unvaccinated children—8% of the time [104]. In 92% of cases, a sample drawn from a 
population with 50% coverage will contain more than 6 unvaccinated children and will 
be classified as having been inadequately covered.  
If the same 19:6 rule is applied to a sample from a health area with coverage between 
50% and 80%, it will be classified as adequate or unacceptable depending on how close 
the coverage falls to the upper and lower bounds of the triage system. The classification 
errors (α and β errors) associated with the middle grounds are higher than the 
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corresponding values at the upper and lower thresholds [104]. Therefore, LQAS 
optimises the identification of extreme performance: worst of worst, which require 
priority attention and/or best of best, so that resources are not wasted. 
2.6.2 LQAS for Health Facility Assessment 
The LQAS method has been applied in the health sector to determine whether a 
particular health programme, or health facility, meets a desired performance threshold 
[104-106]. In Health Facility Assessment (HFA), LQAS is used in a 2-stage sampling 
design. Firstly, LQAS is used to determine whether an acceptable proportion of health 
facilities in a supervision area perform a given clinical task adequately. Typically, at least 
80% of health facilities are expected to have clinicians displaying behaviour consistent 
with clinical guidelines (upper threshold) [104, 106].  Additionally, LQAS is set to detect 
supervision areas with higher error rates in which, typically, only 50% or fewer of the 
health facilities exhibit the appropriate behaviour (lower threshold) [104, 106]. Secondly, 
LQAS is used to determine the number of clients needed to judge adequacy of a single 
provider's performance of a given clinical task. Previous studies have typically used an 
upper threshold of 95% to define adequate performance—expecting a given provider to 
deliver specified services using the correct technique at least 95% of the time. A 
performance threshold of 50% has typically been used to denote unacceptable health 
worker performance [104, 106, 127, 128]. 
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2.7 Overview of malaria diagnostic methods 
2.7.1 Clinical diagnosis 
Prompt and accurate diagnosis of malaria is the mainstay of the WHO malaria control 
strategy. Despite considerable progress in malaria control over the recent years, 
diagnosis of malaria remains problematic due to lack of diagnostic techniques that are 
technically, operationally and financially sustainable at primary care settings in endemic 
countries [134]. Consequently, in most endemic countries, the diagnosis of malaria is 
based on clinical judgment in most health facilities [15, 22].  
Clinical features, including fever, are poor predictors of malaria disease. Several studies 
from different epidemiological settings show that 32% to 93% of patients classified as 
malaria on clinical grounds alone are slide negative (mean: 61%) [11-14]. On the other 
hand some patients with malaria parasites, or non-malarial febrile illnesses (NMFIs), 
such as acute respiratory infection, could be left untreated or are maltreated. This 
increases the potential for resistance to the medicines used, or may result in complicated 
forms of the conditions (malaria or NMFIs) due to improper or lack of treatment. The 
patient and the healthcare system may incur unnecessary and substantial costs as a result 
of such misdiagnosis [11-14].  
2.7.2 Biologic methods 
Research in malaria diagnostics has been limited. Microscopic examination of Giemsa-
stained blood smears was introduced more than 100 years ago and has been used as the 
gold standard technique for malaria since [20]. In the past 50 years, alternative parasite-
based techniques have emerged. They include enzymatic immunoassays (ELISA) and 
immunofluorescence antibody assay (IFA) [20, 22, 134]. These tests detect antibodies to 
the asexual forms of malaria parasites which appear days to weeks after the infection 
and may persist for months. Therefore, they can not distinguish between current or past 
infections, and are therefore of limited value in guiding treatment of malaria [134]. 
Antigen-based methods have also become available. The most significant of these is the 
immunochromatographic assay, which forms the basis of the current commercially 
available malaria RDTs [20, 134]. 
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Much more recently, polymerase chain reaction (PCR), a molecular method that uses 
DNA probes, has also been introduced. PCR techniques are much more sensitive than, 
or as sensitive as, microscopy [20, 22, 134]. However, PCR is costly, difficult to run and 
requires sophisticated equipment and highly qualified technicians. Therefore, currently 
the method is used mainly for research [134].  
Other methods which have emerged recently include fluorescent staining techniques 
such as the quantitative buffy coat (QBC) analysis and acridine-orange staining of thin 
blood smears [20, 22, 134]. Although these techniques appear to have high sensitivity at 
low parasite density (100 parasites/ µL) [135], they are, so far, of limited value in clinical 
settings for the same reasons cited above [22]. Use of deplorased laser light to detect 
malaria pigments, and mass spectrometry have shown limited success [20]  
2.7.3 Microscopic examination 
Microscopic examination remains the gold standard diagnosis of malaria. Microscopy 
has several advantages. It is inexpensive to perform, able to differentiate malaria species 
and quantify parasites [20]. Expert microscopy of Giemsa-stained thick blood film is 
sensitive at low parasite density (5 to 20 parasites/µL) [20-22]. It is useful in parasite 
quantification, species differentiation and staging of parasites, all of which are useful 
indicators in selection and evaluation of treatment. It can also be used for diagnosing 
other conditions. Furthermore, malaria smears provide a permanent record that can be 
used in quality assurance of malaria diagnosis [22].  
However, microscopy has several limitations. It is labour-intensive and time consuming. 
Routine clinical microscopy can not detect very low parasitaemias (<5 to 10 
parasites/µL)[22]; the detection threshold is estimated at 50 to 100 parasites/µl, much 
higher in settings with less skilled microscopist [20, 22]. Mixed infections are often 
missed (requiring thin films).  
In addition, widespread deployment of microscopes in rural health centres, the first 
contact points for most febrile patients, is not feasible in the near future because of the 
high cost of procuring sufficient number of microscopes,  the operational costs, and the 
technical capacity building required [23, 24].  
Because of the operational and technical limitations of microscopy, Rapid Diagnostic 
Test (RDT) is now recommended as a quick and accurate parasite-based technique for 
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use where high quality microscopy is not available [14, 19, 53]. Malaria RDTs have been 
widely tested over the last 20 years [20, 22]; and RDT-based guidelines are now 
operational in many malaria endemic countries to support the diagnosis and treatment 
of febrile patients [25].  
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2.8 Malaria rapid diagnostic tests 
2.8.1 Technology  
An RDT is a device that is capable of detecting malaria antigens in a small volume of 
blood, usually 5 to 15 µL. It is a method based on immune-chromatographic assays. The 
modern malaria RDT consists of antibodies against malarial antigens impregnated on a 
nitro-cellulose strip encased in a cassette [20, 22]. The clinical sample migrates along the 
strip by capillary action (Figure 5 below).  
 
Figure 5: Schematic of how modern malaria RDT works 
 
Source: Dorsey and Hopkins [81] 
Two types of antibodies are used for any target antigen: a capture and a detection 
antibody. The capture antibodies serve to extract and bind the parasite antigens from a 
migrating liquid sample. The detector antibody, joined to an indicator, combines with 
the immobilised target antigen to produce a bright coloured light, usually appearing in 5 
to 20 minutes [20, 22].  
 
Three types of antigens are commonly targeted by the malaria RDTs which are currently 
available. 
Histidine-rich protein-2 (HRP-2): this is a protein unique to P. falciparum. It is produced 
predominantly by the asexual form of the parasite. It is also found in gametocytes which 
can be detected in blood in the absence of the asexual form that causes disease [22]. 
HRP-2 can be detected at parasite concentration that is lower than is possible with other 
target antigens (i.e. <100 parasites/µL). HRP-2 antigen is known to persist in blood for 
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more than 28 days, well after the asexual forms of the parasite that cause disease have 
cleared from the blood. Therefore HRP2-based RDTs are not useful for monitoring 
response to treatment [20, 22]. 
Plasmodium lactate dehydogenase (pLDH), which is an enzyme produced by all species of 
Plamodium. It is produced by both asexual and sexual forms of the parasite. Antibodies 
have been developed that can detect pLDH that are unique to P. falciparum or P. vivax; or 
pLDH which is found in all Plasmodium species (pan malaria). The level of pLDH falls 
rapidly after initiation of therapy, clearing from blood within one week [20, 22]. 
Therefore pLDH-based RDTs are potentially useful for monitoring response to therapy 
[20]. 
Aldolase: this is also an enzyme, produced by all human species of Plasmodium parasites 
and is used as a pan malarial antigen target. It is produced by both asexual and sexual 
forms of the parasite. The level of aldolase also falls rapidly after initiation of therapy 
[20, 22]; hence, aldolase-based RDTs are also potentially useful for monitoring response 
to therapy [20]. 
No evaluations of P. malariae-specific or P. ovale-specific antigens have been published. 
2.8.2 Commercial types 
Commercial malaria RDTs carry 3 major combinations of antibodies to suite different 
malaria epidemiological contexts:  
a) HRP-2-based RDTs: the vast majority of RDTs which are recommended for use 
in sub-Saharan Africa carry anti-HRP-2; hence they are specific to P. falciparum 
[20, 22].  
b) pLDH-based RDTs carry antibodies targeting pLDH produced by either P. 
falciparum or P. Vivax; or pLDH produced by all Plasmodium species (pan-malaria) 
[20, 22].  
c) Combination-type RDTs, are essentially HRP-2-based; in addition, they carry other 
antibodies targeting P. vivax-specific pLDH, pan malaria pLDH or aldolase, thus 
making them capable of detecting mixed infections, or differentiating between 
species [20, 22].  
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2.8.3 Factors influencing performance of RDTs 
Several factors in the manufacturing process and those in the environment may affect 
the diagnostic accuracy of malaria RDTs. Table 5 below describes the main factors 
which may influence the performance of malaria RDTs.  
 
Table 5: Factors influencing performance of malaria RDTs 
FACTOR EXPLANATION  
Test devices  
 Manufacturing  
  Lot used The same product from the same manufacturer may vary in test 
properties because of material modifications over time 
 Transport and storage conditions 
  Humidity  -Humidity rapidly degrades RDT 
  Temperature  -Higher temperatures degrade RDTs by altering the flow characteristics 
of the nitrocellulose wick, deconjugation of the capture antibody-dye 
complex, detachment of capture antibody from wick 
-Drastic temperature changes (freeze-thawing), e.g. during transportation, 
can have similar effect 
 Preparation and interpretation 
  Blood buffer -Controls flows, sometimes lysis 
  Blood volume -Inadequate volume reduces available antigen. Excess volume inhibits 
clearance of blood stain, reducing clarity of test lines 
  Storage & 
duration 
-Lysis of red blood cells occurs during storage, which results in 
decrement of antigen activity over time 
  Visual acuity  -Test line can be faint at low antigen activity (long storage duration, low 
parasite density); it might be difficult to see in poor light, or if the reader 
has poor visual acuity 
  Patient and 
parasite 
-Sequestration of parasites determines antigen concentration and parasite 
density in peripheral blood 
-Antigen production varies with parasite life cycle and between parasites 
-Antigen structure vary between and with parasite species and strains 
-Parasites recovered directly from patients may show different antigen 
activity from that recovered from laboratory cultures 
-Lysis of red blod cells and aggregation of parasitized red blood cells can 
reduce consistency of flow 
  Training  -the quality of RDT prepared by well trained laboratory workers 
(evaluation studies) might vary from that prepared by field workers with 
limited training 
Reference standards 
  Microscopy or 
PCR 
-Poor sensitivity of reference standard reduces apparent RDT specificity 
-Poor specificity of reference standard reduces apparent RDT sensitivity 
Study population  
  Parasite factors -Parasite density affects sensitivity  
-Parasite prevalence affects predictive values 
   -Antigen activity varies between wild and cultured parasites (laboratory 
trials) 
  Patient factors -Treatment history and effectiveness of treatment varies between patients 
-Presence of substance prone to cause false-positive reactions (e.g. 
Rheumatoid factors) can vary between patients 
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For example, commercially distributed RDTs commonly undergo material modification 
after their initial introduction [22, 136]. Thus different batches of the same product 
from the same manufacturer may behave differently in both operational and 
performance characteristics [22, 136]. Further, because RDTs are based on antigen-
antibody interactions, they deteriorate very rapidly on exposure to high temperature and 
humidity. Manufacturers commonly specify storage between 2oC and 30oC. In practice 
RDTs are frequently exposed to >30oc and/or 70% humidity in clinical settings in the 
tropics [20, 22, 65, 136]. Product evaluation trials often use well trained well-trained 
laboratory personnel. In clinical settings, end-users are typically health care workers with 
limited training [20, 22, 65, 136].  
2.8.4 Performance of RDTs in field trials 
The diagnostic accuracy of the common commercially available RDTs has been 
extensively investigated under different transmission settings. Overall, the results show 
considerable inconsistency in the diagnostic accuracy of RDTs [20, 22, 135].Table 6 
below shows the results from an extensive systematic review of RDT performance from 
trials conducted in clinical settings in endemic countries [135]. It shows that HRP-2-
based RDTs are generally more sensitive than pLDH-based RDTs when used in febrile 
patients [135]. Additionally, it reveals that the average sensitivity of both types of RDTs 
is below the threshold of 95%. On the other hand, it shows that the specificity of both 
types of RDTs is generally higher than the recommended threshold of 95% [135].  
Table 6: Sensitivity and specificity of two RDTs in clinical settings in endemic countries 
RDT type 
Number of trials 
reviewed 
Diagnostic accuracy relative to microscopy 
 
Sensitivity (95% CI) Specificity (95% CI) 
HRP-2 13 92.7 (91.0-94.5) 99.2 (98.2-99.9) 
 
pLDH 6 67.1 (62.8-71.3) 98.4 (97.5-99.6) 
      
Source: Ochola 2006 [135]  
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Reviews by Wongs in 2007 and Murray in 2008 also show that the sensitivity and 
specificity of HRP2-based RDTs vary widely in clinical settings where the test is 
performed on febrile patients by trained health workers. Sensitivity was found to vary 
between 85 to 100%; and specificity varied from 90% to 100% [20, 22].  
Inconsistency in results of field trials are usually attributed to design limitations and/or 
may be due to a combination of the factors outlined above [22, 65, 137]. These 
inconsistencies hamper comparability of trials results and broader applicability in routine 
settings [22, 65, 137]. 
2.8.5 WHO product testing 
Inconsistency in results of field trials has led to the introduction of a WHO-led 
collaborative initiative of RDT product testing and quality assurance [20, 22, 65]. This 
initiative aims to standardise the assessment of RDT performance, to guide 
procurement decisions, and to drive improvement in the quality of manufacturing [20, 
22, 65]. Therefore, guidelines and standards have been introduced in order to 
standardise field components of sensitivity/specificity trials of malaria RDTs [65, 68, 
69]. Additionally, limited laboratory-based performance analyses of commercially 
available RDTs are conducted by testing assays against panels of malaria parasite-
infected blood samples. The evaluation is designed to provide comparative data on the 
performance of submitted production lots of RDTs; and to give an indication of which 
products are likely to give higher sensitivity in the field, especially in populations with 
low-density infections [22, 65].  
Product testing involves assessing each product in terms of (a) positivity rate (panel 
detection score), (b) false-positivity rate, and (c) heat (thermal) stability, and (d) ease of 
use [65, 69]. So far three rounds of product testing have been completed since 2006. 
Over the 3 rounds, several RDTs have demonstrated consistently high positivity rates at 
low parasite densities (200 parasites/ µL) [65]. Further, they have demonstrated low 
false positive rates, stability at tropical temperatures, easy-of-use, and ability to detect P. 
falciparum, P. vivax infections or both [65]. 
Laboratory-based studies do not fully depict the complexities and physical stresses to 
which a diagnostic test may be subjected to under field conditions [22]. Therefore, 
standardised field trials are still necessary. Further test performances vary between lots, 
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and widely between similar products, despite standardisation of procedures [65]. 
Therefore, the WHO recommends lot-testing post-purchase and prior to use in the field 
[65].   
Because of the likelihood of  inter-lot variability, the WHO strongly recommends that 
samples from each production lot should be tested pruior to dissemination to the field. 
Accordingly, additional to product testing initiative, the WHO, TDR and FIND support 
national programmes in assessing RDT lots prior to purchase [65]. 
.   
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2.8.6 Factors influencing utility of RDT-based policies in practice 
Several factors interact to determine the incremental cost and clinical outcomes of 
RDT-based policies relative to presumptive treatment of fever. The main factors include 
the diagnostic accuracy of RDTs in different malaria transmission settings, age profile of 
the target population, health worker adherence to RDT-based guidelines and prices of 
inputs—especially prices of RDTs relative to those of antimalarials used in treating 
uncomplicated malaria [21, 22, 138, 139]. Figure 6 displays how the various factors 
might interact to influence clinical outcomes and incremental cost in settings where 
RDT-based policies have replaced or might replace presumptive treatment of fever. 
There is need to quantify the benefits and incremental cost of RDT-based policies using 
analyses which take into account all these factors, and which use actual field data. Such 
analyses could provide more accurate insight into the value of RDT-based policies in 
different settings. 
a) Diagnostic accuracy of RDTs 
Sensitivity  
To be useful diagnostic tools, malaria RDTs in sub-Saharan Africa must achieve 
sensitivity for P. falciparum of at least 95% at parasite density of 100 parasites/µL of 
blood, or higher [20, 22, 139]. Clinical disease may occur at lower parasitaemia in a non-
immune population, such as those in low transmission settings and/or children under 5 
years of age [22]. Therefore, RDTs used in non-immune populations are required to 
maintain high sensitivity (at least 95%) at a concentration of 50 parasites/µL of blood 
[22]. The sensitivity of the currently available RDTs tends to fall far below 95% at 
parasite density lower than 100 parasites/µL of blood. Therefore, there is increased risk 
of morbidity or mortality from missed malaria cases in non-immune population. This is 
a key point of contention against scaling-up the use of RDT-supported guidelines in 
areas where presumptive treatment is currently the norm, especially for use in children, 
until sufficient evidence is provided to support their effectiveness [26, 138]. 
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Figure 6: Determinants of effectiveness and incremental cost of RDT-based policies  
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Specificity  
It is recommended that malaria RDTs must achieve specificity of at least 95% at parasite 
density of 100 parasites/µL of blood, or higher [20, 22, 139]. In high transmission 
settings, RDTs have lower specificity, particularly the HRP-2 type which is 
recommended for endemic high transmission countries [21, 22, 138, 139]. In these 
settings, febrile illnesses are commonly accompanied by parasitaemia and antigenaemia 
that are not related to the illness; and which may persist after initiation of anti-malarial 
therapy [21, 22, 138, 139]. Therefore, the number of false positive diagnoses averted in 
high transmission settings by a highly specific test is marginal. Accordingly, the cost of 
RDT per case of fever could exceed the drugs cost saving per case [21, 22]. Therefore, 
although a standard specificity of 95% is generally recommended [21, 22], lower 
specificity (>90%) is generally acceptable in high transmission regions [139].  
Because RDTs have low specificity in high prevalence areas, many Non-malarial Febrile 
Illnesses (NMFIs) are treated as malaria. The actual agents causing the fever may be left 
untreated, and the patients may deteriorate, because they are malaria parasite positive 
[138]. Therefore, use of RDTs in high transmission settings may not be beneficial from 
both economic and clinical stand points. 
In low prevalence settings, use of RDTs can avert a significant number of false positive 
diagnoses and overtreatment with ACT, which characterise presumptive treatment. 
Therefore, high specificity (at least 95%) is a necessity in low transmission areas [21, 22].  
b) Age group 
In children under 5 years of age, clinical disease may occur at parasite densities which 
are much lower than what the available RDTs are capable of detecting (e.g. < 50 
parasites/µL of blood) [22]. Therefore, compared to symptoms-based treatment, use of 
RDTs to guide treatment in febrile children could result in increased morbidity or 
mortality from missed malaria cases.  
Further, the amount of antimalarials saved in febrile children by the use of RDTs is 
much smaller than the amount saved in older patients. Therefore, the incremental cost 
of using RDTs in children may exceed the average drug cost savings, particularly in high 
prevalence areas [12, 80, 140]. Therefore, the net incremental cost of introducing RDTs 
in a particular setting depends on the age profile of the population in that setting. If the 
users of care in the setting are predominantly younger, RDT-based policies may add 
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cost to the health system relative to presumptive treatment [12, 140]. Analysis of 
incremental cost and effectiveness by age-group is useful in deciding whether or how to 
target RDT-based policies. 
c) Prices of inputs  
The net incremental cost of introducing RDT-based policies depends on the price of 
RDTs relative to the price of the antimalarials used for treating uncomplicated malaria. 
The higher the cost of RDTs relative to the price of antimalarials used, the less likely 
will the use of RDTs in treating febrile patients save any drug costs [12, 13, 141]. The 
recommended cost per test of RDT is US$ <1 for endemic countries [21, 22]. In 2010, 
the average price of P. falciparum-specific (HRP-2) RDTs was US$ 0.51 (range: 0.42 – 
0.88) and US$ 0.69 (range: 0.58 – 1.05) for multi-species test [142]. Two main types of 
ACTs are currently used in treating uncomplicated malaria in endemic countries: 
artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ) [142]. In 2011, the 
average price of an adult dose of AL was US$ 1.30 to US$1.40; and the average price of 
an adult dose of AS-AQ was US$ 0.78 to US$ 0.94 [142].  
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2.8.7 Economic evaluation of RDT-based guidelines 
This section reviews the economic evaluation studies that have thus far been undertaken 
to assess the economic potentials of applying RDT-based guidelines to manage febrile 
patients instead of presumptive treatment of cases. 
a) Definitions  
Full economic evaluation involves comparing the cost of interventions with their effects 
or outcomes. It takes the form of cost-effectiveness analysis (CEA), cost-minimisation 
analysis (CMA), cost-utility analysis (CUA), or cost-benefit analysis (CBA). In CEA, 
outcomes are described in their natural or physical units, e.g. number of deaths averted, 
number of patients cured. CMA is a form of CEA; it is undertaken when the outcomes 
of comparison interventions—e.g. the number of death averted—are the same or 
similar in magnitude. The outcomes in a CUA have two dimensions: length of life and 
the quality of life gained by an intervention. In CBA, outcomes are valued in financial 
terms [143].  
Partial economic evaluation takes many forms [143],  
a) Cost analysis, where interventions are compared in terms of cost only; costs are 
measured per units of outputs (e.g. number of participants diagnosed, treated 
etc) rather than per units of outcomes.  
b) Effectiveness analysis, interventions are compared in terms of their health outcomes 
only  
c) Cost-effectiveness description, where the cost of an intervention is compared with its 
outcome, in the absence of an alternative or comparison intervention 
d) Cost description, showing only the cost of an intervention, in the absence of  a 
comparator 
e) Effectiveness description, showing only the health outcomes of an intervention, in 
the absence of  a comparator 
Therefore, partial evaluations do not give the full picture of the economic worth of an 
intervention or comparison interventions. 
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b) Papers and search strategies 
The search strategy for this section is shown in Appendix 3 (c), search set 24. The 
review identified 4 CEA [72, 140, 144, 145] and 3 cost analysis papers4[12, 13, 33], 
evaluating the effects of RDT-supported treatment versus presumptive treatment of 
fever.  One CEA study was excluded from the review because the method was not clear 
[145]. Of the 6 studies included in the review, only one (cost analysis) used patient-level 
data from a randomised trial [33]. Two cost analysis studies used population-based 
(summary) data from on-going programmes [12, 13]. The remaining 3 (CEA) involved 
the use of models which used estimates of costs and outcomes from literature and 
expert opinion [72, 140, 144]. Table 7 summarises the main features and findings of the 
studies reviewed.  
c) Main features 
These microeconomic studies vary in design and range of inputs included in their 
analyses.  All studies are based on outpatients presenting with uncomplicated fevers and 
are carried out in the context of ACTs. All analyses assume providers‘ perspective. All 
studies, except one, assume perfect clinician adherence to guidelines; the exception is 
the study by Zurovac et al in 2008, which incorporates actual adherence data from a 
randomised trial [33]. All studies analyse variation in costs and outcomes under different 
scenarios of malaria prevalence, participant age, types of ACT and (in some studies) and 
the diagnostic accuracy of the RDT used in the study.  
d) Main findings 
Cost-saving 
All studies measured the degree of cost reductions attributable to the use of RDTs 
under different scenarios. The results suggest that use of RDT to guide the management 
of fever can reduce the cost of diagnosis and treatment by 21% to 25% in low to 
moderate malaria prevalence areas (<50% prevalence) [12, 13, 33, 72, 140, 144]. This is 
conditional on health workers adhering with the guidelines (using the test and treating 
according to the results) all or most of the time.  The analyses also show that use of 
RDT-guideline is unlikely to be cost-saving in high prevalence areas even if health 
workers comply with the guideline [12, 13, 33, 72, 140, 144].  All the analyses show that 
                                                          
4 All the cost analysis papers were reported as cost-effectiveness analyses 
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RDT-supported treatment is not cost-saving for children <5 years [12, 13, 33, 72, 140, 
144].  
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Table 7: Characteristics and findings from economic evaluation studies 
 
STUDY ID Objective & setting Design & parameters Perspective Inputs Participant Interventions Cost-savings Cost-effectiveness
Shillcutt et al 2008
Cost saving & Cost-
effectiveness of RDT vs PT 
in context of ACT; OPD, 
rural, SSA
Design: CEA using 
decision tree model;            
Parameter: age, 
accuracy of diag. test, 
malaria prevalence Providers
RDT, anti-
malarials, 
antibiotics, staff 
time, training, 
supervision 
outpatients, 
febrile
RDT vs PT, 
context of ACT 
(AL)
Probability of RDT saving 
cost at low to moderate 
prevalence (0% - 40%) is 70% 
to 80%
ICER = cost per DALY averted < $150     
95% certainty that RDT is cost-
effective at prevlence <62%; 50% 
certainty at prevalence <81%
Zikusooka et al 2008
Cost savings due to use of 
RDT, in the context of 2 
ACTs (AL, AS-SP), different 
malaria prevalence, 
different age sub-groups
Design: Micro-costing 
using population data; 
Parameter: age, 
accuracy of diag. test, 
malaria prevalence Providers
RDT & 
antimalarials only outpatients, febrile 
RDT vs PT, in the 
context of AL vs 
AS-SP
Cost saving at prevalence up 
to 52% for AL; up to 29% if 
cheaper ACT (ASSP) used; 
Not cost-saving in children
Zurovac et al 2008 
Cost savings due to use of 
RDTs, in the context of 2 
ACTs , different malaria 
prevalence, different age 
sub-groups
Design: micro-costing 
using patient-level 
data from an RCT. 
Parameter: age, 
accuracy of diag. test, 
malaria prevalence Providers 
RDT, ACT, 
antibiotics
outpatient febrile 
& afebrile; 5+ 
years RDTvs PT 
Cost reduction of up to 21% 
in moderate prevalence 
setting (26 - 38%); cost 
increase of 41% in low 
transmission setting
Rolland et al 2006
Cost saving due to use of 
RDT vs PT in context of ACT; 
OPD, in context of 
epidemics
Design: decision tree 
modelling;            
Parameter: age, 
accuracy of diag. test, 
malaria prevalence Providers
RDT, ACT, 
antibiotics outpatients febrile RDT vs PT
Cost saving at prevalence up 
to 55% for AL; up to 21% if 
cheaper ACT (ASAQ) used; 
Lubell et al 2008 (a)
Cost saving & Cost-
effectiveness of RDT vs PT 
in context of ACT; OPD
Design: decision tree 
model;            
Parameter: age, 
accuracy of diag. test, 
malaria prevalence Providers
RDT, ACT, 
antibiotics outpatients febrile RDT vs PT
RDT is cost-saving at low to 
moderate malaria 
prevalence (<50%)
At a DALY value of $ 150, use of RDT 
is preferred up to a prevalence of 
about 70%
Lubell et al 2008 (b)
Cost savings RDT, in the 
context of ACTs , different 
malaria prevalence, 
different age sub-groups
Design: decision tree-
based, interactive 
model            Parameter: 
age, accuracy of diag. 
test, malaria 
prevalence Providers
RDT, ACT, 
antibiotics, staff 
time, supervision outpatient, febrile RDT vs PT
Cost-savings: 30% in low 
prevalence; 25% in 
moderate prevalence; not 
cost-saving in children
ICER = cost perDALY averted < $150 
Cost-effective at low to moderate 
prevalence; not cost-effective at 
high prevalence; not cost effective 
in children
MAIN RESULTSCHARACTERISTICS OF STUDIES
AL: artemether-lumefantrine; ASSP: artesunate+SP; OPD: out-patients’ department;  PT; presumptive treatment; SSA: sub-Saharan Africa 
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Furthermore, the review indicates that the degree of cost saving is dependent on the 
range of inputs included in the analysis. When a broader range of inputs are included 
(antibiotics, staff time, supervision, training), then use of RDT is associated with a 
smaller degree of cost reduction, or is less likely to be cost-saving [72, 140]. Finally, the 
studies show that use of RDTs is more cost-saving when used in the context of more 
expensive anti-malarials [12, 13]. Use of RDT-based guidelines could be associated with 
added cost to the system as the price of anti-malarials falls. 
Notably, the Tanzanian trial-based study which incorporated actual data on clinician 
adherence shows the opposite picture. Whereas use of RDT-based guideline was 
associated with a 21% reduction in cost in settings with moderate malaria prevalence 
(26% - 38% prevalence), use of the same guideline was associated with a 41% increase 
in cost in settings with low malaria prevalence (0% to 1.5% prevalence) [33]. The reason 
for this was that health workers did not follow the RDT-based guideline in the latter 
setting. Most participants were prescribed anti-malarials either presumptively or despite 
having negative RDT results [33]. A CEA model developed by Lubell and colleagues in 
2008 shows that, at the level of anti-malarial prescribing to RDT-negative patients found 
in observational studies and trials, use of RDT-based policy could increase healthcare 
cost by 10% to 250%, depending on the transmission rate [144]. Therefore, the findings 
of the Tanzanian trial, and of the model by Lubell et al, underline the significance of 
clinician adherence in all malaria transmission settings if the objectives of RDT-based 
guidelines have to be realised. Therefore, investment in methods to improve adherence 
to guidelines is essential. 
Cost-effectiveness 
Three studies analysed and presented cost-effectiveness of RDT-based policy as the 
incremental cost per DALY averted by its use, relative to presumptive treatment [72, 
140, 144]. The DALY is a measure of health outcome that incorporates both premature 
death and morbidity or disability, including the harm of treatment. The DALY caused 
by a disease consists of the years of life lost (YLL) and the year of life lived with 
disability (YLD) [141, 143]. One DALY is valued at US$ 150. Therefore an intervention 
that costs <US$150 to avert 1 DALY is considered cost-effective [72, 140, 144].  
When health outcomes are measured in terms of broader measures such as the DALY, 
use of RDT-based guideline is likely to be cost-effective (95% certainty) at malaria 
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prevalences of up to 62% [72, 140, 144]. That is, the cost of averting 1 DALY due to 
fever is likely to be < US$150 within the malaria prevalence in the 0% to 62% range. At 
higher prevalence levels, the incremental cost per DALY averted is likely to be 
>US$150 [72, 140, 144]. 
e) Conclusion 
Use of RDT-based guideline is likely to be cost-saving and cost-effective if used in low 
to moderate malaria prevalence areas, as long as clinicians comply with the guidelines 
most of the time; and especially if RDT use is restricted to older patients. A fall in the 
price of anti-malarials may favour presumptive treatment. It is essential to quantify the 
potential clinical and economic impacts of RDT-supported policies using actual field 
data so that value for money can be accurately assessed.  
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2.9 Implementation of clinical guidelines in Africa 
This section reviews literature on the quality of implementation of clinical guidelines in 
the African context. It shows how the components of healthcare process evaluated can 
affect the reported quality of implementation. The search strategy for this chapter, 
including the electronic databases, has been described in section 2.2. The search strategy 
for this section is shown in Appendix 3 (d), search set 38. The review included studies 
which assessed implementation of any clinical guideline in Africa between 1990 and 
Sept 2011.  
2.9.1 Main features of studies reviewed 
Table 8 below describes the relevant features of the studies included in the analysis.  
Table 8: Characteristics of the studies included in the meta-analysis 
N Characteristics 
No. of 
studies References 
1 No of studies (total) 15  
 
 
W. Africa  6 [113-118] 
 
 
E. Africa  4 [62, 92, 111, 112] 
 
 
S. Africa  3 [91, 109, 110]  
 
 
N. Africa  1 [90] 
 
 
C. Africa  1 [108] 
 
3 Guidelines considered by study 
 
 
 
 
IMCI-related 8 
[62, 90, 92, 109, 113, 115, 
117, 118] 
 
 
IMCI + malaria 1 [112] 
 
 
Fever/malaria 4 [91, 108, 112, 146] 
 
 
Other disease-specific 1 [110] 
 
 
INRUD 1 [114] 
 
4 Procedures assessed by study 
 
 
 
 
Assessment only 2 [114, 118] 
 
 
Treatment only 7 [91, 108-112, 116]  
 
 
Assessment, classification and treatment 2 [62, 115] 
 
 
Assessment, classification, treatment and 
counselling 
4 [90, 92, 113, 117]  
 
5 Methods for data collection  
 
 All 15 studies used a combination of clinical observation, interview of HW and clients, and 
review of records (both clinical and inventory of supplies) 
 
6 Adjustment for clustering and weighting  
 
      Not indicated 4 [109, 110, 114, 118] 
      In all the remaining studies, results  were adjusted  using different methods  
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a) Number and settings 
Fifteen studies were included in the analysis of adherence scores, 13 of which were from 
West, East, and Southern Africa.  
b) Design 
Majority (13/15) of the studies were observational (cross-sectional surveys). Two studies 
were cluster randomised trials (cRCTs) designed to evaluate effects of interventions on 
the quality of guidelines implementation—consisting of pre- and post-intervention 
assessments of performance. For these 2 cRCTs, only the pre-intervention results are 
synthesised in this section. The post-intervention results are synthesised in the following 
section that examines the effect of various interventions on the quality of guidelines 
implementation.  
c) Types of guidelines included in studies  
Nine of the studies assessed adherence to guidelines for Integrated Management of 
Childhood Illness (IMCI): in their original forms, or modified versions, or alongside 
other guidelines. Four studies assessed adherence to guidelines targeting fever/malaria 
management; while one study considered a guideline targeting 4 other specific 
conditions. One study assessed adherence to a guideline developed in the framework of 
International Network on Rational Use of Drugs (INRUD), covering all age groups and 
conditions.  
d) Components of healthcare assessed by studies  
Approximately half of the studies (7/15) assessed adherence in terms of treatment-
diagnosis match only. Few (4/15) studies assessed all 4 components of care: assessment, 
classification, treatment and counselling. 
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2.9.2 Measure of performance 
The studies reviewed present performance in form of a score, defined as the percent of 
all the expected tasks that were performed as per the guidelines under review. They 
provide adherence scores for individual procedures and/or for all the procedures 
combined. In addition, they provide the raw data used in the calculations. This review 
uses the raw data extracted from the reviewed studies to calculate performance scores 
for the components of guidelines assessed. Calculations were undertaken using MS 
Excel 2007. The 95% Confidence Interval (CI) around the scores were calculated using 
the formula for CI for single proportions [147], namely: 
 
CI = p ± z*      
Where: z = z-score (1.96 for 95% CI) 
 p = performance score (percent of tasks performed as per 
guidelines) 
 q = (1-p) 
n = total number of tasks analysed  
  
 71 
 
2.9.3 Main findings 
a) Average scores within and across studies 
A total of 52,678 tasks were analysed, out of 16,480 consultations (average of 3.2 
assessment tasks per consultation). Figure 7 below shows the combined performance 
scores (percent of required tasks performed) for individual studies, and for all the 
studies combined.  
Figure 7: Percent of required tasks performed by studies, with 95% confidence interval 
  
 
The percent of clinical tasks performed as required by the guidelines evaluated varies 
widely, from 26.7% to 79.8%. The combined performance score for all the included 
studies is 48.6%; that is, of the 52,678 tasks analysed, 48.6% were performed according 
to the recommendations of the guidelines evaluated by the reviewed studies. The 
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variability is partly explained by the variability in the types of guidelines reviewed, and by 
the variability in the number and types of procedures and tasks assessed. 
b) Procedures assessed and adherence by specific procedures 
Table 9 below shows the different components of the healthcare process evaluated by 
the studies reviewed, and the combined performance scores for the procedures 
evaluated.  
Four types of clinical procedures were examined by the 15 studies, in various 
combinations:  
i) Assessment, comprising medical history taking and clinical examination 
ii) Classification (diagnosis) 
iii) Treatment (treatment-diagnosis match) 
iv) Counselling (advising clients on treatment) 
Table 9: Tasks performed as required by types of procedures 
Procedures assessed by studies 
Number of studies 
included in the synthesis 
Number 
of tasks 
Tasks performed as required 
Average (95% CI) 
Assessment  6* 23,863 49.8% (49.3% - 50.3%) 
Classification  4* 2,019 38.8% (37.8% - 41.0%) 
Treatment  13 17,814 57.5% (57.2% - 58.3%) 
Counselling  4 8,987 30.3% (29.8% - 31.2%) 
* Studies that provided procedure-specific performance scores are fewer than the total number of studies that assessed the specified 
procedure; some studies provided only average scores for all the procedures combined.  
 
Most (13/15) of the studies reviewed evaluated the quality of treatment as an indicator 
of HW performance—either as the sole indicator of performance (7/15 studies) or 
alongside other components of care. Fewer studies included other aspects of care 
(assessment: 6 studies; classification: 4 studies; counselling: 4 studies).  
The highest performance scores relate to the quality of treatment. Overall, the treatment 
prescribed across the 13 studies matched patient classification 57.5% of the time [62, 
90-92, 108-113, 115-117]. The most problematic procedure was counselling, which was 
performed as expected 30.3% of the time [90, 92, 111, 113]. Patients were classified 
correctly 38.8% [90, 92, 114, 115], while assessment was carried out as expected 49.8% 
of the time [90, 92, 111, 113, 114, 118]. Since performance varies by procedures, the 
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average performance score reported by a study is likely to be influenced by the 
combination of procedures assessed. 
c) Adherence by combination of procedures assessed 
Table 10 below shows the various combinations of procedures included by the reviewed 
studies and the performance scores for the different combinations of procedures.  
Table 10: Percent of tasks performed by number of procedures assessed 
Procedures assessed by 
studies 
Number of 
studies  
Number of 
consultations 
Number 
of tasks 
Tasks performed as required 
Average (95% CI) 
Assessment only 2 2296  7231 44.4% (43.9% - 45.2%) 
Treatment only 7 6402  16,454 49.9% (49.5% - 50.7%) 
Assessment, classification, 
treatment 2 776  10,312 45.9% (45.5% - 46.9%) 
Assessment, classification, 
treatment & counselling 4 7,006  9,631 39.9% (39.4% - 40.9%) 
 
Results from studies which evaluated the quality of treatment alone show that health 
workers performed tasks according to guidelines 49.9% of the time [91, 108-110, 112, 
116]. However, studies which evaluated 3 or 4 components of the health care process 
report lower performance scores. For example, studies that included all the 4 
dimensions of the health care process show that health workers performed tasks 
according to guidelines only 39.9% of the time [90, 92, 113, 117]. 
Therefore, studies that measure performance in terms of treatment-diagnosis match 
only are likely to report a higher quality of performance than is the case when more or 
all aspects of the healthcare process are assessed. 
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2.9.4 Conclusion 
The review shows that the quality of guideline implementation varies widely in Africa. 
This could be due in part to the variability in the types of guidelines assessed, and to the 
variability in the number and types of procedures assessed by the studies reviewed. 
Performance scores were high for prescribing (treatment) and low for other 
components of guidelines. Accordingly, studies which assessed the quality of prescribing 
alone showed better performance scores than studies that assessed the quality of 
implementation of three or more components of guidelines. Assessments based on the 
quality of prescribing alone fail to specify the diagnostic quality of the healthcare 
process, which itself might be inadequate. 
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2.10 Effects of interventions—African context 
This section presents a synthesis of evidence from Africa on the effects of various 
interventions on the quality of implementation of various clinical guidelines. The search 
strategy for this section is shown in Appendix 3 (d), search set 39. The review included 
all studies assessing the effects of various interventions on implementation of any 
clinical guideline in Africa between 1990 and Sept 2011.  
Raw data were extracted from included studies and analysed using Revman 5.1 [148]. 
The studies analysed presented estimates of effects in the form of Odds Ratios (OR) 
and 95% CI. Accordingly, the results of these meta-analyses are presented in the form 
of Odds Ratios (OR) and 95% CI. Estimates of effects of interventions were pooled 
using Mantel-Haenszel method because some studies were quite small and event rates 
sparse. Results were analysed using random-effects analysis because of the variability in 
estimates of effects of the interventions. Random-effects methods assumes that 
variability in results is the result of systematic difference between studies and not due to 
random errors [99]. 
 
The review investigated consistency of effects across various studies and explored the 
causes of any heterogeneity in estimates of effects of interventions. Thus the review 
applied the Chi2 test for heterogeneity with a 10% level of statistical significance, and the 
I2 statistic with value of 0% to 40% representing an insignificant level of heterogeneity; 
values of >40% to 60% to denote moderate levels of heterogeneity; values >60% to 
80% to represent substantial levels of heterogeneity; and values >80% to represent 
considerable heterogeneity—as recommended in the ―Cochrane handbook for 
systematic reviews of interventions‖[99]. 
2.10.1 Training  
Several studies have evaluated the effects of pre-service and in-service training on the 
quality of guideline implementation in Africa between 1998 and 2010, the results of 
which are reviewed below.  
a) Pre-service training (staff qualification) 
Four studies evaluated the effect of pre-service training on the quality of 
implementation of guidelines in Africa. In this analysis, Health Worker (HW) 
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qualifications are used as a proxy to the types of pre-service (basic) training received by 
them. HW qualifications are grouped into two categories, namely ―skilled staff‖ and 
―auxiliary staff‖. The ―skilled staff‖ category comprised nurses/midwives, clinical 
officers/medical assistants, and doctors; and the ―auxiliary staff‖ category consisted of 
nursing aides/nursing assistants and other paraprofessional staff generally labelled as 
auxiliary staff. Figure 8 below shows the number of tasks performed according to 
guidelines by skilled staff versus auxiliary staff. 
 
Figure 8: Effect of staff qualification on the number of tasks performed as per guidelines 
 
 
Overall, performance scores were higher amongst auxillary staff than among skilled 
staff. Three of the studies detected significant association between being an auxiliary 
staff and performing a task as recommended in the guideline under review [90, 112, 
146]. Krause and colleagues did not detect a significant association between staff 
category and performance [114].  
Implications for practice: in Uganda, RDT-based guideline has been inroduced at HCIIs, 
which are manned largely by paraprofessional staff (nursing assistants). The lower 
qualification of the majority of staff in such settings could lead to more effective 
implementation of RDT guidelines.  
b) In-service training 
Eight studies compared the performance of health workers who were trained on the use 
of the guidelines prior to introducing them into the health system, versus those who 
were not trained. The results are summarised in Figure 9 below.  
Study or Subgroup 
Krause, 1998 
Naimoli, 2006 
Rowe, 2003 
Zurovac, 2004 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 15.26, df = 3 (P = 0.002); I² = 80% 
Test for overall effect: Z = 2.40 (P = 0.02) 
Events* 
141 
130 
157 
511 
939 
Total** 
486 
295 
260 
953 
1994 
Events* 
96 
100 
26 
37 
259 
Total** 
310 
150 
29 
53 
542 
Weight 
31.4% 
29.4% 
13.9% 
25.3% 
100.0% 
M-H, Random, 95% CI 
0.91 [0.67, 1.24] 
0.39 [0.26, 0.59] 
0.18 [0.05, 0.60] 
0.50 [0.27, 0.91] 
0.49 [0.27, 0.88] 
Skilled staff Auxiliary staff Odds Ratio Odds Ratio 
M-H, Random, 95% CI 
0.01 0.1 1 10 100 
Favours auxiliary staff Favours skilled staff 
*Events: number of tasks performed as per guidelines 
** Total: Total number of tasks assessed 
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Figure 9: Effect of in-service training on the number of tasks performed as per guidelines  
 
Overall, performance scores were significantly higher at facilities where the health 
workers were trained prior to introducing the guidelines than at facilities where they 
were not. There was considerable variability in effects of the intervention (I2 = 94%, 
P<0.00001). Four studies detected significant association between in-service training 
and the number of tasks performed according to guidelines [90, 108, 117, 146]. The rest 
of the studies did not detect significant association between in-service training and the 
number of tasks performed as per guidelines [91, 93, 149, 150].  
The reasons for the variability in results could be the same as given above (variability in 
the types of guidelines reviewed, and in the number and types of procedures and tasks 
assessed). The variability in results could also be explained by a possible variation in the 
quality of in-service trainings, and by the amount of time elapsed between the training 
and the studies. In most studies, assessment of implementation was done between 1 and 
5 years after the initial training. Human capital theory suggests that knowledge acquired 
through training decays over time, especially if not backed-up by refresher training 
and/or constant practice [59].  
c) Refresher training 
Rowe and colleagues analysed the trend in clinicin adherence to IMCI guidelines in 
Kenya over a period of time, and the effect of refresher training on performance over 
time [62].  
 
Study or Subgroup 
Naimoli, 2006 
Osterholt, 2006 
Osterholt, 2009 
Rowe, 2000 
Rowe, 2003 
Rowe, SY 2007a 
Rowe,2009 
Zurovac, 2004 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 123.85, df = 7 (P < 0.00001); I² = 94% 
Test for overall effect: Z = 2.00 (P = 0.05) 
Events* 
184 
185 
24 
26 
59 
144 
173 
322 
1117 
Total** 
231 
264 
55 
68 
79 
181 
265 
499 
1642 
Events* 
42 
62 
10 
76 
124 
62 
30 
252 
658 
Total** 
214 
85 
33 
136 
210 
85 
119 
507 
1389 
Weight 
12.8% 
12.6% 
11.2% 
12.4% 
12.5% 
12.4% 
12.8% 
13.3% 
100.0% 
M-H, Random, 95% CI 
16.03 [10.07, 25.53] 
0.87 [0.50, 1.50] 
1.78 [0.71, 4.44] 
0.49 [0.27, 0.89] 
2.05 [1.15, 3.64] 
1.44 [0.79, 2.63] 
5.58 [3.43, 9.06] 
1.84 [1.43, 2.37] 
2.12 [1.01, 4.42] 
Trained on guideline Not trained Odds Ratio Odds Ratio 
M-H, Random, 95% CI 
0.01 0.1 1 10 100 
Favours control Favours in-service 
training *Events: number of tasks performed as per guidelines 
** Total: Total number of tasks assessed 
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Figure 10: Treatment adherence scores over time relative to second refresher training (IMCI 
guideline) 
 
Note: quarters = quarter of a year 
Source: SY Rowe (2007) [62] 
The findings from their analysis (Figure 10 above) show that adherence to IMCI 
guideline declined steadlily following initial in-service training. The first refresher 
training led to improvements in adherence, above the level observed after the initial (in-
service) training. However, the second refresher training was followed by a decline in 
treatment adherence scores. Therefore, whilst refresher training may help to reduce the 
rate of forgetting, the effectiveness of multiple refresher trainings is questionable. 
However, the results may have been due to random error or bias given that there were 
considerably fewer observations post second refresher training, a single study source 
and likely design effect. 
2.10.2 Availability of guidelines 
Figure 11 below shows the results from 5 studies which investigated the effect of 
availability of guidelines at health facilities on the quality of guideline implementation. 
The studies compare HW performance at facilities with guidelines on the day of the 
survey versus those at facilities without guidelines on the day of the survey.   
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Figure 11: Effect of availability of guidelines on number of tasks performed as per guidelines 
 
The results from the 5 studies are mixed (I2 = 92%, P<0.00001). Two studies reveal 
significantly lower performance scores at facilities with job aids than at facilities without 
[114, 150]. Three studies show siginificantly higher performance scores at facilities with 
job aids than those without job aids [93, 112, 146].  
2.10.3 Availability of essential drugs 
Three studies investigated the association between availability of essential drugs at 
surveyed facilities and the quality of guideline implementation. Essential drugs were 
those deemed by the studies as being necessary in providing the basic health services 
which were specified in the guidelines assessed. They are not detailed in this review. The 
results from the studies are summarized in Figure 12 below. 
Figure 12: Effect of availability of essential drugs on number of tasks performed as per guidelines 
 
Two studies detected no association between availability of indicator drugs at surveyed 
facilities and the number of tasks performed according to guidelines [93, 150]. One 
study detected significantly higher performance scores at facilities where indicator drugs 
were not available on the survey day than at facilities where the drugs were available on 
Study or Subgroup 
Rowe, 2000 
Rowe, SY 2007a 
Zurovac, 2004 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 3.57, df = 2 (P = 0.17); I² = 44% 
Test for overall effect: Z = 1.62 (P = 0.11) 
Events* 
74 
83 
297 
454 
Total** 
150 
104 
573 
827 
Events* 
28 
69 
282 
379 
Total** 
54 
87 
433 
574 
Weight 
24.9% 
21.0% 
54.2% 
100.0% 
M-H, Random, 95% CI 
0.90 [0.49, 1.68] 
1.03 [0.51, 2.09] 
0.58 [0.45, 0.74] 
0.73 [0.50, 1.07] 
Drugs available Drugs not available Odds Ratio Odds Ratio 
M-H, Random, 95% CI 
0.01 0.1 1 10 100 
Favours absence 
of essential drugs 
Favours availability of 
essential drugs 
*Events: number of tasks performed as per guidelines 
** Total: Total number of tasks assessed 
Study or Subgroup 
Krause, 1998 
Rowe, 2000 
Rowe, 2003 
Rowe, SY 2007 
Zurovac, 2004 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 49.10, df = 4 (P < 0.00001); I² = 92% 
Test for overall effect: Z = 0.66 (P = 0.51) 
Events* 
136 
5 
133 
133 
187 
594 
Total** 
378 
25 
183 
167 
276 
1029 
Events* 
28 
97 
50 
385 
385 
945 
Total** 
54 
179 
106 
730 
730 
1799 
Weight 
20.1% 
16.0% 
20.6% 
21.3% 
22.0% 
100.0% 
M-H, Random, 95% CI 
0.52 [0.29, 0.93] 
0.21 [0.08, 0.59] 
2.98 [1.80, 4.92] 
3.51 [2.34, 5.25] 
1.88 [1.41, 2.52] 
1.29 [0.61, 2.73] 
GL available GL not available Odds Ratio Odds Ratio 
M-H, Random, 95% CI 
0.01 0.1 1 10 100 
Favours absence of 
guidelines 
Favours availability 
of guidelines 
*Events: number of tasks performed as per guidelines 
** Total: Total number of tasks assessed 
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the survey day[112]. Overall, availability of indicator drugs did not seem to have an 
effect on the quality of guideline implementation.  
2.10.4  Supervision  
a) Frequency of supervision  
Seven studies investigated the effect of supervision frequency on the quality of guideline 
implementation by comparing the performance scores for health workers who had 
received variable number of supervision visits over the 6 months prior to the survey. 
This analysis compares the performance scores for health workers supervised at least 
once during the 6 months prior to the survey versus the scores for HWs not supervised 
at all during the same period. The results are summarised in the Figure 13 below.   
 
Figure 13: Effect of frequency of supervision on number of tasks performed as per guidelines 
 
Overall, supervised health workers performed better than unsupervised health workers. 
However, there was considerable variability in estimates of effects of the intervention (I2 
=93%, P<0.00001). Four studies detected statistically significant difference in 
performance scores among the two groups of HWs, all of which were in favour of 
supervised health workers [93, 112, 117, 146]. However, only two of these detected a 
difference that was clinically significant (Rowe 2009: OR = 12.78, 95% CI: 7.14 to 
22.84; Zurovac 2004: OR = 2.06, 95% CI: 1.57 to 2.70). Three studies detected no 
significant association between performance frequency of supervision [90, 108, 149]. 
b) Quality of supervision  
Three studies evaluated the effect of quality of supervision on the quality of guideline 
implementation [91, 110, 150]. ―Quality‖ supervision was defined as a supervisory visit 
Study or Subgroup 
Naimoli, 2006 
Osterholt, 2009 
Rowe, 2000 
Rowe, 2003 
Rowe, SY 2007b 
Rowe,2009 
Zurovac, 2004 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 82.96, df = 6 (P < 0.00001); I² = 93% 
Test for overall effect: Z = 2.76 (P = 0.006) 
Events* 
60 
19 
79 
123 
3983 
113 
430 
4807 
Total** 
123 
34 
158 
166 
4964 
146 
698 
6289 
Events* 
22 
12 
23 
60 
1701 
26 
135 
1979 
Total** 
52 
31 
46 
123 
2187 
123 
308 
2870 
Weight 
13.6% 
10.9% 
13.6% 
14.8% 
16.7% 
14.2% 
16.2% 
100.0% 
M-H, Random, 95% CI 
1.30 [0.68, 2.50] 
2.01 [0.75, 5.40] 
1.00 [0.52, 1.93] 
3.00 [1.83, 4.93] 
1.16 [1.03, 1.31] 
12.78 [7.14, 22.84] 
2.06 [1.57, 2.70] 
2.18 [1.25, 3.77] 
Supervised Unsupervise
d 
Odds Ratio Odds Ratio 
M-H, Random, 95% CI 
0.01 0.1 1 10 100 
Favours not being 
supervised 
Favours being 
supervised 
*Events: number of tasks performed as per guidelines 
** Total: Total number of tasks assessed 
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during which the supervisor observed and gave feedback on the health worker‘s 
performance. Figure 14 summarises the results from the three studies.  
Figure 14: Effect of quality of supervision on number of tasks performed as per guidelines 
 
The 3 studies did not detect a significant association between HW performance and the 
quality of supervision (receiving or not receiving feedback) (OR = 1.02; 95% CI: 0.61 to 
1.72; N = 265; 3 studies).  
2.10.5 Conclusion  
Evidence from Africa suggests that a variety of interventions can improve the quality of 
guideline implementation. However, their effects are widely variable and may be context 
specific. Notably, the evidence suggests that paraprofessional staff are likely to comply 
with clinical guidelines better than professional staff. The evidence from this review 
underscores the significance of in-service training as a predictor of effective guideline 
implementation. However, the effect of in-service training on the quality of guideline 
implementation appears to be short-lived. Whilst refresher training may help to reduce 
the rate of forgetting, the effectiveness of multiple refresher trainings seems 
questionable—although these results need to be intepreted with caution as it is based on 
a single study source, with considerably fewer observations post second refresher 
training, and because of a likely design effect. 
It is not clear from the available evidence if availability of guidelines at facilities has a 
sigificant bearing on health worker performance. However, availability of indicator 
drugs does not seem to have any effect on health worker adherence to guidelines. While 
the evidence suggests that exposure to supervision can improve the quality of guideline 
implementation, the quality of supervision (in terms of providing feedback to health 
workers) does not seem to be an important factor.  
  
Study or Subgroup 
Osterholt, 2006 
Rowe, 2000 
Trap, 2001 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 3.45, df = 2 (P = 0.18); I² = 42% 
Test for overall effect: Z = 0.07 (P = 0.94) 
Events* 
36 
27 
65 
128 
Total** 
48 
49 
120 
217 
Events* 
24 
52 
76 
152 
Total** 
36 
109 
120 
265 
Weight 
21.7% 
33.9% 
44.4% 
100.0% 
M-H, Random, 95% CI 
1.50 [0.58, 3.89] 
1.35 [0.68, 2.65] 
0.68 [0.41, 1.15] 
1.02 [0.61, 1.72] 
Supervision with feedback Sup with no feedback Odds Ratio Odds Ratio 
M-H, Random, 95% CI 
0.01 0.1 1 10 100 
Favours supervision 
with no feedback 
Favours supervision 
with feedback 
*Events: number of tasks performed as per guidelines 
** Total: Total number of tasks assessed 
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2.11 Summary of literature review 
The diffusion model (2.3) specifies the type and sequence of research required in 
assessing the value and applicability of a new healthcare technology before 
dissemination for routine use. It identifies specific attributes for assessment at each level 
of research, which is useful in assessing complex healthcare interventions such as the 
RDT-based guideline. The Diffusion of innovation model is complimented by the 
Donabedian model of health systems performance (2.5.2) which shows the causal 
linkage between structural, process and outcomes attributes of quality.  
Several levels and types of research are required in assessing a technology, from product 
development (phases 1 and 2) through to demonstration (phase 5). With regard to 
RDTs, extensive phase 1 and phase 2-level evaluations (product developments and the 
quality of manufacturing) have already taken place and are on-going (2.4). The current 
question is whether RDT-based guidelines can be effective in clinical settings and if they 
can be implemented sufficiently in clinical practice. Therefore, this thesis focuses on 
phase 3 through 5- level research (efficacy, effectiveness and implementation), basing on 
the current debates and theory.  
A systematic review of RCTs was chosen to evaluate efficacy of the intervention 
because it was not feasible to undertake an RCT in the context of this thesis due to 
financial and time constraints. RCTs are considered the best design for attributing 
outcomes to an intervention. However, the literature suggests that RCTs are 
characterised by several methodological limitations that may limit the power of RCTs to 
detect effects of a complex intervention. In particular, the Donabedian model of health 
systems performance suggests that the causal linkage between a complex public health 
intervention such as the one under evaluation, and clinical outcomes, is weak and may 
be difficult to demonstrate by means of an RCT. The thesis draws from this knowledge 
in discussing results of chapter 3 (assessment of efficacy) and in chapter 6 (general 
discussion). RCTs are also critcised for the potential threats to external validity of 
evidence. In the context of this thesis, knowledge of efficacy is necessary to aid 
interpretation of evidence from effectiveness trials. Therefore, this limitation is 
irrelevant. A systematic review has the advantage that it can pool together a variety of 
evidence from a broader context. As such, it might represent the best evidence for 
decision making at a broader level. Literature suggests that systematic reviews can lead 
to generalisable conclusions by identifying similar effects in various populations.  
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In sub-section 2.5.5 the literature proposes a number of quasi-experimental designs 
which can be used in assessing effectiveness of an intervention, such as basic pretest-
posttest design, control-group pretest-posttest design, and intervention versus control 
group comparison. The Ugandan effectiveness trial (chapter 4) used a control-group 
pretest-posttest design which is useful in assessing the role of maturation and history. 
Demonstration studies can show the extent to which various elements of a multi-
component intervention are actually implemented. In addition, it can identify key factors 
within the user system which can affect implementation of the policy in routine 
practice—which may need to be investigated, or which may need to be addressed prior 
to or during wide-scale implementation (2.3). For example, guideline implementation 
may reflect structural challenges (e.g. availability of relevant inputs, support training and 
supervision, policies and patients' expectations). However, according to Donabedian 
model of systems performance (2.5.2), compliance with structural standards does not 
mean that high quality care is being provided; nor does their use in quality assessment 
imply that high quality care cannot be provided unless these standards are complied 
with. Knowledge of the validity of the causal linkage between structure, process and 
outcomes is useful in interpreting results of chapters 3, 4 and 5. 
The literature describes implicit and explicit methods used in measuring HW 
performance, and indicates that explicit methods such as the LQAS are much more 
strict and action-oriented (2.5.2). LQAS method is used in chapter 5 to assess guideline 
implementation. The LQAS method has several advantages over implicit methods 
which measure quality in terms of point estimates (e.g. percent, averages). Judgement of 
quality is based on explicit pre-set standards, which allows the identification of poorly 
performing HWs or areas that require urgent action.  
In section 2.7, the literature provides an overview of several biologic malaria diagnostics 
that have emerged over the last 100 years. Their application in rural clinical settings has 
been limited, mainly by technical capacity constraints and cost. Section 2.8 describes the 
RDT technology, types, factors influencing performance, performance in field trials, and 
the WHO product testing initiative. It provides an overview of factors affecting utility 
of an RDT-based policy in practice and reviews economic evaluation studies of RDT-
based treatment relative to symptoms-based treatment. It shows that the potential 
effects of RDT-based policies depends on a number of factors, including the type of 
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assay, its diagnostic accuracy, HW adherence, malaria endemicity, and population 
profiles. Several reviews indicate that RDTs may fail to achieve the desired sensitivity of 
95% at parasite density of ≥ 100 parasite/100 µL of blood even under controlled trials 
conditions. Errors in using RDTs in routine practice could significantly exacerbate the 
diagnostic accuracy of RDTs. Use of RDT-based guideline is likely to be cost-saving and 
cost-effective if used in low to moderate malaria prevalence areas, as long as clinicians 
comply with the guidelines most of the time; and especially if RDT use is restricted to 
older patients. A fall in the price of anti-malarials may favour presumptive treatment.  
The effect of various factors on the utility of RDT-based policies was explored in the 
analysis in chapter 4. The influence of malaria endemicity informed the selection of 
districts (from both high and low prevalence districts) for the survey of practice in 
chapter 5. 
Section 2.9 reviews implementation of guidelines in African context. Several studies 
indicate that the quality of guideline implementation varies widely. Studies vary in the 
components of guidelines assessed. Studies assessing fever-oriented guidelines 
frequently focus on the quality of prescribing, which tends to overestimate the quality of 
implementation. Further, studies frequently use implicit measures of performance. 
Evidence from Africa also suggests that a variety of interventions can improve the 
quality of guideline implementation (2.10). The interventions consist of factors outlined 
in the diffusion of innovation and the Donabedian models and are usually assessed in 
surveys of fever-oriented guidelines. They have been assessed in the survey in chapter 5. 
Paraprofessional staff are likely to comply with clinical guidelines better than 
professional staff. Support services such as in-service training and supervision are 
generally associated with improved HW adherence to guidelines. The effect of in-service 
training on guideline implementation appears to be short-lived; hence the need for 
refresher training and experiential learning. Availability of guidelines at facilities appears 
to have mixed effects on guideline implementation, while availability of essential drugs 
may to have no significant influence on guideline implementation.  
Information from sections 2.9 and 2.10 are used in discussing results in chapter 5. 
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Chapter 3  Effects of RDT-based Policy on quality of 
care under optimal conditions 
3.1 Introduction 
The purpose of this chapter is to determine if RDT-based policies can lead to better 
quality of patient care relative to treatment based on clinical judgement, when delivered 
under carefully controlled conditions. To answer this question, the chapter synthesises 
evidence from randomised trials which compare the effects of treatment protocols 
based on results of RDTs for malaria versus treatment based on clinical diagnosis of 
people with fever. A new technology may be ineffective in real-world settings because it 
is not efficacious [40]. Once a new technology is shown to be efficacious under optimal 
conditions, it is then useful to carry out larger more pragmatic studies to assess if it can 
be effective in actual practice, and to carry out health services research to evaluate the 
quality of implementation of the intervention in actual practice [40, 41, 50].  
3.1.1 Research question 
Do carefully controlled trials show that treatment policies for treating fever which are 
based on RDT results lead to better quality of care than treatment based on clinical 
judgement? 
3.1.2 Aim 
To review evidence from RCTs to determine if RDT-based policies for fever lead to 
better quality of patient care than presumptive treatment under optimal conditions 
3.1.3 Objectives   
1) To establish the quality of implementation of RDT-based policies under optimal 
conditions 
2) To compare the effects of treatment policies using RDTs versus clinical 
judgement in treating febrile patients in malaria endemic areas 
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3.2 Methods   
3.2.1 Analyses undertaken in this review 
Table 11 provides a summary of the evidence synthesized in this chapter from the trials 
included in the review. 
Table 11: Summary of results synthesised in this review 
Variables  Analyses  
Implementation HW response to negative RDT results  
Primary 
outcomes 
Patients still unwell at day 4+ of follow-up 
Patients prescribed any anti-malarials 
Secondary 
outcomes 
Patients prescribed antibiotics 
Slide positive cases missed by RDTs 
Slide negative cases prescribed antimalarials 
 
3.2.2 Criteria for considering studies for this review   
Studies fulfilling the following characteristics were selected for the review: 
a) Design: individual and cluster randomised trials  
b) Interventions: trials comparing clinical protocols based on RDTs for fever 
versus protocols based on clinical diagnosis of malaria. Trials comparing RDT-
based protocols versus microscopy-based protocols were excluded, except if 
they included clinical diagnosis as a second comparison. 
c) Participants: trials comparing the 2 protocols (in (b) above) in outpatients with 
fever, or with a history of fever in the preceding 48 hours; or outpatients 
suspected to be having malaria by clerking clinicians. The review focuses on 
malaria in endemic areas. Trials conducted in non-endemic areas (e.g. fever in 
travellers in Europe) were excluded. 
d) Outcomes: trials evaluating any of the following outcomes:    
Primary outcomes   
1. Patients still unwell at day 4+ of follow-up 
2. Patients prescribed any anti-malarials 
Secondary outcomes   
1. Patients prescribed antibiotics 
2. Microscopy-negative patients prescribed anti-malarials 
3. Microscopy-positive patients not prescribed anti-malarials 
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3.2.3 Search methods for identification of studies   
We attempted to identify all relevant studies regardless of language or publication status 
(i.e. published, unpublished, in press, and ongoing). 
a) Electronic searches   
We searched the following databases on 26 January 2011 and on 28 October 2011, using 
the search term described in Appendix 4: (a) Cochrane Infectious Disease Group 
Specialized Register, (b) Cochrane Central Register of Controlled Trials (CENTRAL), 
published in The Cochrane Library (2011 issues 1&4), (c) MEDLINE, (d) EMBASE, (e) 
CINHAL, (f) PschINFO, and (g) Science Citation Index.   
In addition we searched the metaRegister of Controlled Trials (mRCT) and the WHO 
trials register using ―malaria‖ AND ―rapid diagnostic test*‖ OR ―presumptive 
treatment‖ as search terms (26 January 2011 & 28 October 2011).   
This search strategy yielded a total 233 abstracts of trial reports, after removing 
duplicates (first search: 202; repeat search: 31); and 8 records of on-going trials. Table 12 
summarises the sources searched and the hits retrieved from each. 
Table 12: Electronic databases searched and hits retrieved 
SOURCE 
Hits Retrieved 
January 2011 October 2011 TOTALS  
REPORTS    
  Cochrane Infectious Disease Group Specialized Register 21 13 34 
  MEDLINE (PubMed) 239 64 304 
  EMBASE  59 10 69 
  Cochrane CENTRAL  150 3 153 
  Science Citation Index 116 24 140 
  PsycINFO 0 1 1 
  CINHAL 5 9 14 
  Final number of records in database      
before deleting duplicates & irrelevant titles 590 124 715 
after deleting  duplicates and irrelevant titles 202 31 233 
 
ONGOING STUDIES    
  WHO Trials register 1 0 1 
  mRCT website 6 1 7 
  Final number of ongoing trials after deleting duplicates 7 1 8 
    
ALL MATERIALS    
before deleting duplicates & irrelevant titles 597 125 723 
after deleting  duplicates and irrelevant titles 209 32 241 
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b) Searching other resources   
Researchers and Organization 
In addition, we contacted researchers in the field to identify additional studies that may 
be eligible for inclusion. This strategy did not yield additional materials. 
Reference lists  
Furthermore, we checked the reference lists of all trials selected from studies identified 
by the search strategy described above. This strategy also did not yield additional 
materials. 
3.2.4 Data collection and analysis   
i) Selection of studies   
John Odaga (JO) and Joseph A. Lokong (JAL) independently screened the abstracts in 
the search list generated by the search of electronic databases for potentially relevant 
articles. We applied 2 criteria to identify potential candidates for inclusion in the review. 
An abstract was listed for further scrutiny if it satisfied both of the following selection 
criteria: 
a. interventions compared: if one of the comparison interventions in the trial 
was  a policy based on malaria RDT  
b. outcome: if the trial evaluated at least one of the outcomes listed in 3.2.1 
(d) above.  Trials which evaluated accuracy of RDTs, but which did not 
evaluate their effects on the outcomes listed above were dropped. 
The selection process is illustrated in the flow diagram (Figure 15) below.  
JO and JAL compared their lists of potentially relevant titles. Both authors identified the 
same studies (9) for possible inclusion in the review. JO retrieved the full texts of the 
selected (9) articles, which were made available to both authors. Both JO and JAL 
independently assessed each of the 9 studies to select those to include in the review, 
based on the inclusion criteria listed in 3.2.1(a – d) above. A study was included in the 
review if it satisfied all of the characteristics described in 3.2.1(a – d) above (study types, 
settings, population, interventions, comparison and outcomes). JO and JAL discussed 
the lists of studies identified for inclusion between them. Any disagreements were 
resolved by referring to the original articles and/or through discussions, and, where 
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necessary, by consulting Paul Garner (PG) and Sarah Donegan (SD). Four trials were 
included in the review [34-37], and are described further in Characteristics of included 
studies table Appendix 5. Trials that were excluded are listed in the Characteristics of 
excluded studies table, which also describes the reasons for the exclusion Appendix 6 
[32, 120, 121, 151, 152] 
Figure 15: Diagram showing electronic records identified, screened and included in synthesis 
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Systematic  Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
(www.prisma-statement.org) 
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ii) Data extraction and management   
JO and PG independently extracted outcomes data from the included trials, guided by a 
standard data extraction form (Appendix 7). Any disagreements were resolved by 
referring to the original paper and through discussions. Where necessary, clarification 
was sought from trial authors. Study authors were directly contacted to provide relevant 
data found missing in the included studies (e.g. number of participants by age group, the 
number of health centres excluded from analysis). 
Extracting data from cluster randomised trials 
Two of the included studies were cluster randomised trials in which the unit of 
randomisation were health facilities but analyses performed at patient level [35, 37]. The 
ideal data to extract in this circumstance is the direct estimate of the measure of effect 
(e.g. RR with its CI) from an analysis that accounts for clustering [99]. The 2 cluster 
randomised trials included in this review [35, 37] differed in the extent to which they 
dealt with clustering with regard to various outcomes of interest. 
Yeboah-Antwi and colleagues (2010): JO and PG extracted estimates of measures of 
outcome which were adjusted for clustering & baseline imbalance using Generalised 
Estimating Equations (GEE) with Exchangeable Correlations Matrix (ECM) [37]. JO 
entered extracted data (adjusted RR and 95% CI) into RevMan 5.1[148] using the 
Generic Inverse Variance (GIV) method as recommended in the ―Cochrane handbook 
for systematic reviews of interventions‖ [99]. GIV analysis is a statistical method of 
combining estimates of effects calculated from raw data with estimates of effects which 
have been extracted from studies and entered into Revman 5.1 as such (e.g. as RR & 
95% CI rather than as raw data) [99].    
Skarbinski and colleagues (2009): Skarbinski and colleagues [35] took into account a design 
effect of 2 in their sampling design. The reported measure of outcome—net change in 
prescribing of antimalarials—was not appropriate for this review. Therefore, JO and PG 
independently extracted summary data from which JO calculated crude RR and 95% CI 
using RevMan 5.1[148]. JO adjusted the 95% of the RR for clustering using the 
approximate analysis method which involves inflating the standard errors using a design 
effect of 2—as  recommended in the ―Cochrane handbook for systematic reviews of 
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interventions‖[99]. JO entered the adjusted estimates into Revman 5.1 [148] using the 
GIV method[99].   
Extracting data from individual randomised trials 
Two studies were individual randomised trials [34, 36].   
Bissoffi and colleagues (2009): The review authors independently extracted the direct 
estimates of measures of outcomes (RR and 95% CI), and number of participants. JO 
entered data into RevMan 5.1 [148]using the generic inverse variance method [99]. 
Ansah and colleagues (2010): Effects of the intervention were captured in the form of ORs 
and 95% CI. These estimates were left in crude form for some outcomes and adjusted 
for clustering and potential confounders for others. The authors independently 
extracted raw data outcomes from which JO calculated RRs and 95% CIs for all relevant 
outcomes. JO entered estimates of measures of outcome into RevMan 5.1 [148]using 
the generic inverse variance method [99]. 
iii) Assessment of risk of bias in included studies   
JO and PG independently assessed and judged the quality of the selected papers using 
the criteria described in the Cochrane‘s collaboration's tools for assessing risk of bias 
[99]. Risk of bias was assessed against seven items: (a) how allocation sequence was 
generated (b) how allocation was concealed to participants, investigators and outcome 
assessors; (c) blinding of participants and investigators; (d) blinding of outcome 
assessors; (e) completeness of outcomes data (number analysed relative to number 
randomised) (f) selective reporting: whether all pre-specified outcomes are reported; (g) 
other sources of bias. The review authors judged and classified the degree of risk of bias 
in each study along each risk of bias item as "High Risk", "Low Risk", or "Unclear" [99]. 
In addition the review authors summarised the degree of a particular risk of bias across 
all included studies [99]. 
iv) Measures of guideline implementation  
Because of data limitation, only 2 indicators are used to assess HW performance; 
namely, the proportion of RDT-positive patients who are prescribed antimalarials, and 
RDT-negative patients for whom antimalarials were prescribed. HWs were expected to 
respond correctly—prescribe antimalarials to RDT-positive patients and to withhold 
antimalarials to negative RDT patients—at least 95% of the time. Otherwise 
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implementation of the guideline or HW performance was judged to be inadequate [104, 
106, 127, 128, 140]. Analysis was undertaken in MS Excel 2007. 
v) Measures of treatment effect   
Estimates of effects of the intervention were measured in the form of Risk Ratio (RR) 
and 95% CI. To permit meta-analysis, data were entered into RevMan 5.1 using the GIV 
approach—by entering the natural logs of treatment effects and the natural logs of their 
standard errors [99, 148].  
vi) Unit of analysis issues   
Analyses of all outcomes were carried out at individual (patient) levels using generic 
inverse variance method, taking into account clustering and baseline imbalance as 
described in section 3.2.4 above. 
vii) Assessment of heterogeneity   
We assessed the results of the review for heterogeneity among studies by inspecting the 
forest plots. We applied the Chi2 test for heterogeneity with a 10% level of statistical 
significance, and the I2 statistic with value of 0% to 40% representing an insignificant 
level of heterogeneity; values of >40% to 60% to denote moderate levels of 
heterogeneity; values >60% to 80% to represent substantial levels of heterogeneity; and 
values >80% to represent considerable heterogeneity [99]. 
viii) Data synthesis   
We carried out a full analysis of all included studies, irrespective of the risk of bias. Data 
from the studies were combined using the generic inverse variance methods in Revman 
5.1 [148]. Estimates of treatment effects and corresponding standard errors were 
entered into RevMan 5.1 [148] using the GIV approach—by entering the natural logs of 
treatment effects and the natural logs of their standard errors [99]. Because of 
considerable heterogeneity in estimates of one of the primary outcomes (prescribing of 
antimalarials), data were analysed using random-effects methods. Random-effects 
methods incorporate the assumption that the studies are estimating different but related 
intervention effects. That is, the method assumes that variability in results is the result 
of systematic difference between studies and not due to random errors [99]. 
ix) Subgroup analysis and investigation of heterogeneity   
We performed subgroup analysis for the primary outcomes with considerable 
heterogeneity [35-37] by stratifying results age-groups and degree of HW compliance 
with guidelines. We applied the Chi2 test for sub-group difference with a 10% level of 
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statistical significance, and the I2 statistic with value of 0% to 40% representing an 
insignificant level of heterogeneity; values of >40% to 60% to denote moderate levels of 
heterogeneity; values >60% to 80% to represent substantial levels of heterogeneity; and 
values >80% to represent considerable heterogeneity [99]. Data did not permit sub-
group analysis by the following potential causes of heterogeneity: malaria transmission 
intensity, referral level of the health facility, and qualification/experience of clinicians 
(for anti-malarial and antibiotics prescribing). Only one study provided results by 
seasons [35]; hence we did not perform subgroup analysis of the combined results by 
season.      
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3.3 Results   
3.3.1 Description of studies   
Detailed descriptions of the studies included in the review are found in Characteristics of 
included studies table (Appendix 5). The following sections describe the main features of 
the studies which were included in the review. 
a) Results of the search   
Of the 233 abstracts and 8 titles of on-going studies retrieved, 9 studies were 
considered; all of which are from Africa. 
 
b) Included studies   
Four randomised controlled trials were included: from West Africa (2), East Africa (1) 
and Southern Africa (1) (Appendix 5) 
Settings 
All studies were carried out in basic healthcare facilities without microscopes, and 
manned mainly by paraprofessional staff. One trial consisted of 2 comparison arms: 
RDT-based guideline compared with microscopy-based guideline; and RDT-based 
guideline compared with clinical diagnosis. Only the latter arm is included in this review 
[36]. Two studies do not describe the malaria transmission rates in the study areas [34, 
36]. Two studies [35, 37] are carried out in high and low endemicity areas but they 
present the results in combined form. 
Design 
Two of the studies randomised clusters (health facilities) [35, 37] while two randomised 
individual patients [34, 36]. One of the cluster randomised trials [35] incorporated 
parallel pre-test and post test comparisons. 
Participants 
Table 13 summarises the number of participants randomised and the number analysed 
for primary outcomes by the studies reviewed. 
The number of participants randomised in the included studies is 9545. The individual 
randomised trials included patients of all age groups. Bisoffi and colleagues [34] 
included 2169 patients from 10 health centres; and Ansah and colleagues randomised 
3452 patients from 3 health centres [36]. 
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Table 13: Number of participants randomised and analysed by studies 
 
Ansah 
(2010) 
Bisoffi 
(2009) 
Yeboah-
Antwi (2010) 
Skarbinski 
(2009) Total  
Number of health facilities 3 10 31 30 74 
Target population* All  All  <5 years ≥5 years - 
Number randomised 3452 2169 3125 799 9545 
Number analysed for primary outcome 3442
1
 2169
1,2
 3125
3,4
 669
1
 9405 
Loss to follow-up 0.3%
1
 0.0%
1,2
 0.0%
3,4
 16.3%
1
 1.5% 
*of those with fever or suspected of having malaria 
Footnotes 
1 numbers presented refer to patients prescribed antimalarials 
2number analysed in assessing clinical outcomes was lower in Bisoffi et al: 2095; loss to follow-up = 3.4% 
3 numbers presented refer to patients assessed for clinical outcomes 
4number of patients prescribed antimalarials in Yeboah-Antwi et al was lower: 3047; loss to follow-up: 2.5%  
 
 
The cluster randomised trials targeted different age groups. Yeboah-Antwi and 
colleagues randomised a total 3125 children (< 5 years of age) from 31 aid posts [37] 
while Skarbinski and colleagues randomised 799 older patients (5+ years) from 30 health 
facilities [35]. See Characteristics of included studies table (Appendix 5) for further 
details. 
Number of facilities enrolled 
Studies randomising individual patients enrolled relatively fewer health facilities (3 
health centres in Ghana [36] and 10 health centres in Burkina Faso [34]) than those that 
randomised facilities (clusters): 30 and 31 in Zambia and Kenya respectively [35, 37]. 
Prescribers  
Table 14 shows the category and number of HWs who provided care to patients during 
the trials. 
Table 14: Quaification and number of HWs who were assessed 
Study ID Qualification of attending HW   Number of HWs/facility 
(average) 
Ansah, 2010-GHA Mostly enrolled nurses, some registered 
nurses/midwives, a few auxiliary nurses 
Number not indicated 
Bisoffi, 2009-B’FASO Nurses (level not specified) Number not indicated 
Skarbinski 2009-KEN Not described Number not indicated 
Yeboa-Antwi 2010-ZAM Community health workers 1.2 
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In 3 studies, the HWs consisted of either nurses or auxiliary HWs [34, 36, 37]. 
Skarbinski and colleagues did not describe the type of HWs involved in the study [35]. 
However, the facilities enrolled in the study included health centres and hospitals which 
presumably had more qualified staff (e.g. clinical officers).  
Only one trial indicated the number of HWs included in the study, whereby there was 
mostly 1 HW per community health post [37]. 
Interventions 
Introduction of RDT-based policies was preceded by training of health facility staff. In 
each of the trial from Zambia, Ghana and Burkina Faso, training lasted for 3 days [34, 
36, 37]. In Kenya, HWs received training for only half of a day [35]. All trainings 
emphasized the use of RDTs and restricting prescribing of antimalarials to RDT 
positive cases only. There was no report as to whether other components of the 
guideline (e.g. clinical assessment, management of patients with negative RDT results) 
were equally emphasized. In Ghana and Burkina Faso, members of the research team 
carried out the tests and then sent the results to the health workers for interpretation 
and treatment. This intervention was aimed at optimising the quality of RDT tests and 
minimising work pressure on HWs. In Zambia, the community health workers (CHW) 
received intensive monitoring characterised by monthly assessment of HW performance 
and feedback. In addition, the research team provided the CHWs with bicycles to aid 
communication with the monitoring team based at designated health centres. No 
additional interventions are reported in the Kenyan trial.  
Outcomes 
Table 15 below shows the outcomes evaluated by the various studies included in the 
review. All the trials included in the review (4) report on effects of RDT-based 
guidelines on prescribing of antimalarials. Only one of these provide further data on 
effects of the guidelines on prescribing of antimalarials to slide negative patients; and on 
the number of missed malaria cases [36].   
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Table 15: Outcomes evaluated by studies included in the review 
 
OUTCOMES OF INTEREST 
STUDY ID* 
Clinical 
outcomes 
Prescribing of 
anti-malarials 
Prescribing of 
antibiotics 
Total number of 
outcomes evaluated 
Ansah, 2010-GHA   √ √ 2 
Bisoffi, 2009-B’FASO √ √  √ 3 
Skarbinski 2009- KEN   √   1 
Yeboa-Antwi 2010-ZAM √ √   2 
TOTAL (STUDIES) 2 4 2   
*GHA: Ghana; B‟FASO: Burkina Faso: KEN: Kenya; ZAM: Zambia 
 
Two trials report on effects of the intervention on clinical outcomes [34, 37]; and 2 
report on effects of the intervention on prescribing of antibiotics [34, 36]. 
c) Excluded studies   
Five studies were excluded and the reasons for the exclusion are summarised in the 
Characteristics of excluded studies table (Appendix 6). Studies were excluded because the 
designs and/or comparisons were inappropriate [32, 120, 121], or because there was no 
comparison [151, 152].  
3.3.2 Risk of bias in included studies   
This section provides an overview assessment of Risk of Bias (ROB) in the studies 
included in the review. Details of ROB items assessed per study and the judgements 
made are presented in Figure 16 and Figure 17. Detailed descriptions of each ROB item 
and the reasons for the judgement can be found in ―Characteristics of included studies 
table‖ in Appendix 5. Further details are below. 
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Figure 16: Review authors' judgements about the amount of ROB per item per study 
 
 +   Low risk of bias          ?    Unclear risk of bias           -    High risk of   
  
 
Figure 17: Cumulative percent of studies with varying levels of ROB per item  
 
 
For a particular risk of bias item, percentages indicate the cumulative proportions of studies characterised by increasing levels 
of risk of bias, specified by the successive colour codes  
In 3 trials [34-36], random numbers were generated by means of a computer. One study 
did not describe the method of sequence generation [37]. Ansah and colleagues 
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concealed allocation by placing the numbers in sealed envelopes [36]. Bisoffi and 
colleagues and Yeboah and colleagues did not indicate if allocation was concealed or not 
[34, 37]. Allocation was not concealed by Skarbinski and colleagues [35]. 
In all studies, participants and personnel were not blinded to the interventions, test 
results/diagnoses, treatment prescribed, and where applicable, treatment outcomes. No 
statistically significant imbalance in baseline characteristics of enrolled patients was 
detected between comparison groups in 3 trials [34-36]. Yeboah-Antwi and colleagues 
[37] report an imbalance in the two arms in the number of children presenting with fast 
breathing, for which adjustment was made. 
a) Allocation (selection bias)   
The review judged the risk of bias in sequence generation as low in 3 studies [34, 36, 37] 
and as unclear in 1 study [35]. Concealment of allocation was judged as low risk in one 
study [36], as unclear (not described) in one study [34], and as high-risk in 2 the studies 
[35, 37]. 
b) Blinding (performance bias and detection bias)   
Blinding was judged as high risk in all the included studies. Given the nature of the 
intervention (use of a diagnostic in a clinical setting), it was practically not possible to 
blind the study participants and personnel of the interventions, test results, prescriptions 
and clinical outcomes. 
c) Incomplete outcome data (attrition bias)   
The review judged attrition bias as low risk (≤ 3%) in 3 studies [34, 36, 37] and as high 
risk in 1 study [35]. Analyses were based on available cases with complete data (available 
case analysis) [99].  
d) Selective reporting (reporting bias)   
All outcomes which were pre-specified in the methods section of the reports (and in the 
protocols) were reported in the results section. The risk of reporting bias was judged to 
be low. 
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e) Other potential sources of bias   
Three of the studies report imbalance in the number and qualifications of the clinicians 
which they adjusted for using different methods [34, 36, 37]. In one study, attrition rate 
was high (30%) and unequal in both arms [35]. This could be a potential source of bias. 
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3.3.3 Quality of implementation 
Two indicators were used to assess the quality of practice in a controlled condition; 
namely, (a) proportion of RDT-positive patients for whom antimalarials were prescribed 
(b) the proportion of RDT-negative patients for whom antimalarials were prescribed. 
HWs were expected to respond correctly to negative RDT results at least 95% of the 
time. Otherwise implementation of the guideline or HW performance was judged to be 
inadequate [104, 106, 127, 128, 140]. Only 3 studies provided data for the first indicator 
[34-36]. HW response was adequate in all three trials: 98% to 100% of cases with 
positive RDT results were prescribed antimalarials. HW performance with regard to the 
second indicator is summarised in Table 16. 
Table 16: HW performance based on patients with negative RDTs who received antimalarials in 
RDT arms  
Study ID 
Cases with negative RDTs 
prescribed antimalarials Classification of HW 
adherence* N % (95%CI) 
   Yeboah-Antwi 2010 ZAM  704 0.4% (0.3%, 0.5%) High 
   Skarbinski 2009 KEN  346 41.0% (38.4%, 43.6%) Low 
   Ansah 2010 GHA  1013 49.5% (47.9%, 51.1%) Low 
   Bisoffi 2009 B’Faso 494 81.0% (79.2%, 82.8%) Low  
   All 8893 11.8% (11.4%, 12.1%) Low  
* This classification is based on a threshold of 5% used in several health facility surveys, whereby a HW is 
expected to perform a given clinical task using the wrong technique less than 5% of the time; otherwise his 
performance (adherence) is judged to be inadequate or low [104, 106, 127, 128]; and on a model developed by 
Lubell and colleagues which suggests that the economic advantage (cost-saving) gained by using HRP-2-based 
RDTs over presumptive treatment is lost once the number of RDT negatives cases who are prescribed 
antimalarials exceeds 5% in children (<5 years) and/or in high prevalence areas [140].  
 
It is notable from Table 16 that HW adherence to negative RDT results was generally 
low and varied widely between trials. HW adherence was high in Zambia where HWs 
prescribed antimalarials to only 0.4% of children with negative RDT results [37]. HW 
adherence was low in 3 trials [34-36]. HW adherence was notably very low adherence in 
Burkina Faso where HWs prescribed antimalarials to as many as 81% of children and 
adults with negative RDT results [34]. HWs in the 4 trials received different types of 
extra interventions aimed at optimising performance (see ‗interventions‘ on page 45 
above).  
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3.3.4 Effects of interventions   
Primary Outcomes 
a) Patients prescribed anti-malarial drugs 
Overall, the four trials included in this analysis show that fewer patients were prescribed 
antimalarials in the RDT group (combined RR = 0.71, 95% CI 0.56 to 0.90). See Figure 
18 for details. Three of the four trials detected significant reductions in prescribing of 
antimalarials in favour of RDT use [35-37]. One study detected no statistical difference 
in the proportion of patients receiving antimalarials in the two arms (RR = 1.02, 95% CI 
0.99 to 1.06) [34].  
Figure 18: Number prescribed anti-malarials in RDT arm versus clinical diagnosis arm 
 
 
 
The results show considerable heterogeneity in the effects of the intervention (Chi2 = 
175.78, df = 3, (P < 0.00001), I2 = 98%). These estimates of effects were assumed to be 
systematically different in the different studies for reasons specified in the literature 
review, section 2.8.3 (Figure 6), namely age profile of target population, HW adherence 
to RDT-based guidelines, and local malaria prevalence. Accordingly, sub-analyses were 
undertaken to investigate if the heterogeneity could be explained by variability in 
participants‘ age groups and HW adherence to RDT results. Because of data limitation, 
sub-group analysis was not performed to investigate the effect of other potential causes 
of heterogeneity. 
 
 
 
 
Study or Subgroup 
Yeboah-Antwi 2010 ZAM 
Skarbinski 2009 KEN 
Ansah 2010 GHA 
Bisoffi 2009 B'FASO 
Total (95% CI) 
Heterogeneity: Chi² = 175.78, df = 3 (P < 0.00001); I² = 98% 
Test for overall effect: Z = 2.78 (P = 0.006) 
Events 
27.5% 
40.9% 
70.0% 
89.3% 
99.1% 
54.2% 
92.7% 
87.2% 
Total 
963 
359 
1719 
1058 
4099 
Total 
2084 
310 
1723 
1111 
5228 
Weight 
13.5% 
24.3% 
31.1% 
31.1% 
100.0% 
*IV, Random, 95% CI 
0.23 [0.14, 0.38] 
0.76 [0.60, 0.96] 
0.76 [0.74, 0.79] 
1.02 [0.99, 1.06] 
0.71 [0.56, 0.90] 
RDT guideline Clinical diagnosis Risk Ratio 
Risk Ratio 
*IV, Random, 95% CI 
0.2 0.5 1 2 5 
Favours RDT 
guideline 
Favours clinical 
diagnosis 
Event
s  
*IV: Inverse variance 
 105 
 
Sub-group analysis by age group 
Figure 19 displays analysis of the results by age groups (< 5 years versus ≥5years). 
 Figure 19: Number prescribed anti-malarials in RDT arm versus clinical diagnosis arm by age 
groups 
 
 
The trial by Bisoffi and colleagues was not included in this analysis because data were 
not disaggregated by age groups.  
The sub-group analysis shows the effect of the intervention was similar in both age-
groups (children <5 years: RR = 0.49, 95% CI: 0.16 to 1.48, versus older children and 
adults 5+ years: RR = 0.71, 95%CI: 0.68 to 0.74).  The test for sub-group difference 
shows that variability in age-group does not explain heterogeneity in estimates of effects 
detected between the trials (Chi2 = 0.44, df = 1 (P = 0.51), I2 = 0%). Therefore, in this 
synthesis, age was not a significant factor in the variability of estimates of effects of the 
intervention. It can also be noted that considerable heterogeneity in estimates of effects 
persists in <5 years sub-group after stratifying results by age group (Chi2 = 338.7, df (P 
= 0.00001); I2 = 100%). This further indicates that the variability in effects of the 
intervention may be due to factors other than variability in age-groups. 
 
 
 
 
 
Study or Subgroup 
< 5yrs 
Yeboah-Antwi 2010 ZAM 
Ansah 2010 GHA 
Subtotal (95% CI) 
Heterogeneity: Chi² = 338.77, df = 1 (P < 0.00001); I² = 100% Test for overall effect: Z = 1.27 (P = 0.21) 
5+ yrs 
Ansah 2010 GHA 
Skarbinski 2009 KEN 
Subtotal (95% CI) 
Heterogeneity: Chi² = 0.56, df = 1 (P = 0.45); I² = 0%; Test for overall effect: Z = 16.16 (P < 0.00001) 
Test for subgroup differences: Chi² = 0.44, df = 1 (P = 0.51), I² = 0% 
Events 
27.5% 
80.5% 
65.8% 
40.9% 
Events 
99.1% 
92.5% 
92.8% 
54.2% 
Total 
963 
519 
1482 
1200 
359 
1559 
Total 
2084 
550 
2634 
1173 
310 
1483 
*IV, Random, 95% CI 
0.28 [0.25, 0.31] 
0.86 [0.82, 0.91] 
0.49 [0.16, 1.48] 
0.71 [0.68, 0.74] 
0.76 [0.64, 0.90] 
0.71 [0.68, 0.74] 
RDT guideline Clinical diagnosis Risk Ratio Risk Ratio 
*IV, Random, 95% CI 
0.2 0.5 1 2 5 
Favours RDT 
guideline 
Favours clinical 
diagnosis 
*IV: Inverse variance 
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Sub-group analysis by HW adherence 
Estimates of effects were stratified by degree of HW adherence to RDT results to 
explore if HW adherence could explain the heterogeneity in results between studies. The 
results are shown in Table 17  
  Table 17: Effect of intervention stratified by HW adherence to guideline  
HW 
adherence  Studies 
Total  Effect 
Heterogeneity RDT Clinical   RR  (95% CI) 
High  1[37] 963 2084  0.23  (0.14, 0.38) Not applicable 
Low 3[34-36] 3136 3144  0.85  (0.66, 1.08) Chi
2
 = 148.3, df = 2 (P = 0.00001), I
2
 = 95.3% 
 
Test for subgroup difference: Chi
2
 = 21.44, df = 1 (P = 0.00001), I
2
 = 95.3% 
 
Table 17 shows that systematic differences in HW adherence between the studies 
accounts for 95.3% of the variability in estimates of effects between the studies (Test for 
sub-group differences: Chi2 = 175.78, df = 2 (P<0.00001), I2 = 95.3%). The magnitude 
of effect of the intervention varied according to the degree of HW adherence to RDT 
results. Significant decline in prescribing of antimalarials was detected in intervention 
HCs where HW adherence was high (RR, 0.23, 95% CI 0.14, 0.38) [37]. No significant 
difference was detected in prescribing of antimalarials by the trials characterised by low 
HW adherence at intervention HCs (combined RR = 0.85, 95% CI: 0.66, 1.08) [34-36].  
b) Patients still unwell at follow-up  
No difference was detected in the proportion of patients who still had fever at follow up 
(seen 4 to 7 days after treatment): combined RR = 0.89; 95% CI = 0.62 to 1.28; 2 
studies [34, 37]. See Figure 20 for details. None of the individual trials detected a 
difference in the proportion of patients who still had fever at follow up.  
Figure 20: Patients still unwell at follow-up at day 4+ in RDT arm versus clinical diagnosis arm. 
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Bisoffi 2009 B'FASO 
Yeboah-Antwi 2010 ZAM 
Total (95% CI) 
Heterogeneity: Chi² = 1.38, df = 1 (P = 0.24); I² = 28% 
Test for overall effect: Z = 0.63 (P = 0.53) 
Events 
9.3% 
5.6% 
Events 
10.0% 
5.5% 
Total 
1024 
1017 
2041 
Total 
1071 
2108 
3179 
Weight 
68.0% 
32.0% 
100.0% 
*IV, Random, 95% CI 
1.01 [0.73, 1.41] 
0.68 [0.38, 1.20] 
0.89 [0.62, 1.28] 
RDT guideline Clinical diagnosis Risk Ratio Risk Ratio 
*IV, Random, 95% CI 
0.5 0.7 1 1.5 2 
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guideline 
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diagnosis 
*IV: Inverse variance 
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Secondary outcomes 
a) Targeting of antimalarials 
One study subjected all participants to reference slide microscopy in order to investigate 
if the use of RDTs in treatment of fever resulted in better targeting of antimalarials. It 
examined if all malarial patients (slide positive cases) received antimalarials, and whether 
fewer non-malarial fevers (slide negative cases) received antimalarials after introducing 
RDTs [36]. The results are summarised below. 
Microscopy positive patients not prescribed anti-malarials 
No significant difference was detected between RDT and clinical diagnosis arms in the 
proportion of reference slide positive patients not prescribed antimalarials (RR = 1.21, 
95% CI 0.64 to 2.28; one study) [36] (Figure 21 below).  
Figure 21: Slide positive cases not prescribed antimalarials in comparison arms 
 
 
Microscopy negative patients prescribed anti-malarials 
Significant difference was detected in the proportion of slide negative cases of fever 
prescribed antimalarials in favour of RDT-guideline (RR = 0. 60, 95% CI 0.57 to 0.64; 
one study) [36]. See Figure 22 below. 
 
Figure 22: Slide negative cases prescribed antimalarials in the comparison arms 
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b) Patients prescribed antibiotics  
Results from the two trials which evaluated this outcome show considerable variability 
in the effects of the comparison guidelines on the proportion of participants prescribed 
antibiotics (I2 = 88%; p = 0.004) (Figure 23).  
Figure 23: Number prescribed antibiotics in the RDT arm versus clinical diagnosis arm 
 
 
Ansah and colleagues (2010) detected a significant increase in the proportion of 
participants prescribed antibiotics in the RDT arm [36]. This increase was observed 
exclusively in older (5+ years) participants in whom prescribing of antibiotics nearly 
doubled (RR = 1.97, 95% CI 1.69 to 2.30) (not shown in Figure 23). No difference was 
detected in children (<5 years) (RR = 1.02, 95% CI 0.84 to 1.23). Bisoffi et al detected 
no significant association between the intervention and the proportion of participants  
prescribed antibiotics [34]. 
  
Study  
Ansah 2010 GHA 
Bisoffi 2009 B'FASO 
Total (95% CI) 
Heterogeneity: Chi² = 8.11, df = 1 (P = 0.004); I² = 88% 
Test for overall effect: Z = 0.97 (P = 0.33) 
Event 
52.9% 
26.6% 
Event 
54.8% 
22.3% 
Total 
1719 
1058 
2777 
Total 
1723 
1111 
2834 
Weight 
30.6% 
69.4% 
IV, Fixed, 95% CI 
1.19 [1.06, 1.34] 
0.97 [0.90, 1.05] 
1.03 [0.97, 1.10] 
RDT guideline Clinical diagnosis Risk Ratio Risk Ratio 
IV, Fixed, 95% CI 
0.5 0.7 1 1.5 2 
Favours RDT 
guideline 
Favours control 
*IV: Inverse variance 
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3.4 Discussion   
This chapter reviews evidence from RCTs in order to answer the question whether 
RDT-based policies can be sufficiently implemented under carefully controlled 
conditions and whether its application in such conditions can lead to better prescribing 
and clinical outcomes. Effects are compared relative to treatment policies for fever 
based on clinical judgement.  
3.4.1 Summary of main results   
a) Guideline implementation 
Overall, HW adherence to guideline was poor. Whereas HWs prescribed antimalarials to 
virtually all (98% to 100%) participants with positive RDT results, HW response to 
negative RDT results was generally poor, and varied widely. Adherence to negative 
RDT results was high in only one trial in which antimalarials were prescribed to only 
0.4% of patients with negative RDT results [37]. HW adherence was inadequate in 3 
trials, in which as many as 40% to 81% of patients with negative RDTs received 
antimalarials [34-36]. HW adherence to RDT-based guideline appears to be 
unpredictable even under relatively optimal conditions.  
The reasons for the variability HW adherence between studies are not entirely clear. We 
know from the literature review that a number of factors can positively influence HW 
adherence to guidelines, including supervision [93, 112, 117, 146], HW qualifications 
[90, 112, 146], and training [90, 108, 117, 146]. Further, material or monetary incentives 
are also known to improve HW performance [153, 154]. Variability in these factors may 
explain the heterogeneity in HW adherence to RDT test results, which exists between 
the trials.  
In Zambia, on top of training, supply of RDTs and guidelines, the community health 
workers received a bicycle each and were intensely and regularly monitored [37]. HWs in 
other studies did not receive any material incentives or similar level of supervision [34-
36]. Hence the CHWs in Zambia could have been more motivated to perform than 
HWs in other trials. Secondly, we know from the literature review that auxiliary staff 
tends to adhere to guidelines better than professional staff [90, 112, 146]. In Zambia, the 
attending HWs consisted of community (auxiliary) health workers from health posts 
[37]. In both Ghana and Burkina Faso, the attending HWs consisted of mostly nurses 
from dispensaries or health centres [34, 36]; while in Kenya, the HWs consisted of a 
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variety of cadres of staff from dispensaries, health centres and hospitals [35]. Therefore, 
variability in settings and qualification of HWs might have partly contributed to the 
heterogeneity in HW adherence to guidelines between studies.  
Although the content of trainings appeared similar in all trials, the quality of delivery 
could have varied between studies. For example, training was provided for 3 days in 
each of the trials in Zambia, Ghana and Burkina Faso [34, 36, 37], in Kenya HWs 
received training for half a day [35]. Thus poor HW performance in Kenya could have 
been partly due to the short training duration. 
Efficacy trials are aimed at optimising performance [40, 98]. On account of the 
indicators of HW performance analysed, this objective was only achieved in the 
Zambian trial. The results show that HW performance is likely to vary even under 
relatively favourable conditions. As a minimum, regular support supervision of HW may 
be required during the introduction of an RDT-based guideline. 
b) Effect on antimalarials prescribed 
The evidence indicates that RDT-based policies can reduce the amount of antimalarials 
prescribed in cases of fever in endemic areas. However, the magnitude of effect of the 
intervention appears to depend partly on the degree of HW adherence to guidelines, 
especially on the extent to which they comply with negative test results. The higher the 
proportion of RDT-negative cases who are prescribed antimalarials in the RDT arm, the 
smaller is the effect of the intervention on the amount of antimalarials prescribed. 
Because HW adherence was generally poor, the effect of the intervention on prescribing 
of antimalarials was also marginal.  
Other factors could have also been responsible for the inconsistency in the effect of the 
intervention. Variability in the prevalence of malaria in the settings where the studies 
were conducted may have significant influence on the effect of the intervention. The 
amount of over-use of antimalarials averted by use of RDTs is greater in low malaria 
prevalence areas than is high prevalence areas [12, 13]. The studies included in this 
review either did not describe the malaria endemicity of the study contexts [34, 36] or 
they present results in combined form [35, 37]. Although variability in the age profile of 
the population is another possible reason for heterogeneity in effect of the intervention 
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on usage of antimalarials, this review shows that variability in age-group group was not 
an important factor.  
One of the contentious issues about the use of RDTs to guide treatment in fever 
patients is that it could lead to missed diagnosis of malarial cases [26, 70]. The review 
detected no difference between RDT and clinical diagnosis arms in the proportion of 
reference microscopy positive patients missing anti-malarials. However, this outcome 
was examined in one trial only [36]. The same trial shows that use of RDTs can 
significantly avert inappropriate prescribing of antimalarials [36].  
c) Effect on prescribing of antibiotics 
The review reveals considerable variability in the effects of the comparison guidelines 
on the proportion of participants prescribed antibiotics. While the trial in Ghana 
detected a significant increase in the proportion of participants prescribed antibiotics in 
the RDT arm [36], the one from Burkina Faso detected no difference between the 
comparison arms [34]. Overall, effect of the intervention under controlled conditions is 
still unclear. 
Usage of antibiotics is thought to be an indicator of how parasite negative patients are 
managed [138, 155]. Variability in prescribing of antibiotics might reflect variability in 
the way RDT-negative patients are managed in different settings. Generally, users of 
RDT-based guidelines appear to be unclear about how to manage parasite-negative 
patients [32, 34-37, 120, 121, 151]. However, this finding might also reflect variability in 
availability (i.e. shortage) of essential antibiotics.  
d) Effect of clinical outcomes 
The review did not demonstrate a difference between RDT and clinical diagnosis arms 
in the proportion of participants still symptomatic at follow-up evaluation (4 - 7 days 
after treatment).  
This could be due to a variety of factors. Firstly, differences in outcomes may be small. 
In order to detect small differences in effects, randomised trials require large sample 
sizes. For the studies included in this review, sample size calculations were based on 
anticipated differences between groups in prescribing of antimalarials—which may be 
bigger than differences in clinical outcomes. Therefore, sample sizes used in these 
studies may have been too small to detect differences in clinical outcomes. Secondly, in 
Bisoffi et al. (2009), clinician adherence to RDT-based guidelines was poor [34]. 
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Therefore, the difference in the quality of prescribing provided in the two arms may not 
have been significantly different.  
Thirdly, we know from the literature review that outcomes data are usually less sensitive 
in measuring quality of care [85]. This is especially true if measures are implicit, such as 
the subjective measures used in this study. Differences in outcomes may not be detected 
even if there is improvement in the quality of the process of care. On the other hand, 
differences in outcomes may be due to antecedent factors [85].  
3.4.2 Comparison with other studies or reviews  
Non-randomised trials have also shown that use of RDT-based guidelines in routine 
practice can reduce prescribing of antimalarials in settings where presumptive treatment 
is the norm, especially in low transmission areas [32, 120, 121]. A weekly cross-over trial 
from Zanzibar (Tanzania) detected a reduction (from about 5% to 2.5%) in the risk of 
persistent symptoms after introducing RDT guidelines (OR 0.5, 95% CI 0.3 to 0.9, P = 
0.005)[121]. These studies did not evaluate the effects of RDT-based policies on 
prescribing of antibiotics. Further randomised controlled trials are required to enable a 
robust conclusion about the effects of RDT-based policy on prescribing of antibiotics 
and clinical outcomes. 
3.4.3 Limitations  
a) Use of prescribing as a measure of quality 
In this chapter, analysis of HW adherence is based on prescribing of anti-malarials 
relative to RDT results. RDT-based guidelines are aimed at improving the quality of the 
process of care as a whole, including clinical assessment, RDT performance and patient 
counselling. Notably, the quality of clinical assessment is crucial in the differential 
diagnosis of the causes of RDT-negative fevers, and in targeting antibiotics [19, 70-72]. 
Use of prescribing data alone as a measure of adherence to guidelines fails to fully 
describe the overall quality of care in fever patients, and the quality of the diagnostic 
processes of care specifically [109, 113, 149]. Additionally, prescribing data are known to 
over-estimate the overall quality of care [62, 90-92, 108-113, 115-117]. Therefore, HW 
performance may have been much poorer in the studies analysed than is portrayed by 
the data on prescribing of antimalarials.  
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b) Heterogeneity 
The trials analysed vary considerably in design, number of supplementary interventions, 
implementation, and settings. This probably reflects the limitations of using archetypical 
RCT design to attribute effects to a complex public health intervention. Variability in 
methods and settings hampers the ability to compare results from these trials.  
c) Design effect 
Data on prescribing tend to be highly correlated because they reflect the similarity in the 
quality of care offered to several cases by a few HWs. Randomisation, whether at 
individual or cluster level, may not address clustering of prescribing data, especially 
when the number of facilities enrolled is small, and there are a few HWs per facility 
[102]. When analysis is undertaken at patient level, clustering (design effect) reduces the 
power of the study to detect differences in effect between groups, and results in over-
precise estimates—except if appropriate adjustments are made [99, 102]. Of the studies 
included in this analysis, cluster randomised trials took into account potential clustering 
of effects in the calculation of sample size—thereby recruiting 30 and 31 health facilities 
respectively. Individual randomised trials did not take clustering into account, and 
recruited 3 and 10 health facilities respectively. Therefore, in the latter group of trials, 
effects of the intervention on prescribing of antimalarials and antibiotics may have been 
masked by clustering. 
d) Use of RCTs in a complex intervention 
The primary purpose of an RCT is to attribute outcomes to interventions and to explain 
how interventions work. RCTs are generally unsuitable for attributing effects to 
elements of a complex intervention because it is difficult to identify the components of 
the intervention which is responsible for an observed effect [74]. This review detected 
variability in implementation of guidelines, which potentially could help explain 
differences in outcomes. However, the trials lacked data on most of the process 
attributes that could have been used to demonstrate causal relationship. Therefore, 
while we know how HW adherence to RDT results impact on usage of antimalarials, it 
is unclear how implementation of other components of the guideline could impact on 
other outcomes indicators—notably prescribing of antibiotics and clinical outcomes. 
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e) Strict selection criteria 
The research quality criteria used to select studies for inclusion in this review may have 
been overly biased against studies with large effects of the intervention, but whose 
designs were deemed to be sub-optimal as per the selection criteria, for example 
D‘Acremont et al (2011), Kyabayinze et al. (2011) and Msellem et al. (2009) [120, 121, 
156]. On the hand, the criteria may have been biased towards interventions with 
marginal effects because the designs of the studies met the selection criteria, for example 
Skarbisnki et al (2009) [35]. Consequently the studies reviewed are too few to support a 
robust conclusion about the effects of RDT-based guidelines relative to clinical 
diagnosis. Further, the combined intervention effects may be smaller than would have 
been if quasi-experimental studies were also included in the review.  
f) External validity 
The trials included in this review were conducted under relatively favourable conditions 
characterised by standardised interventions [34, 36, 37], well resourced settings [34-37], 
motivated HWs [37], homogeneous population [35, 37], and intense monitoring of 
intervention [37]. As such the evidence from the individual trials may not be 
generalisable to the general population in routine practice [98]. In the context of this 
thesis, knowledge of efficacy is necessary to aid interpretation of evidence from the 
effectiveness trial in chapter 4 [40]. The external validity of the evidence in this chapter 
is not a primary objective of this thesis. Yet generalisable conclusions can still be drawn 
from this chapter because the systematic review pools together similar effects in a 
variety of populations [98] 
g) Use of outcomes indicators to measure quality 
Outcomes data are usually a less sensitive measure of quality of care. This is especially 
true if measures are implicit, such as the subjective measures used in this study. 
Differences in outcomes may not be related to the factors under the control of the HW. 
Rather, they might be due to the influence of antecedent factors [85]. Therefore, a lack 
of improvement in clinical outcomes should not be considered to indicate lack of 
improvement in the overall quality of care [85].  
 
  
 115 
 
3.5 Authors' conclusions   
Policies based on RDTs instead of clinical diagnosis in fever management may 
significantly reduce usage of antimalarials if applied under optimal conditions. However, 
HWs may not adhere to the guideline sufficiently enough to result in significant 
improvements in prescribing of antimalarials, even under these conditions which are 
designed to optimise performance. We are also uncertain about the effect of the policy 
on prescribing of antibiotics and on clinical outcomes. Therefore, if a lack of effect is 
detected in the effectiveness (pragmatic) trial in chapter 4, we can not know if it is 
because the intervention is, in fact, inefficacious, or whether it is due to inappropriate 
design or invalid measure; or if it is due to poor implementation. 
3.5.1 Implications for research   
More efficacy trials may be required in order to make a robust conclusion about the 
effects of the intervention on clinical outcomes. Trials need to be more standardised in 
design, interventions, implementation and settings so that results are more comparable. 
Trials need to take design effects into account, even for prescribing outcomes. Perhaps 
more explicit indicators are needed to measure clinical outcomes.  
Studies evaluating effects of the intervention on clinical outcomes need to include an 
assessment of implementation of all components of the guideline. Given the limitations 
of RCTs in assessing complex public health interventions, quasi-experimental can be 
more useful for attributing effects to a multi-component intervention. When 
incorporated into a model, variation in implementation of various components of a 
guideline may be used to predict specific outcomes attribute [85]Future studies should 
enrol larger numbers of health facilities, and should analyse results by malaria 
endemicity in the study settings to facilitate comparison of results.  
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Chapter 4 
Analysis of data from a pragmatic trial  
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Chapter 4    Effect of RDT-based policy on quality of 
care in routine practice 
4.1 Introduction 
In this chapter I present the analysis of an existing dataset from a pragmatic trial in 
Uganda in order to determine if application of an RDT-based guideline through routine 
practice can lead to improved prescribing, improved clinical outcomes and lower 
healthcare cost relative to presumptive treatment. Additionally, it describes the quality of 
implementation of the RDT-based guideline for Uganda in routine practice—in terms 
of HW‘s use of RDTs, diagnostic accuracy of RDTs and HW response to RDT results. 
Further, it evaluates the impact of variability in malaria endemicity and age profile on 
the magnitude and direction of effects of the new policy. The evidence from this 
chapter can inform judgement as to whether it is worthwhile, from both economic and 
clinical perspectives, to scale-up the use of RDT-based policy for fever in all age groups 
in all malaria transmission settings in Uganda; or whether to target its use to specific age 
groups and transmission settings. 
The dataset analysed in this chapter comes from a trial which was designed to evaluate 
the diagnostic accuracy of RDTs, and to compare the effectiveness of an RDT-
supported guideline for fever versus presumptive treatment in government HCs in 
Uganda. It was carried out in 2008 in high, medium and low malaria transmission 
settings. The trials was conducted by the Uganda Malaria Surveillance Project 
(UMSP)—a collaborative initiative comprising researchers at Makerere University in 
Uganda, the University of California and San Francisco in the US, and the Uganda 
Ministry of Health (MOH)  (see protocol, Appendix 9).  
This dataset had, up to the time of this analysis, not been analysed and results presented 
elsewhere.  
4.1.1 Research question 
Does the evidence from a pragmatic trial in Uganda show improved quality of patient 
care when treatment policy for fever based on RDT results is applied to a large 
population through routine health services? 
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4.1.2 Aim 
To review evidence from a pragmatic trial to determine if RDT-based policies for fever 
lead to better quality of patient care than presumptive treatment when applied in routine 
practice 
4.1.3 Objectives  
To use the existing data set to: 
1. Describe the quality of guideline implementation in routine practice 
2. Compare effects of a treatment policy for fever based on RDTs versus a policy 
based on clinical diagnosis in relation to: 
a. prescribing of anti-malarials and antibiotics  
b. clinical outcomes 
c. cost 
3. Assess if a treatment policy for fever based on RDTs leads to better targeting of 
antimalarials than a policy based on clinical diagnosis. 
 
The analysis takes place in settings with high, medium and low malaria transmission 
intensity. Where relevant, results are analysed for different age groups (< 5 years versus 
5+ years). 
 
 
 
 
  
 121 
 
4.2 Methods 
This section briefly describes the main features of the UMSP trial, and outlines my 
research strategy for analysing the dataset. A more detailed description of the trial which 
generated the database is found in Appendix 9.   
4.2.1 Trial design 
a) Setting 
The trial was conducted in 3 districts representing 3 malaria transmission settings: 
Tororo (High transmission), Jinja—peri-urban setting (medium transmission) and 
Mubende (low transmission setting). Table 18 below offers further descriptive 
information about the study sites. 
Table 18: Characteristics of the Study Sites 
 
DISTRICTS 
TORORO JINJA MUBENDE 
Location Rural, E. Uganda 
Peri-urban, S.E Uganda, 
near Lake Victoria Rural, S.W. Uganda 
Malaria transmission 
intensity 
High Medium  Low 
Landscape  
Plane, dry 
savannah grassland Hilly grassland Hilly grassland 
Sources: [75]    
b) Design and Data Inventory 
Figure 24 below depicts the trial design and the sets of data used in the analysis. 
Health facilities 
In each of the 3 districts, the team identified two health centres (HCs) for the 
evaluation, all of which without the capacity for microscopy. In both Tororo (high 
transmission) and Jinja (low transmission), the pairs of HCs identified had referral level 
(HC IIIs), while the pair enrolled in Mubende (low transmission) were HC IIs (referral 
level II status). The recommended staffing norm for Uganda is shown in Appendix 2. A 
typical HC III is manned by at least 3 staff, comprising any of the following cadres: 
clinical officers, registered nurses/midwives, enrolled nurses/midwives, nursing 
assistants and laboratory technician/assistants. A typical HC II is manned by at leat 2 
staff consisting of any of a nurse or midwife or nursing assistants. According to the 
protocol (see Appendix 9) each of the HC selected (a) lacked basic microscopy services, 
(b) had at least 3 clinical staff, (c) had a workload of at least 500 patients per month and 
(d) was within radius of Uganda Malaria Surveillance Project (UMSP) sentinel sites. 
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Treatment of malaria was based on clinical judgement at all sites prior to the study. The 
HCs were randomly assigned to the intervention and control arms. At each HC, data 
were collected in 2 phases: before and after the intervention, with each phase lasting 2 
months. 
Figure 24: Trial design and data inventory 
 
 
Purposive selection of 6 HCs from 3 districts representing 3 malaria transmission 
settings: (a) High = 2 HC III; (b) Medium =2 HC III; Low = 2 HC II 
 
2 months of collection of baseline data; 9870 participants (fever = 64.0%). 
Data set (a) 
 Age 
 Presence or history of fever 
 Patients prescribed anti-malarials 
 Patients prescribed antibiotics 
 Patients prescribed analgesics 
 
Randomisation of HCs from each 
transmission zone into intervention 
arm and control arm 
Intervention HCs: 3 days of training, 1 
day of support follow-up, provision of 
RDT and job aids 
 
Control HCs: continue with presumptive 
treatment as usual 
Data set (b) 
 RDT done 
 RDT results 
 Microscopy results 
Data set (c) 
 Age 
 Presence or history of fever 
 Patients prescribed anti-malarials 
 Patients prescribed antibiotics 
 Patients prescribed analgesics 
 
 
2 months collection of follow-up data 
Total = 6138; Fevers = 3963 (69.5%) 
 
2 months collection of follow-up data 
Total = 5702; Fevers = 3997 (70.1%) 
 
Data set (d) 
Clinical status at follow-up on day 5 
(available fever cases evaluated = 928) 
Sub-sample of 25%  
(Total = 1535; fevers = 991 
 
 
Data set (c) 
 Age 
 Presence or history of fever 
 Patients prescribed anti-malarials 
 Patients prescribed antibiotics 
 Patients prescribed analgesics 
 
 
Sub-sample of 25%  
(Total = 1426; fevers = 999) 
 
Data set (d) 
Clinical status at follow-up on day 5 
(available fever cases evaluated = 842) 
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Participants 
The trial recruited all ambulatory patients presenting at the facilities, except those with 
severe conditions, or those who did not consent. However, for the purposes of this 
report, analysis of effects of the intervention was based on participants presenting with 
fever, with or without other symptoms.  
Baseline survey 
The trial was preceded by 2 months of baseline survey during which surveillance data 
were collected on every outpatient with regard to their age, gender, symptoms, 
diagnosis, and treatment prescribed. Follow-up evaluations of patients‘ health outcomes 
were NOT conducted during the baseline survey. In addition, there was no 
parasitological confirmation and typing of malaria during the baseline survey. 
Interventions 
Following the baseline survey, one of the health centres in each district was randomly 
selected to receive to receive the intervention. The intervention consisted of: (a) 3-day 
training in the use of RDTs and RDT-based guideline, (b) provision of RDT kits 
(Paracheck HRP2-based test, manufactured by Orchid Biomedicals (Goa, India), (c) 
provision of guidelines, and (d) additional support training, 2 weeks after the initial 
training. No additional supplies were provided apart from RDT kits and guidelines. 
Once data collection commenced, no additional support training and supervision was 
provided as part of the trial. Health workers selected the patients for RDTs, performed 
the RDTs and read the results of the test.  There was no interference with their 
decisions on who to test, and how to respond to the test results.  
The control HCs in each district did not receive similar training, or RDT kits and related 
job aids, and continued with presumptive treatment as before.  
Post-intervention survey 
Surveillance data collection (age, symptoms, RDT performance, diagnosis, 
prescriptions) continued for 2 more months post-intervention. A sub-sample of the 
study participants (25%) were selected through systematic random sampling from each 
intervention and control HC. They were followed-up and their clinical outcomes 
evaluated at day 5 post treatment initiation. Outcomes were based on self report, 
recorded as one of the following: (a) Improved; (b) No change; (c) Worse; (d) Unable to 
state 
 124 
 
Quality control 
At the time of RDT preparation, a research assistant prepared blood smear for reference 
microscopy. The research assistant stained the smears with 2% Giemsa for 30 minutes, 
mounted them with DPX (distyrene, plasticizer, xylene mountant) and cover slips, and 
stored them in slide boxes. The smears were read at a UMSP reference laboratory in 
Kampala by experienced technicians, who were blinded to the results of the patients‘ 
RDT results. Smears were evaluated for the presence of parasitaemia (asexual forms) 
and gametocytes.  A slide was considered negative when examination of 100 high power 
fields did not reveal asexual parasites or gametocytes.  For quality control, all slides were 
re-read by a second microscopist, and a third reviewer settled any discrepant readings. 
4.2.2 Summary of data collected 
Table 19 below summarises the data used in the analyses that follow 
Table 19: Data used in analysis 
Data  Study arms Source (survey)  
Objectives in which 
data are used 
 RDT done  
 RDT results 
 Microscopy results 
Intervention 
HCs only 
Follow-up  
(dataset (b)) 
Objective 1 
Objective 3  
 
 Age  
 Presence or history of fever  
 Anti-malarials prescribed  
 Antibiotics prescribed 
 Analgesics prescribed 
Intervention 
and control 
HCs 
Baseline and 
follow-up  
( datasets (a)+(c))  
Objective 2  
Objective 3  
 
 Clinical status on day 5 Intervention 
and control 
HCs 
Follow-up  
( data sets (d))  
Objective 2 
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4.2.3 Analyses undertaken in this chapter 
 This section shows how the variables in objectives 1 to 3 were measured using datasets 
(a), (b), (c) and (d). The analyses focus on participants with fever only. 
Table 20: Summary of the analyses carried out in chapter 4 
Variables  Analyses  
Objective 1 
(implementation) 
Use of RDTs and prescribing of antimalarials relative to RDT results  
Diagnostic accuracy of RDTs (sensitivity and specificity) 
Objective 2 
(primary 
outcomes) 
Change in prescribing of antimalarials and antibiotics after 
intervention 
Change in cost after intervention 
Difference in clinical outcomes between intervention and control HCs 
Objective 3 
(secondary 
outcomes) 
Slide positive cases missed by RDTs 
Slide negative cases prescribed antimalarials 
 
4.2.4 Quality of guideline implementation 
The thesis uses data sets describing the use of RDTs and microscopy (dataset (b)) at 
intervention HCs to assess two critical aspects of implementation of RDT-based 
policies, namely HW performance (adherence to guideline) and diagnostic accuracy of 
RDTs. Because of data limitation, this analysis does not evaluate the quality of 
implementation of other components of the guideline such as medical history, clinical 
examination and advice on medications.  Implementation of all components of the 
guideline is assessed in Chapter 5 using a Health Facility Assessment (HFA) tool.  
a) HW performance 
Because of data limitation, judgement of HW performance is based on assessment of 3 
tasks only: (a) use of RDTs, (b) prescribing of antimalarials in response to positive RDT 
results, and (c) prescribing of antimalarials in response to negative RDT results. HWs 
were expected to perform each of the 3 tasks correctly at least 95% of the time. 
Otherwise implementation of the guideline or HW performance was judged to be 
inadequate [104, 106, 127, 128, 140]. The 95% threshold has been used in several health 
service surveys [104, 106, 127, 128]. An economic model developed by Lubell and 
colleagues in 2008 also suggests that the economic advantage (cost-saving) gained by 
using HRP-2-based RDTs over presumptive treatment is lost once HW compliance 
with RDT-based guidelines falls below 95% in children (<5 years) and/or in high 
prevalence areas [140]. 
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b) Diagnostic accuracy of RDT test 
Sensitivity, specificity, false positive and false negative error rates are calculated by cross-
tabulating RDT results with microscopy results. Sensitivity and specificity of RDT at a 
given site was considered high if the respective measure had a value of at least 95% and 
90% [20, 22, 139].  
4.2.5 Primary outcomes 
a) Change in prescribing of anti-malarials and antibiotics 
This objective assesses the effect of implementing an RDT-based guideline on 
prescribing of anti-malarials and antibiotics—the 2 most commonly prescribed items in 
this trial, the 2 items with the greatest implications for cost [12, 13, 33, 140] and the 2 
items at the centre of debate [26, 138].  
Effect is measured as an absolute change from baseline (within 95% CI). It is calculated 
by subtracting the percent of participants prescribed the relevant drugs after introducing 
RDTs (dataset (c)) from the percent at baseline (data set (a)). At each intervention 
setting, change in prescribing is calculated for the pair of intervention and control HCs. 
The results at an intervention HC in a given transmission setting can be compared with 
that at a corresponding control HC to rule out the effects of extraneous factors on the 
results observed at the intervention HC5.  
b) Calculating change in costs 
Perspective: Cost was calculated from the perspective of the provider of care.  
Inputs: I included the cost of biomedical consumables that were used frequently in the 
diagnosis and treatment of fever cases (data sets (a) and (b)); namely anti-malarials, 
antibiotics and antipyretics or analgesics.  
Table 21 below shows the items analysed, the corresponding dosage requirements, unit 
prices and the cost for a full dose required for an average individual in a particular age 
category.  
                                                          
5
 To rule out the role of extraneous factors occurring between pre-test and post-test, which can affect the 
outcome under study, e.g. (a) history: any external event such as stockout of anti-malarials (b) maturation: 
internal changes such as exposure to knowledge (122. Bonate, L.P., Aanalysis of pretest-posttest 
designs2000: Chapman and Hall/CRC. 
 
 127 
 
Table 21 Recommended quantities, unit prices and cost of included inputs 
Items  
Required quantity per case 
(average) 
Unit price* 
US$ (2008)   
Cost per case**  
US$ (2008) 
RDT kits           
<5 1   0.6   0.6 
5+ 1   0.6   0.6 
All 1   0.6   0.6 
            
ACT           
<5 6   0.084   0.504 
5+ 24   0.084   2.016 
All 24   0.084   2.016 
            
Antibiotics: septrin           
<5 3   0.01   0.03 
5+ 20   0.01   0.2 
All 20   0.01   0.2 
            
Antibiotics: others           
<5 6   0.02   0.12 
5+ 40   0.02   0.8 
All 40   0.02   0.8 
            
Weighted cost of antibiotics***         
<5 
   
0.104 
5+ 
   
0.692 
All 
   
0.692 
            
Analgesics           
<5 3   0.003   0.009 
5+ 18   0.003   0.054 
All 18   0.003   0.054 
Source: STG, MOH 
 
NMS 
   
* per tablet/capsule or test 
** assuming full dose as per guideline 
***septrin tablets were prescribed 1.6 times more often than other (6-hourly) antibiotics. A weighted 
average cost of antibiotics are used in analysis of cost, taking into consideration the relative frequency 
of prescribing of the two categories of antibiotics 
 
STG: Standard Treatment Guideline 
MOH: Ministry of health user manual (RDT-based guideline), Uganda  
NMS: National Medical Stores, Uganda 
 
 
 128 
 
In this table, some of the items (e.g. analgesics, ―other antibiotics‖) are grouped 
together.  The list of the full range of specific items6 included in the cost analysis, the 
corresponding dosage requirements and unit prices are shown in Appendix 10 and 
Appendix 11. 
Items that were occasionally prescribed, or were not typically used in the diagnosis and 
treatment of fever cases were excluded (e.g. vaccines, Vitamin A supplements, anti-
helminths). Other programmatic costs (e.g. staff time, the cost of training and support 
supervision) were also excluded because they were not contained in the database, and 
the responsible key informants were not available to provide the necessary information. 
Calculating cost: The cost of any item prescribed to an individual was calculated as: 
Cost = quantity x unit price 
Data sets (a) and (c) only show the types of biomedical consumables prescribed for each 
study participant. They do not show the quantity prescribed or whether the participant 
received all the required items. The analysis assumed that all the identified items were 
prescribed according to the standard treatment guidelines [157, 158], and that all the 
items were received.  
Since the regimens for medicines are age dependent, quantities are computed by age 
groups. For each item prescribed to an individual in a particular age group, I assumed 
the dosage requirement for the average age of an individual in that age group, as shown 
below 
Table 22: Average age of participants by age-groups 
Age group Average age 
a) < 5 years 1.6 years 
b) 5+ years 25 years 
c) All  18.5 years 
 
 
The total cost (for the recommended quantity) of an item that was prescribed to a 
participant in a given age group is obtained by multiplying the required quantity for that 
individual, by the unit price of the item. Prices were extracted from the National 
                                                          
6 E.g. antimalarials: ACT, quinine, SP 
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Medical Stores (NMS) catalogue and price indicator of 2008—which represents the 
official government prices of the items for the period under review [159]. Prices were 
captured in Uganda Shillings (UGX), and subsequently converted to 2008 US$, at an 
exchange rate of UGX 2177.56—the average exchange rate in 2008 as per Bank of 
Uganda [160]. 
Measure of effect: Effect is measured as absolute change from baseline (within 95% CI). 
This is calculated for every study site by subtracting the post-intervention cost from the 
baseline cost. The results show the amount of money added to, or saved by the 
healthcare system, by using RDT-supported guideline to treat a case of fever instead of 
presumptive treatment. Change in cost is calculated for both intervention and control 
HCs. This allows results from intervention HCs to be compared across 3 transmission 
settings to assess if they are significantly different. Further, the result from an 
intervention HC in a given transmission setting can be compared with that at a 
corresponding control HC to rule out the effects of extraneous factors on the results 
observed at the intervention HC.  
 
c) Difference in clinical outcomes between groups 
Data on clinical outcomes is provided for 25% of participants. Measurement of 
outcomes was based on self-reports, and were recorded as (a) Improved; (b) No change; 
(c) Worse; (d) Unable to state. The frequencies for health states (b), (c) and (d) were low 
at most HCs. Therefore, for the purpose of this analysis, responses are grouped into 2 
categories: ―improved‖ and ―not improved‖, where the latter comprises health states 
(b), (c) and (d). 
Assessment of clinical outcomes was carried out at both intervention and control HCs 
during the follow-up surveys.  Since clinical outcomes were not assessed at baseline, this 
analysis does not make a before-and-after comparison as is done in the analysis of 
change in prescribing and cost. Instead, it compares clinical outcomes between each pair 
of intervention and control sites using data set (d). For each pair of HC, I computed the 
percent of patients reporting improvements in their conditions 5 days after initiation of 
treatment. The effect of using a RDT-supported guideline at each transmission zone is 
measured as the ratio of the percent of patients reporting improvement in the 
intervention arm to the percent in the control arm (i.e. RR, 95% CI).  
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4.2.6 Secondary outcomes 
a) Missed cases of malaria after introducing RDTs 
Sub-analysis was undertaken to determine the percent of reference slide positive cases 
who were not prescribed antimalarials at the intervention HCs after introducing RDTs. 
The analysis is undertaken by cross-tabulating the variables ―any antimalarials‖ versus 
―microscopy results‖. The percent of slide positive cases who were not prescribed any 
antimalarials is compared with the false negative (β) error rates at the same HCs. The 
results show the impact of diagnostic inaccuracy of RDTs on the number of malarial 
cases not prescribed any antimalarials.  
 
b) Slide-negative fevers given antimalarials after introducing RDTs 
The analysis described in (a) above also generates the percent of reference slide-negative 
cases prescribed antimalarials at the intervention HCs. These results are compared with 
the false positive (α) error rates at same HCs. They show the impact of diagnostic 
inaccuracy of RDTs on the proportion of slide negative (non-malarial) fevers that are 
still prescribed antimalarials despite use of RDT test.  
4.2.7 Statistical analysis 
Analysis of primary outcomes was carried out using SPSS (PASW statistics 18) to 
compute summary statistics (percent, means and medians) and Revman 5.1 to generate 
confidence intervals (CIs) around measures of effect (differences or risk ratios). For 
computing 95% CIs around summary statistics (e.g. percent, averages)—such as in 
baseline characteristics, clinician adherence, accuracy of RDTs— analyses were carried 
out using MS Excel 2007 as follows.  
CIs around proportions were calculated using the formula for CI for single proportions 
[147], namely: 
CI = p ± z*      
Where: z = z-score (1.96 for 95% CI) 
 p = event rate (percent) 
 q = (1-p) 
n = sample size  
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CIs around arithmetic means for a sample population were calculated by substituting the 
values of standard error (SE) in the following formula.  
 
CI = mean ± z*SE;  
- where z = z-score (1.96 for 95% CI)   
 
Means and SEs were generated using SPSS (PASW statistics 18)  
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4.3 Results  
4.3.1 Characteristics of the study population 
The UMSP trial was located in 3 districts representing 3 malaria transmission settings: 
Tororo (high), Jinja, peri-urban setting (medium), and Mubende (low). Six health centres 
(HCs), 2 from each district, were randomised to the intervention or control arm.  The 
comparison HCs in each district were similar in characteristics: each district pair was of 
level II or III referral status; each HC had at least 3 clinical staff, and each had a 
workload of ≥ 500 patients per month. None of the HCs was capable of performing 
blood slide microscopy for malaria. Table 23  below summarises the study participants.  
Table 23: Study participants 
Variable* 
District Setting Intervention HCs   Control HCs 
Baseline survey               
Total number of 
participants (N) 
Tororo High 1653    2130  
Jinja Medium 1843    1626  
  Mubende Low 1394    1224  
              
Age of participants with 
fever (yrs):  
median (Q1, Q3) 
Tororo High 14 (2, 27)   12 (2, 27) 
Jinja Medium 19 (9, 30)   18 (7, 29) 
Mubende Low 20 (12, 30)   20 (11, 32) 
        
Participants with fever: 
N(%) 
Tororo High 985 (59.6%)   1446 (67.9%) 
Jinja Medium 1006 (54.6%)   1168 (71.8%) 
  Mubende Low 942 (67.6%)   771 (63.0%) 
              
                
Follow-up survey               
Total number of 
participants (N) 
Tororo High 3209    2668  
Jinja Medium 1915    1480  
  Mubende Low 1014    1554  
                
Age of participants with 
fever (yrs):  
median (Q1, Q3)  
Tororo High 5 (1.4, 22)   10 (1.7, 25) 
Jinja Medium 15 (4, 28)   15 (4, 29) 
Mubende Low 20 (10, 30)   21 (8, 28) 
        
Participants with fever: 
N(%)  
Tororo High 2288 (71.3%)   1909 (71.6%) 
Jinja Medium 1073 (56.0%)   1140 (77.0%) 
  Mubende Low 602 (59.4%)   948 (61.0%) 
                
Fever patients with positive 
blood slides for malaria:  
% (95% CI) 
Tororo High 53.5 (53.2, 57.4)  -  
Jinja Medium 36.5 (33.5, 39.5)  -  
Mubende Low 29.3 (25.6, 33.0)  -  
*N =total number; Q1, Q3 = 1st and 3rd quartiles; CI = confidence interval 
 133 
 
A total of 21,710 participants were enrolled during the 4-month study period (2 months 
of baseline survey and 2 months of post-intervention data collection): 9870 during 
baseline and 11,840 during the follow-up surveys. There was no systematic difference 
between the study arms in change (increase or decrease) in enrolment during the follow-
up survey (see Table 23).  
During both surveys, the participants enrolled in Tororo (high transmission) were 
generally younger than those enrolled in Jinja (medium transmission) and Mubende (low 
transmission). There was no difference in participants‘ age between any pair of 
comparison HCs. Additionally, at each study site, there was no difference in the age of 
participants enrolled at baseline versus those enrolled during the follow-up survey; the 
notable exception was the intervention site in Tororo (high transmission), where the 
participants recruited after the intervention were much younger than those recruited at 
baseline (5 years vs. 10 years respectively). 
More than 65.8% of the participants (14283) had fever, with notable variability in the 
prevalence of fever between sites and within sites (before vs. after intervention).  
The prevalence of malaria in fever was assessed at intervention sites only, and only 
during the follow-up survey7. Overall, the percent of fever patients with positive blood 
slides at the intervention centres was 53.3% in Tororo (high transmission), 36.5% in 
Jinja (medium transmission) and 29.3% in Mubende (low transmission). The prevalence 
of malaria in fever patients was higher in younger participants than in older counter 
parts, being 2 times higher in a high transmission setting, and 1.6 times higher in 
medium and low transmission settings (not shown in Table 23). 
4.3.2 Baseline values of study variables 
Baseline data were not analysed prior to randomisation, and were not used in matching 
the HCs. In this section I present the baseline values for 3 outcome variables at the 
various study sites: (a) patients prescribed any anti-malarials, (b) patients prescribed 
antibiotics and (c) the average cost of diagnosing and treating a case of fever. The aim is 
to show any similarities and/or imbalance, at baseline, between comparison HCs. Data 
                                                          
7 Reference microscopy was performed at the intervention sites after introducing RDT-based guideline, to 
assess the accuracy of RDTs 
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on clinical outcomes are not presented here because the relevant data were not captured 
during baseline.  
Table 24: Baseline values of study variables 
      Control HCs   Intervention HCs 
Variable District Setting Value (95% CI)   Value (95% CI) 
                
Patients prescribed 
any anti-malarials (%) 
Tororo High 88.7 (87.1, 90.4)   92.9 (91.3, 94.5) 
Jinja Medium 97.3 (96.4, 98.4)   93.3 (91.8, 94.9) 
  Mubende Low 99.5 (99.0, 100.0)   99.4 (98.9, 99.9) 
                
Patients prescribed 
any antibiotics (%) 
Tororo High 53.1 (50.5, 55.7)   43.7 (40.6, 46.8) 
Jinja Medium 55.1 (52.2, 58.0)   50.7 (47.6, 53.8) 
  Mubende Low 39.5 (36.0, 43.0)   51.4 (48.2, 54.6) 
                
Cost of diagnosing 
and treating 1 case of 
fever(2008 US$)  
Tororo High 1.44 (1.39, 1.49)   1.47 (1.41, 1.53) 
Jinja Medium 1.97 (1.92, 2.01)   1.86 (1.81, 1.92) 
Mubende Low 2.07 (2.02, 2.13)   2.04 (1.99, 2.09) 
 
Overall 94.5% of fevers were prescribed anti-malarials at baseline. The percent of cases 
prescribed anti-malarials was similar across the 3 transmission zones. In Mubende (low), 
virtually all participants were prescribed antimalarials at baseline. The percent of cases 
prescribed antimalarials in Tororo (high transmission) was significantly lower. 
Statistically significant differences were detected between the pair of HCs in Tororo 
(high) and Jinja (medium) in the amount of anti-malarials prescribing at baseline. No 
significant imbalance was detected between the pair in Mubende.  
About half (49.7%) of fever cases were prescribed any antibiotics at baseline. There 
were significant imbalances between the comparison HCs in Tororo (high) and 
Mubende (low) in the percent of cases prescribed antibiotics. No significant imbalance 
was detected between the pair in Jinja (medium). No systematic pattern in prescribing of 
antibiotics was detected relative to malaria transmission settings. 
The cost of diagnosing and treating a case of fever at all the study sites ranged from just 
under US$ 1.45 to just over US$ 2.0, with an overall average of US$ 1.78 (2008US$). 
The lower the malaria transmission intensity, the higher was the average cost. There was 
no baseline imbalance in cost between any pair of comparison HCs. 
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4.3.3 Quality of implementation of RDT-based guideline 
This section describes the quality of implementation of RDT-supported guideline in 
terms of 2 critical success factors: 
(a) Clinician adherence with the requirement to test all suspected cases of malaria 
(fever) prior to treatment; and to restrict anti-malarials to those with positive 
RDT tests only 
(b) Accuracy of the RDT results (sensitivity, specificity, α- and β-errors).  
Clinician adherence 
Table 25 below summarises HWs use of RDTs and response to the results in patients 
presenting with fever. 
Table 25: Use of RDTs, HW response to RDT results, and diagnostic accuracy of RDTs 
       Intervention HCs 
Variable District Setting N* % (95% CI) 
           
Patients tested with RDT  Tororo High 2221 97.3 (96.6, 98.0) 
  Jinja Medium 1044 97.9 (97.0, 98.8) 
  Mubende Low 594 98.7 (97.8, 99.6) 
           
Patients with positive RDT & 
prescribed anti-malarials  
Tororo High 1617 99.4 (99.0, 99.8) 
Jinja Medium 475 98.7 (97.7, 99.7) 
  Mubende Low 189 100 (100, 100) 
           
Patients with negative RDT & 
prescribed anti-malarials  
Tororo High 604 0.7 (0.0, 1.4) 
Jinja Medium 569 0.0 (0.0, 0.0) 
  Mubende Low 405 0.5 (0.0, 1.2) 
*N: number of febrile patients analysed 
At least 97% of all fever cases at each intervention site were tested with RDTs prior to 
treatment. In addition, virtually all (98.7% to 100%) fever cases that tested positive on 
RDT were prescribed anti-malarials. On the other hand, practically none (<0.8%) of 
those that tested negative on RDT received any anti-malarials. These results show that 
HWs complied adequately with all the requirements of the guidelines regarding use of 
RDTs and prescribing of antimalarials. Accordingly, the clinicians are judged as having 
shown high adherence to these components of the guideline. 
Diagnostic accuracy of RDTs 
Table 26 displays the performance of RDTs against reference microscopy in febrile 
patients, by transmission settings. 
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Table 26: RDT results versus reference microscopy results in patients with fever 
   Results of reference microscopy 
   + - 
  
+ 98.0% (n =1163) 43.9% (n = 451) 
Tororo  
(High) 
RDT results 
- 2.0% (n = 24) 56.1% (n = 577) 
  
  Total 1187 1028 
     
  
+ 95.5% (n = 341) 15.2% (n = 94) 
Jinja  
(Medium) 
RDT results 
- 4.5% (n = 16) 84.8% (n = 523) 
  
  Total 357 617 
     
  
+ 82.8% (n = 144) 10.5% (n = 144) 
Mubende  
(Low) 
RDT results 
- 17.2% (n = 30) 89.5% (n = 374) 
  
  Total 174 418 
n = number of events; % refers to the proportions of cases detected by RDT out of the column total  
 
The sensitivity of RDTs was high in high transmission (98.0%; 95% CI: 97.4% to 
98.6%) and medium transmission (95.5%; 95% CI: 94.3% to 96.7%) transmission 
settings; it was low (82.8%; 95% CI: 79.8% to 85.8%) in low transmission setting. 
Accordingly, false-negative error rates of RDT were 2%, 4.5% and 17.2% at high, 
medium and low transmission sites respectively. Specificity of RDT varied between high 
and low (89.5%; 95% CI: 87.5% to 91.0%) in low transmission setting. The specificity 
of RDTs was low in both medium (84.8%) and high (56.1%) transmission settings. 
Accordingly, false positive error rates of RDT were 10.5%, 15.2% and 43.1% in low, 
medium and high transmission settings respectively.  
Therefore, implementation of the RDT-guideline was characterized by high clinician 
adherence to the recommendations of the guideline. It was also characterised by a high 
false positive (α-error) rate at the high transmission site, and by high false negative (β-
error) rate at the low transmission site.  
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4.3.4 Change in prescribing of antimalarials after intervention 
Table 27 below displays the amount of change in the proportion of fever patients 
prescribed anti-malarials at intervention sites after introducing RDT-based guidelines. 
Additionally, it displays similar results for corresponding control sites. The summary 
data showing the number of patients prescribed antimalarials before and after the 
intervention are shown in Appendix 12. 
Table 27: Change in proportion of patients prescribed antimalarials after intervention 
District Setting 
  Intervention HCs   Control HCs 
 N* % (95% CI)  N* % (95% CI) 
Tororo High  3273 -22.1 (-24.6, -19.6)  3355 5.9 (4.0, 7.8) 
Jinja Medium  2079 -48.9 (-52.3, -45.5)  2308 1.0 (-0.2, 2.2) 
Mubende Low  1544 -60.2  (-64.1, -56.3)  1719 -0.2 (-0.9, 10.5) 
*N: total number of febrile participants analysed at each site, before and after intervention. Summary 
statistics showing number analysed and number prescribed antimalarials before and after intervention is 
shown in Appendix 12 
The analysis shows that prescribing of anti-malarials reduced significantly at all the 
intervention sites after introducing RDT-based guidelines. In addition, it shows 
significant differences between the transmission zones in the decline in the usage of 
antimalarials. The percent of patients prescribed anti-malarials declined by 22.1% in 
Tororo (high transmission); by 48.9% in Jinja (medium transmission) and by 60.2% in 
Mubende (low transmission). Therefore, the lower the malaria transmission intensity, 
the higher was the decline in the number of patients prescribed anti-malarials after 
introducing RDT guideline at the intervention sites. 
There was no significant reduction in prescribing of anti-malarials at any of the control 
sites during the corresponding periods.   
A sub-group analysis (Table 28) shows that the decline in usage of anti-malarials at the 
intervention sites was more notable among older participants (≥5 years old) than in 
younger children (<5 years old). The decline among participants who were ≥5 years old 
versus those who were <5 years old was 5.5 times higher in Tororo (high transmission), 
1.5 times higher in Jinja (medium transmission) and 1.2 times higher in Mubende (low 
transmission).  
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Table 28: Change in proportion of patients prescribed antimalarials at intervention HCs, by age 
group 
District Setting 
  < 5 years   < 5 years 
 N* % (95% CI)  N* % (95% CI) 
Tororo High  1804 -7.7 (-7.73, -7.67)  1469 -42.1 (-42.13, -42.07) 
Jinja Medium  605 -36.7 (-36.79, -36.61)  2015 -55.8 (-55.83, -55.77) 
Mubende Low  343 -52.0 (-52.06, -51.94)  1201 -73.3 (-73.31, -73.29) 
*N: total number of febrile participants analysed at each site, before and after intervention. Summary 
statistics showing number analysed and number prescribed antimalarials before and after intervention is 
shown in Appendix 12 
 
4.3.5 Change in prescribing of antibiotics after intervention 
Table 29 below shows the change in the proportion of fever patients prescribed 
antibiotics at intervention sites after introducing RDT-based guidelines. Corresponding 
figures are presented for relevant control sites. Data showing the number prescribed 
antibiotics before and after introducing RDT-based guidelines are found in Appendix 13 
Table 29: Change in proportion of patients prescribed antibiotics after intervention 
District Setting 
  Intervention HCs   Control HCs 
 N* % (95% CI)  N* % (95% CI) 
Tororo High  3273 -5.0 (-8.7, -1.3)  3355 -0.4 (-3.8, 3.0) 
Jinja Medium  2081 -2.7 (-7.0, 1.5)  2308 -4.7 (-8.8, -0.6) 
Mubende Low  1544 -4.6  (-9.7, 0.5)  1719 -0.6 (-5.2, 4.0) 
*N: total number of febrile participants analysed at each site, before and after intervention. Summary 
statistics showing number analysed and number prescribed antibiotics before and after intervention is 
shown in Appendix 13 
In general, use of the RDT-guideline did not lead to large declines in the amount of 
antibiotics prescribed at any of the intervention sites (reduced by 5% or less). There was 
a marginal but significant decline in the amount of antibiotics prescribed at the 
intervention HC in high transmission area. No statistically significant declines were 
detected at the intervention sites in medium and low transmission areas. At the control 
HCS, there was a marginal but significant decrease in prescribing of antibiotics in Jinja 
(medium transmission area). No significant changes were detected in high and low 
transmission areas. In general, there was no systematic pattern in the effects of the 
intervention on prescribing of antibiotics  
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4.3.6 Change in cost after introducing RDT-based guidelines  
Table 30 shows the change in the cost of medical consumables per case of fever at 
intervention sites, after introducing RDT-based guidelines. It also shows changes in cost 
at corresponding intervention HCs. The costs consist of the values of biomedical 
consumables used in diagnosing and treating a case of fever. The absolute values from 
which these differences were computed are shown in Appendix 14. 
Table 30: Change in average healthcare cost after intervention (2008 US$) 
District 
Transmission 
setting 
Intervention HCs  Control HCs 
US$ 
(2008) (95% CI)  
US$ 
(2008) (95% CI) 
Tororo High 0.02 (-0.21, 0.25)  -0.02 (-0.21, 0.25) 
Jinja Medium -0.33 (-0.54, -0.12)  -0.22 (-0.40, -0.06) 
Mubende Low -0.50 (-0.69, -0.31)  -0.16 (-0.39, 0.07) 
 
After introducing RDT-supported guideline, no significant change in healthcare cost 
was detected at the intervention HC in high transmission setting. In medium and low 
transmission settings, the cost of medical consumables per case of fever fell 
significantly, by US$ 0.33 (17.7%) and US$ 0.50 (24.5%) respectively. Therefore, the 
lower the malaria transmission intensity in an area, the larger was the amount of cost-
saving which was accrued by the use of RDT-based guidelines.  
No significant change in cost was detected at the control HCs in high and low 
transmission settings. However, a significant decline in cost was detected at the control 
HC in medium transmission zone, although the amount of change at the corresponding 
intervention HC was 1.5 times higher. 
A sub-group analysis by age (Table 31) shows that among children (<5 years), use of the 
RDT guideline was associated with an increase in cost at all the intervention HCs—
although the increase was not statistically significant in medium transmission setting.  
Table 31: Change in healthcare costs at intervention sites, by age groups 
District 
Transmission 
setting 
< 5 years  5 + years 
US$ 
(2008) (95% CI)  
US$ 
(2008) (95% CI) 
Tororo High 0.61 (0.47, 0.75)  -0.23 (-0.56, 0.10) 
Jinja Medium 0.47 (-0.09, 0.85)  -0.47 (-0.69, -0.25) 
Mubende Low 0.42 (0.13, 0.71)  -0.65 (-0.85, -0.45) 
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On the other hand, the intervention was associated with significant cost savings among 
older children and adults (5+ years) at the intervention sites in low and medium 
transmission settings. The cost of diagnosing and treating an older case of fever (5+ 
years old) fell by US$ 0.47 (20.7%) in medium transmission setting and by US$ 0.65 
(27.1%) in low transmission setting. No significant decline in cost was detected among 
the older participants in high transmission setting. (Appendix 15 shows the average cost 
at the intervention HCs before and after introducing RDTs) 
4.3.7 Difference in clinical status between comparison groups  
During the follow-up survey, a sub-sample (25%) of all fever patients were randomly 
selected from each intervention and control centre. They were followed-up and their 
clinical status evaluated at day 5 after treatment initiation. Because assessment of clinical 
status was not carried out at baseline, comparison of clinical status is made between the 
pair of HCs within each transmission setting using data from follow-up survey only 
(data set (d)).  
Clinical assessments were based on self-reports, by the patients or their caretakers. 
Figure 25 below shows the percent of patients from each arm reporting improvement in 
symptoms after 5 days of treatment.  Appendix 16 presents the various perceived 
clinical states at day 5 by age groups.  
 
 
A high proportion of fever patients from both arms reported improvement in their 
clinical status at day 5 of treatment at each of the study sites (89.2% to 97.2%). At all of 
the transmission settings, no significant difference was detected between the 2 study 
arms in the percent of fever patients reporting improvement in their symptoms.  
Study or Subgroup 
High transmission 
Medium transmission 
Low transmission 
% 
90.7 
96.3 
97.2 
Total 
571 
216 
141 
% 
89.2 
95.9 
95.2 
Total 
388 
267 
187 
Risk Ratio [95% CI] 
1.02 [0.97, 1.06] 
1.00 [0.97, 1.04] 
1.02 [0.98, 1.07] 
PT* 
Risk Ratio [95% CI] 
0.5 0.7 1 1.5 2 
Favours 
PT* 
Favours RDT-guideline 
RDT-guideline 
* PT = presumptive treatment arm 
Figure 25: Patients reporting improvement in symptoms at day 5 of treatment 
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Therefore, neither RDT-supported guideline nor presumptive treatment was 
significantly superior to the other in terms of the effect of their use on clinical 
outcomes.  
4.3.8 Missed malaria cases 
Table 32 shows the number of true malaria cases (with positive slides) that were not 
prescribed any anti-malarial treatment at intervention sites after introducing RDT 
guidelines. It also shows the false negative error rates due to RDT at corresponding 
sites.  
Table 32: Slide positive cases not prescribed anti-malarials at intervention HCs  
Variable Site Setting* N** % (95% CI) 
Patients with positive BS 
not prescribed anti-malarials 
Tororo High  1189 1.9 (1.1, 2.7) 
Jinja Medium  358 5.9 (3.5, 8.3) 
Mubende Low  174 17.2 (11.6, 22.8) 
* malaria transmission intensity in the region 
**N: total number of febrile patients with positive reference slides 
 
The proportion of slide positive cases that were not prescribed antimalarials in Tororo 
(high transmission) and Jinja (medium transmission) was 2% and 4.5% respectively. In 
Mubende (low transmission) more than 17% of slide positive cases were not prescribed 
anti-malarial treatment. Most (>70%) of the malarial cases that missed anti-malarial 
treatment were older children and adults (>5 years old) (not shown in Table 21). 
Table 32 also shows that the percent of missed malaria cases corresponds with the RDT 
false negative error rates at the corresponding sites, namely 2%, 4.5%and 17.2% 
respectively (see Table 26). This implies that the observed under-treatment of malaria at 
the intervention HCs can be attributed almost exclusively to the inaccuracy of the RDT, 
rather than to clinician non-compliance.  
4.3.9 Slide-negative fevers prescribed anti-malarials 
Table 33 shows the number of slide negative cases that were prescribed anti-malarials at 
intervention sites after introducing RDT guidelines. In addition, it displays the false 
positive (α) error rates due to RDT at corresponding sites.  
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Table 33: Slide negative cases prescribed anti-malarials at intervention HCs  
Variable Site Setting* N % (95% CI) 
Patients with negative BS 
and prescribed anti-
malarials 
Tororo High  1032 43.1 (40.1, 46.1) 
Jinja Medium  622 15.0 (12.2, 17.8) 
Mubende Low  419 11.0 (8.0, 14.0) 
* malaria transmission intensity in the region 
**N: total number of febrile patients with negative reference slides 
The results show that, during RDT era, the proportion of cases prescribed anti-malarials 
at high, medium and low transmission sites was 43.1%, 15.0% and 10.5% respectively. 
These numbers correspond with the false positive error rates due to RDT at the 
respective intervention sites, which are 43.9%, 15.2% and 10.5% respectively (see Table 
26). Therefore, use of the guideline did not eliminate over-use of antimalarials totally. 
This over-use of antimalarials can be attributed almost entirely to the diagnostic 
inaccuracy of RDT rather than to clinician non-compliance. 
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4.3.10 Summary of main findings 
The analysis shows a high level of clinician adherence to RDT-supported treatment. At 
least 97% of all fever patients were tested for malaria with RDT across all intervention 
sites. In addition, nearly all (>98%) patients testing positive on RDT were prescribed 
anti-malarials. On the other hand, practically none of those testing negative were 
prescribed any anti-malarials.  
Prior to introducing RDT-based guidelines, the majority (>90%) of fever patients were 
prescribed anti-malarials. After introducing RDT-supported guidelines, anti-malarial 
prescribing declined by 22%, 49% and 60% at the intervention sites in settings with 
high, medium and low malaria transmission respectively. Relative to younger patients 
(<5 years), anti-malarial prescribing declined in older patients (≥5 years) at the 
corresponding sites by a factor of 5.5, 1.5 and 1.2 respectively.  
Despite the near-perfect compliance with RDT-based guideline, their use did not 
completely eliminate over-use of anti-malarials at intervention HCs. The percent of 
slide-negative patients prescribed anti-malarials in the era of RDT was 43.1%, 15% and 
11% in high, medium and low transmission setting, corresponding with the RDT α-
error rates at the respective sites. 
RDT-supported treatment resulted in some malarial (slide positive) fever patients not 
receiving anti-malarials at the intervention sites. The proportion of malarial fever 
patients not given anti-malarials at the intervention sites at high, medium and low 
transmission sites was 1.9%, 5.9% and 17.2% respectively. These figures closely 
correspond with the RDT false-negative error rates at the respective sites, namely 2.0%, 
4.5% and 17.2% respectively.  
Use of the RDT-based guideline did not have any clear-cut effect on antibiotics usage.  
The analysis did not demonstrate convincingly whether or not the use of RDT was 
superior to presumptive treatment in terms of patients‘ clinical outcomes. Reported 
improvements in symptoms were similar (>90%) in both arms, but the findings were 
not statistically significant. 
Prior to the intervention, the cost of treating a case of fever presumptively ranged from 
US$1.45 (high transmission) to US$ 2.0 (low transmission), with no imbalance between 
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any pair of comparison HCs. After the intervention, no significant change in cost was 
detected at the intervention HC in high transmission setting. At the HCs in medium and 
low transmission settings, the post-intervention cost of diagnosis and treatment fell by 
US$ 0.33 (17.7%) and US$ 0.50 (24.5%) respectively. In both medium and low 
transmission settings, cost-savings were accrued exclusively in older children and adults: 
US$0.47 (20.7%) and US$0.65 (27.1%) respectively. Use of the guidelines in younger 
children resulted in additional costs to the healthcare system at all the intervention sites. 
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4.4 Discussion 
This chapter uses a dataset from a pragmatic trial from Uganda to answer the question 
whether an RDT-based guideline can be sufficiently implemented in routine practice 
and whether its application in routine practice can lead to better prescribing, better 
clinical outcomes and significant cost-saving. Effects are compared relative to a 
treatment policy for fever based on clinical judgement.  
4.4.1 Quality of implementation of guideline 
a) Clinician adherence 
The results of this analysis show that, even in routine practice settings, HWs can request 
RDTs and respond to the results as per the new guidelines They suggest that HWs may 
have high confidence in RDT-based guidelines in routine practice. These findings 
contrast with the results observed in 3 of the 4 trials synthesized in chapter 3 in which 
as many as 40% to 80% of patients with negative RDT results were prescribed 
antimalarials [34-36]. They also differ from evidence from observational studies carried 
out in routine clinical settings, which show that large numbers of fever patients are 
either treated presumptively or are prescribed antimalarials despite having a negative 
RDT results—despite exposure to training, and the presence of RDTs and job aids [32, 
33]. However, these findings are consistent with those from Zambia by Yeboah and 
colleagues where HWs used RDTs and prescribed antimalarials according to the results 
most of the time. A more recent non-randomised study from Uganda—carried out in 
the same epidemiological settings as this trial—detected high utilisation of RDTs. 
However, an average of 30% of fever patients with negative RDTs were given 
antimalarials despite regular support supervision [11], which also found high RDT 
utilisation by health workers.  Therefore, the adherence levels shown in this analysis 
appear to be uncommon. 
It is unclear why HWs showed high level of adherence to RDT results in this trial. 
Literature suggests that factors such as being a paraprofessional staff [90, 112, 146], 
adequate in-service training [90, 108, 117, 146] and support supervision [93, 112, 117, 
146] are associated with high level of adherence to guidelines. The cadres of staff 
involved in this trial appear to be similar to those in the trials analysed in chapter 3 and 
in several other observational studies. In this trial, there was no formal support 
supervision offered to HWs once data collection has commenced. Therefore, in this 
 146 
 
trial, high utilisation of RDTs and adherence to results may be attributed to adequate 
training and the continued informal interactions with researchers. However, due to data 
limitation, we do not know how proficient HWs were in implementation other 
components of the guideline, notably clinical assessment, the multiple steps in carrying 
out an RDT test, and patient counselling. These limitations are discussed further in 
section 4.4.7 (a). 
b) Accuracy of RDT 
In addition, the analysis confirms that use of HRP-2 RDTs is characterised by varying 
levels of false positivity, which is considerably high in high transmission settings. In this 
analysis, over-use of antimalarials remained substantially high in high transmission 
settings. This indicates that, despite adequate clinician compliance with the guideline, 
use of RDT-based guidelines does not totally eliminate over-use of anti-malarials—
especially in high transmission settings. This undermines a key objective of RDT-based 
policies in high malaria transmission areas: which is to reduce over-use of antimalarials 
and to save cost [14, 32-35, 53].  
The evidence from this analysis and other studies [135, 161] suggest that use of RDTs to 
guide treatment of fever may be associated with a risk of malarial fevers not being 
prescribed antimalarials, due to the lower sensitivity of RDT relative to presumptive 
treatment of fever. In this analysis, this risk was highest in a low transmission setting, 
where the sensitivity of an HRP-2 type RDT was only 82.8%. The sensitivity of HRP-2 
RDTs falls at parasite concentration < 50 parasites/µL of blood, e.g. in non-immune 
population in low prevalence areas and in children [22] (see literature review, section 
2.8.3). Therefore, in non-immune individuals, clinical disease can occur at parasite 
densities lower than the lower detection limits of the common RDTs (see literature 
review). In this analysis, it is unclear if the high false negative error rate in low 
transmission setting is the result of errors committed in carrying out the tests, or if it is 
due to reduced sensitivity of RDTs at low parasite concentrations.  
Two previous evaluations of HRP2-based assays were conducted in 1999 (ParaSight™-
F test)[162] and 2002 (Paracheck Pf® test, Orchid Biomedical Systems, Goa, India)[163] 
in malaria transmission settings similar to Mubende. In both studies, RDTs were 
performed by health unit staff and results compared against reference microscopy. In 
both studies, the RDTs evaluated had sensitivity of at least 97% at parasite density 
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above 500/µL, and specificity of at least 86 % against. In one of the studies, sensitivity 
was reportedly lower (figures not provided) at parasite densities below 100/ µL [163]. A 
more recent assessment of RDT performance in similar settings, carried out during both 
dry and rainy seasons, detected an average sensitivity of 91% of an HRP2-based assay 
(Paracheck Pf® test, Orchid Biomedical Systems, Goa, India) [164]. Therefore, a 
sensitivity of 82.8% for an HRP2-based assay (Paracheck Pf® test (Orchid Biomedical 
Systems, Goa, India) appears atypical, and might signal a lack of proficiency in the use 
of RDTs by health unit staff. 
An objective of introducing RDT-based policies instead of presumptive treatment is to 
target antimalarials to slide positive fever cases [19, 138]. These results suggest that RDT 
guided treatment of fever may not result in better targeting of antimalarials in slide 
positive cases, as some of them are missed. Presumptive treatment of fever is more 
likely to cover all or most malarial fevers with antimalarials than RDT-guided treatment. 
4.4.2 Effect on prescribing of anti-malarials 
The analysis also suggests that, despite the high false positive error rate associated with 
HRP-2 type of RDTs, use of the guideline in routine clinical settings can considerably 
reduce anti-malarials prescribing at all transmission settings. However, use of the 
guideline is more effective in reducing usage of antimalarials in older participants (5+ 
years) than in children (<5 years), and in lower transmission settings than in high 
transmission settings.     
In chapter 3, it was noted that the impact of RDT-based guidelines on prescribing of 
antimalarials is dependent on the degree of HW compliance with RDT results. For 
example, usage of antimalarials declined by 77% point (RR = 0.23; 95% CI: 0.14, 0.38) 
in a trial where HWs prescribed antimalarials to RDT-negative patients 0.6% of the time 
[37]. On the other hand  there was no difference in prescribing of antimalarials between 
RDT and presumptive treatment arms in trials where HWs prescribed antimalarials to 
RDT-negative patients more than 80% of the time (RR = 1.02, 0.95, 1.09) [34]. Trials in 
which HWs showed partial compliance detected marginal declines in prescribing of 
antimalarials [35, 36]. Evidence from this chapter shows the effect of RDT-based 
policies in a context of near perfect compliance. Therefore, in the pragmatic trial, 
variability in prescribing across sites is explained largely by the local malaria prevalence. 
This clearly illustrates that local malaria epidemiology is an important determinant of the 
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magnitude of effect of RDT-based policy on prescribing of antimalarials [14, 21, 22, 
139, 144]. Implementation of RDT-based policies may need to be targeted according to 
pattern of malaria prevalence in a country, rather than adopting a one-size-fits-all policy 
for all regions within the country.  The trials synthesized in chapter 3 did not 
disaggregate results by malaria prevalence—which undermines our ability to compare 
the results of this analysis with those in chapter 3. 
4.4.3 Effects on prescribing of antibiotics 
RDT-based policies are intended to aid the identification of parasite-negative individuals 
in whom alternative diagnoses can be sought [19, 70-72]; and to aid better targeting of 
antibiotics relative to clinical diagnosis [72, 165]. Owing to the lack of capacity to 
differentiate between the different causes of non-malarial fevers at lower level health 
facilities, use of RDT-based guidelines could lead to increased and unnecessary use of 
antibiotics [138, 155].  
The results of this analysis suggest that use of RDT-based guidelines may not have 
significant effect on antibiotics usage, especially in low and medium transmission 
settings. A small (4.7%) but statistically significant reduction in prescribing of antibiotics 
was also detected at the control HC in Jinja (medium) transmission. The reason for this 
is unclear; perhaps it was due to shortage of antibiotics. In the absence of definitive 
diagnoses of the causes of non-malarial fevers, this analysis cannot judge if prescribing 
of antibiotics for RDT-negative fevers, or if withholding them from RDT-positive cases 
constituted rational prescribing [138]. 
In chapter 3, it was noted that one of the trials detected no significant difference in 
prescribing of antibiotics between the two comparison arms (RR = 0.97, 95% CI: 0.90 
to 1.05)[34]; while one trial detected a significant (19%) increase in prescribing of 
antibiotics in the intervention arm (RR = 1.19, 95% CI: 1.06 to 1.34), especially in older 
age group (>5 years) [36]. However, a cross-over trial from Zanzibar (Tanzania) found 
that use of RDT-supported guidelines was associated with a 40% increase in antibiotics 
prescribing [121]. A more recent observational study  in Tanzania also found that, 
relative to presumptive treatment of fever patients, use of RDT-based guidelines was 
associated with a 44% increase in antibiotics usage [156].  
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Therefore, the evidence from this analysis and previous studies indicate that use of 
RDT-based guidelines in routine clinical settings may not result in a significant change 
in antibiotics prescribing. In any case, it may lead to an increase in prescribing of 
antibiotics.  
4.4.4 Clinical outcomes 
One of the drawbacks of RDT-based policies relative to clinical diagnosis is the 
increased risk of mortality and morbidity from missed malaria cases, especially in 
children [26]. This analysis detected no statistically significant difference in clinical 
outcomes among fever patients treated according to RDT guidelines versus those 
treated clinically. This suggests that the low sensitivity (17.2% false positivity error rate) 
of RDTs at the low transmission site did not influence morbidity significantly. 
We noted in chapter 3 that the two trials which evaluated effect of the intervention on 
clinical outcomes also detected no significant difference in clinical outcomes between 
the comparison arms (RDT vs. clinical diagnosis) [34, 37]. However, the cross-over trial 
from Zanzibar (Tanzania) detected a statistically significant reduction (from about 5% 
to 2.5%) in the risk of persistent symptoms after introducing RDT guidelines (OR = 
0.5, 95% CI: 0.3 to 0.9, p = 0.005)[121].  
In general, the evidence from this analysis and those in chapter 3 suggests that neither 
an RDT-supported policy nor a presumptive treatment of fever is significantly superior 
to the other in terms of their effects on clinical outcomes. However, it is possible that 
the analyses in chapters 3 and 4 failed to detect a difference between the comparison 
interventions because of design and measurement limitations.  
We know from literature that measures of clinical outcomes are usually not sensitive 
enough for demonstrating differences in quality of care, especially subjective ones such 
as those evaluated in this thesis (chapters 3 and 4) [85]. The intervention is applied at 
the level of HWs, yet clinical outcomes are assessed at the level of the patient. Clinical 
outcomes may be influenced by several factors other than the intervention—such as 
effectiveness of treatment, patient compliance with treatment, and demographics [85]. 
As such, clear differences in the quality of care as shown by process measures may not 
translate into differences in clinical outcomes [85]. Therefore, a lack of improvement in 
clinical outcomes (in both chapters 3 and 4) may indicate that the indicators of clinical 
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outcomes evaluated in chapters 3 and 4 are not valid for demonstrating differences in 
the effects of the interventions; and may not imply that there was lack of improvement 
in the overall quality of care [85].  
Further, different components of a complex intervention (such as the guideline under 
evaluation) may be linked to different outcome indicators [74]. For example, the value 
of antimalarials saved per patient is directly linked to the extent to which HWs use 
RDTs and prescribe antimalarials relative to RDT results. On the other hand, 
improvement in clinical outcomes is expected mainly from improved management of 
non-malarials fevers [19, 70-72]—as long as HWs are proficient in using RDTs. 
Management of RDT negative patients at low referral facilities requires good clinical 
acumen which a dispensary or HC staff might lack [138]; and adequate clinical 
assessment [138, 155, 157, 166]—which we have not been able to evaluate in both 
chapters 3 and 4 because of data limitation. It is possible that there was no difference 
between the comparison interventions in the quality of care offered to parasite negative 
patients.   
4.4.5 Treatment costs  
This analysis suggests that use of RDT-supported policy instead of presumptive 
treatment of fever can reduce healthcare cost in normal clinical practice by 25% and by 
18% in low and medium malaria transmission settings respectively. The potential of the 
policy to save cost in high transmission settings is questionable. More notably, 
significant savings are accrued exclusively in older patients (5+ years). In children (< 5 
years old) use of the policy to guide treatment of fever results in added cost to the 
healthcare system in all transmission settings, despite adequate clinician adherence to 
guidelines.  
A significant decline in cost worth US$ 0.22 (95% CI: US$-0.40 to US$-0.06) was 
detected at the control HC in medium transmission setting (the cost-saving at the 
corresponding intervention site was US$ 0.33). This may be a signal that declines in cost 
(or resource use in general) may be a result of shortages of supplies or inputs in the 
health system—a factor which could not be investigated by this analysis. 
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In this particular analysis which is based on HRP-2 type of RDT, the potentials for cost-
saving at the high transmission site could have been partly undermined by the low 
specificity of RDTs in this setting [138]. 
The analysis in this chapter shows the amount of cost that can be saved in different 
malaria transmission settings and in different age groups when HWs comply with an 
RDT-based guideline adequately. These findings are consistent with those from the 
economic models summarised in the literature review, which suggest that use of RDTs 
to guide fever management can reduce healthcare cost by 21% to 25% in low to 
moderate malaria prevalence areas if clinicians adhere adequately with RDT-based 
guidelines [12, 13, 33, 72, 140, 144].  The findings of this analysis contrasts with those 
from another pragamatic trial from Tanzania. Whereas use of RDTs was associated with 
a 21% reduction in healthcare cost in moderate malaria transmission areas, its use was 
associated with a 41% increase in cost in high transmission areas [33]. The reason for 
this was that HWs did not follow the guideline in low transmission areas [33]. 
Therefore, when applied in a context of adequate HW adherence to guidelines, RDT-
supported policy for malaria can save money in routine practice in low and medium 
transmission, especially if their use is limited to older children and adults. In high 
transmission settings, the effect of the policy on cost-saving is questionable, even 
among older patients—even if HWs adhere adequately with the guideline.  
It can be noted that in Jinja (medium transmission), the proportion of participants with 
fever was consistently higher in the control HC than in the intervention HC, despite the 
fact that the pair of HCs were similar in staffing, participants‘ age and (lack of) capacity 
for microscopy. Because analyses of resource use were based on before-and-after 
comparisons, the imbalance between comparison HCs may not have significantly 
influenced the results at the respective HCs. However, the imbalance may have 
implications for budget impact analysis since we do not know which of the pair 
represents the typical HC in the region in terms of epidemiology of fever. 
4.4.6 Usefulness of the analysis 
The findings of this analysis can inform decisions as to whether it is worthwhile, from 
an economic perspective, to scale-up the use of RDT-supported guideline to eligible 
HCs in all transmission settings, or whether to limit its application to low and medium 
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transmission settings only; and whether to use it in all age-groups or target older 
children and adults (5+ years) only [26, 70, 138].  
These results suggest that it makes economic sense to restrict the use of RDT-based 
policy to older patients (5+ years) and to low and medium transmission zones only. Its 
use in children adds cost to the healthcare system, while the potential for cost saving in 
high transmission areas is equivocal. However, varying diagnostic strategies for malaria 
by transmission settings can pose practical challenges in implementation [26, 70]. 
Therefore, from a practical standpoint, the policy could be implemented across the 
whole country as long as its use is limited to 5+ years old. Cost-effectiveness analyses in 
which longer-term and broader outcome measures such as the DALY are used, suggest 
that use of RDT-based guideline can be cost-effective (95% certainty) at malaria 
prevalence of up to 62% [72, 140, 144]. 
Thus, from practical and economic standpoints, it seems sensible to scale-up the use of 
RDT policy to HCs without capacity for microscopy in all malaria transmission settings 
in Uganda, as long as its use is limited to older patients (5+ years).  
This analysis offers a comprehensive evidence base on the merits of RDT-based policy 
(accuracy of RDT, clinician adherence, prescribing practices, outcomes and cost 
implications) based on patient-level data. Therefore, it offers a relatively more accurate 
and more complete basis for decision making in Uganda, than the existing body of 
evidence reviewed in this thesis. In addition, the results from this analysis provides more 
accurate data which can be used in modelling cost-effectiveness of RDT-based policy in 
Uganda, and similar contexts.  
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4.4.7 Limitations of the study 
a) Assessing the quality of implementation 
The RDT guideline for Uganda describes 5 major components of the healthcare process 
that needs improvement: (a) assessment, which includes medical history and clinical 
examination; (b) use of RDT; (c) patient classification (diagnosis) (d) treatment and (e) 
counselling [157]. In this chapter, analysis of HW adherence is based on the use of 
RDTs and prescribing of anti-malarials relative to RDT positive and RDT negative 
results only. Use of these 3 indicators alone in the assessment of adherence to the 
guideline fails to fully describe the quality of the diagnostic processes in the care of 
patients with fever, and the degree of adherence to the guideline [109, 113, 149]. In 
particular, the quality of clinical assessment is crucial in the differential diagnosis of the 
causes of RDT-negative fevers, and in targeting antibiotics. Therefore, a comprehensive 
and simultaneous assessment of all components of the guideline is necessary in order to 
identify all the elements which need improvement. This limitation is addressed by the 
assessment described in Chapter 5. 
b) Range of inputs included in cost analysis  
In this analysis, I included the cost of biomedical consumables only. Other 
programmatic costs (e.g. staff time, the cost of training and support supervision) were 
excluded because they were not contained in the database, and because the key 
informants were not available to provide the necessary information. The cost 
implications of an intervention depend on the types and range of inputs included in the 
analysis [72, 140]. If these programmatic costs were also included the analysis, the 
results could have shown a smaller amount of cost savings attributable to RDT-
supported treatment, even in low and moderate transmission areas; or the analysis could 
have shown added cost to the healthcare system instead [72, 140]. On the other hand, 
the analysis only captures short-term outcomes, which fails to reflect all the possible 
consequences of treatment. When health outcomes are measured in terms of longer-
term and broader measures such as the DALY, use of RDT-based guideline is likely to 
be cost-effective (95% certainty) at malaria prevalence of up to 62% [72, 140, 144]. 
Therefore, this analysis does not capture the full economic worth of RDT-based policy. 
Nevertheless, the evidence base provided by this analysis is sufficient to answer the 
policy-relevant questions that this analysis set out to answer. The evidence from this 
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analysis can feed into future cost-effectiveness analysis of RDT-based policy in Uganda 
or similar countries. 
c) Skewed cost data 
The analysis uses cost data that is skewed to the right. As such the mean cost values 
shown in this analysis are slightly higher than the corresponding median values. This is 
typical of trial-based cost data [143]. The standard approach would have been to 
calculate costs in terms of medians [143]. In terms of costs, this is inappropriate because 
the decision maker needs to be able to link the summary measure of cost per patient 
with the overall budget impact [143]. This can only be achieved with the mean. Methods 
of dealing with skewed cost data is still an area for research [143]. Those that have been 
suggested—such as data transformations and non-parametric methods—have 
limitations and are contested [143, 167, 168]. Because of these methodological 
uncertainties, and because of the need to use summary measures which can be used for 
budget impact analysis, costs were presented in form of the mean. 
d) Lack of data on malaria status at baseline and at control HCs 
The dataset does not include data on malaria status of participants (based on blood 
slides) at baseline, and at control HCs. Therefore, this analysis could not estimate the 
degree to which RDT-supported treatment guideline might have reduced overuse of 
anti-malarials.  
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4.5 Conclusion 
This thesis has demonstrated that RDT-based guidelines can be implemented 
sufficiently in routine practice. It has also shown that when applied in a context of 
adequate HW adherence, use of RDT-supported guidelines for fever can reduce 
prescribing of antimalarials and save money in primary care settings in low and medium 
transmission settings in Uganda, especially if their use is limited to older children and 
adults. In high transmission settings, the effect of the policy on cost-saving is 
questionable, even among older patients. This thesis indicates that use of RDT-based 
guideline may not significantly change prescribing of antibiotics in routine practice, 
although evidence from other pragmatic trials suggest that its use could lead to a 
significant increase in prescribing of antibiotics in routine practice. Although its use is 
associated with increased risk of missed malaria cases, the effect of the policy on clinical 
outcomes is uncertain. More evidence from randomised trials is required to further 
examine effects of RDT-based policies on clinical outcomes relative to presumptive 
treatment in routine clinical settings.  
Therefore, the policy for treating fever based on RDTs instead of clinical diagnosis may 
significantly avert irrational usage of antimalarials and save healthcare cost in routine 
practice. However, its effect on clinical outcomes in routine practice is uncertain. If the 
decision to scale-up implementation of RDT-based guidelines is based purely on 
economic considerations, then the analysis in this chapter and previous models suggest 
that it would be sensible to restrict implementation of the policy to low and medium 
transmission settings, and to use it in older patients (5+ years old) only. Considering the 
practical challenges associated with implementing a diverse policy for a single disease in 
a country, it seems more prudent to scale-up the use of RDT policy to eligible HCs in all 
malaria transmission settings in Uganda, as long as its use is limited to older patients (5+ 
years). 
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Chapter 5   Implementation of RDT-based guideline in 
current practice 
5.1 Introduction 
5.1.1 Overview  
This chapter consists of a survey of current practice to evaluate the quality of actual 
practice and adequacy of support services in the districts where RDT-based guidelines 
have been rolled out for small-scale implementation in Uganda. The survey uses a tool 
which consists of a checklist for assessing the quality of the following components of 
the guideline: (a) clinical assessment, (b) use of RDTs, (c) patient classification, (d) 
treatment prescribed, and (e) advice on medications. Additionally, the tool includes 
checklists for assessing adequacy of essential supplies, training and supervision. The 
survey assesses whether HWs can sufficiently implement all components of an RDT-
based guideline in routine clinical settings in Uganda. Assessment is carried out in 
children (< 5 years old), and in settings with high and low malaria transmission 
respectively. In addition, it assesses the adequacy of inputs in clinical practice and of 
support activities in the selected districts. The survey focused on children (<5 years) 
mainly because the tool used in this study was adapted from an HFA tool designed for 
assessing implementation of Integrated Management of Childhood Illness (IMCI) 
guidelines [169, 170]. The generic HFA tool has been field-tested before [170] and used 
in several previous surveys [92, 171, 172]. Evidence on the relationship between age of 
study participants and HW adherence to guidelines (prescribing) is generally equivocal 
[90, 91, 93, 108, 112, 115, 116].  
5.1.2 The health system in Uganda 
a) Service delivery 
Health service delivery system in Uganda is structured into 7 referral levels, namely HCI, 
HCII, HCIII, HCIV, general hospital, regional referral hospitals and national referral 
hospitals. Table 34 below shows the designated geographic coverage, the target 
population and the services provided at each level of facility. Appendix 2 summarises 
the recommended staffing for each level of care.  
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Table 34: Levels of health service delivery in Uganda (2011) 
Responsibility  Referral level 
Administrative 
level 
Target 
population Services provided 
D
is
tr
ic
t 
lo
ca
l 
g
o
v
er
n
m
en
t 
(d
is
tr
ic
t 
h
ea
lt
h
 s
ys
te
m
) 
HCI Village  1,000 Community-based preventive 
and promotive health services 
HCII Parish  5,000 Preventive, promotive, 
outpatient curative services, 
outreach care 
HCIII Sub-county  20,000 – 
25,000 
All services at HCII, maternity, 
inpatient services and 
laboratory services 
HCIV County  100,000 All services at HCIII, 
emergency surgery and blood 
transfusion  
General 
hospital 
District  300,000 – 
500,000 
All services at HCIV, 
radiology, in-service training, 
consultation & research to 
community-based programmes 
M
in
is
tr
y 
o
f 
h
ea
lt
h
 
Regional 
referral hospital 
Regional  2,000,000 All services at general 
hospitals, specialist services: 
pathology,  psychiatry, ENT, 
ophthalmology, dentistry, 
intensive care, consultant 
surgical and medical services 
National 
referral hospital 
National  Country wide Specialist services, teaching 
and research 
Source: Health Sector Strategic Plans (HSSP) II and III (Uganda) [173, 174] 
 
Basic health services are provided through HCIs to general hospitals.  The responsibility 
for the delivery of basic services is devolved to the district local government.  Specialist 
services are offered at regional and national referral hospitals which are autonomous. 
The Ministry of Health (MoH) is responsible for the formulation and dissemination of 
policies, strategic plans, standards, guidelines; and for monitoring health sector 
performance. In addition, the MoH is responsible for nationally coordinated 
programmes such as emergency preparedness and epidemics control [173, 174].  
An HCI consists of a team of community volunteers (the Village Health Team (VHT)) 
that works as a link between health facilities and the community. It has no physical 
structure. HCIIs are the first level of contact between the formal health sector and the 
communities. They serve the majority of the population.  HCIIs provide out patient 
care and community outreach services only. They have no capacity for microscopy. An 
HCII is manned by 2 or 3 staff consisting of an enrolled nurse, enrolled midwife and/or 
a nursing assistant [173, 174]. 
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The new RDT-based guideline for fever is intended to be used at HCIIs, which lack the 
capacity for microscopy, and where the most qualified staff is either an enrolled nurse or 
enrolled midwife.  
b) RDT-based guideline for Uganda 
In Uganda the RDT-supported policy for treating fever was adopted in 2009. The 
Uganda Ministry of Health has accordingly revised its guidelines and training manual in 
line with WHO recommendations [3, 157]. RDT-based guidelines have since been 
introduced in government-owned Health Centres (HCs) without the capacity for quality 
microscopy. So far only 6 districts are covered, out of a total of 72:—4 from a low 
malaria transmission zone and 2 from a high transmission zone.  
The new guideline has 7 main components [157]: 
1) Assessing patients with fever and selecting patients for RDT testing 
2) Performing and reading an RDT 
3) Managing a patient with fever and a positive RDT 
4) Managing a patient with fever and a negative RDT 
5) Recognition and referral of patients with severe illness 
6) Patient education  
7) RDT storage and monitoring 
Although the new RDT-based guideline came to effect only recently, ACT has been in 
use as the first line treatment for malaria in Uganda since 2002. The new RDT-based 
guideline incorporates the previous guideline on the use of ACTs [175]. In addition to 
specifying when to prescribe ACT and other antimalarials, the new guideline also 
describes the dosages of these drugs by age-group and weight8 [157].   
c) Supply chain in the public sector  
Health facilities in the public sector receives supplies through two distribution 
mechanism: pull and push systems 
Pull system  
                                                          
8 The dosing of the recommended ACTs is more complex than that of the anti-malaria drugs previously 
used (CQ-SP combination) 157. Uganda Ministry of Health Malaria Control Programme, User's 
Manual: Use of rapid diagnostic tests (RDTs) for malaria in fever case management in Uganda; Near-final draft: 31 
January 2009, 2009. 
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In the main, drugs and medical supplies are procured and distributed to health facilities 
through a pull (demand-based) system. In this system, individual health units determine 
the types and quantities of drugs and supplies required based on local demand patterns, 
distribution frequencies, costs and inventory level [176-178]. Typically, individual health 
unit orders are consolidated into one order at Health Sub-District (HSD) level.  Each 
HSD submits its consolidated order to the district, which submits them separately to 
National Medical Stores (NMS)—a government parastatal responsible for procuring and 
supplying medical goods within the public system.  NMS packs the order for each HSD, 
which is then invoiced on behalf of the health units.  The HSD then unpacks the 
consolidated NMS consignment and re-packs and distributes them according to original 
health unit orders. Occasionally, health unit orders are individually packed and invoiced 
by NMS, but distributed in one consignment to the district. They are then distributed to 
individual health units as described above.  
Push system 
Occasionally selected items are supplied through the push (kit) system. A central 
authority (e.g. NMS, an NGO) determines the types and quantities of items required by 
health units. Health units of the same referral level receive a standard kit (same items, in 
the quantities) of the selected items [176-178]. Health unit orders are individually packed 
at NMS but are distributed in one consignment to the district headquarters. Supplies are 
unpacked, re-packed and then distributed to individual health units by the district 
supplies officers or by HSD heads. Cost of procurement and distribution is borne by 
the central authority. The push system is normally used in emergency relief efforts 
where demand exceeds supply, e.g. insecurity, outbreaks, natural disaster [176]. The 
push system also applies where the health system cannot satisfy normal demand 
patterns for reasons of cost and availability, e.g. when an expensive product has just 
been introduced into the system and/or is not readily available in the country [176].  
Supply of ACTs and RDTs 
At the time of the survey, ACTS were provided to health facilities mainly through the 
pull system while RDT kits were provided through the push system. Since the official 
introduction of the RDT-based guideline, supplies of both ACTs and RDTs have been 
erratic and unreliable. At the time of this survey , all eligible HCs had run out of RDT 
kits for a period of 8 to 9 months, forcing clinicians to revert to presumptive treatment. 
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As part of this survey, additional stocks of RDT kits and ACTs were supplied to 
selected HCs through the district supply chain system prior to the survey dates..  
5.1.3 Aim  
To assess the quality of actual practice when an RDT-based guideline is rolled out to 
health services in a district as a whole 
5.1.4 Research questions  
Is the RDT-based policy being implemented sufficiently in the districts where it has 
been rolled-out in Uganda? 
5.1.5 Specific Objectives 
1. To establish if all components of an RDT-based guideline for fever are 
implemented to acceptable standards in Uganda 
2. To determine if essential inputs and support services required for effective 
implementation of RDT-guidelines in febrile children are adequate in Uganda  
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5.2 Methods 
5.2.1 Study location 
The study takes place in two districts where RDT guideline has been introduced by the 
Ugandan Ministry of Health (MOH) for small-scale implementation: (a) Kisoro in South 
West Uganda—a setting with low malaria transmission; and (b) Gulu in Northern 
Uganda—a setting with high malaria transmission (See Figure 26).  
Figure 26: Map of Uganda showing the two districts where the survey was conducted 
 
The two districts are among the six districts in which the Uganda MOH has introduced 
the guideline during 2009: 2 districts in high malaria transmission area, and 4 districts in 
low malaria transmission area. The survey took place at government-owned health 
centres (HCs) of referral level II (HCIIs), where RDT-based guidelines had been 
introduced.  HCIIs represent the first level of clinical care, a setting without the capacity 
for microscopy. 
 
 
GULU 
KISORO 
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5.2.2 Design  
A survey was carried out in the 2 districts in November and December of 2011. The 
two districts represent a practical setting for Uganda, which is a context of chronic 
shortages of medical supplies. In light of foreseen shortages, the study supplied HRP2-
based RDT kits (Clearview
®
 Malaria P.f., British Biocell International Ltd) and ACTs 
(Artemether/Lumefantrine 20/120 mg tablets). These supplies were made available 
through the normal supply chain to avoid the risk of preferred response bias[179, 180]. 
Supplies were delivered to the respective district health offices, from where they were 
distributed to selected facilities by the district supplies officer at least one day prior to 
the survey date. Health workers were not aware that the study supplied these materials. 
Therefore, they did not have prior information about the study‘s purposes and what 
behaviour was expected of them. Health workers were asked (by the supplies officers) 
to use the items as they deemed fit.  
The survey consisted of 3 main parts: (a) an assessment of HW performance of a set of 
clinical tasks which are specified in the RDT-based guideline, (b) an assessment of the 
adequacy of selected inputs (staffing, drugs and equipment) that are essential in the 
provision of care to a child with fever, and (c) an assessment of the adequacy of support 
activities (training and support supervision).  
The survey used a tool which comprised of a checklist for assessing the quality of the 
following components of the guideline: (a) clinical assessment, (b) use of RDTs, (c) 
patient classification, (d) treatment prescribed, and (e) advice on medications. 
Additionally, the tool included checklists for assessing adequacy of essential inputs, 
training and supervision. The survey tool was adapted from a Rapid Health Facility 
Assessment (R-HFA) tool for assessing implementation of guidelines for Integrated 
Management of Childhood Illness (IMCI) [169, 170]. The tool was modified by 
incorporating items for assessing specific RDT-oriented procedures specified in the 
RDT-guideline for Uganda—specifically, the steps in carrying out an RDT and essential 
equipment and supplies which are required in order to carry out an RDT effectively 
[157].  
The survey uses the Lot-Quality Assurance Sampling (LQAS) method to judge if the 
quality of practice, or if the quality of essential supplies and support services in the 
surveyed district is acceptable, basing on pre-defined performance benchmarks. LQAS 
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principles were discussed in chapter 2. Their application in this survey is described in 
the following sections. 
5.2.3 Sampling and decision rules 
A three-stage sampling design was applied. The 2 districts in which the survey was 
located were randomly selected: 1 from a high malaria transmission zone, and 1 from a 
low malaria transmission zone. In each zone, a district was selected by randomly 
drawing a name from a hat containing names of eligible districts in the transmission 
zone. Then a 2-stage LQAS-based sampling design was applied:  
 to select a sample of Health Centres (HCs) within each district to determine 
whether an acceptable proportion of the HCs met a set performance target for 
specific indicators measured in each of the aforementioned modules (5.2.2 
above) 
 to select a sample of consultations within each HC consisting of children (<5 
years) with fever, which were observed in order to judge the adequacy of a single 
provider's performance. 
 
a) Sampling HCs  
Sample size 
To classify performance of HCs in a district as either high or low, four parameters were 
set beforehand, in consultation with the Ministry of Health officials.  
i. The desired performance threshold (pU):  At least 80% of HCs in each district 
was expected to demonstrate adequate performance for each specific indicator 
included in the assessment.   
ii. A lower threshold below which performance was deemed highly unacceptable 
(pL) was set at 50%.    
iii. The probability of misclassifying a district with high performance as having low 
performance (α error) was set at <0.10.  
iv. The probability of misclassifying a district with low performance as high (β 
error) was also set at <0.10.   
These parameters were used to calculate the LQAS sample size of HCs to enrol in the 
study, to obtain the decision rule, and to obtain the exact values of the associated 
misclassification errors. Table 35 below shows the number of eligible HCs in each 
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district. Owing to the small total number of HCIIs in each district, the hypergeometric 
rather than the binomial formula was used to calculate the sample size and to  determine 
the decision rule for each district [181].  The hypergeometric formula provides a finite 
population correction when computing the sample size for a population [104].  Basing 
on the conditions above and the number of HCIIs in each district, the hypergeometric 
formula yielded the sample size (n), decision rules (d) and classification (α and β) errors 
shown in Table 35 below.  
 
Table 35: Number of HC II, sample size and decision rules 
District 
Number of 
HC IIs (N) 
Sample 
Size (n) 
Number 
selected 
Decision 
rule (d) α-error β-error 
Kisoro 12 8 8 6 0.078 0.030 
Gulu 21 10 10 7 0.049 0.095 
TOTAL 33 18 18 - - - 
 
Decision rule for district performance 
Decision rule (d) refers to the minimum number of HCs in a district required to meet 
the desired performance target (upper threshold) for the district to be classified as high 
performance. In Gulu district, for example, if ≥ 7 out of the sampled 10 HCs were 
found to meet the performance threshold for an indicator (e.g. patient assessment), the 
district as a whole was judged to be high performance with regard to this indicator. It 
was assumed there was no justification to not classify the district in the high category 
(which is that at least 80% of the 21 HCIIs in the district used the guideline as 
expected). This judgement is subject to risks of misclassification (α and β errors) of 
0.049 and 0.095, respectively. Therefore, with n = 10 and d = 7, there is at least a 95.1% 
(1- α) probability of correctly classifying Gulu district as high performance with regard 
to a particular indicator if indeed ≥80% of all the HCs in the district met the 
performance benchmark for the specified indicator; and only a 9.5% probability of 
misclassifying it as high performance if only ≤ 50% of all the HCs in the district meet 
the performance threshold. A similar interpretation applies to Kisoro district with n = 8 
and a decision rule of 6; and α and β errors of 0.078 and 0.030 respectively. LQAS 
method identifies the ends of the distribution. Therefore, the computed sample sizes (n) 
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and the decision rules (d) optimise the identification of the best of the best and worst of the 
worst performance districts with a small amount of error9.  
The Operating Characteristics Curve (OCC) in Figure 27 below shows the probability of 
classifying a district either as high or as low performance basing on the respective values 
of ―n‖ and ―d‖, and the true performance quality of the district against a given indicator. 
If the true performance quality of the district against an indicator falls between 50% and 
80% thresholds, it is likely to be classified as high or as low performance depending on 
how close the performance is to the thresholds.  
                                                          
9 In Public Health, we are more interested in identifying those who are at high risk—the worst of the 
worst 
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Figure 27: Operating Characteristic Curves for HFAs in Gulu and Kisoro districts for sample 
sizes of 10 and 8 with decision rules of 7 and 6 respectively 
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Selecting the HCs 
Eligible HCs consisted of government-owned HCIIs where use of RDT-based 
guidelines had been introduced by the Uganda MOH. HCIIs with functional 
microscopes were excluded because they were in the process of being upgraded to 
HCIIIs.  Eligible HCs were selected through stratified random sampling, with counties 
representing the strata. Random selection was undertaken by drawing names of the 
eligible HCs from a hat. The number selected from each county reflects the 
proportionate distribution of eligible HCIIs. In Kisoro district, the team did not observe 
the required number of patients (n = 6) in 2 of the HCs initially recruited into the study. 
The survey team replaced them by selecting other HCs which were nearest to them.   
b) Sampling HWs and consultations 
Sample size  
In order to assess the HC, study assessed the performance of the HW who was most 
experienced in providing clinical care to a child with fever at the HC. LQAS was used to 
calculate the number of consultations (n) to observe in order to judge the performance 
of the individual HW, and to obtain the decision rule (d) for guiding the judgement. In 
this context, ―d‖ refers to the minimum number of correct tasks the HW was expected 
to perform out of a set of consultations, in order for the HW to be classified as high 
performance. Because the number of children presenting with fever at HCIIs is 
presumed to be infinite, the study uses the binomial formula to calculate ―n‖ and ―d‖ 
[104, 106]. Calculation was based on four pre-set parameters:  
i. Performance threshold (pU): the HW was expected to perform the 
selected clinical tasks according to the RDT-guidelines at least 95% of 
the time. 
ii. Lower threshold (pL): the level of performance deemed seriously below 
the performance threshold that it was considered highly ―unacceptable‖. 
This threshold was set at 50%. The lower threshold is set at 50% 
because we assume that the distribution of health worker performance is 
bimodal. Health workers either know the correct technique and use it, or 
they are ignorant of it and perform accordingly most of the time. 
iii. The risk of judging a HC as a failure when in fact the observed HW 
achieved the performance benchmark (α error). The maximum 
permissible α-error was set at 0.10.  
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iv. The risk of judging a HC as adequately adhering to the guideline when in 
fact the observed HW performed at the pL threshold (β error). The 
maximum permissible β-error was set at 0.10.  
Decision rule for HW performance 
On the basis of these standards, the LQAS rule is to assess the HW performance for a 
set of tasks carried out on 6 patients (n = 6). For every 6 observations, no more than 
one error was permitted for any task or indicator. That is, the decision rule (d) was for 
the HW to perform a given task as expected at least 5 out of 6 times; otherwise the HC 
was judged as having failed to adhere adequately to the step or component of HC 
specified in the guideline. This judgement is subject to risks of misclassification (α and β 
errors) of 0.033 and 0.109 respectively.  Therefore, this 6:5 design is 96.7% sensitive for 
identifying HWs that use recommended clinical norms 95% of the time, and 89.1% 
specific for HWs using the recommended norms ≤ 50% of the time. On the basis of 
this HW classification, the proportion of HCIIs in a district judged as adequately 
adhering to RDT guidelines was computed, and the result used to judge the 
performance of the district as a whole as explained in section 5.2.3 above.   
This application of LQAS using binomials and the standards quoted above have been 
used in several surveys [104, 106, 127, 128] and were discussed with officials of the 
Ministry of Health and the districts prior to their application in Gulu and Kisoro 
districts.  
c) Selecting patients 
The study selected 6 consecutive consultations that were deemed eligible for 
observation of performance of an individual HW. Eligible patients consisted of children 
(aged 0 – 59 months old) attending outpatient clinics with uncomplicated fever, or a 
history of fever in the previous 24 hours.   
Presence or a history of fever was a basis for inclusion into the study. A child was 
excluded from observation if s/he was showing danger signs, or signs of complications 
(Table 36 below). Use of RDT is not a pre-requisite in children presenting with severe 
illnesses [19, 157]. Fewer than 6 children could have been observed if children with 
severe illnesses were also included. However, we did not come across any child with 
symptoms and signs of severe illness. 
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Table 36: Danger signs of severe illness 
 Convulsions or fits – now or within the past 2 days 
 Not able to drink or breast feed 
 Vomiting everything – not able to keep down food, fluid, or drugs 
 Changes in mental state – patient is confused, very sleepy (lethargic or drowsy), or in 
coma (unconscious) 
 Extreme weakness (prostration) – patient is unable to sit or stand without support 
 Severe difficulty in breathing (respiratory distress) 
 Severe anemia – pale palms, fingernails, eyelids 
 Severe dehydration – coated tongue, sunken eyes, skin pinch 
Source: Uganda ministry of health (user‟s manual)[157] 
 
5.2.4 Data collection 
a) Observing the HW 
A trained research assistant familiar with the local language observed the HW seeing 
children with fever (assessment, use of RDTs, dispensing and counselling). The HW 
was requested to explain the purpose of this research to the caretakers of selected 
patients; and that an observer would be sitting in the consultation room to observe the 
consultation process. The HW invited the observer into the consultation room once 
consent was given by the caretaker. Each eligible patient whose caretaker consented to 
participating in the study was assigned a code number; which was recorded on a 
checklist used for the clinical observations, and on the instrument used to guide exit 
interviews. If, upon completion of the observation, the research team deemed that the 
observed child was ineligible (e.g. child was 5+ years; child had no history of fever), the 
relevant data were excluded and another observation carried out until 6 eligible 
consultations were observed10. 
Aspects of care assessed 
Each HW was observed performing a total of 150 clinical tasks, 25 per child enrolled 
into the study. The tasks were drawn from 5 clinical procedures: (a) medical history (6 
tasks), (b) clinical examination (6 tasks), (c) using RDT (11 tasks), (d) drug choice 
                                                          
10 The research team took a brief history of the presenting complaints outside the consultation rooms as 
part of the exit survey. 
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relative to diagnosis (1 task) and (e) counselling/explaining treatment to patients (1 
task). The specific tasks assessed are listed in Appendix 19.  
Scales of measurement 
The response to each item on the observation checklist was a ―Yes‖, or ―No‖ or ―NA‖ 
(not applicable). A ―yes‖ response means that the HW performed the expected task as 
recommended in the guideline; and a ―no‖ response means s/he did not. A ―yes‖ or 
―no‖ response was not applicable if, for example, a caretaker volunteered information 
about the presence of a symptom of interest (e.g. cough). In the final analysis, ―Yes‖ 
and ―NA‖ responses were combined into one category (a ―pass‖ or ―success‖). 
Excluding ―NA‖ responses would result in fewer than 6 responses per indicator. Basing 
on these categorical responses, the number of times each task was performed as 
expected (i.e. the number of passes or successes) was counted out of 6 observations.  
The 6:5 decision rule was then applied to judge the HW performance. 
Judging HW performance across procedures 
For a procedure consisting of multiple of tasks a HW had to perform all the individual 
tasks successfully in order to judge the entire procedure as having been performed 
adequately—i.e. the HW had to perform each of the constituent tasks correctly in at 
least 5 of 6 consultations in order to pass the entire set of tasks. For example, medical 
history taking consisted of 6 specific tasks (Appendix 19). If a HW asked about history 
of fever or history of cough in at least 5 of the 6 children, s/he was judged as having 
―passed‖ in performing those two tasks. On the other hand, if the HW asked about 
history of each of the other four symptoms in fewer than 5 children, s/ he was judged 
as having ―failed‖ to perform each of the latter 4 tasks adequately. The HW in question 
was then judged as having failed in medical history taking as a whole. This procedure 
follows the LQAS principle for the second stage sampling of using d=5 as the decision 
rule.  In short, in 6 observations at least 5 correct behaviours or responses are required. 
Table 39 below shows the number of successes per procedure, which represents the 
number of HWs that performed all the tasks included in a given procedure according to 
the specified standard.  
b) Assessing adequacy of inputs 
This section describes the protocol for assessing the availability of the following inputs 
which are essential for basic health facility functioning in the context of RDT-guidelines: 
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(a) essential drugs (b) RDT kits (c) Guidelines (d) equipment (e) staff. The assessment 
was carried out by observing the consultation rooms and stores, and by reviewing 
records of supplies and equipment. The decision rules for judging district performance 
(Table 35 above) were then applied to classify the districts as having either high or low 
performing health facilities for each of the specific indicator items assessed.  
Availability of drugs 
The indicator drugs chosen for this assessment were ACT for malaria, cotrimoxazole 
(CTX) for pneumonia or Acute Respiratory Infection (ARI), ORS for acute diarrhoea, 
ciprofloxacin (CIPRO) for dysentery, and Vitamin A (Vit. A). The study assessed 
availability of essential drugs on the day of the visit as well as over the 6 months 
preceding the survey11. A drug was considered available on the survey day if the study 
team observed at least one sealed basic unit (e.g. a tin or a packet) of the item. Items 
that were already open for use were not counted. In addition, the drug must have still 
been valid (not expired) to be considered available. ACTs which were distributed to the 
sampled HCs as part of the survey were not counted as part of the HC stock.  
If the HC had several valid drugs and one or more non-valid drugs, then the HC failed 
this step. Furthermore, the study assessed whether the HC experienced stock-outs of 
any of the indicator drugs in the preceding 6 months—basing on the HC records 
and/or HW‘s report. If the HC experienced stock-out of any of the indicator drugs 
during the 6 months under review, then the HC failed this step. 
Availability of RDT kits 
Similarly, RDTs were considered available on the survey day if the study team observed 
at least one sealed box (10 tests) of the item, which must have still been valid (not 
expired). Items that were already open for use were not counted. RDT kits which were 
distributed to the sampled HCs as part of the survey were not counted as part of the 
HC stock.  
Availability of guidelines 
The study assessed the availability of the latest, nationally-mandated guidelines for the 
care of children with fever. Two types of fever-oriented guidelines were expected, 
                                                          
11 In Uganda, supplies in government-owned HCs are normally replenished every 3 months; a 6-month 
time frame was considered to observe availability of inputs (especially of RDT kits) over a longer term. 
The degree to which competency deteriorates is related to the length of disruption of exposure to a new 
technology 
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namely, RDT-based guidelines and IMCI guidelines. Relevant material could be in the 
form of a booklet or a wall chart. A facility was considered to have all the mandated 
guidelines if it had both IMCI and RDT-related guidelines, in any form.  
Availability of equipment 
The study team checked the consultation rooms for availability of equipment which are 
essential in providing care to a child with fever. The assessment focused on 5 items: an 
infant scale, an adult scale, a timer (for counting respiratory rates and timing RDT 
process), a thermometer and an ORS cup or jar.  Each item was considered available if 
it was observed by the study team and deemed to be functional. 
Staffing 
The cadres of staff typically recommended at a HCII are enrolled nurses (1), enrolled 
midwives (1), and nursing assistants (2) [182]. Staff availability was assessed by 
comparing the number of staff recruited in different positions relative to the official 
requirements for HCIIs: whether all the required positions for a particular cadre of staff 
had been filled. The study did not assess the extent of absenteeism. Where a HC had a 
HW that was more qualified than is officially recommended—e.g. a registered nurse, 
instead of an enrolled nurse, the relevant position was considered to have been filled.  
c) Assessing adequacy of support activities 
The study assessed HW exposure to in-service training and support supervision—two 
activities considered essential for introducing and scaling up the use of a new guideline. 
HWs who were observed providing care to the sick child on the day of the survey were 
interviewed about the dates of the most recent in-service trainings in fever management 
that they attended, and the content of the trainings. In addition, they were interviewed 
about exposure to support supervision in the preceding 3 months as well as the 
particular types of support offered during the visits. The decision rules for judging 
district performance (Table 35 above) were applied to classify the districts as having 
either high or low performing HCs with regard to the activities assessed.  
 
 
d) Assessing adequacy of counseling  
The study team interviewed care takers of enrolled patients as they left the clinic.  The 
exit interview was conducted using a short structured questionnaire and checklist to 
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determine whether the caretaker was given advice on the child‘s diagnosis, the 
prescriptions, or the dosing. During the interview, the team further documented the 
details of the drugs prescribed to the child, including the dosing. This latter information 
was used to judge whether the diagnoses indicated by the HW matched the treatment 
prescribed.  
5.2.5 Data collection tools 
The survey used a tool adapted from the HFA tool for assessing the quality of care and 
health systems support for the Integrated Management of Childhood Illness (IMCI) 
policy. As already mentioned, the IMCI-HFA tool consists of 4 modules: (a) checklist 
for clinician observation of treatment of sick children, (b) questionnaire for exit 
interviews (c) checklist for assessment of infrastructure, equipment, drugs and supplies 
(d) questionnaire for health worker interview [170]. Because the focus of the research 
was on the quality of fever case management, the tool was modified by incorporating 
items which reflect the standard procedures described in the RDT-based guideline for 
managing fever [157]. Specifically, the adaptations involved  
a) including steps in carrying out an RDT 
b) including items for assessing RDT storage 
c) excluding items for assessing inputs (drugs, supplies and infrastructure) that 
were deemed to have no direct effect on implementation of  RDT-based  
guidelines (e.g. presence of vaccines, presence of a pit latrine)  
5.2.6 Training of research assistants  
In each district, data collection was preceded by a one-day training of a Research 
Assistant (RA). The RAs were experienced clinical officers with experience in survey 
methods. The RAs advised on clarity of questions, typographical errors, ease of 
translation of questions, and the reliability of the items. The training included 
demonstrations on the use of RDT kits and role play. In addition, the RAs participated 
in the final selection of HCs and scheduling of activities. Recommended changes were 
few and minor. The RAs carried out clinical observations and exit interviews as they 
were fluent in the local languages.  I implemented the other modules of the HFA tool. 
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5.2.7 Field-testing of tools 
The generic IMCI-HFA tools had been field-tested [170] and used before [92, 171, 172]. 
It was also used in Uganda (Gulu) in November 2010. However, the adapted, 
fever/malaria-specific version used in this study was pre-tested at one HC during the 
training of the RA in Gulu district in December 2010. 
5.2.8 Data management and analysis  
Data were independently entered into 2 separate data bases in MS Excel 2007 and 
checked for data entry errors using the COMPARE subroutine in Epi Info 3.5.2. 
Discrepancies were corrected by referring to the questionnaires. The analysis used SPSS 
(PASW statistics 18) to compute performance scores, and Excel 2007 to generate 
relevant tables and graphs. 
5.2.9 Ethical considerations 
The study protocol was reviewed and approved by the Ethics Committee in Liverpool 
School of Tropical Medicine and by the Uganda National Council for Science and 
Technology (UNCST). The UNCST wrote introductory letters to the respective District 
Authorities, which were used to secure verbal clearance from the latter. The research 
team explained the purpose of the research and the procedures to the health workers. 
The health workers did the same to the caretakers, in particular about the presence of 
the RAs in the consultation room. The team obtained consent from the health workers 
and, through the health workers, from caretakers before proceeding with observation 
and other aspects of the survey. The information and consent form can be found in 
Appendix 17 
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5.3 Results 
5.3.1 Characteristics of the population 
The surveys were conducted in Gulu (district in high malaria transmission zone) and 
Kisoro (district in low malaria transmission zone). The surveys were carried out in 
November and December of 2011.  
On the day of the survey, nursing assistants and enrolled nurses and midwives 
constituted most (70%) of the providers of care to children with fever in Gulu district. 
The same cadres of HWs were the sole providers (100%) of care to children in Kisoro 
district (Table 37 below).   
Table 37: Qualification of HWs who attended to the sick child in the surveyed health centres 
Qualification of attending clinician 
Gulu (n = 10) Kisoro (n = 8) 
Number     % Number  % 
Clinical officer 1 10.0% 0 0.0% 
Registered nurse/midwife 2 20.0% 0 0.0% 
Enrolled nurse/midwife 4 40.0% 3 37.5% 
Nursing assistant 3 30.0% 5 62.5% 
 
The study observed a total of 108 outpatient consultations from 18 HCs in 4 weeks: 60 
consultations from 10 HCs in Gulu and 48 consultations from 8 HCs in Kisoro. The 
consultations consisted of children (0 – 59 months of age) presenting with 
uncomplicated fever. Table 38 shows the diagnoses made by the health workers from 
these consultations. 
Table 38: Health workers' diagnoses by district 
DIAGNOSES  
Gulu district 
(High transmission) 
Kisoro district 
(Low transmission) 
(60 consultations) (48 consultations) 
Acute respiratory infections (ARI) alone 46.7% 27.1% 
Malaria alone 18.3% 14.6% 
Malaria and other diagnosis 26.7% 29.2% 
Other conditions (excluding malaria & ARI) 8.3% 29.2% 
 
In Gulu (high transmission), the vast majority (91.7%) of the consultations was 
classified either as Acute Respiratory Infections (ARI) alone (46.7%) or as malaria 
(45%)—either alone or as a co-diagnosis. All the diagnoses specified as ARI and/or 
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malaria were based on the use of RDT. Other conditions were considered where RDTs 
were not used.  
In Kisoro (low transmission), most (43.8%) of the consultations were classified as 
malaria (alone or as a co-diagnosis). A substantial number (29.2%) of patients were 
classified into conditions other than malaria or ARI. Most diagnoses in Kisoro (low 
transmission) were not based on RDT results. Only 29.2% of the diagnoses in the 
district were accompanied by use of RDTs.  
5.3.2 Health worker performance 
a) Performance by procedures 
In both districts, none of the HWs performed all the 5 procedures satisfactorily. Only 
two procedures were performed to satisfactory standards: treatment prescribed (Gulu, 
high transmission) and Counselling (Kisoro, low transmission). Treatment matched the 
diagnosis indicated by the HW in at least 5 of 6 consultations at 7 HCs in high 
transmission area (Gulu). Thus the high transmission district (Gulu) was judged as high 
performance with regard to appropriateness of treatment prescribed (d = 7). In low 
transmission area (Kisoro), counselling was provided as expected—to at least 5 of 6 care 
takers per HC—at 6 HCs. Therefore, the low transmission district (Kisoro) was judged 
as high performance with regard to care taker counselling (d = 6). Both treatment and 
counselling are one-task procedures. Performance of multi-task procedures—namely 
medical history, clinical examination and use of RDT—was inadequate in both districts; 
i.e. none of the HWs in either district performed all the essential components of each of 
these procedures to satisfactory standards. Notably, at only 2 of the HCs in high 
transmission area (Gulu) did the HWs follow all the required steps in using a RDT in at 
least 5 of 6 consultations. In low transmission area (Kisoro), none of the HWs used 
RDT satisfactorily in at least 5 of 6 consultations. 
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Table 39: Performance of HWs by healthcare procedures 
 
 
GULU  
(High transmission)  
(n=10; d = 7) 
 
KISORO  
(Low transmission)  
(n=8; d = 6) 
Procedure Description *Success 
**District 
performance   *Success 
**District 
performance 
 
Medical 
history  
 
HW asks about all essential 
symptoms  
0 Low 
 
0 Low 
       
Clinical 
examination      
HW performs all essential 
clinical examination tasks  
0 Low 
 
0 Low 
       
Use of RDT                                                                                                      
HW follows all required 
steps in using RDT  
2 Low
 
0 Low 
       
Treatment 
Treatment matches 
diagnosis  
7 High 
 
4 Low 
       
Counselling 
HW explains treatment to 
participants 
6 Low   6 High 
       
All 
procedures 
HW performs all observed 
clinical tasks as required  
0 Low 
 
0 Low 
* Number of health workers that performed all the tasks included in a given procedure according to the specified 
standard 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
 
n = sample size (HCs); d = decision rule 
 
b) Performance by specific tasks  
This section describes HWs‘ performance for each of 25 clinical tasks observed. This 
analysis identifies the most problematic steps in managing fever in children.  The results 
are displayed in Table 40 below. 
Medical history: within the category of medical history, the tasks with low successes in 
both districts were: asking about feeding, asking about vomiting and asking about 
convulsions. That is, HWs rarely asked about symptoms which are indicative of severe 
forms of illnesses in children.  
Clinical examination: None of the HWs observed met the performance threshold for any 
of the clinical examination tasks. Hence, adherence to all clinical examinations tasks was 
low in both districts 
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RDT performance: In high transmission area (Gulu), utilisation of RDT was high. Most 
RDT-related tasks were performed satisfactorily. The most problematic steps were (a) 
checking the expiry date; (b) writing the patient‘s name on the cassette; (c) allowing 
fingers to dry before pricking; and (d) waiting at least 15 minutes after buffer (HWs 
often read results within 2 minutes after adding buffer).  
In low transmission area (Kisoro) utilisation of RDT was low. Performance of all the 
essential tasks required in carrying out a RDT was unsatisfactory, mainly due to errors 
of omission. HWs rarely considered malaria as a possibility and rarely used RDT if the 
patient presented with features of ARI; except if such a patient looked ill or had high 
fever at the point of consultation.  
Drug choice: Treatment-diagnosis match was high in high transmission area (Gulu). It was 
low in low transmission area (Kisoro), partly because the HWs did not prescribe some 
of the medications required for the diagnoses they made, and because of prescribing 
ACT presumptively or to test negative patients.   
Counselling: The number of patients counselled about the treatment prescribed was 
inadequate in high transmission area (Gulu).  Counselling was high in low transmission 
area (Kisoro).  
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Table 40: Performance of HWs by specific clinical tasks 
 
 
GULU  
(High transmission)  
(n=10; d = 7) 
 
KISORO  
(Low transmission)  
(n=8; d = 6) 
Procedure Tasks *Success 
**District 
performance   *Success 
**District 
performance 
Medical 
history  
 
HW asks 
about: 
Fever 10 High 
 
8 High 
Cough or difficulty in breathing 8 High 
 
4 Low 
Diarrhoea 2 Low 
 
3 Low 
Feeding 1 Low 
 
0 Low 
Vomiting 1 Low 
 
0 Low 
Convulsions 0 Low 
 
0 Low 
        
Clinical 
examination      
 
HW checks 
for: 
Vaccination status 0 Low  0 Low 
Dehydration 0 Low  0 Low 
Respiration rate 0 Low  0 Low 
Conjunctiva: pallor and jaundice 0 Low  0 Low 
Throat for redness 0 Low  0 Low 
Ear for discharge or sores 0 Low  0 Low 
           
Use of RDT                                                                                                     
HW: 
Requests RDT 9 High  1 Low 
Checks expiry date 6 Low  0 Low 
Puts on gloves 8 High  1 Low 
Writes Patent‘s name on cassette 5 Low  1 Low 
Cleans patient‘s finger 9 High  1 Low 
Allows finger to dry before prick 3 Low  0 Low 
Uses pipette to collect blood 9 High  1 Low 
Puts blood into position A 9 High  1 Low 
Puts buffer in position B 9 High  1 Low 
Waits at least 15 min after buffer 4 Low  0 Low 
Communicates RDT results 8 High  1 Low 
 
        
Treatment Treatment matches diagnosis 7 High  4 Low 
        Counselling Health worker explains 
treatment 
6 Low  6 High 
* Success: number of health workers that met the performance threshold with regard to the specified task 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
 
n = sample size (HCs); d = decision rule 
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5.3.3 Adequacy of inputs 
a) Availability of essential drugs 
This section describes the adequacy of essential drugs in terms of their availability in the 
health facility on the day of the visit, and during the 6 months preceding the survey.  
Number of facilities with essential drugs in stock on survey day 
Table 41 shows the percent of HCs with the drugs in question on the day of the survey. 
 
Table 41: Performance of districts based on availability of essential drugs on survey day 
  
GULU  
(High transmission) 
(n = 10; d = 7) 
 KISORO  
(Low transmission) 
(n = 8; d = 6) 
Essential drugs  *Success 
**District 
performance 
 
*Success 
**District 
performance 
ACT for malaria 10 High  7 High  
Cotrimoxazole for pneumonia 6 Low  4 Low 
ORS for acute diarrhoea 7 High  8 High 
Ciprofloxacin for dysentery 0 Low  1 Low 
Vitamin A 9 High  8 High  
   All essential drugs 0 Low  1 Low 
* Success: number of HCs with the listed drugs in stock on day of visit 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
 
n = sample size (HCs); d = decision rule 
 
Neither Gulu nor Kisoro had adequate amounts of all the essential drugs in stock on the 
day of the survey. In both districts, the most problematic drugs were cotrimoxazole for 
treating ARI and CIPRO for treating dysentery. Otherwise ACT, Vitamin A and ORS 
were available in adequate amount on the day of the survey.  
Availability of essential drugs over the preceding 6 months 
Table 42 below shows the number of HCs that did not experience any stock-out of the 
listed essential drugs. None of the districts had adequate stocks of all the essential drugs 
throughout the 6 months preceding the survey. In high transmission area (Gulu), the 
stock of most of the essential drugs was low during the 6 months period under review; 
except for Vitamin A. In low transmission area (Kisoro), the stocks of ACT, ORS and 
Vitamin A were adequate throughout the 6 months period prior to the survey; only 
CTX and CIPRO were in short supply during this period. 
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Table 42: Performance of districts based on availability of drugs during 6 months prior to 
survey 
  
GULU  
(High transmission) 
(n = 10; d = 7) 
 KISORO  
(Low transmission) 
(n = 8; d = 6) 
Essential drugs  *Successes 
**District 
performance 
 *Successe
s 
**District 
performance 
   ACT for malaria 6 Low  8 High  
   Cotrimoxazole for pneumonia 5 Low  4 Low 
   ORS for acute diarrhoea 5 Low  6 High 
   Ciprofloxacin for dysentery 3 Low  0 Low 
   Vitamin A 7 High  8 High  
   All essential drugs 0 Low  0 Low 
* Success: number of HCs that did not experience stock-outs of the specified item 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
 
n = sample size (HCs); d = decision rule 
 
b) Availability of RDT 
Neither of the districts had adequate stock of RDT. In both districts, RDT kits had 
been out of stock for an average of 8 months, and HWs had reverted to presumptive 
treatment. RDT kits which were supplied as part of the survey was not counted in the 
HC stocks. 
c) Availability of guidelines 
The study assessed the availability of the latest, nationally-mandated guidelines for the 
care of children with fever. A facility was considered to have all the mandated guidelines 
if it had both IMCI and RDT-related guidelines. Table 43 below summarises the 
number of HCs where the 2 types of guidelines were available (in any forms) and were 
easily accessible. 
Neither of the 2 districts had the required guidelines in sufficient number. None of the 
job aids assessed was available in sufficient number in high transmission area (Gulu). 
Wall charts—explaining how to carry out a RDT procedure or how to treat a case with 
positive or negative results—were available in sufficient number in low transmission 
area (Kisoro). Otherwise, there was shortage of other types of key job aids in low 
transmission area as well.  
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Table 43: Performance of districts based on availability of mandated guidelines on survey 
day 
  
GULU  
(High transmission) 
(n = 10; d = 7) 
 KSORO  
(Low transmission) 
(n = 8; d = 6)) 
Guidelines or wall charts  *Successes 
**District 
performance 
 
*Successes 
**District 
performance 
   Wall charts***  5 Low  6 High 
   IMCI algorithm (wall chart) 6 Low  3 Low 
   RDT/ACT user manual 2 Low  1 Low 
   IMCI guidelines 6 Low  1 Low 
   Both IMCI and RDT-based job aids 6 Low  2 Low 
 * Success: number of HCs with relevant guidelines 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
***guide on how to carry out a RDT procedure/on treating RDT positive and negative patients 
 
n = sample size (HCs); d = decision rule 
  
d) Availability of equipment 
Assessment of the availability of essential equipment was based on 5 items required in 
the management of a child with fever, namely infant scale, adult scale, timer (for 
counting respiratory rates and timing RDT process), thermometer and an ORS cup/jar. 
Table 44 displays the results.  
 
Table 44: Performance of districts based on availability of equipment on survey day 
 Essential equipment 
GULU  
(High transmission) 
(n = 10; d = 7) 
 KISORO  
(Low transmission) 
(n = 8; d = 6) 
*Successes 
**District 
performance 
 
*Successes 
**District 
performance 
   Infant scale 10 High  8 High 
   Adult scale (for older children) 5 Low  5 Low 
   Timer  7 High  3 Low 
   Thermometer 7 High  2 Low 
   ORS cup/jar 1 Low  1 Low 
   All essential equipment 1 Low  0 Low 
*Success = number of HCs with the relevant equipment 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
 
n = sample size (HCs); d = decision rule 
 
Neither of the 2 districts had sufficient stock of all essential equipment at the time of 
the survey. In Gulu, the problematic items were adult scales and ORS cup/jar. In 
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Kisoro, all the listed pieces of equipment were in short supply, except infant scales 
which were in sufficient number.  
e) Availability of sanctioned staff 
Staff availability was assessed by comparing the official staffing requirements for HCIIs 
versus the positions filled for different cadres. The results are summarised in Table 45 
below. Gulu district (high transmission) had sufficient number of professional staff 
while Kisoro district (low transmission) had sufficient number of both professional and 
paraprofessional staff. However, none of the HCs in either district had sufficient 
number of all the required cadres of staff.  
Table 45: Performance of districts based on availability of required staff  
  
GULU 
(High transmission) 
(n = 10; = 7) 
 KISORO 
(Low transmission) 
(n = 8; d = 6) 
Types of staff *Successes 
**District 
performance 
 
*Successes 
**District 
performance 
Professional staff (enrolled 
nurse/midwife) 
7 High 
 
6 High 
 
 
  
 
 
Paraprofessional staff (nursing 
assistants) 
5 Low 
 
6 High 
 
 
  
 
 
All recommended staff 3 Low  5 Low 
* Success: number of HCs with required number of staff as per the staffing norm of 2009 (Human resource for health: 
Uganda [182])  
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance  
 
n = sample size (HCs); d = decision rule 
 
5.3.4 Adequacy of support activities  
a) In-service training in fever management 
The HWs who provided care to the sick child on the day of the survey were interviewed 
about the dates of the most recent in-service trainings in fever management that they 
attended, and the content of the trainings. Table 46 below describes their responses. 
 
Training in fever case management was adequate in high transmission area (Gulu). 
Notably, exposure to most aspects of the RDT-based guideline was found to be 
 187 
 
adequate. The aspects that were reported to have not been adequately covered included 
(a) managing a case with a negative RDT test, and (b) managing a case with ARI.  
Table 46: Performance of districts based on training in fever case management 
  
GULU 
(High transmission) 
(n = 10; d = 7) 
 KISORO 
(Low transmission) 
(n = 8; de = 6) 
 
*Success 
**District 
performance 
 
*Success 
**District 
performance 
Most recent training attended by 
provider 
  
 
  HWs receiving training in past 1-3 years ago* 7 High  4 Low 
Content of training  
 
 
 Evaluating patient with fever 7 High  4 Low 
Selecting patient for RDT 7 High  4 Low 
Performing RDT/reading RDT result 7 High  4 Low 
Managing patient with positive RDT result 7 High  4 Low 
Managing patient with negative RDT result 3 Low  4 Low 
Recognising/referring severe illness 7 High  4 Low 
Patient education/counselling 7 High  4 Low 
RDT storage/monitoring 7 High  4 Low 
Treatment with ACT 7 High  4 Low 
Management of pneumonia/ARI 6 Low  1 Low 
 *Success: number of HWs trained. In Gulu, 6 HWs trained in previous 12 months; in Kisoro, all 4 HWs trained 
between 1to 2 years previously 
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
n = sample size (HCs); d = decision rule 
 
Training in fever case management was low in low transmission area (Kisoro). 
Consequently, exposure to all the relevant aspects of the RDT-based guideline was 
inadequate. 
b) Supervision  
The study assessed both the frequency of support supervision offered to the interviewed 
HW, and the particular types of support offered during such visits. The results are 
summarised in Table 47. 
Exposure to support supervision during the 3 months preceding the survey was high in 
both districts. In Gulu, exposure to most of the expected support activities was 
adequate, notably observing and giving feedback on the HW‘s work. The problematic 
support activities were drug delivery and giving updates on policies. In Kisoro, most of 
 188 
 
the expected support activities were not adequately provided, except for checking of 
records and observing the HW‘s work. Feedback on the HW‘s work was inadequate.  
Table 47: Performance of districts based on number and quality of supervision 
  
GULU 
(High transmission) 
(n = 10; d = 7) 
 KISORO 
(Low transmission) 
(n = 8; d = 6) 
Most recent visits *Success 
**District 
performance 
 
*Success 
**District 
performance 
Supervision in last 3 
months 10 High 
 
8 High 
           
Types of support 
offered      
 
    
Delivered supplies 6 Low  1 Low 
Checked records 8 High  8 High 
Observed provider's work 8 High  8 High 
Gave feedback 8 High  5 Low 
Gave update 6 Low  5 Low 
Discussed problems 7 High  4 Low 
Checked drugs supply 9 High  4 Low 
*Success: number of HWs who were supervised in the last 3 months/who received the specified support  
**High = satisfactory or adequate performance; Low = unsatisfactory or inadequate performance 
 
n = sample size (HCs); d = decision rule 
 
  
 189 
 
5.3.5 Summary of findings 
Table 48 shows a score card for the two districts for the 4 inputs items and the 2 
process items included in the assessment. 
 
HW performance 
None of the HWs met the performance threshold for all the tasks observed. Therefore, 
both districts failed to adequately adhere to the recommendations of the RDT-based 
guidelines. Adherence was high in Gulu for prescribing the correct medication for the 
diagnosed illness and in Kisoro for client-counselling —all of which were single-task 
procedures. Medical history taking and clinical examination were seriously incomplete in 
both districts. Notably, HWs rarely asked about symptoms that are indicative of the 
severe forms of illness in children with fever. RDT was performed in 91.7% of 
consultations in Gulu—a high malaria transmission setting; compared to 29.2% of 
consultations in Kisoro—a low malaria transmission setting.  
a) Adequacy of essential inputs and support activities 
None of the districts had adequately stocked all the essential drugs either on the day of 
the survey or during the preceding 6 months. The most problematic drug items were 
cotrimoxazole (for treating pneumonia or ARI) and CIRPO (dysentery)—both on the 
survey day and during the 6 months prior. ACT was notably available in adequate 
amount in both districts on the survey day; and during the preceding 6 months in 
Kisoro. The stock of RDT was unacceptably low in both districts, both on the day of 
the visit and throughout the 6 months preceding the survey. In addition, there were 
insufficient numbers of relevant guidelines as well as essential equipment in both 
districts. Although none of the districts had adequate number of all the recommended 
staff, both districts had adequate number of professional staff. In-service training on 
fever case management (in the context of RDT) was high in high transmission area 
(Gulu): the topic which was addressed insufficiently was the management of a patient 
with a negative RDT result. In low transmission area (Kisoro), training was generally 
inadequate, and all topics were insufficiently covered. Support supervision was adequate 
in both districts.  
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Table 48: Overall performance of the two districts assessed  
Domain 
Input/ 
activity Indicators 
Gulu 
(n = 10) 
(d = 7)* 
Kisoro 
(n = 8) 
( d= 6)* 
HW 
performance 
Medical 
history  
HCs where HW ask about all essential 
symptoms  
0 
Low 
0 
Low 
Clinical 
examination      
HCs where all essential clinical examination 
tasks are assessed 
0 
Low 
0 
Low 
Use of RDT                                                                                                      
HCs where HW follow all required steps in 
using RDT  
2 
Low 
0 
Low 
Treatment 
HCs where all treatment prescribed are 
appropriate to the diagnosis  
7 
High 
4 
Low 
Counselling 
HCs where HW explains treatment to all care 
takers 
6 
Low 
6 
High 
All 
procedures 
HCs where HW performs all observed clinical 
tasks as required  
0 
Low 
0 
Low 
Inputs 
Drugs  
HCs with all (5) first line drug items for 
childhood fever in the surveyed HCs on the day 
of the survey (ORS, CTX, CIPRO, ACT, VIT 
A) 
0 
 
Low 
1 
 
Low 
HCs with no stock-outs of the essential drug 
items in the preceding 6 months 
0 
 
Low 
0 
 
Low 
RDT 
HCs with at least one basic unit (sealed pack) of 
RDT kits available on day of visit 
0 
Low 
0 
Low 
Guidelines  
HCs with all nationally-mandated guidelines for 
managing a child with fever, being available and 
accessible on the day of the survey (IMCI 
guideline/wall chart (algorithm) and RDT/ACT 
user manual or wall chart guide on performing 
RDT + wall chart on treatment according to 
RDT results) 
6 
 
Low 
2 
 
Low 
Equipment  
HCs with all essential equipment required to 
support the management of a child with fever 
on day of survey (infant scale, adult scale, timer, 
thermometer, ORS cup/jar) 
1 
 
Low 
0 
 
Low 
Staffing 
HCs with all the sanctioned clinical staff as per 
the day of the survey 
3 
 
Low 
5 
 
Low 
Support 
activities 
(Processes) 
Training  
HCs in which interviewed HWs reported 
receiving training on guidelines for fever in the 
preceding 1-3 years 
7 
 
High 
4 
 
Low 
Supervision 
HCs in which interviewed HWs reported 
receiving support supervision in the preceding 3 
months 
10 
 
High 
8 
 
High 
 *d: decision rule   
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5.4 Discussion 
This chapter evaluates the quality of implementation of RDT-supported policy in a 
district as a whole. It assesses the quality of delivery of all components of the guideline 
as well as adequacy of key health systems inputs and support activities. Assessment of 
HW adherence is based on observation of consultations of children (< 5years) 
presenting with fever. The HW was observed performing 4 clinical procedures (a) 
clinical assessment (medical history and clinical examination), (b) use of RDT, (c) 
treatment prescribed, and (d) counselling of care takers about therapy. The survey 
compares HW adherence from high and low malaria transmission settings. It identifies 
the problematic elements of the health care process which may need strengthening. It 
also assesses the adequacy of relevant inputs and support activities essential for effective 
implementation of guidelines.  
Since use of RDT-based guidelines is intended to improve patient care, particularly of 
non-malarial fevers [19, 70-72], the quality of the diagnoses made and the 
appropriateness of treatment prescribed by the HWs are priority problem areas in the 
assessment of HW performance. The quality of diagnosis and type of treatment 
prescribed also impact on healthcare cost. Accordingly, the following tasks were 
considered critical in evaluating HW adherence to RDT guideline in Uganda (a) 
assessment (medical history and clinical examination), which includes all tasks except 
checking for vaccination status; (b) use of RDT, which includes requesting and using 
RDT in all fever patients, use of a loop or pipette to collect the blood, putting blood 
and buffer in the appropriate wells and waiting for at least 15 minutes after buffer 
before reading the test results; and (c) the type of treatment prescribed. Counselling of 
care takers is important in ensuring effective treatment. It does not directly influence the 
quality of diagnosis and the type treatment prescribed. Therefore, it was not considered 
a priority problem area. 
5.4.1 Health worker adherence 
The results show that neither of the districts implemented the guideline sufficiently. 
Adherence was particularly low in the diagnostic steps: medical history taking and 
clinical examination.  Notably, HWs very rarely asked about symptoms that are 
indicative of the severe forms of illness in children with fever. In addition, and 
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surprisingly, use of RDT was remarkably lower in Kisoro—a low malaria transmission 
setting—than in Gulu—a high malaria transmission setting. 
Previous evaluations of implementation of IMCI guidelines—including one from 
Uganda—have also shown low performance scores, with patient counselling being the 
most problematic procedure and treatment prescribing showing the best scores[90, 92, 
93, 113].  Performance of assessment tasks has been found to vary widely across studies, 
from 27.3% in Benin [115]to 86.9% in Morocco [90], averaging at 49.8% (95% CI: 
49.3% to 50.3%). In this survey, the pooled scores for assessment tasks (medical history 
and clinical examination) were 16% in Kisoro and 25% in Gulu. The findings in this 
survey show that performance of assessment tasks in the districts assessed appears to be 
on the poorer side compared to the performance reported in several surveys of IMCI 
guidelines [90, 92, 93, 113]. It is acknowledged that meaningful comparison of the 
findings of this survey with previous studies is hampered by variability in context; 
number of tasks assessed and design effects, which might be larger than anticipated.   
It appears that, in managing a case of fever, HWs tend to focus more on use of RDTs 
and/or correct prescribing of antimalarials relative to RDT results than, on carrying out 
complete clinical assessment and other components of the guideline. This might be 
because of the way RDT-based guidelines have been portrayed during trainings, which 
tend to emphasize more of the former than the latter, as was noted with the trials 
synthesized in chapter 3 [34-37]. Several other training programmes have also had 
similar unbalanced emphasis on implementation of different components of RDT-based 
guidelines [32, 120, 121, 151]. This survey has also shown that trainings did not 
adequately address management of patients with negative RDT results, even in the 
district where in-service training was found to be adequate.  
By emphasising use of RDTs and prescribing of anti-malarials more than other 
components of the guideline, HWs might have a mindset that RDT-based guidelines are 
a tool for preserving ACTs or antimalarials. Relative to presumptive treatment, use of 
RDTs probably does not improve care in parasite positive cases of fever since some of 
them are missed [138]. The main clinical advantage of using RDTs in fever case 
management is in aiding the identification of parasite negative cases in whom alternative 
diagnosis can be sought [19, 70-72]. This depends on complete assessment of patients 
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[138, 155, 157, 166]. Guidelines and training programmes need to be very clear about 
this objective.  
This survey found a stark difference between the two districts in the use of RDTs. Use 
of RDTs was high in high transmission area and low in low transmission area. In high 
malaria transmission area, HWs used RDT in 91.7% of the consultations. In low 
transmission area, HWs used RDT in only 29.2% of the consultations. Use of RDTs in 
fever case management is potentially cost-saving  and cost-effective in low to moderate 
malaria transmission settings, as shown by the results of the analysis of trial data from 
Uganda in chapter 4, and by previous economic models12 [12, 13, 33, 72, 140, 144]. Both 
the analyses in chapter 4 and previous economic models show that use of RDTs in high 
malaria transmission settings is unlikely to be cost-saving, or cost-effective, even if HW 
adherence to the guideline is perfect.  Therefore, the pattern of utilisation of RDTs 
observed in this survey—showing low utilisation of RDT in low transmission district 
and high utilisation of RDTs in a high transmission district—is contrary to expectations. 
A similar pattern of use of RDTs in fever case management was observed in Kenya, and 
was found to be associated with substantial increase in healthcare cost in a low 
transmission setting [33]. If this pattern is replicated more widely, then RDT-based 
treatment policies for fever may lose their economic advantage over presumptive 
treatment, even in low and moderate transmission areas, in Uganda. The substandard 
quality of assessment exacerbates the overall quality of care in both settings. 
The pooled performance scores13 in this survey was 52% in high transmission area 
(Gulu) and 21% in low transmission area (Kisoro)(Appendix 20). These scores are much 
lower than those obtained from correct use of RDTs and prescribing of antimalarials as 
the sole indicators of the quality of implementation of RDT guidelines [35-37, 120, 121]. 
Assessments based on prescribing alone tend to give higher adherence scores [90, 91, 
109, 110, 112, 146, 150] than those based on multiple procedures/indicators [33, 92, 93, 
113, 115, 117]. HWs tend to prescribe treatment according to the diagnoses they 
indicate. Hence it is logical for treatment scores to be high. Therefore, the findings of 
this survey give a more accurate picture of the quality of implementation of the RDT-
                                                          
12 Literature review: section 2.8.7 
13 Percent of all the tasks that were performed according to guideline 
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based guideline in routine practice in Uganda. It indicates that the problem of non-
adherence is much deeper than is normally reported.   
5.4.2 Adequacy of inputs and support activities 
The findings of this evaluation suggest that the health system is not adequately 
supportive of the routine use of the RDT-based guideline. Notably, RDT kits were 
found to have been out of stock for 8 to 9 months in both districts and HWs had 
reverted to presumptive treatment at the time of the survey14.   
Inadequacy of inputs may not explain fully the poor HW performance in both districts. 
For example, although both districts had insufficient number of guidelines, the effect of 
accessibility to guidelines on HW performance is generally equivocal [93, 112, 114, 146, 
150]15. Availability of essential drugs does not appear to be the reason for poor HW 
performance either. Prescribing of treatment was appropriate in high transmission area 
(Gulu). Inappropriate treatment in low transmission area (Kisoro) was mainly due to 
prescribing of anti-malarials presumptively and due to polypharmacy (prescribing more 
drugs than was needed for the diagnosis indicated by the HW).  
Shortage of RDT over a prolonged period of time may have had the biggest impact on 
(low) guideline implementation. Human capital theory underlines the importance of 
consistency of use of a new technology in order to maintain proficiency over time16 [28, 
31, 41, 42, 46], especially if its use requires the acquisition of new skills [41]. An LQAS 
assessment of family planning services in Kenya found that service providers who 
continued to use their skills had better skills-retention level than those who were no 
longer offering the same services at the time of the survey [106]. Therefore, the 
prolonged disruption in the use of RDTs could have resulted in loss of interest and loss 
of skills in its use [60, 61, 106, 183, 184]. However, this factor per se cannot explain the 
difference in performance quality between the two districts since the problem of 
shortage of RDTs was general and appears to have affected both districts equally. 
Exposure to in-service training was low in low transmission area (Kisoro); and this may 
have contributed further to poor performance in the district—although the evidence on 
                                                          
14 RDT kits which were supplied as part of the survey was not counted in the HC stocks 
15 See Literature review, section 2.10.2 
16 See Literature Review, section 2.3.2 
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the effect of in-service training on adequacy of adherence to guidelines is considerably 
variable [90, 91, 93, 112, 117, 146]. Further, lack of refresher trainings could have 
affected performance quality in both districts. The positive effect of in-service training 
on adherence to guidelines is generally modest [185] and short-lived [62]; and needs to 
be topped-up and reinforced by regular refresher trainings and constant exposure to the 
innovation.   
In a nutshell, shortage of job aids, lack of refresher trainings and prolonged shortage of 
RDTs could all explain the poor performance quality in both districts. Inadequate 
exposure to initial in-service training may explain the poorer performance quality in low 
transmission area (Kisoro). 
5.4.3 Usefulness of the findings 
The survey presents performance scores based on a comprehensive and simultaneous 
assessment of all aspects of the healthcare process as stipulated in the RDT-guideline. 
Therefore, it presents a more comprehensive measurement of adherence to RDT-
guideline [109, 113]. Accordingly, it portrays the quality of the entire process of health 
care for patients with fever in the context of the new guideline [109, 113]. 
The results of this survey helps to identify elements of the healthcare process with a 
particular need for improvement or more emphasis [113]. In both Gulu and Kisoro 
districts, improvements are required in the clinical assessment component of the 
guideline (medical history and clinical examination) in order to improve the quality of 
care, especially in non-malarial fevers. In Kisoro, particular emphasis is required on use 
of RDTs to support diagnosis in fever patients and on the need to use the results to 
guide prescribing of medications. In Gulu, particular improvement is needed in 
counselling of care takers. These improvements can be brought about through refresher 
trainings and/or support supervision, and by making job aids available and accessible to 
HWs. It is imperative for health authorties to main an adequate level of RDT kits at the 
facilities at all times for the suggested improvements to take place and for the new 
guideline to be implemented to acceptable quality. 
To my knowledge, this is the first study in Africa that provides a comprehensive picture 
of the quality of implementation of the RDT-based guideline, alongside a systematic 
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assessment of the systems readiness in supporting the routine implementation of the 
guideline. 
Furthermore, this study is unique in the sense that it uses LQAS method which has the 
advantage of identifying local variation in performance indicators (e.g. facility-specific 
performance of clinical tasks), while collecting data for regional and national 
assessments [106]. An example of facility-specific performance is shown in Appendix 19 
for HW performance indicators. Therefore, interventions aimed at improving HW 
performance can be targeted at both district and facility levels. For indicators measured 
at district level only (e.g. adequacy of health systems inputs), interventions can not be 
targeted at facility levels.  
The LQAS shows how the 6:5 observation rule can give a quick portrait of the quality 
of different aspects of care; and how the decision rule can be used alongside the 
checklists for HFA as a supervisory tool [106]. 
5.4.4 Study limitations 
This study focuses on children only and could be biased. However, there is no evidence 
from this study that the age of the patients was a factor in deciding whether or not to 
perform an RDT. When an RDT was used, HWs adhered strictly to the results. Because 
it focuses on children, the data generated is of limited value in modelling the cost 
implications of using RDT-based guidelines in the general population.  
The sample size in the LQAS method is too small to measure coverage (point estimates) 
at a facility level, but could be combined to measure coverage at the district level [106, 
186]. In this analysis, the pooled number of observations per district was still too small 
to give accurate point estimates of district-level adherence scores. As such these (pooled 
point estimates) may not be useful in economic evaluation models.  
The study shows high adherence scores for the quality of treatment prescribed—
measured as the match between diagnosis and drug choice. However, LQAS-based 
methods only describe whether or not a patient was classified into a diagnostic category. 
The quality of diagnoses upon which treatment is based may be conditional on the 
quality of prior clinical assessments and RDT test [113]. Additionally, an important 
element of the quality of treatment in a child includes the dosing regimens of the 
medications prescribed—which are age and weight dependent, particularly the dosing 
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regimen of ACTs [17, 157, 187]. No ―gold standard‖ assessments of the patients were 
performed to judge the validity of the diagnoses made by the health workers; or to 
assess whether the dosages of drugs prescribed were appropriate for weight and age. 
Therefore, it is probable that the amount of errors associated with treatment choices 
was higher than is reported by this study.  
Health providers are known to improve their practices once they are aware that they are 
being observed or their performance is being assessed (Hawthorne effect) [188, 189]. 
This implies that the level of HWs performance observed in this study may be better 
than it is in normal everyday practice. In spite of this, HWs performance was generally 
low in both districts, implying that HWs might execute even fewer of the required tasks 
when they are not being observed. Further, because the survey uses the most 
experienced HW to represent a HC, the performance reported in this survey may be 
interpreted to be better than usual. In reality we observed the same staff that would 
normally carry out the same tasks in everyday practice. Therefore, the risk of bias 
associated with observing the ―most experienced‖ HW is considered to be negligible. In 
any case, the performance of most tasks was low in both districts. 
Because of language barrier, the RAs carried out clinical observations and exit 
interviews. As such there is a risk of observer error. The performance of the RAs during 
training suggests that the level of such a risk is negligible. 
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5.5 Conclusions 
The results of this survey show that the quality of implementation of the RDT-based 
guideline through routine health services was inadequate in both high and low malaria 
transmission districts. Notably, implementation was much poorer in the low 
transmission district where the use of RDT is expected to be of a greater economic 
potential. Basing on the pattern of adherence, use of the RDT-based guideline may not 
be economically beneficial in routine clinical settings in Uganda.  
Several areas of the guideline require improvement. Clinical assessment of patients was 
seriously incomplete in both districts, and needs to be emphasized through further 
interventions. Additional areas for improvement include counselling (Gulu-high 
transmission), use of RDT (Kisoro-low transmission) and prescribing (Kisoro-low 
transmission). Improvements can be brought about through refresher trainings, support 
supervision, provision of job aids and regular supply of RDT kits. These interventions 
could be undertaken prior or during dissemination of the guideline for wide-scale 
implementation. Without these improvements, use of RDT-based guidelines may not 
result in better management of fevers relative to presumptive treatment.  
It is also evident that the health system is not adequately supportive of the routine use 
of the guideline and is in need of strengthening. Apart from ACTs, ORS and Vit A, 
most of the essential inputs required for the management of the sick child were lacking 
on the day of the visit. Most significantly, there was a prolonged disruption in the supply 
of RDTs in both districts. Several HCs were lacking necessary job aids, especially in 
Kisoro district. A number of HWs from both districts had not attended in-service 
training in the use of the guideline; whilst there was an urgent need for refresher 
training.  
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Chapter 6   General discussion and conclusions 
6.1 Overview  
This thesis aimed to establish if implementing an RDT-based guideline instead of 
presumptive treatment of fever leads to better quality of patient care relative to 
presumptive treatment when delivered using carefully controlled studies and through 
routine clinical practice. In particular, the thesis  
a) reviews evidence from RCTs to determine if RDT-based policies for fever lead 
to better quality of patient care than presumptive treatment under optimal 
conditions 
b) analyses data from a pragmatic trial to determine if RDT-based policies for fever 
lead to better quality of patient care than presumptive treatment in routine 
practice 
c) assesses the quality of actual practice when an RDT-based guideline is rolled out 
to health services in a district as a whole 
The thesis consists of 3 studies which reflect the sequence of evaluation of a new 
healthcare technology, from assessment of efficacy, through assessment of effectiveness 
to assessment of current practice (Table 49).  A Cochrane review of evidence from 
randomised trials in Africa is used to evaluate the effect of RDT-based policies on the 
quality of patient care in relatively optimal conditions. An analysis of existing dataset 
from a pragmatic trial from Uganda is used to evaluate the effect of an RDT-based 
policy on the quality of patient care and on incremental cost in routine practice in 
Uganda. A Health Facility Assessment (HFA) is used to determine the quality of current 
practice and adequacy of support services when RDT-based guidelines are rolled out to 
health services in a district as a whole as routine practice.  
6.2 Summary of results 
Major findings from the 3 studies are summarised in Table 49, which also specifies the 
indicators assessed in 2 or more studies, and those that were study-specific.    
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Table 49: Summary of main findings from chapters 3, 4 and 5 
Variables Indicators Systematic review (RCTs) Pragmatic trial  Survey of current practice  
Quality of 
practice  
Adequacy of clinical assessment No data No data Inadequate  
Use of RDTs No data Most cases (97%) were tested with 
RDTs prior to any treatment.  
―Low‖ in low transmission district; 
―high‖ in high transmission district 
 
Quality of use ―low‖ in both high and 
low transmission districts.* 
 RDT-positive cases getting 
antimalarials 
98% to 100% received 
antimalarials (3 studies) 
98% to 100% received  
antimalarials (all transmission 
settings) 
All cases with positive RDTs received 
antimalarials in both high and low 
transmission districts 
 RDT-negative cases getting 
antimalarials 
0.4% received antimalarials in 
1 study (high adherence) 
 
40% to 81% received 
antimalarials in 3 studies 
(poor adherence) 
0.5% received antimalarials in all 
transmission settings (high 
adherence) 
None of the cases with negative RDT 
results received antimalarials in both 
high and low transmission districts 
 Advice on medications No data No data Adequate in low prevalence district; 
inadequate in high prevalence district 
     
Outcomes Patients receiving antimalarials  Wide variability in results: 
number declined significantly 
where adherence to RDT 
results was high. No 
difference in prescribing 
where adherence to RDT 
results was low. 
Significant decline in proportion 
of patients prescribed antimalarials 
in all transmission areas. Highest 
in the low prevalence district and 
lowest in the high transmission 
district— effect higher among 
older (>5 years old) patients 
Not measured 
 Patients receiving antibiotics 2 studies: increased in one 
study. No difference detected 
in another  
Declined by 5% in high 
transmission setting. No 
significant change in medium and 
low transmission settings 
Not assessed 
*HWs failed to follow some critical steps in carrying out the test 
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Variables Indicators Systematic review (RCTs) Effectiveness trial  Survey of current practice  
Outcomes 
(continued) 
Patients unwell 4 – 7 days 
after treatment 
No difference detected 
between RDT and clinical 
diagnosis arms 
No difference detected between 
RDT and clinical diagnosis arms 
Not assessed  
 Cost  No data Significant decline in low and 
medium transmission settings 
only. Significant declines in older 
(> 5yreas old) patients only 
Not assessed  
 Malaria cases missed No difference (1 study) Corresponds to RDT false 
negative error rates.  High in low 
prevalence areas.  
Not assessed 
 Non-malarial cases prescribed 
antimalarials 
Significant declines, but 
remains high at intervention 
sites (1 study) 
Corresponds with RDT false 
positive error rates. High in high 
transmission setting; low in low 
transmission setting.  
Not assessed 
     
System 
readiness 
Essential inputs No data No data RDTs: inadequate supply—out of 
stock for 8 months in both districts.  
Essential drugs: inadequate supply in 
both districts 
Guidelines: inadequate presence in the 
health facilities 
Equipment: inadequate in both districts 
Staff: inadequate in both districts 
 Support services No data No data In-service training: inadequate in low 
prevalence district; adequate in high 
prevalence district.  
No refresher training in 2-3 years.  
Support supervision was adequate in 
both settings 
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6.2.1 Cochrane review 
Do carefully controlled trials show that treatment policies for treating fever which are based on RDT 
results lead to better quality of care than treatment based on clinical judgement? 
Four trials met the inclusion criteria (n=9545): 2 individually randomised and 2 cluster.  
a) Quality of practice 
Two indicators were used to assess the quality of practice in controlled conditions; 
namely, (a) proportion of RDT-positive patients for whom antimalarials were prescribed 
(b) the proportion of RDT-negative patients for whom antimalarials were prescribed. 
HWs were expected to perform each of the two tasks correctly at least 95% of the time. 
Otherwise the quality of practice or HW performance was judged to be inadequate [104, 
106, 127, 128, 140]. Only 3 studies provided data for the first indicator [34-36]. HW 
response was adequate in all three trials: 98% to 100% of cases with positive RDT 
results were prescribed antimalarials. HW response varied widely with regard to the 
second indicator. HW performance was adequate in only one trial in which antimalarials 
were prescribed to 0.4% of patients with negative RDT results [37]. HW performance 
was inadequate in 3 trials: patients with negative RDTs for whom antimalarials were 
prescribed varied from 40% to as many as 81% [34-36]. Therefore, the quality of 
practice was adequate in one trial only, in which HWs withheld antimalarials from 
99.6% of patients who had negative RDTs. 
b) Primary outcomes 
Fewer patients were prescribed antimalarials in the intervention (RDT) facilities than in 
the control (clinical diagnosis) facilities (combined RR = 0.71, 95% CI 0.56 to 0.90, 4 
trials, n = 9327).  
 Estimates of effects of the intervention varied considerably across the 4 studies 
(Chi2 = 175.78, df = 3, (P < 0.00001), I2 = 98%).  
 Studies detected substantial decline in prescribing of antimalarials at intervention 
HCs where HW adherence was high (RR = 0.23, 95% CI 0.14 to 0.38) [37].  
 Trials with low HW adherence at intervention HCs detected no significant 
difference in prescribing of antimalarials between the two arms (combined RR = 
0.85, 95% CI: 0.66 to 1.08) [34-36].  
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 Variability in age group did not influence the effect of the intervention (test for sub 
group difference: Chi2 = 0.44, df = 1 (P = 0.51), I2 = 0%).  
Studies detected no significant difference between RDT and clinical diagnosis arms for 
patients who were still unwell between days 4 - 7 (RR = 0.89, 95% CI: 0.68 to 1.28). 
c) Secondary outcomes 
Targeting of antimalarials  
 One study detected a significant reduction in the intervention arm in non-
malaria fevers (reference microscopy negative patients) prescribed anti-malarials 
(RR = 0.60, 95% CI: 0.57 to 0.64).  
 The same study detected no difference between RDT and clinical diagnosis arms 
in true malaria cases (reference slide positive patients) not receiving anti-
malarials (RR = 1.21, 95% CI: 0.64 to 2.23)[36]. 
Antibiotics prescribing  
No significant difference was detected between the 2 arms in the amount of antibiotics 
which was prescribed (RR = 1.03, 95% CI: 0.97 to 1.10; 2 studies) [34, 36].  
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6.2.2 Effectiveness trial 
Does the evidence from a pragmatic trial in Uganda show improved quality of patient care when 
treatment policy for fever based on RDT results is applied to a large population through routine health 
services? 
a) Quality of practice 
This trial took place in low, medium and high transmission settings. Judgement of HW 
performance was based on assessment of 3 tasks: (a) use of RDTs, (b) prescribing of 
antimalarials in response to positive RDT results, and (c) prescribing of antimalarials in 
response to negative RDT results. HWs were expected to perform each of the 3 tasks 
correctly at least 95% of the time. Otherwise the quality of practice or HW performance 
was judged to be inadequate [104, 106, 127, 128, 140].  
RDTs were used in at least 97% of participants across all intervention sites. At least 
98% of patients with positive RDT results received antimalarials. Less than 0.7% of 
participants with negative RDT results were prescribed any antimalarials. Therefore, 
HW performance was adequate in all malarial transmission settings, and in all age 
groups.  
b) Primary outcomes 
After introducing RDT-supported guidelines,  
i) prescribing of antimalarials declined significantly in all transmission settings, 
as follows:  
 high transmission by 22.1% (95% CI: -24.6% to -19.6%)  
 medium transmission by 48.9% (95% CI: -52.5% to -45.5%)  
 low transmission by 60.2% (95% CI: -64.1% to -56.3%).  
 
ii) Prescribing of antibiotics  
The marginal change in prescribing of antibiotics was as follows  
 high transmission:  -5.0% (95% CI: -8.7% to -1.3%)  
 medium transmission: -2.7% (95% CI: -7.0% to 1.5%)  
 low transmission: -4.6% (95% CI: -9.7% to 0.5%) 
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iii) Healthcare cost  
 high transmission: no significant change detected: US$ +0.02 (95% CI: US$ 
-0.97 to US$+1.06). 
 medium transmission: reduced by 17.7%, amounting to a cost saving of US$ 
0.33 per case of fever (95% CI: US$ -0.54 to US$-0.12). Reduced in older 
children and adults (5+ years) only. 
 low transmission: reduced by 24.5%, amounting to a cost-saving of US$ 0.50 
per case of fever (95% CI: US$ -0.69 to US$-0.31).  Reduced in older 
children and adults (5+ years only). 
 
iv) Clinical outcomes 
No difference was detected between RDT and clinical diagnosis arms in the number of 
patients still unwell at day 5 
 high transmission: RR = 1.02 (0.97 to 1.06) 
 medium transmission: RR = 1.00 (0.97 to 1.04) 
 low transmission: RR = 1.02 (0.98 to 1.07) 
c) Secondary outcomes (targeting of antimalarials) 
After introducing RDTs at intervention HCs some non-malarial (reference slide-
negative) patients received anti-malarials at intervention HCs despite high HW 
adherence to guideline. The number in high, medium and low transmission settings was 
43.1%, 15% and 11% respectively. These numbers correspond with the RDT α-error 
rates at the respective sites, namely 43.9%, 15.2% and 10.5% respectively.  
 
On the other hand, some malarial (slide positive) fever patients were missed at the 
intervention sites after introducing RDTs. The proportion missed at high, medium and 
low transmission sites was 1.9%, 5.9% and 17.2% respectively. These figures closely 
correspond with the RDT false-negative error rates at the respective sites, namely 2.0%, 
4.5% and 17.2% respectively.  
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6.2.3 Survey of current practice 
Are all components of an RDT-based guideline being implemented to acceptable standards in the 
districts in Uganda where RDT-based policy has been rolled out for routine implementation? How 
adequate are essential health systems inputs and support services? 
a) Quality of practice 
A survey of current practice took place one year after rolling out the RDT-supported 
policy for fever for small-scale implementation. The assessment took place in 2 districts 
representing low and high malaria transmission intensity respectively. All components of 
care specified in the RDT-based guideline for Uganda were assessed, consisting of a 
total of 25 tasks. The study used the LQAS technique to assess the quality of practice in 
a district as a whole, based on the quality of guideline implementation at constituent 
HCs. A district was judged as high performance if at least 80% of the sampled HCs in it 
implemented the RDT-based guideline adequately. An HC was judged as high 
performance if the most experienced HW at the HC performed each of the 25 tasks 
correctly at least 95% of the time. These standards have been used in several LQAS-
based surveys [104, 106, 127, 128] and were discussed with officials of the Ministry of 
Health and the districts prior to application.  
None of the HWs met the performance threshold for all the tasks observed. Therefore, 
the quality of practice was judged to be inadequate in both high and low transmission 
districts. Clinical assessment was particularly incomplete in both transmission areas. 
More surprisingly, RDT was requested in only 29.2% of consultations in an area with 
low malaria prevalence, compared with 91.7% of consultations in an area with high 
malaria prevalence. In both high and low transmission districts, HWs committed errors 
in several steps involved in performing an RDT test. Most critically, RDT results were 
read hurriedly, often within 2 minutes of the recommended 15 minutes waiting period. 
The quality of prescribing of antimalarials was low in low prevalence area, mainly due to 
low utilisation of RDTs. In high prevalence area, prescribing of antimalarials matched 
RDT results most of the time. Therefore, prescribing of antimalarials was judged as 
being appropriate in high transmission setting despite the fact that the quality of clinical 
assessment and RDT test was poor.  
b) Essential inputs and support services 
None of the districts had adequate stock of all essential drugs required for effective 
implementation of the RDT-supported guideline—on the survey day or during the 
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preceding 6 months. RDTs were out-of-stock in both districts, both on the day of the 
visit and throughout the 6 months preceding the survey. ACTs were available in 
adequate amount on survey day in both districts. In the preceding 6 months, supply of 
ACTs was erratic in an area with high malaria prevalence, but adequate in an area with 
low malaria prevalence. The most problematic drug items were cotrimoxazole (for 
treating pneumonia or ARI) and CIRPO (dysentery)—both on the survey day and 
during the 6 months prior. Relevant guidelines and essential equipment were also in 
insufficient number in both districts. Although none of the districts had adequate 
number of all the recommended staff, both districts had adequate number of 
professional staff. In-service training on use of RDT-based guidelines was adequate in 
high prevalence district but low in low prevalence district. Support supervision was 
adequate in both districts.  
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6.3 General discussion 
The basis for adopting a new technology should be the evidence that it is more effective 
than the intervention currently or previously in use, and that, once scaled-up, it can be 
implemented sufficiently [40, 41]. Effectiveness is achieved only if an efficacious 
intervention is implemented sufficiently and the target audience is receptive to or 
adheres to it. Accordingly, the main questions regarding utility of RDT-based guidelines 
has been whether they can be implemented sufficiently in routine practice and whether 
their use in routine practice can lead to better outcomes than treatment based on clinical 
judgement [14, 26, 34]. There are indeed concerns that RDT-based treatment may lead 
to increased morbidity due to missed diagnosis of malaria cases [26, 34].  
6.3.1 Is the intervention efficacious and effective? 
a) Effect on clinical outcomes 
The review in chapter 3 included two trials which evaluated effects of RDT-based 
guidelines on clinical outcomes under experimental conditions. None of the 2 studies 
detected a significant difference in clinical outcomes between RDT and clinical 
diagnosis arms. Additionally, the analysis of data from effectiveness trial in chapter 4 
also detected no statistically significant difference in clinical outcomes between RDT-
based treatment group and clinical diagnosis group—even in a low transmission area 
where more than 17% of malarial fevers were missed by RDTs.  According to the 
literature review presented in section 2.5, failure to demonstrate differences in outcomes 
between comparison groups might be due to (a) inadequate implementation of an 
intervention, (b) inefficacy or weak causal relationship between the intervention and 
clinical outcomes, (c) low level of acceptance by the target population, and (d) 
methodological limitations. A combination of these factors may have precluded 
demonstration of effects of RDT-based guidelines both under experimental and semi-
experimental conditions.  
Were interventions poorly implemented? 
We do not know if all components of RDT-guidelines were implemented sufficiently in 
the trials analysed in chapters 3 and 4. On account of the indicators assessed—i.e. HWs‘ 
use of RDTs and prescribing of antimalarials relative to RDT results—we can construe 
that RDT-based guidelines were poorly implemented in the trial by Bisoffi and 
colleagues in Burkina Faso (chapter 3) [34]. The authors acknowledge that inadequate 
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HW adherence to RDT results may have undermined the ability of this trial to detect 
any significant difference in clinical outcomes between the comparison groups [34]. On 
account of the same measures, we can conclude that RDT-based guidelines were 
sufficiently implemented in Zambian children in the trial by Yeboah-Antwi and 
colleagues (chapter 3) [37]; and in the effectiveness trial from Uganda (chapter 4). 
However, these latter 2 trials also detected no significant difference in clinical outcomes 
between the comparison groups. Therefore, if the indicators assessed were indicative of 
the overall level of guideline implementation, then insufficient implementation would 
not fully explain failure of the trials to detect differences in clinical outcomes. In reality, 
we do not know if guideline implementation was adequate in both efficacy and 
effectiveness trials, since measurement was based on a limited set of indicators, which 
are known to over-estimate overall performance of HWs. It is possible that other vital 
components of the guideline have been poorly implemented, thereby hampering 
demonstration of effects in both studies.  
Is it weak causal linkage? 
Efficacy trials are concerned with demonstrating whether or not an intervention works, 
and how and why it works [40, 97]. The causal relationship between a clinical guideline 
and clinical outcomes is complex [73, 74]. A clinical guideline targets change in HW 
performance. Therefore, its most direct effect consists of the proficiency with which 
HWs execute clinical tasks. Implementation of a clinical guideline is linked to clinical 
outcomes indirectly through its effect on the quality of the process of care. Additionally, 
literature suggests that change in clinical outcomes is determined by several other 
factors which may be independent of the change in HW performance, such as the 
efficacy of medications received, patients‘ adherence to medications, and antecedent 
factors such patients‘ demographics [83, 86]. Therefore, adequate implementation of a 
guideline may not translate into significant differences in clinical outcomes because of 
the effects of intermediary factors. Conversely, improvement in clinical outcomes does 
not necessarily indicate that a guideline is efficacious or effective.  
Furthermore, literature indicates that in a multifaceted intervention like an RDT-based 
guideline, different components may be linked to different outcome attributes [73, 74]. 
For example, we know that RDT-directed prescribing may save antimalarials cost. At 
the same time, it may result in increased morbidity due to increased risk of some 
malarial cases missing antimalarials [26]. For this reason, it is presumed that 
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improvement in clinical outcomes may result mainly through identification of parasite 
negative patients in whom alternative diagnosis can be sought [19, 70-72], through 
adequate clinical assessment [138, 155, 157, 166].  
Like several observational and quasi-experimental studies evaluating the utility of RDT-
based guidelines [32, 120, 121, 151, 152], the trials analysed in chapters 3 and 4 did not 
evaluate implementation of several vital components of the guideline—notably clinical 
assessment and proficiency in the use of RDTs, which can significantly influence the 
quality of diagnoses. Therefore, we do not know for certain, the components of the 
guideline, which if adequately implemented, may have led to significant improvement in 
clinical outcomes. In essence, the clinical outcome attributes assessed may not be valid 
measures of efficacy and effectiveness of RDT-based guidelines.  
Is it poor adherence by patients? 
Patients who are denied antimalarials on account of their negative RDT results may 
obtain antimalarials from other sources if they believe that malaria is the cause of their 
illnesses. Further patients who do not improve on the current treatment may also seek 
further treatment elsewhere and may not be accounted for in evaluation of outcomes. 
These behaviours can mask differences in clinical outcomes between the comparison 
interventions; and might explain the failure to detect a difference in clinical outcomes in 
Mubende (low transmission) where more than 17% of malarial patients were missed by 
the use of RDTs.   
Is it due to methodological limitations? 
Conditions for demonstrating causal relationship did not pertain fully in the trials which 
evaluated clinical outcomes in chapter 3. For example, allocations were not concealed in 
all the trials and this could have led to selection bias [34, 37]. Further, in both trials, 
study participants, providers  and outcomes assessors were not blinded to the 
intervention, test results, diagnoses, treatment prescribed and outcomes assessed [34, 
37]. Lack of allocation concealment and/or blinding is known to bias results towards 
positive outcomes rather than null effects [99]. Therefore, the results of the trials in 
chapter 3 and the analysis in chapter 4 may not have been due to these methodological 
limitations. 
Further, the criteria used in selecting studies for inclusion in the review in chapter 3 may 
have been biased towards trials with no significant effects. On the other hand, they may 
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have been biased against trials considered to have sub-optimal designs, but which may 
have had large effect size [73].  
Therefore, we are unclear whether or not use of RDT-based guidelines has any effects 
on clinical outcomes; or the components of the guidelines with the most significant 
effects on clinical outcomes. More carefully controlled trials which also assess 
implementation of all components of RDT-based guidelines may help identify any 
causal linkage between various components of the RDT-based guideline and various 
outcome indicators.  
b) Effect on prescribing and cost 
The analysis in chapter 4 shows that use of RDT-supported guidelines in the treatment 
of fevers can lead to significant savings in drug costs in older children and adults (5+ 
years), and in low to medium transmission settings. Costs consisted of the values of 
resources used (RDTs, antimalarials, antibiotics and analgesics) during an effectiveness 
trial which was characterised by high utilisation of RDTs and near perfect HW 
adherence to RDT results. The analysis detected no significant change in the values of 
antibiotics and analgesics used before and after introducing RDTs. Effectively, cost-
savings were accrued by averting inappropriate use of antimalarials.  
These findings are consistent with those from several economic evaluations which are 
based on assumption of perfect HW adherence with regards to use of RDTs and 
response to RDT results [12, 13, 72, 140, 144]. However, our evidence is inconsistent 
with an effectiveness trial from Kenya where inadequate adherence to RDT results in a 
low transmission setting was found to be associated with a substantial increase in the 
cost of diagnosing and treating a case of fever.   
The analyses in chapter 3 and several observational studies indicate that HWs adherence 
to RDT results and prescribing of antimalarials can vary even under carefully controlled 
conditions [32-37].  Additionally, evidence from chapters 3 and 4 of this thesis also 
shows that use of RDT-based guideline may have no effect on prescribing of antibiotics 
[34], or it may increase its usage [36]. Further, two effectiveness trials from Tanzania 
also indicate that RDT-directed treatment may substantially increase prescribing of 
antibiotics [121, 156]. Increase in prescribing of antibiotics wound discount cost-savings 
accrued by averting irrational prescribing of antimalarials. Therefore, in light of the 
unpredictable HWs response to RDT results and unclear effect of the intervention on 
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prescribing of antibiotics, we can not predict with certainty how application of an RDT-
based guideline might impact on the magnitude of drug cost saved in routine practice.  
These results need to be interpreted with caution. We know that data on prescribing are 
correlated, and potential design effects may have reduced the power of the studies 
analysed to detect significant and/or larger effects of the intervention on prescribing 
and costs, and may have resulted in over-precise estimates [99, 102]. Further, the 
analysis of costs captures the values of biomedical consumables only, and therefore 
underestimates costs. However, studies which have incorporated programmatic costs in 
their analyses (e.g. staff time, training cost, and supervision cost) have also reported 
significant cost-savings in low and medium transmission settings [72, 140]. It is likely 
that this analysis would have nevertheless detected significant cost-savings in older 
children and adults, and low to medium transmission areas, were it to include 
programmatic costs.  
6.3.2 Can it be implemented sufficiently in routine practice? 
The results of the survey of current practice in Uganda suggests that once scaled-up for 
use in routine practice with limited supervision, none of the components of an RDT-
based guideline might be implemented to acceptable standards. Implementation of the 
diagnostic components, namely assessment and steps in performing an RDT, could be 
particularly problematic.  
To my knowledge, this is the first survey of an RDT-based guideline which attempts to 
evaluate the implementation of all components of the guideline, alongside an assessment 
of essential health systems factors. The findings are consistent with those from previous 
evaluations of IMCI-oriented guidelines in Africa, which reveal that the quality of 
guideline implementation is often much poorer than is portrayed by indicators of quality 
of prescribing alone [33, 90-93, 109, 110, 112, 113, 115, 117, 146, 150]. Performance 
scores for clinical assessment in the context of IMCI has been found to vary widely 
across studies [90, 92, 93, 113], from a low of 27.3% in Benin [115] to a high of 86.9% 
in Morocco [90]. The pooled performance scores for clinical assessment in the 2 
districts surveyed—16% in Kisoro and 26% in Gulu—appear to be on the poorer side 
compared to the performance scores reported in several surveys of IMCI guidelines (see 
pooled scores in Appendix 20). It is acknowledged that meaningful comparison of our 
findings with those of previous surveys is hampered by variability in contexts, the small 
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sample size in our survey, number of tasks assessed in various surveys, and design 
effects.   
Adequate clinical assessment is considered vital in improving the quality of diagnoses, 
and probably clinical outcomes, especially in fever cases who are parasite negative [138]. 
For example, a sub-analysis of diagnostic pathways in an evaluation study of an IMCI 
guideline in Benin revealed that some of the diagnoses upon which treatment was based 
were false because of errors related to inadequate clinical assessment of patients; yet 
treatment matched diagnoses all the time in those circumstances [149]. The sample size 
involved in the sub-analysis was small. However, an evaluation of IMCI guideline in 
Ghana which involved follow-up of patients and evaluation of outcomes found no 
association between the extent of clinical assessment and clinical outcomes [118]. 
Additionally, an assessment of an IMCI guideline in Benin in which patients were re-
evaluated by expert research staff found out that HWs often prescribed effective 
treatment despite deviation from guidelines [115]. These finding raise questions about 
the effectiveness of the current clinical criteria in guiding treatment in a child with fever. 
The accuracy of symptoms-based diagnoses and treatment in HCs manned mainly by 
nurses and paraprofessional staff is bound to vary. Inadequate clinical assessment may 
exacerbate the ability of the staff to make accurate working diagnoses.  
We know from economic models (chapter 2) and the analyses in chapter 4 that use of 
RDTs can significantly save cost of medical consumables in low to medium 
transmission areas and in older children and adults only. Contrary to expectations, use 
of RDTs was low in Kisoro (low transmission district) and high in Gulu (high 
transmission district). We do not know if this behaviour pattern is reflective of low 
transmission and high transmission regions in Uganda generally. Additionally, we do not 
know if HWs in both districts would have behaved differently towards older patients.  
A similar pattern in the use of RDTs in fever case management has been reported in 
Kenya, where it was found to be associated with a substantial increase in diagnosis and 
treatment cost in a low transmission setting [33]. If low utilisation of RDTs as observed 
in Kisoro district in Uganda, and in Kenya is indicative of HWs‘ behaviour in low 
transmission areas as a whole, then RDT-based treatment policies for fever may lose 
their economic advantage over treatment based on clinical diagnosis, even in low and 
moderate transmission areas.  
 216 
 
More disturbing was the finding in both districts that, when RDTs were used, HWs 
committed errors in several steps involved in performing the test. Most critically, HWs 
read the results hurriedly, often within 2 minutes of the recommended 15 minutes 
waiting period. This could be a signal that the quality of RDTs in routine practice where 
there is limited supervision could be poorer than is known from findings from trials.  
Already we know from literature that, even under experimental conditions, RDTs often 
fail to achieve the desired sensitivity of 95% at parasite density of ≥ 100 parasite/100 µL 
of blood [20, 22, 65, 135]. Errors in using RDTs could significantly exacerbate the 
sensitivity of RDTs, increasing the risk of morbidity and mortality from missed malaria 
cases, especially in low transmission areas and in children [26, 138]. Although evidence 
from efficacy studies (chapter 3) suggests that the risk of missed malaria cases is small 
and similar in both RDT and clinical diagnosis arms, evidence from the effectiveness 
trial (chapter 4) indicates that this risk can be substantial. More than 17% of slide 
positive patients were not detected by RDTs at the site in low transmission setting, 
which might indicate poor proficiency in carrying out an RDT test in a trial setting.  
Several health systems factors are known to positively influence HWs adherence to 
guidelines to various extents (section 2.10). Support services such as in-service training 
and supervision are generally associated with improved HW adherence to guidelines [90, 
93, 108, 112, 117, 146]. Availability of guidelines has been found to have mixed effects 
on guideline implementation [93, 112, 114, 146, 150], while availability of essential drugs 
appears to have no significant influence on guideline implementation [93, 112, 150].  
The health systems in the two districts assessed were characterised by prolonged 
shortage of RDTs, shortage of job aids and lack of refresher trainings, all of which may 
explain the poor performance quality in both districts. Human capital theory (sub-
section 2.3.2) underlines the importance of consistency of use of a new technology in 
order to maintain proficiency over time [28, 31, 41, 42, 46], especially if its use requires 
the acquisition of new skills [41]. An LQAS assessment of family planning services in 
Kenya found that HWs who continued to use their skills had better skills-retention level 
than those who were no longer offering the same services at the time of the survey 
[106]. RDTs are a central component of the new intervention. Prolonged disruption in 
the use of RDTs could have resulted in loss of interest and loss of skills in its use in 
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both districts [60, 61, 106, 183, 184]. Inadequate exposure to in-service training may 
have exacerbated the performance quality in Kisoro district (low transmission area).  
In essence, introduction and sufficient implementation of the intervention requires 
strengthening of the health system by ensuring regular supplies of RDTs and job aids, 
and by providing sufficient in-service training and support supervision. Additionally, 
because of the likelihood of inter-lot variability, the WHO strongly recommends that 
countries should develop mechanisms for lot-testing at national level, and for regular 
random testing the level of use [65] 
6.3.3 Has the intervention been evaluated sufficiently? 
The technology under evaluation is a complex policy, of which use of RDTs is just one 
component. The current debate, and the focus of this thesis, is whether there is 
sufficient evidence to show that the policy can be effective in clinical settings. Extensive 
laboratory-based [65] and field-based trials [20, 22, 135] have been carried out, and are 
ongoing, aimed at improving the quality of manufacturing and performance of assays. 
However, limited evaluation has been undertaken to determine utility of RDT-based 
guidelines in the field.  
As shown in this thesis, both observational [32, 33, 120] and randomised trials [34-37] 
examining utility of RDT-based guidelines have focused mainly on the effect of the 
intervention on prescribing of antimalarials. Although variable, evidence from these 
studies indicate that RDT-based guidelines can be effective in reducing use of 
antimalarials and treatment cost in older children and adults in low and medium 
transmission areas—as long as HWs use RDTs and prescribe antimalarials according to 
the results. Qualitative research could provide an in-depth knowledge into context-
specific factors responsible for variability in HW use of RDTs and adherence to RDT 
results. Fewer trials [34, 36] and observational studies [121, 156] have evaluated effects 
of the intervention on prescribing of antibiotics. The effectiveness trial analysed in 
chapter 4 is the most recent. They show that the intervention may not have any effect 
on prescribing of antibiotics or they may increase it.  
Studies examining clinical outcomes have been more limited: 2 trials analysed in chapter 
3 [34, 37], the effectiveness trial analysed in chapter 4 and one observational study [121]. 
Only the observational study detected a marginal but statistically significant difference in 
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persistence of fever (2.5% in RDT arm, and 5% in clinical diagnosis arm) [121]. 
Therefore, effects of the intervention on clinical outcomes need further examining, 
because this is currently the most contentious aspect of the policy, and given the 
possibility of high false positive error rate in routine practice as shown in chapter 4 and 
as implied in chapter 5. Studies evaluating effects of the intervention on clinical 
outcomes need to include an assessment of implementation of all components of the 
guideline. When incorporated into a model, variation in implementation of various 
components of a guideline may be used to predict specific outcomes attribute [85]. 
Given the limitations of RCTs in assessing complex public health interventions, quasi-
experimental can be useful for attributing effects to a multi-component intervention. 
Clinical outcomes might not be a valid indicator of improvement in the quality of 
practice. However, there is need to demonstrate that RDT-based guidelines are not 
inferior to clinical diagnosis in terms of their effects on clinical outcomes.  
If the decision for wide-scale application of an RDT-based guideline is to be based on 
clinical outcomes, then we can conclude that, presently, there is insufficient evidence to 
support that decision. It is recognised, however, that RDT-based guidelines have already 
being rolled out in some countries [25], despite the insufficient evidence of their effects 
on clinical outcomes. The bases for those decisions are unclear. If policy makers decide 
to disseminate the policy on the basis of economic potentials, then the evidence from 
literature and this thesis (chapter 4) suggest that it would be prudent to restrict their 
application to low and medium transmission settings and in older children.  
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6.3.4 What this research contributes 
Use of theory-based model: This thesis has shown how the diffusion of innovation 
model can be used to provide a framework for systematically and comprehensively 
reviewing a complex healthcare technology. By applying the diffusion of innovation 
model to the evaluation of the RDT-supported policy for treating fever, this thesis has 
provided different types of information which policy makers might require in making 
adoption and implementation decisions, including an indication of: 
 how the quality of implementation of the guideline and outcomes might vary 
within and between carefully conditions versus in routine practice 
 key health systems barriers that might need to be addressed should the decision 
be taken to scale-up implementation of the innovation 
Comprehensive assessment of guideline implementation: The thesis assessed the 
quality of delivery of all components of the guideline one year after being rolled out for 
small scale implementation. Therefore, it provides a comprehensive picture of what the 
quality of practice might be after scaling-up the implementation in routine practice. It 
also shows the quality of all the specific components of the healthcare process, 
including the diagnostic procedures.  
 It identifies critical components of the guidelines which are being implemented 
poorly, and which need to be improved through specific interventions prior to 
wide-scale implementation.  
 It indicates that assessments based on the use of RDTs and appropriateness of 
antimalarials alone may over-estimate the overall quality of implementation of 
the guideline [109, 113].  
 To my knowledge, this is the first study in Africa that provides a comprehensive 
picture of the quality of implementation of RDT-based guidelines, alongside a 
systematic assessment of the state of essential health systems inputs and support 
services which are required for routine implementation. 
Use of LQAS method to prioritise areas for improvement: In this thesis I used Lot 
Quality Assurance Sampling (LQAS) method to assess whether districts are adequately 
embracing the RDT guidelines in routine clinical care. LQAS optimises the 
identification of extreme performance: worst of worst, which require priority attention 
 220 
 
and/or best of best, so that resources are not wasted. Through the application of LQAS 
techniques, this thesis has been able to specify components of the guideline which 
require urgent attention [106]. 
Effect of multiple factors on effects of intervention: We know that several factors 
interact to influence the effect of the intervention (section 2.8.3). The existing studies 
either do not describe the prevalence of malaria in the setting studied, or they present 
results in a combined form [34-37]. In this thesis, I used patient-level data to show how 
variability in malaria prevalence, age group of the target population and HW adherence 
all combine to influence the effects of the intervention. This information can be useful 
in deciding whether and how to target the policy to different epidemiological settings 
and population groups in order to optimise its benefits.  
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6.4 General Conclusions 
6.4.1 Conclusions about the research questions 
The main questions this thesis set out to answer were whether RDT-based guidelines 
can be implemented to acceptable standards in routine practice and whether their use in 
routine practice can lead to better quality of care in patients with fever—in terms of 
prescribing, cost and clinical outcomes—relative to symptoms-based treatment. 
Effectiveness can be achieved only if an efficacious intervention is implemented 
sufficiently and that the target audience adheres to it. The thesis provides evidence on 
efficacy of the intervention in order to aid interpretation of effectiveness results. 
 Evidence from the review of RCTs, the effectiveness trail from Uganda  and other 
studies show that antimalarial use is lower in low, medium and high malaria 
transmission settings when RDTs are used to guide treatment of fever instead of 
presumptive treatment. This research shows that this results in savings from drug 
costs in older children and adults with fever in low and medium transmission areas.  
 
 Health worker adherence and use of RDTs results vary widely, even under 
experimental conditions. Therefore, the amount of antimalarials and costs saved by 
RDT-based guidelines instead of presumptive treatment of fever may vary widely in 
routine practice with limited supervision.  
 
 The review, the effectiveness trial from Uganda and other studies show that RDT-
based policies may have no effect on prescribing of antibiotics or it may increase it. 
Therefore, in some settings, the amount of cost-savings accrued by averting 
irrational prescribing of antimalarials may be discounted by an increase in 
prescribing of antibiotics.  
 
 This study combined with others, still does not confirm whether or not use of 
RDT-based guidelines has any effects on clinical outcomes. We do not know if this 
is due to weak causal linkage between the intervention and outcomes, insufficient 
implementation of vital components of the guideline or due to methodological 
limitations. Further, the thesis has shown that RDT-guided treatment may be 
associated with increased risk of missed diagnosis of malaria in routine practice. 
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However, we do not know if this can result in significant increase in the risk of 
morbidity or mortality in routine practice. 
 
 A case study of Uganda suggests that when delivered through routine services, none 
of the components of an RDT-based guideline is implemented to acceptable 
standards. The diagnostic components, namely assessment and steps in performing 
an RDT, are particularly poorly implemented. Therefore, while the policy can save 
drug costs through the use of RDTs, it may not improve the quality of diagnoses, 
especially among parasite negative fevers. 
 
 The Uganda case study also shows the policy is being rolled out in a health system 
which lacks essential inputs and support services required for its effective 
implementation. This may exacerbate the quality of guideline implementation in 
routine practice 
 
Therefore, if restricted to older children and adults (5+ years) in low and medium 
transmission settings, RDT-based policies for fever can significantly reduce usage of 
antimalarials and save drug cost in routine practice where presumptive treatment is the 
norm. However, because of the unpredictable HWs response to RDT results and 
variable effect of the intervention on prescribing of antibiotics, we can not predict with 
certainty how application of an RDT-based guideline might impact on the magnitude of 
cost savings in routine practice. There is insufficient evidence to suggest that the policy 
is superior to presumptive treatment of fever in terms of effects on clinical outcomes. 
HW proficiency in carrying out clinical assessment, RDTs and counselling is poor when 
the policy is delivered through routine health services characterised by insufficient 
supplies and training.   
6.4.2 Implications for practice and policy 
The evidence in this thesis and other research is insufficient to support a wide-scale 
implementation of RDT-based policy for fever on account of its effects on clinical 
outcomes. If policy makers decide to scale-up application of the policy on account of its 
economic potentials, then the evidence from literature and this thesis (chapter 4) 
suggests that it is worthwhile to restrict their application to low and medium 
transmission settings and in older children and adults.  
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Varying diagnostic strategies for malaria by transmission settings can pose practical 
challenges in implementation [26, 70]. Therefore, from a practical standpoint, the policy 
could be implemented across the whole country as long as its use is limited to 5+ years 
old. Cost-effectiveness models which incorporate longer-term and broader outcome 
measures such as the DALY, seem to favour use of RDT-based guidelines even in high 
transmission settings if their use is restricted to 5+ years old (See 2.8.7) [72, 140, 144].  
Improvements are required in implementation of all components of the guideline. 
Particular emphases are required on clinical assessment, criteria for selecting patients for 
RDTs, steps in performing an RDT and response to RDT test.   
 Without improvements in clinical assessment, the quality of diagnosis in parasite-
negative individuals cannot be improved. Emphasis on the use of RDTs and 
appropriate prescribing of antimalarials alone may create the impression that the 
new policy is only a tool for preserving antimalarials. 
 Without improvements in the steps involved in carrying out an RDT in routine 
practice, several parasite-positive individuals might be missed, resulting in increased 
morbidity, especially in low prevalence areas where use of the guideline is 
recommended.  
 If HWs do not use RDTs as required, or if they do not prescribe antimalarials 
according to the results, then the economic advantage of RDT-based guidelines over 
presumptive treatment is lost even in low to moderate transmission areas.  
 These improvements can be achieved through additional interventions, such as 
refresher trainings, regular support supervision, and provision of job aids and 
regular supply of RDT kits.  
HWs need to perform a minimum volume of tasks with the aid of an innovation in 
order to maintain an acceptable performance quality. Therefore, it is imperative for 
health authorities to main an adequate quantity of RDT kits and guidelines at health 
facilities at all times so that HWs can implement RDT-based guidelines consistently.  
6.4.3 Implications for research   
a) There is need for in-depth, context-specific, qualitative research to investigate 
why HW vary in their use of RDT-based guidelines. Qualitative methods can 
reveal context-specific factors underlying variability in HW use of RDT-based 
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guidelines. This information can be useful in tailoring interventions aimed at 
inducing or maintaining behaviour change in users of the technology.  
 
b) Researchers evaluating implementation of RDT-based guidelines should use 
multiple indicators that enable an assessment of all components of the 
guidelines. Methods which assess all components of the guideline can identify 
elements which are poorly implemented. Use of LQAS methods can help 
identify components that require urgent attention. 
 
c) The evidence from this thesis is unclear about the effects of RDT-based policies 
on clinical outcomes. More outcomes data are required from randomized trials 
in order to inform a more robust conclusion about the effects of the 
intervention on clinical outcomes. Quasi-experimental designs which allow the 
implementation of various components of the guideline to be assessed may 
permit attribution of effects to specific components of the guideline. 
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Appendices 
Appendix 1 Formula for binomial distribution 
    
  
        
         
where: 
Pa = the probability of selecting ―a‖ items of desired quality in a sample of ―n‖ items 
p  = the desired performance standard (e.g. 80% of items of desired quality) 
q  = the expected proportion of items of undesired quality (1-p) 
n  = sample size 
a  = the number of items of desired quality 
n-a  = number of items of undesired quality (defective items, also referred to as ―d‖)  
 
Adapted from Valadez (1991) [104] 
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Appendix 2 Recommended staffing for various levels of health facilities in Uganda 
 
Referral level Staffing 
HC I Village health team  
HC II 2 minimum staff:  
- Enrolled nurse (1) 
- Enrolled midwife (1)  
- Nursing assistant (1) 
HC III 3 minimum staff: 
- Senior clinical officer (1)  
- Clinical officer (1)  
- Enrolled midwife (2)  
- Nursing officer-nursing (1) 
- Enrolled nurse (3)  
- Laboratory technician (1)  
- Laboratory assistant (1) 
- Nursing assistant (3) 
- Health assistant (1) 
HC IV 23 minimum staff 
- Senior medical officer (1) 
- Medical officer (1) 
- Senior nursing officer (2) 
- Nursing officer-nursing (1) 
- Nursing officer-midwife (4) 
- Nursing officer-psychiatry (1) 
- Enrolled nurse (3) 
- Enrolled midwife (8) 
- Nursing assistant (5) 
- Clinical officer (1) 
- Clinical officer-eye (1) 
- Health Inspector (4) 
- Laboratory technician (2) 
- Assistant VCO officer (1) 
- Theatre assistant  (2) 
- Laboratory assistant (2) 
- Health assistant HA (2) 
General hospital The following are minimum requirements 
- Medical officers (4) 
- Public dental officers (2) 
- Dispensers (2) 
- Senior nursing officers (5) 
- Nursing officers-nursing (17) 
- Nursing officers-midwifery (3) 
- Enrolled psychiatrics (2) 
- Enrolled nurse (46) 
- Enrolled midwife (25) 
- Nursing assistants (15) 
- Clinical officers (5) 
- Radiographers (2) 
- Orthopaedic officers (2) 
- Anaesthetic officers (2) 
- Theatre attendants (2) 
- Laboratory technicians (2) 
Regional referral hospital No data 
National referral hospital No data 
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Appendix 3 Detailed Search Strategy for Electronic Databases-Chapter 2 
a) Concepts and methods 
Search set Search terms 
1 Malaria  
2 Transmission  
3 Intensity  
4 1-3/and 
5 Endemicity 
6 1 and 5 
7 Holoendemic* 
8 Hyperendemic* 
9 Mesoendemic* 
10 Hypoendemic* 
11 7-10/or 
12 Spleen  
13 Parasite  
14 12 or 13 
15 Rate*  
16 14 and 15 
17 Effective* 
18 Pragmatic  
19 Efficac*  
20 17 or 18 or 19 
21 Trial*  
22 20 and 21 
23 Demonstration  
24 Implementation  
25 Process  
26 23 or 24 or 25 
27 Evaluation  
28 26 and 27 
29 Quality  
30 Care  
31 29 and 30 
32 Framework  
33 Model  
34 32 or 33 
35 29 and 30 and 34 
36 Cluster  
37 Design effect 
38 Inter-cluster correlation coefficient 
39 36 or 37 or 38 
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b) Malaria rapid diagnostic tests: technology, diagnostic accuracy and performance 
Search set Search terms 
1 Malaria 
2 Fever 
3 Febrile illness 
4 1 or 2 or 3 
5 Parasitological 
6 Parasite-based 
7 Definitive  
8 Microscop* 
9 Rapid diagnostic test* 
10 RDT* 
11 Assay* 
12 5-11/or 
13 Diagnos* 
14 13 
15 Accuracy  
16 Sensitivity 
17 Specificity 
18 Performance 
19 15-18/or 
20 Requirement* 
21 20 
22 4 and 12 and 14  
23 12 and 19 
24 12 and 20 
 
 
c) Malaria rapid diagnostic tests; economic evaluation 
Search set Search terms 
1 Cost*  
2 Cost-effective* 
3 Cost effective* 
4 Effective* 
5 Efficacy  
6 Efficacious  
7 Cost-benefit 
8 Cost benefit 
9 Utility  
10 Cost-utility 
11 Cost utility 
12 1-11/or 
13 Evaluation 
14 Analysis  
15 Study  
16 13 or 14 or 15 
17 Malaria 
18 Fever 
19 Febrile illness 
20 17 or 18 or 19 
21 Rapid diagnostic test* 
22 RDT* 
23 21 or 22 
24 12 and 16 and 20 and 23 
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d) Theory of diffusion of innovations (search set 37), implementation of guidelines in Africa 
(search set 38), effects of intervention on quality of implementation of guidelines in Africa 
(search set 39) 
Search set Search terms 
1 Treatment practice* 
2 Management* 
3 Prescription behaviour* 
4 Adher* 
5 Compliance 
6 Complying 
7 Implement* 
8 Adopt* 
9 Diffusion 
10 1-9/or 
11 Clinic* 
12 Health* 
13 11 or 12 
14 Guideline* 
15 Protocol* 
16 Innovation* 
17 New knowledge 
18 Evidence 
19 14-18/or 
20 Theory 
21 Theories 
22 Model* 
23 20 or 21 or 22 
24 Intervention* 
25 Training 
26 Supervision 
27 Drug* 
28 Medicine* 
29 Supplies 
30 Equipment 
31 Job aid* 
32 Support 
33 24-32/or 
34 Africa 
35 Developing countries 
36 34 or 35 
37 10 and 13 and 19 and 23 
38 10 and 13 and 19 and 36 
39 10 and 13 and 19 and 33 and 36 
 
 
e) Use of LQAS methods 
Search set Search terms 
1 Lost Quality Assurance Method 
2 LQAS 
3 1 or 2 
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Appendix 4 Detailed Search Terms for Electronic Databases-Chapter 3  
 
 
  
Search set Search terms 
1 Malaria 
2 Fever 
3 Febrile illness 
4 1 or 2 or 3 
5 Rapid diagnostic test* 
6 RDT* 
7 Presumptive treatment 
8 Syndromic approach* 
9 Treatment practice* 
10 Management* 
11 Prescription behaviour* 
12 Definite diagnosis 
13 5-12/or 
14 randomized controlled trial* 
15 random allocation 
16 double blind method 
17 single blind method 
18 randomly 
19 Clinical trials* 
20 14-19/or 
21 4 and 13 and 20** 
    
  ** Search terms 14-19 will not be applied to CENTRAL 
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Appendix 5 Characteristics of included studies  
a) Ansah 2010 GHA   
Methods Trial design: individually randomised controlled trial  
Patients evaluated on day 28 after initial contact  
Reference slides taken on all patients 
Participants Children and adults with suspected malaria 
Exclusion: pregnancy, illness requiring admission, non-compliance with 
allocated test/treatment, not living locally  
Number randomised: 3452 
Number analysed for primary outcome (prescribing of antimalarials): 3348 
(9.6% loss to follow up) 
Interventions Rapid diagnostic test plus treatment versus clinical diagnosis plus treatment.  
(A second component examining RDT vs microscopy did not meet our entry 
criteria) 
Health workers in both groups received training and held guidelines 
RDT performed by research team 
Health workers did not fully comply with guidelines: 49.5% of participants 
with negative RDT results received antimalarials 
Outcomes Primary 
Patients treated with anti-malarial treatment who did not have malaria based 
on reference slides. 
 
Secondary 
1. Patients not receiving antimalarial treatment who were malaria reference 
slide positive.  
2. Patients prescribed antibiotics 
3. Patients with positive reference slides not prescribed anti-malarials 
4. Patients correctly treated (i.e. patients that were slide positive and treated 
with AM + patients that were slide negative and  not prescribed anti-
malarial treatment  
Notes Country: Ghana 
RDT: OptiMAL-IT 
Setting: 3 health centres, of all referral levels 
Transmission: not indicated 
Dates: July 2007 to December 2008 
Funding: Gates Malaria Partnership 
Risk of bias table  
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low  risk
 Computer generated blocks of 10 
Allocation concealment 
(selection bias) 
Low  risk
 Numbers placed in sealed opaque envelopes 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
Loss to follow-up was low and comparable in both 
settings (≤3%) 
Selective reporting (reporting 
bias) 
Low  risk
 
Reported on all outcomes specified in prospective 
trial register.  
Other bias Low  risk
 
No other sources of bias identified 
Blinding of participants and 
personnel (performance bias) 
Unclear risk
 
Study participants and staff were aware of allocated 
tests, the results and prescriptions 
Blinding of outcome 
assessment (detection bias) 
Low  risk
 
Blood slides read by 2 independent microscopists 
blind to study allocation and RDT result. 
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b) Bisoffi 2009 B'FASO   
Methods Trial design: individually randomised clinical trial, lasting 2 months, 1 
month in rainy season, 1 month in dry season 
Participants Number randomised: 2169 (1058 in RDT arm, 1111 in presumptive 
treatment arm) 
Number analysed for primary outcomes: (a) prescribing of antimalarials 
analysis 2169 (0% loss); (b) clinical outcomes: 2095 (3.4% loss) 
Inclusion: age ≥ 6 years; axillary temperature ≥ 37.5o C 
Exclusion: severe malaria 
Interventions Intervention: RDT for fever 
Control: Presumptive treatment 
Both groups received training and held guidelines 
RDT performed by research team 
Health workers did not comply with guidelines most of the time: 81% of 
participants with negative RDT results received antimalarials 
Outcomes Primary: patients with fever on day 4  
Secondary: 
(1) patients still experiencing other symptoms on day 4; 
(2) patients given anti-malarials 
(3) patients given antibiotics 
Notes Country: Burkina Faso 
RDT: Paracheck 
Setting: peripheral health centres, 
Sampling: Convenient selection of health centres to ensure rural/urban 
representativeness 
Transmission: Not described 
Dates: 2006; end of dry season and rainy season 
Funding: UNIDEA-UNICREDIT Foundation 
Risk of bias table  
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low  risk
 Computer generated random list 
Allocation concealment 
(selection bias) 
Unclear risk
 Not indicated 
Incomplete outcome data 
(attrition bias) 
Low  risk
 
Loss to follow-up was generally low (95.4% dry 
season; 97.3% rainy season) but not differentiated 
by study group 
Performed available case analysis, although 
reported to have performed intention-to-treat 
analysis 
Selective reporting (reporting 
bias) 
Low  risk
 
Reported on all study outcomes described in the 
methodology 
Other bias Low  risk
 
No other sources of bias identified 
Blinding of participants and 
personnel (performance bias) 
High risk
 
Both the study participants and personnel were 
aware of intervention allocation 
Blinding of outcome 
assessment (detection bias) 
High risk
 
Both the study participants and personnel were 
aware of the diagnosis made and treatment 
prescribed 
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c) Skarbinski 2009 KEN   
Methods Trial design: cluster randomised trial, randomised by health facilities 
 Stratified random selection of facilities, by transmission settings (high/low) and 
facility type (hospitals, health centres and dispensaries) 
Took into account a design effect of 2 in sampling 
Reference slides taken; results not reported 
Study lasted 4 months 
Participants Inclusion: age ≥ 5 years, irrespective of condition 
Number of participants randomised: Intervention arm: 799 
Number analysed for primary outcome (prescribing of antimalarials): 669  
Interventions Intervention: RDTs for fever patients ≥ 5 years 
Control: Presumptive treatment of fever 
Both groups received training and held guidelines 
RDT performed by health workers 
Health workers did not fully comply with guidelines: 41% of participants with 
negative RDT results received antimalarials 
Outcomes Primary outcomes: 
1.       Fever patients prescribed ACT 
2.       Microscopy negative patients prescribed ACT 
Secondary outcomes: 
1.        RDT negative patients prescribed ACT; and RDT positive patients 
prescribed ACT 
2.        Patients prescribed ACT presumptively 
3.        Patients with known alternative diagnosis receiving ACT 
Notes Country: Kenya 
RDT: Paracheck  
Setting: all referral levels of facilities, 60 in total, 30 in each arm 
Transmission: all transmission levels included 
Dates: June to September 2006 
Funding: USAID 
Risk of bias table   
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk
 Systematic allocation 
Allocation 
concealment 
(selection bias) 
High risk
 
Although probabilistic sampling was used in selecting the 
participating health facilities, the participants had 
foreknowledge of intervention assignments 
Incomplete outcome 
data (attrition bias) 
High risk
 
Per protocol analysis; loss to follow-up was high (16.3%), 
more at the intervention facilities (20.2%) than at control 
facilities (11.2%) 
Selective reporting 
(reporting bias) 
Low  risk
 
Reported on all pre-specified outcomes (prescribing of 
ACT); did not explicitly report on overall anti-malarial 
prescribing, but the summary data were available for 
inclusion in the review. 
Other bias Low  risk
 
Baseline imbalance minimised by stratifying facilities by 
level and randomly selecting within each level 
Summary data were adjusted for baseline imbalance 
Loss of whole clusters: not reported 
Results could be biased towards the null, because some 
facilities in the comparison arms had RDT 
Blinding of 
participants and 
personnel 
High risk
 Both the study participants and personnel were aware of 
intervention allocation 
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(performance bias) 
Blinding of outcome 
assessment 
(detection bias) 
High risk
 Both the study participants and personnel were aware of 
the diagnoses and prescriptions 
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d) Yeboah-Antwi 2010 ZAM   
Methods Trial design: cluster randomised, by health posts. Pairs matched by 
distance from health centre, then randomised  
Patients follow-up and clinical status evaluated 5 – 7 days after initial 
contact 
Participants Inclusion: Children (6mo – 5 years); presenting with fever with or without 
other conditions 
Total enrolled and randomised: 3125 (1017 in the RDT arm and 2108 in 
the clinical diagnosis arm) 
Number analysed: (a) analysis 1.1: 3125; (b) analysis 1.2: 3047 (available 
case analysis) 
Interventions Intervention: RDT-aided algorithm 
Control: Clinical algorithm 
Both groups received training and held guidelines 
RDT performed by health workers; additional interventions provided to 
increase adherence to guidelines 
Health workers complied with guidelines most of the time: only 0.4% of 
participants with negative RDT results received antimalarials 
Outcomes 1. Children with fever who received AL 
2. Children still experiencing symptoms at follow-up (day 5 – 7) 
Notes Country: Zambia 
RDT: ICT Malaria Pf (ICT Diagnostics) 
Setting: Community health posts, manned by community health workers 
with 6-week training in basic clinical skills, rural and urban 
Sampling: 42 community health posts 
Transmission: High prevalence (valley) and low prevalence (plateau) areas 
Dates: Between December 2007 and November 2008 
Funding: Not provided 
Risk of bias table  
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low  risk
 
Authors report random allocation; numbers were 
generated by random number generator. 
Allocation concealment 
(selection bias) 
High risk
 
Participants were aware before hand, of the 
diagnostic procedures they were assigned to 
Incomplete outcome data 
(attrition bias) 
High risk
 
Differential loss to follow-up: 4% in the RDT arm 
vs. 31.4% in the control health posts. Undertook 
per protocol analysis 
Selective reporting (reporting 
bias) 
Low  risk
 Reported on all pre-specified outcomes 
Other bias Low  risk
 
Recruitment bias was low:-pairs of aid posts were 
matched by distance then randomised 
Baseline imbalance: selected clusters were similar 
and imbalance was adjusted for 
Loss of whole clusters; no loss was reported 
Blinding of participants and 
personnel (performance bias) 
High risk
 
Both the study participants and personnel were 
aware of the diagnostic procedures applied 
Blinding of outcome 
assessment (detection bias) 
High risk
 
Both the study participants and personnel were 
aware of the diagnostic outcomes, and the 
medications prescribed 
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Appendix 6 Characteristics of excluded studies  
 
Study Reason for exclusion 
Chinkhumba 2010  Not a randomised trial but a cross-sectional survey, without a comparison 
group 
Faucher 2010   Not randomised trial; and examined the effect of withholding anti-malaria 
to RDT-positive children rather than comparing RDT-based policy with 
presumptive treatment 
Kyabayinze 2010   Not a randomised trial 
Msellem 2009  Not a randomised study (weekly cross-over of intervention) 
Reyburn 2007   On account of the comparison-which was policy based on microscopy, 
rather than presumptive treatment 
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Appendix 7 Data extraction form 
 
Study ID:   
Design: Individual randomised, open label, clinical trial 
 
 RDT-based policy Clinical diagnosis 
Outcomes (and subgroups)  Events Total Events Total 
Patients prescribed antimalarials      
≤ 5      
5 +     
All     
     
Microscopy positive patients not prescribed 
antimalarials 
    
≤ 5      
5 +     
All     
     
Microscopy negative patients prescribed anti 
malarials 
    
≤ 5      
5 +     
All     
     
Patients prescribed antibiotics     
≤ 5      
5 +     
All      
     
Patients still not well at follow-up (day 4+)     
≤ 5      
5 +     
All     
     
Comments:  
Number randomised:  
Number analysed:  
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Appendix 8 Summary statistics for outcomes assessed in Chapter 3 
 
1.0 ALL PATIENTS 
    1.1 Patients prescribed anti-malarials 
  
Experiment Control 
 
Study or Subgroup Events Total Events Total 
 
Yeboah-Antwi 2010* 27.5% 963 99.1% 2084 
 
Skarbinski 2009 40.9% 359 54.2% 310 
 
Ansah 2010 70.0% 1719 92.7% 1723 
 
Bisoffi 2009 89.3% 1058 87.2% 1111 
      1.2 Microscopy positive patients missing anti-malarials 
 
 
Ansah 3.2% 647 2.7% 633 
      1.3 Microscopy negative patients receiving anti-malarials 
 
Ansah 53.9% 1072 90.1% 1090 
      1.4 Number prescribed antibiotics 
   
 
Bisoffi 2009 52.9% 1058 54.8% 1111 
 
Ansah 2010 26.6% 1719 22.3% 1723 
      1.5 Patients still unwell at follow-up at day 4, or after 
 
 
Yeboah 2010 9.3% 1017 10.0% 2108 
 
Bisoffi 2009 5.6% 1024 5.5% 1071 
      2.0 SUBGROUPS 
    2.1 Fever patients getting anti-malarials 
2.1.1 <5 years 
    
 
Yeboah-Antwi 2010* 27.5% 963 99.1% 2084 
 
Ansah 2010 80.0% 519 92.5% 550 
      2.1.2  5 + years 
    
 
Ansah 2010 65.8% 1200 92.8% 1173 
 
Skarbinski 2009 40.9% 359 54.2% 310 
      
 
*RRs calculated from these summary statistics may be different from the 
ones in the analysis. In the analysis, the review authors extracted RRs 
which had been adjusted for clustering and baseline imbalance 
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Appendix 9 Description of the UMSP trial (Chapter 4) 
Settings 
The trials were run in 3 districts representing high (Tororo), medium (Jinja) and low (Mubende) 
transmission settings   
Design 
The study was a cluster randomised control trial, with parallel baseline and follow-up surveys at each 
study site. It was conducted between 9th January 2008 to 25th June 2008, lasting 4 months in each facility 
(2 months of pre-test and 2 months of pos-test data collection).  
Figure 28: Design of the trial conducted by the Uganda Malaria Surveillance Project in 2008  
 
Source: Dorsey and Hopkins [81] 
In each of the 3 zones, two health centres (A and B) were identified for the evaluation. The health centres 
included were at referral levels II and III (HC II and HC III), all of which without the capacity for 
microscopy.  Fever treatment was presumptive prior to the study. The health centres (HC) were included 
if they were within 15 km radius of the UMSP sentinel site, had a workload of ≥ 500 patients per month 
and had at least 3 clinical staff. 
Baseline Survey 
The trial was preceded by 2 months of baseline survey during which surveillance data were collected on 
every outpatient at the selected HCs, with regard to their age, gender, symptoms, diagnosis, and 
treatment. Follow-up evaluations of patients‘ clinical outcomes were NOT conducted during the baseline 
survey; neither were parasitological confirmation and typing of malaria parasites done during the baseline 
survey. 
Intervention 
Following the baseline survey, one of the health centres in each district was randomly selected to receive 
training in RDT use and fever case management, and was subsequently provided with RDT kits 
 
2 months collection of 
baseline surveillance data at 
both health centers 
Intervention: 3-day training course 
and provision of RDTs, and 1-day 
follow-up 2 weeks later 
at selected health center (A) 
2 months collection of surveillance and 
follow-up data at both health centers 
Study completion and analysis 
One week before intervention: 
Random selection of one health center for training in 
RDT use and fever case management 
Health centers A and B 
(No intervention at health center B, 
continue usual care) 
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(Parachek®, HRP-2-based test)17 and the RDT-based training/treatment manual[175]. The other health 
centre in each district continued with presumptive treatment based on IMCI algorithm.  
All the staff from the intervention health centres received hands-on instruction on the preparation and 
interpretation of RDTs. The training focused on the criteria for selecting patients for RDT, hands-on 
preparation and interpretation of RDT results, and the management of fever patients with positive or 
negative RDT. Other topics included recognition of symptoms of severe conditions and the appropriate 
referral of patients with severe illness; counselling of patients on treatment; RDT storage and stock 
management.  
The training lasted for 3 days; and was conducted by the same team of trainers, who were experienced in 
training and in the use of RDT. The hands-on instructions on the preparation and interpretation of the 
RDTs were based on the WHO pictorial training materials (as available at:  
http://www.wpro.who.int/sites/rdt/using_rdts/RDT+Instructions+and+Training.htm) 
At the intervention centres, blood samples were extracted from the participating patients for RDT; in 
addition, smears were made for reference microscopy and some blood was stored on filter paper for PCR 
to confirm parasitaemia and type malaria species. However, parasite confirmation and typing was NOT 
performed at the control health centres even during the intervention phase of the trials. 
A follow up, one-day support training was offered to the clinicians in the intervention health centres at 2 
weeks after the initial training, aimed at reinforcing the techniques for performing and interpreting RDTs. 
However, there was no interference with the clinicians‘ decisions—to test and/or treat patients according 
to the guideline.  
Follow-up 
Surveillance data collection continued for 2 more months after the introduction of RDT and the guideline 
at each intervention site. Data were regularly gathered on RDT performance at all the intervention sites; 
and on prescribing practices at all the study sites (both intervention and control facilities). At each of the 
intervention and control facilities, twenty five percent of patients were systematically recruited for follow-
up survey to assess and document their clinical outcomes at day 5 post treatment initiation. The patients 
or their parents/caretakers were advised to return to the health centre for the follow-up evaluation 5 days 
after their initial contact with the health worker, or to seek appropriate care earlier if their conditions 
deteriorated.  During the follow-up visits, participants were asked to describe their response to therapy 
received on day 0 encounters with the clinician, including any intervening care-seeking behaviour (e.g. 
additional health-care sought or medications taken following the initial day 0 encounters).  A participant 
who did not turn up for the follow-up evaluation by day 6 was considered lost to follow-up.  
Participants 
All ambulatory patients presenting at the facilities were included in the study, except those who presented 
with severe conditions, or did not consent18. Patients were sequentially recruited into the study, as long as 
they satisfied the aforementioned criteria.  
Sample size 
Based on previous surveillance work in Uganda, it was estimated that approximately 1000 patients would 
be seen each month at each health centre19 [81]; and that during the two months of baseline surveillance, 
30%, 40% and 60% of patients would be treated for malaria at the health centers from the low, medium 
                                                          
17
 Manufactured by Orchid Biomedicals – Goa, India 
18 However, for the purposes of this report, analysis of effects was based on participants presenting with fever only.  
19 i.e. 2000 during baseline and 2000 after introducing the intervention 
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and high transmission intensity sites, respectively.  Firstly, the trial aimed to test the hypothesis that the 
intervention of RDTs and training would lead to a significant reduction in the proportion of patients 
treated for malaria, compared to the non-intervention groups at each of the 3 malaria transmission 
intensity areas. Secondly, it aimed to test the hypothesis that the intervention would result in no 
significant difference in the proportion of patients with inadequate response to initial therapy, compared 
to the non-intervention group (i.e. non-inferiority analysis).   The study was powered at 80% to detect a 
10% reduction in the proportion of patients treated in the intervention arm at one-sided significance level 
of 5%; and to show non-inferiority between the study arms at two-sided significance level of 5%. It was 
assumed that in the non-intervention group 10% of patients would have an inadequate response to initial 
therapy, and that the proportion of patients with an inadequate response to initial therapy in the 
intervention group would be no higher than 15.3%. On the basis of these assumptions, the minimum 
number of observations required to show a significant reduction in the proportion of patients treated for 
malaria in the intervention arm was calculated to be 92. However, all consenting eligible patients attending 
the clinics during the study periods were recruited. The study planned to select 25% of all enrolled 
patients for evaluation of clinical outcomes at day 5 (i.e. every fourth of the expected 2000 patients during 
the post-intervention phase, giving an estimated 500 patients per study site). It was estimated that 10% of 
patients would refuse to participate and an additional 10% of patients would not return for their 5-day 
follow-up interview, leaving a sample size of 400 for each site for outcomes evaluation.   
Quality control 
Members of the study teams were trained on the study protocol prior to the onset of the study. During 
the study, case record forms and books were reviewed by the study coordinator and/or assistants for 
completeness and accuracy.  The study coordinator met frequently with the site staff to ensure 
consistency in data collection.  To ensure quality of reference microscopy (the gold standard test), each 
research slide was independently reviewed by two expert microscopists, and any discrepancies in slide 
readings were reviewed and resolved by a third microscopist. Before the beginning of the study at each 
site, positive and negative blood samples were obtained and standard aliquots frozen and stored in 
Kampala for quality control testing of RDTs
20
. Each lot of RDTs underwent quality control testing 
according to WHO guidelines.
21   
Data entry and characteristics of the trial database used in the analysis 
Data from the survey case records were double-entered into EPI INFO 6.04d to verify their accuracy.  A 
check program was written into the database to limit the entry of incorrect data and ensure entry of data 
into required fields. Two back-up files of the database were created after each data entry session.   
The baseline and follow-up survey data were entered into two separate databases; and a third one where 
baseline and follow-up survey data sets were merged. This analysis used the merged database. It provides 
data on the total number of patients seen over the 4 months study period, their demographic profiles, the 
presenting symptoms, the diagnosis made and the type of treatment provided. In addition, it provides 
data on whether an RDT was performed on a patient, the RDT result, treatment given, and outcome of 
illness at day 5 post-treatment. Furthermore, it provides data on the malaria status of participants during 
the follow-up surveys, but at the intervention sites only
22
.  
                                                          
20
 HRP2 levels remain stable in frozen blood for at least a year (81. Dorsey, G. and H. Hopkins, Effectiveness and 
safety of training in fever case management incorporating rapid diagnostic tests (RDTs) for malaria at peripheral health centers in Uganda; 
draft version 1.0, 2007, Uganda Malaria Surveillance Project (UMSP). 
 
21
 World Health Organization. Malaria rapid diagnosis: Making it work. WHO informal consultations, 2003. 
22
 Parasitological conformation was undertaken to assess the accuracy of RDT; and so was performed during the 
follow-up surveys at the intervention sites only 
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Appendix 10 Unit prices of items prescribed in trial 
 
Category Item 
Prices 
(US$)* Unit 
Information 
Source 
 DIAGNOSTICS RDTs  $ 0.6  Test NMS 
ANTIBIOTICS 
Ampicillin  $ 0.01  Capsule  NMS 
Ampiclox  $ 0.03  Capsule  NMS 
Amoxycillin  $ 0.02  Capsule  NMS 
C/amphenical  $ 0.01  Capsule  NMS 
Ciprofloxacin   $ 0.03  Tablet NMS 
Cotrimoxazole  $ 0.01  Tablet NMS 
ANTI-MALARIALS 
AL  $ 0.084  Tablet NMS 
CQ  $ 0.00  Tablet NMS 
Quinine  $ 0.04  Tablet NMS 
SP  $ 0.02  Tablet NMS 
ANALGESICS 
Aspirin  $ 0.001  Tablet NMS 
Indomethacin  $ 0.003  Tablet NMS 
Ibuprofen  $ 0.003  Tablet NMS 
Paracetamol  $ 0.003  Tablet NMS 
Diclofenac  $ 0.046  Tablet NMS 
Information Source:   
NMS=National Medical Stores catalogue and price indicator of 2008  
 
*Exchange rate = US$ 1 = 2177.56 UGX (Uganda Shillings) 
 
 
Appendix 11 Recommended quantities of items as per MOH guideline 
 
 
Age Groups 
MEDICATION 6 mo – 3 yrs >3yrs – 5yrs >5yrs - 7yrs >7yrs–12 yrs >12 yrs 
RDT  1 1 1 1 1 
AL  6 12 12 18 24 
CQ  3 5 6 7 10 
Quinine  3.75 7.5 7.5 15 30 
SP  0.5 1 1.5 2 3 
CTX (400+80 mg)* 2.5 5 5 10 20 
Other Antibiotics** 5 10 10 20 40 
Aspirin 2.25 4.5 4.5 9 18 
Indomethacin 2.25 4.5 4.5 9 18 
Ibuprofen 2.25 4.5 4.5 9 18 
Paracetamol 2.25 4.5 4.5 9 18 
Diclofenac 2.25 2.25 4.5 4.5 9 
* CTX =  co-trimoxazole 
** In general, CTX was prescribed about 1.6 times more often than all the other antibiotics combined. For the purpose of 
this analysis, all antibiotics are grouped into 2 categories: co-trimoxazole and others. The analysis applies the average price 
for other listed antibiotics to all those that fall in the ―other‖ category. (Lubell et al (2008) applies the average price of 
antibiotics to the total number of recipients [140]). 
 
The analysis assumes that a unit (tablet/capsule) of each ―other antibiotics‖ contains 250mg of the active agent; and that 
each of the ―other antibiotics‖ were prescribed 6 hourly 
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Appendix 12 Patients prescribed antimalarials before and after intervention by age and sites 
 
    TORORO   JINJA   MUBENDE 
  
(High transmission) 
 
(Medium transmission) 
 
(Low transmission) 
   Age Before After Change*   Before After Change*   Before After Change* 
 
(Yrs) % (N) % (N) (%) 
 
% (N) % N (%) 
 
% (N) % (N) (%) 
                   Intervention Sites <5 91.0 (444) 83.3 (1360) -7.7 
 
92.0 (238) 55.3 (367) -36.7 
 
98.9 (183) 46.9 (160) -52.0 
 
5+ 94.5 (541) 52.4 (928) -42.1 
 
93.8 (768) 38.0 (706) -55.8 
 
99.5 (759) 26.2 (442) -73.3 
 
All  92.9 (985) 70.8 (2288) -22.1 
 
93.3 (1006) 44.4 (1073) -48.9 
 
99.4 (942) 39.2 (602) -60.2 
                   Control Sites <5 91.1 (629) 93.4 (934) 2.3 
 
96.0 (272) 98.3 (354) 2.3 
 
98.3 (119) 99.1 (214) 0.8 
 
5+ 86.9 (817) 95.8 (975) 8.9 
 
97.1 (896) 97.8 (786) 0.7 
 
99.7 (652) 99.3 (734) -0.4 
 
All 88.7 (1446) 94.6 (1909) 5.9 
 
97.3 (1168) 98.3 (1140) 1.0 
 
99.5 (771) 99.3 (948) -0.2 
*percentage change from baseline 
 
  
  
Appendix 13 Patients prescribed antibiotics before and after introducing RDTs 
 
 
 
 
 
Appendix 14 Average treatment cost before and after intervention 
 
   Average cost (2008 US$) 
Site District Setting Before (B)  After (A) 
Change 
(A-B)  (95% CI) 
Intervention Tororo High 1.47 1.49 0.02 (-0.21, 0.25) 
 Jinja Medium 1.86 1.53 -0.33 (-0.54, -0.12) 
 Mubende Low 2.04 1.54 -0.50 (-0.69, -0.31) 
       
Control Tororo High 1.44 1.43 -0.02 (-0.19, 0.17) 
 Jinja Medium 1.97 1.74 -0.22 (-0.40, -0.06) 
 Mubende Low 2.07 1.91 -0.16 (-0.39, 0.07) 
 
  
Sites & settings 
Intervention sites 
High transmission 
Medium transmission 
Low transmission 
Control sites 
High transmission 
Medium transmission 
Low transmission 
% 
43.7 
50.7 
51.4 
53.1 
55.1 
39.5 
Total 
985 
1006 
942 
1446 
1168 
771 
% 
38.7 
48.0 
46.8 
52.7 
50.4 
38.9 
Total 
2288 
1075 
602 
1909 
1140 
948 
%   [95% CI] 
-5.0 [-8.7, -1.3] 
-2.7 [-7.0, 1.6] 
-4.6 [-9.7, 0.5] 
-0.4 [-3.8, 3.0] 
-4.7 [-8.8, -0.6] 
-0.6 [-5.2, 4.0] 
Before (B) After (A) Change (A-B) Change (A-B) 
% [95% CI] 
-50 -25 0 25 50 
Favours RDT-guideline Favours 
presumptive 
treatment 
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Appendix 15 Average cost at intervention HCs before and after introducing RDTs, by 
age group 
   
   
Average cost (2008 
US$) 
District Setting Age Before (B) After (A) 
Tororo High <5 0.52 1.13 
  5+ 2.25 2.02 
     
Jinja Medium <5 0.54 1.01 
  5+ 2.27 1.80 
     
Mubende Low <5 0.57 0.99 
  5+ 2.39 1.74 
 
 
 
 
 
 
Appendix 16 Perceived clinical status of patients at day 5 of follow-up  
 
  TORORO  JINJA  MUBENDE 
  (High transmission)  (Medium transm)  (Low transmission) 
Age 
group Status  Control Intervention  Control Intervention  Control Intervention 
< 5   Improved  93.8 92.4  97.8 97.3  97.4 100 
 No change 0.5 0.3  0.0 0.0  2.6 0.0 
 Worse  5.2 7.0  2.2 2.7  0.0 0.0 
 Can‘t tell 0.5 0.3  0.0 0.0  0.0 0.0 
 (N) (211) (342)  (93) (74)  (39) (33) 
          
5+ Improved  83.6 88.2  94.8 95.8  94.6 96.3 
 No change 1.1 2.2  0.6 0.0  0.0 0.0 
 Worse  14.7 9.6  4.6 3.5  5.4 3.7 
 Can‘t tell 0.6 0.0  0.0 0.7  0.0 0.0 
 (N) (177) (229)  (174) (142)  (148) (108) 
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Appendix 17 Information sheet and consent form (Chapter 5 - HFA) 
CONSENT FOR STRCUTURED OR INDEPTH INTERVIEWS WITH THE 
PRESCRIBER AND/OR STAFF INCHARGE OF THE HEALTH UNIT  
(Administered by me (JOHN ODAGA)) 
 
Hello, it is a pleasure meeting you. My Name is JOHN ODAGA, a researcher from Uganda Martyrs 
University, and a student of Liverpool School of Tropical Medicine, UK. Thank you for sparing this 
time to participate in this interview. 
I am carrying out a research on the management of fever (―temperature‖) in children in order to 
document the causes and treatment of fever in this Health Centre (HC). In addition, I would like to 
find out if the essential inputs and support required in managing a child with fever are adequate in 
this HC. Your HC was randomly selected to participate in this study. 
I will be asking you questions about various activities and inputs which are required in the 
management of a child with fever. I would like to learn and document the process of managing a 
child with fever in this HC. For this reason, I will ask to observe 6 consultations of children with 
fever, with the most senior health worker. I understand that the District Health Office recently 
supplied this HC with stocks of RDTs and ACTs. Feel free to use them as you deem fit. In addition, 
we will ask to briefly interview the care takers of the children selected for the observation as they 
exit the facility. This will entail reviewing the prescriptions received by the children here today. 
Further, I will ask to go through your stock cards and to assess the consultation room and store for 
selected equipment.   
No patient names will be reviewed, recorded, or shared. Data will be summarised in general terms 
without specifying the participating facilities or individuals. Neither your name nor the name of this 
HC will be provided, and any reports that use this facility's data will only present information in 
aggregate form so that the facility cannot be identified. Your name and all information that you give 
me will be kept strictly confidential.  
The information gathered may not be immediately and directly beneficial to you, or this HC. The 
information will only be used for the purpose of the research. The information may be used by the 
MOH for planning service improvement or for further studies of health services.  
I have come along with a research assistant who will assist me in observing the consultations and in 
conducting exit surveys with the caretakers, and to review supplies and clinic attendance records. 
Please, I would like to request you to explain the purpose of this research to the care takers of 
selected patients; and that an observer will be sitting in the consultation room to observe the 
consultation process.  
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You or/and patients‘ care takers are free to refuse to participate in the study, or to withdraw at any 
stage, and this will not affect our opinion about you or the health centre. If you have further queries 
in future, you are free to contact me on 0772 619 450. Otherwise, you are free to ask any questions 
right now. 
 
Declaration of Client 
I have understood the descriptions above about the study. I have had time to ask questions and they 
have been answered to my satisfaction. I agree to take part in the study. 
 
Printed Name and Title of Informant 
………………………………………………………………………. 
 
Date ……………………………. Signature …………………………………………. 
 
 
Printed Name of Person obtaining consent 
………………………………………………………………. 
 
Date ……………………………. 
Signature……………………………………………………………. 
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Appendix 18 Questionnaires and Checklists used in LQAS-based Health Facility Survey 
 
 
Facility Code: Interviewer Code:
Date of Observation
dd mm
READ CONSENT FORM TO HEALTH WORKER. READ CONSENT FROM TO THE CHOSEN CARETAKERS BEFORE  THEY ENTER THE CONSULTATION ROOM.
OBSERVE SIX CONSECUTIVE ELIGIBLE CLINICAL CASES.  
ELIGIBLE CASES ARE ARE SICK CHILDREN, 1-59 MONTHS OF AGE, WHO HAVE BEEN BROUGHT TO THE CLINIC WITH COMPLAINT OF FEVER OR A HISTORY OF FEVER. 
THEY MAY OR MAY NOT HAVE OTHER COMPLIANTS
THERE IS A SEPARATE COLUMN FOR EACH OF THE SIX CASES OBSERVED. WHERE RELEVANT, CIRCLE YES, NO, OR NOT APPLICABLE FOR EACH QUESTION.
QUESTIONS CODING CLASSIFICATION
100 GENERAL INFORMATION AND PRESENTING COMPLAINTS CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
 
100A RECORD THE EXACT TIME THAT THE CARETAKER ENTERS THE EXAMINATION ROON
TIME: TIME: TIME: TIME: TIME: TIME:
101 A. WHAT TYPE OF HEALTH WORKER EXAMINED THE CHILD?
Write the letter code corresponding to the appropriate title below:
A = Clinical officer; B = Reg. Nurse/Mid wife; C = Enrolled Nurse/Midwife; D = Nursing Assistant; E = 
Other (specify)
102  AGE OF CHILD (IN COMPLETED MONTHS - 1 TO 59)-- ASK THE CARE TAKER IF THE CHILD'S 
AGE IS NOT RECORDED ON THE MEDICAL FORM
103 A. WEIGHT OF CHILD (IN KG) -- RECORD "NA" if not indicated or taken
104 REASON FOR VISIT (Circle the letter code(s) corresponding to ALL the condition/s that apply)                                                                                  
(SHOULD ONLY BE FOR CASES WITH FEVER/MALARIA, WITH OR WITHOUT OTHER 
CONDITIONS)
A B C A B C A B C A B C A B C A B C
A = FEVER/MALARIA ONLY; B = FEVER + COUGH/DIFFICULT IN BREATHING; C = FEVER + 
DIARRHOEA; D = FEVER+COUGH+DIARRHOEA; E = FEVER+ANY OTHER CONDITION
D E D E D E D E D E D E
MODULE 1: CLINICAL OBSERVATION OF SIX CONSECUTIVE FEBRILE CHILDREN
Year
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PATIENT EVALUATION:--HISTORY TAKING CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
QUESTIONS  
            
105 DOES THE HEALTH WORKER.
A. ASK ABOUT FEVER OR HISTORY OF FEVER (NA if caretaker volunteers this information while in 
the consultation room before  HW asks)? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
B. ASK ABOUT COUGH OR DIFFICULT BREATHING OR HISTORY (NA if caretaker volunteers this 
information while in the consultation room before HW asks)? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
C. ASK ABOUT DIARRHEA OR HISTORY OF DIARRHEA (NA if caretaker volunteers this information 
while in the consultation room before HW asks)? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
D. ASK ABOUT THE ABILITY TO FEED OR BREASTFEED (NA if caretaker volunteers this information 
while in the consultation room before HW asks; or if child >2 yrs)? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
E. ASK WHETHER THE CHILD VOMITS EVERYTHING (NA if caretaker volunteers this information 
while in the consultation room before HW asks)? Y N NA N N NA N N NA N N NA N N NA N N NA
F. ASK ABOUT THE PRESENCE OF CONVULSIONS (NA if caretaker volunteers this information while 
in the consultation room before HW asks)? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
PATIENT EVALUATION:--PHYSICAL EXAMINARION CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
QUESTIONS  
106 DOES THE HEALTH WORKER
A. CHECK THE EYES/CONJUCTIVE/PALMS/FINGER NAILS, SOLES FOR PALLOR AND 
JAUNDICE? Y N Y N Y N Y N Y N Y N
B. CHECK THE THROAT FOR REDNESS Y N Y N Y N Y N Y N Y N
C. CHECK THE EARS FOR DISCHARGE/SORES Y N Y N Y N Y N Y N Y N
E. COUNT RESPIRATORY RATE WITH TIMING DEVICE? (NA if no cough or difficult breathing) Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
107
DOES THE HEALTH WORKER REQUEST FOR/PERFRM AN RDT OR MICROSCOPY TO RULEOUT 
MALARIA?;  IF 'NO' JUMP TO SECTION 109 Y N Y N Y N Y N Y N Y N
108 TEST RESULT:   POS = POSITIVE; NEG = NEGATIVE; INT = INDETERMINATE POS NEG INT POS NEG INT POS NEG INT POS NEG INT POS NEG INT POS NEG INT
109
DID THE HEALTH WORKER COMMUNICATE THE RESULT OF THE RDT TEST TO THE 
PATIENT/CARETAKER Y N Y N Y N Y N Y N Y N
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CLASSIFICATION AND TREATMENT OF PATIENT CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
QUESTIONS
110 DOES THE HEALTH WORKER CLASSIFY THE CHILD AS HAVING (Fill in the appropriate Code)
A. FEVER OR (uncomplicated) MALARIA ONLY?
B. FEVER/MALARIA + OTHER CONDITIONS (e.g. ACUTE RESPIRATORY INFECTIONS)
C. ACUTE RESPIRATORY INFECTIONS ONLY (ARI)--including Pneumonia
D. OTHER CONDITIONS, EXCLUDING MALARIA AND/OR ARI (SPECIFY)
[NB. IF THE HEALTH WORKER CLASSIFYS THE CHILD AS HAVING SEVERE DISEASE (SEVERE 
PNEUMONIA, SEVERE MALARIA, OR SEVERE FEBRILE ILLNESS) EXCLUDE HIM/HER FROM THE 
OBSERVATION]
TREATMENT (PRECRIPTION AND COUNSELLING)
111 DOES THE HEALTH WORKER PRESCRIBE
A. ACT FIXED COMBINATION: COARTEM?
Colour Codes: Yellow/Blue/Brown/Green Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
B. ACT FIXED COMBINATION: ARTESUNATE-AMODIAQUINE? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
C. OTHER ANTI-MALARIA DRUGS Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
IF YES, PLEASE SPECIFY THE APPROPRIATE DRUGS IN THE ................................. ................................. ................................. ................................. ................................. .................................
SPACES PROVIDED (examples are given below) ................................. ................................. ................................. ................................. ................................. .................................
................................. ................................. ................................. ................................. ................................. .................................
................................. ................................. ................................. ................................. ................................. .................................
C. COTRIMOXAZOLE OR AMOXYCILLIN ? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
E. CIPROFLOXACIN? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
C. ANTIBIOTICS Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
IF YES, PLEASE SPECIFY THE APPROPRIATE DRUGS IN THE ................................. ................................. ................................. ................................. ................................. .................................
SPACES PROVIDED (examples are given below) ................................. ................................. ................................. ................................. ................................. .................................
................................. ................................. ................................. ................................. ................................. .................................
................................. ................................. ................................. ................................. ................................. .................................
D. ORS (or IV fluids - only  in case of severe dehydration)? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
112 DOES HEALTH WORKER EXPLAIN TO CARETAKER HOW TO GIVE
A. ACT? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
B. OTHER ANTI-MALARIAL DRUGS? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
C. ANTIBIOTICS? Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
113 RECORD THE EXACT TIME THAT THE CONSULTATION ENDS
TIME: TIME: TIME: TIME: TIME: TIME:
[Examples; Artemether monotherapy, Artesunate monotherapy, Choloroquine, SP, Amodiaquine, 
Glucodexine, etc]
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Supervisor Recode for HW performance - treatment: Does classification (Q.110) match the medication 
prescibed (Q.111)? CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
A. malaria or fever / ACT Match Match Match Match MatchNot match Match
B. malaria or fever + other conditions / ACT + antibiotics Match Match Match Match Match Match
C. ARI / antibiotics / no antibiotics Match Match Match Match Match Match
D. diarrhea without blood / ORS but no antibiotic Match Match Match Match Match Match
E. diarrhea with blood / Ciprofloxacin or other antibiotics Match Match Match Match Match Match
F. No pneumonia, fever/malaria or diarrhea / no antibiotic(unless indicated for other than pneumonia or 
dysentery) or no antimalarial
Match Match Match Match Match Match
HW performance - treatment (All match (A-F)?) Y N Y N Y N Y N Y N Y N
# Y (out of 6 cases) _____
NOTE ANY QUALITATIVE OBSERVATIONS HERE:
Not match Not match
Not match
Not match Not match
Not match
Not match
Not match
Not match
Not match
Not match
Not match Not match
Not match
Not matchNot match
Not match
Not match
Not match
Not match Not match Not match Not match Not match
Not match Not match
Not match Not match
Not match
Not matchNot matchNot matchNot match
Not match Not match
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Facility Code: Interviewer Code:
Date of Observation
dd mm
CODING CLASSIFICATION
CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
QUESTIONS  
200 RECORD THE EXACT TIME THAT THE CARETAKER ENTERS THE TEST ROOM (IF TEST IS 
PERFORMED BY ANOTHER HEALTH WORKER IN A SEPARATE ROOM); OR THE TIME WHEN THE 
HEALTH WORKER STARTS TO PREPARE FOR THE TEST TIME: TIME: TIME: TIME: TIME: TIME:
201
WAS THE RDT PERFORMED BY THE CLERKING HEALTH WORKER OR COMPLEMENTARY 
HEALTH WORKER Y N Y N Y N Y N Y N Y N
202 WHAT TYPE OF HEALTH WORKER PERFORMED THE RDT?
Write the letter code corresponding to the appropriate title below. Please, answer this question even if 
the Health worker concerned is the same one that clerked the patient
A = Clinical officer; B = Reg. Nurse/Mid wife; C = Enrolled Nurse/Midwife; D = Nursing Assistant; E = 
Other (specify)
203 DOES THE HEALTH WORKER.
A. CHECK THE EXPIRY DATE ON THE PACK Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
B. PUT ON NEW GLOVES TO PERFORM RDT ON THIS PATIENT Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
C. WRITE THE PATIENT’S NAME ON THE CASSETTE Y N NA N N NA N N NA N N NA N N NA N N NA
D. CLEAN THE PATIENTS FINGER WITH A SPIRIT SWAB Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
E. ALLOW THE PATENT'S FINGER TO DRY BEFORE PRICKING Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
F. USE A LOOP TO COLLECT THE DROP OF BLOOD ON THE PATIENT'S FINGER Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
G. PUT THE DROP OF BLOOD INTO THE SQUARE HOLE (AT POSITION A) Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
H. PUT SIX (6) DROPS OF BUFFER INTO THE ROUND HOLE AT POSITION B Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
I. NOTE  DOWN THE TIME (IN MINS) WHEN THE HEALTH WORKER ADDS BUFFER ON TO THE 
RDT
J. NOTE  DOWN THE TIME WHEN THE HEALTH WORKER READS AND RECORDS THE  RESULT 
OF RDT
K. WAIT 15 MINUTES AFTER ADDING BUFFER (CAN BE RECORDED LATER) Y N NA Y N NA Y N NA Y N NA Y N NA Y N NA
204 RDT TEST RESULT:   POS = POSITIVE; NEG = NEGATIVE; INT = INDETERMINATE POS NEG INT POS NEG INT POS NEG INT POS NEG INT POS NEG INT POS NEG INT
205
DID THE HEALTH WORKER COMMUNICATE THE RESULT OF THE RDT TEST TO THE 
PATIENT/CARETAKER Y N Y N Y N Y N Y N Y N
NOTE ANY QUALITATIVE OBSERVATIONS HERE:
MODULE 2: OBSERVATION OF RDT PERFORMANCE ON SIX CONSECUTIVE CHILDREN WITH FEVER
Year
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Facility Code: Interviewer Code: Date:
dd mm
OBTAIN INFORMED CONSENT FROM EACH CARETAKER IF THE SUPERVISOR HAS NOT ALREADY DONE SO.
CODING CLASSIFICATION (PUT CASE CODE AT TOP OF EACH COLUMN)   
NO. QUESTIONS
CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
300
301
Y N Y N Y N Y N Y N Y N
302
Y N Y N Y N Y N Y N Y N
303
Y N Y N Y N Y N Y N Y N
304 YES……………. 1 YES……………. 1 YES……………. 1 YES……………. 1 YES……………. 1 YES……………. 1
 NO (end interview) 2 NO (end interview) 2 NO (end interview) 2 NO (end interview) 2 NO (end interview) 2 NO (end interview) 2
 DON’T KNOW 3 DON’T KNOW 3 DON’T KNOW 3 DON’T KNOW 3 DON’T KNOW 3 DON’T KNOW 3
305 Y N Y N Y N Y N Y N Y N
306 Did you receive all the medications prescribed?Yes, I Received all 1 Yes, I Received all 1 Yes, I Received all 1 Yes, I Received all 1 Yes, I Received all 1 Yes, I Received all 1
No, I Received some 2 No, I Received some 2 No, I Received some 2 No, I Received some 2 No, I Received some 2 No, I Received some 2
No, I did not receive any 3 No, I did not receive any 3 No, I did not receive any 3 No, I did not receive any 3 No, I did not receive any 3 No, I did not receive any 3
I don't know if I received all 4 I don't know if I received all 4 I don't know if I received all 4 I don't know if I received all 4 I don't know if I received all 4 I don't know if I received all 4
MODULE 2: EXIT INTERVIEW (CARETAKERS OF SIX OBSERVED SICK CHILDREN)
What illness(es) did the health worker tell you 
your child had?                                                                        
[Refer to the Child's card and record the 
diagnosis given; otherwise list down the 
complaints recorded]
Did the Health worker perform a blood test on 
your child today? [Skip to 204 if the answer 
is NO]
yy
Did the Health worker explain to you what the 
test was for?
Did the health worker explain the result of the 
test to you?
Did the health worker give or prescribe any 
medicines for yor child today?
Did the health worker explain why he 
prescribed for you these particular medicines; 
or why he did not prescribe for you any 
medicines (or some medicines)?
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NO. QUESTIONS
CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
307
Med name: Med name: Med name: Med name: Med name: Med name:
01 WRITE NAME OF MEDICATION 1
MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No
a. How much will you give each time? Amount: Amount: Amount: Amount: Amount: Amount:
b. How many times a day will you give it? #times/day: #times/day: #times/day: #times/day: #times/day: #times/day:
c. For how many days will you give it? #days: #days: #days: #days: #days: #days:
Med name: Med name: Med name: Med name: Med name: Med name:
02 WRITE NAME OF MEDICATION 2
MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No
a. How much will you give each time? Amount: Amount: Amount: Amount: Amount: Amount:
b. How many times a day will you give it? #times/day: #times/day: #times/day: #times/day: #times/day: #times/day:
c. For how many days will you give it? #days: #days: #days: #days: #days: #days:
Med name: Med name: Med name: Med name: Med name: Med name:
03 WRITE NAME OF MEDICATION 3
MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No MF 5 Yes No
a. How much will you give each time? Amount: Amount: Amount: Amount: Amount: Amount:
b. How many times a day will you give it? #times/day: #times/day: #times/day: #times/day: #times/day: #times/day:
c. For how many days will you give it? #days: #days: #days: #days: #days: #days:
Thank you for participating. We will use this information to help improve health services in this area.
CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
MED1 Correct Not Corr.
MED2 Correct Not Corr.
MED3 Correct Not Corr.
Y N
# Y out of 6 observations ____
NOTE ANY QUALITATIVE OBSERVATIONS HERE:
Y N Y
Not Corr. Correct
Correct
N
Not Corr.
Correct
Is the caretaker's description of medication  
dose, frequency, and duration correct (Q.307)?
Y N
Not Corr.
HW performance - counselling: Knowledge correct 
for all medications? (Y/N)
Y N
Correct Not Corr. Correct Not Corr.
N Y
Not Corr.
Not Corr. Correct Not Corr.
Correct Not Corr. Correct Not Corr. Correct Not Corr. Correct
Not Corr. Correct
M
E
D
IC
A
T
IO
N
 3
Supervisor Recode for HW performance - 
counseling
Correct
Not Corr. Correct
Not Corr. Correct Not Corr. Correct
Agreement 
Can you please show me the medications or prescriptions given to you by the health worker? 
ASK THE MOTHER TO SHOW YOU EACH MEDICINE OR PRESCRIPTION GIVEN TO HER. THEN WRITE DOWN THE NAME OF EACH MEDICINE BELOW (UNDER "MEDICINE 1," "MED. 
2," AND "MEDICINE 3.", ETC) ASK HER ABOUT THE AMOUNT TO BE GIVEN EACH TIME, THE NUMBER OF TIMES A DAY TO GIVE IT, AND THE NUMBER OF DAYS IT IS TO BE GIVEN.
M
E
D
IC
A
T
IO
N
 1
Agreement Agreement Agreement Agreement 
Agreement Agreement 
Agreement 
Agreement Agreement Agreement Agreement 
M
E
D
IC
A
T
IO
N
 2
Agreement Agreement Agreement Agreement Agreement Agreement 
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Facility Code: Interviewer Code: Date:
yy
OBTAIN INFORMED CONSENT  
NO. QUESTIONS CODING CLASSIFICATION GO TO
309 Can you please show me where children are seen for treatment VISUAL AND AUDITORY PRIVACY …………… 1
INSPECT FOR AUDITORY AND VISUAL PRIVACY. VISUAL BUT NOT AUDITORY PRIVACY ……………. 2
MARK AS "BOTH" IF THERE IS A DOOR THAT CAN CLOSE VISUAL NOR AUDITORY PRIVACY ……………. 3
MARK AS "VISUAL" IF THERE IS A DRAPE OR CURTAIN
IN THE CHILD CONSULTATION AREA, CHECK WHETHER EACH OF THE ITEMS BELOW IS EITHER IN THE ROOM WHERE THE SERVICE IS GIVEN
OR IN AN ADJACENT ROOM. 
310 ITEMS FOR SICK (a) AVAILABILITY (b) FUNCTIONING
CHILD CONSULTATIONS OBSERVED REPORTED, NOT DON'T YES NO DON'T 
 NOT SEEN AVAILABLE KNOW KNOW
01 Infant scale that is accessible 1 --> b 2 --> b 3 9 1 2 9
02 Adult (standing) scale that is accessible 1 --> b 2 --> b 3 9 1 2 9
03 Timer or Clock/watch with second hand 1 --> b 2 --> b 3 9 1 2 9
04 Thermometer 1 --> b 2 --> b 3 9 1 2 9
05 Refrigerator or cold box for storing vaccines 1 --> b 2 --> b 3 9 1 2 9
06 Cup and spoon for oral rehydration 1 2 3 9 1 2 9
07 Jar or pitcher for oral rehydration solution (ORS) 1 2 3 9 1 2 9
311 INSPECT THE CONSULTATION AREA FOR THE OBSERVED AND OBSERVED BUT REPORTED, NOT DON'T
PRESENCE OF THE FOLLOWING (WALL) CHARTS IN CONS. AREA NOT IN CONS. AREA NOT SEEN AVAILABLE KNOW
01 RDT-based Treatment Algorithm 1 2 3 4 9
02 IMCI (sick child) Treatment Algorithm 1 2 3 4 9
312 ASK TO SEE THE FOLLOWING OBSERVED AND OBSERVED BUT REPORTED, NOT DON'T
GUIDELINES IN CONS. AREA NOT IN CONS. AREA NOT SEEN AVAILABLE KNOW
01 MOH RDT/ACT USER'S MANUAL 1 2 3 4 9
02 Wall charts for RDT based treatment with ACT 1 2 3 4 9
313 ASK TO OBSERVE THE ROOM AND FACILITIES WHERE RDT SUPPLIES ARE KEPT
OBSERVED
OPEN AIR NOT OBSRVED
01 Describe the type of storage facility where the RDT kits are CARD BOARD COOL BOX (e.g. on a shelf, OTHER
kept (e.g. in an ordinary cardboard box, in a cool on a shelf) BOX table, etc) (Describe)
1 2 3 4 ......................... 9
........................
02 Roofing material IRON SHEETS GRASS OTHER NOT OBSRVED
1 2 3 4 9
03 Presence of a ceiling YES NO DON'T KNOW 9 NOT OBSRVED
1 2 9 9
04 Check if the temperature of the room is recorded RECORDED TO DAY RECORDED OVER THE LAST 3 MONTHS
1 YES (Records the highest temprature noted, if recorded more than once ……………….) 1 YES (Record the highest temperature)
……………………………..
2 NO 2 NO
 
05 Amount of light in the storage room DIM LIGHT BRIGHT LIGHT NOT OBSERVED
1 2 9
--> go to b (to indicate whether functioning or not)
MODULE 3: HEALTH FACILITY CHECKLIST (INFRASTRUCTURE, EQUIPMENT, SUPPLIES, DRUGS)
mmdd
 256 
 
 
ASK TO SEE THE FOLLOWING DRUGS AND SUPPLIES.  IF THE ITEM IS LOCATED IN A DIFFERENT PART OF THE FACILITY, GO THERE TO OBSERVE IT. 
 IF YOU ARE UNABLE TO SEE AN ITEM, ASK IF IT IS AVAILABLE AND THE EXPIRATION DATES HAVE NOT PASSED.  FOR EACH ITEM, CIRCLE THE APPROPRIATE CODE.
314 INDICATOR DRUGS AND RDT KITS (b) TOTAL NUMBER OF DAYS (c) NOT OBSERVED/COUNTED
(a) EXACT QUANTITY AVAILABLE TODAY OUT OF STCOK
(in single units, e.g tablets, capsules, vials) IN THE LAST 6 MONTHS
01 COARTEM
A) Yellow blister Packs 1 Number of doses ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
   
B) Blue Blister Packs 1 Number of doses ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
   
C) Brown Blister Packs 1 Number of doses ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
   
D) Green Blister Packs 1 Number of doses ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
    
02 AMODIAQUINE-ARTESUNATE COMBINATION 1 Number of doses ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
    
03 OTHER ANTI-MALARIA DMEDICINES
A) Other anti-malaria drugs(Tab Quinine) 1 Number of Tablets ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
     
B) Other anti-malaria drugs (Name) 1 Number of Tablets ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
     
C) Other anti-malaria drugs (Name) 1 Number of Tablets ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
04 RDT kits 1 Number of kits ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
05 COTRIMOXAZOLE  FOR ARI 1 Number of Tablets ………………………… 1 Number of days O/S ……………
A) For Childrfen (Junior Tablets)
2 Not Counted 2 Not Counted
    
B) For Children (Syrups) 1 Number of Vials ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
    
C) For Adults (Tablets) 1 Number of Tablets ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
    
06 ORS PACKETS FOR DIAORRHEA 1 Number of kits ………………………… 1 Number of days O/S ……………
2 Not Counted 2 Not Counted
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316 ASK TO SEE THE RECORD SYSTEM FOR ORDERING AND ACCEPTING DELIVERY OF DRUGS AND SUPPLIES.  IF YOU ARE NOT ABLE 
TO SEE THE RECORDS THEN ASK FOR THE FOLLOWING INFORMATION. REVIEW THE FIRST LINE ANTI-MALARIAL (ACT)
REVIEW ENTRIES ABOUT ACTs
OBSERVED REPORTEDLY AVAILABLE, NOT OBSERVED
01 Review the date of the most recent order of DATE IS 
anti-malarial / ACT and tell me the date please. DATE IS IN MORE THAN DATE IS IN DATE IS NO RECORD
LAST 3 MO. 3 MO. NO DATE LAST 3 MO. MORE THAN NO DATE AVAILABLE
(1) (2) (3) (4) (5) (6) (7)
02 Review the quantity of the most recent delivery . DELIVERY DELIVERY DOES QUANTITY DELIVERY DELIVERY DOES QUANTITY 
Is this amount the same as the quantity ordered? AGREES WITH NOT AGREE IN ORDER AGREES WITH NOT AGREE IN ORDER NO RECORD
ORDER WITH ORDER MISSING ORDER WITH ORDER MISSING AVAILABLE
(1) (2) (3) (4) (5) (6) (7)
03 Does the Balance as recorded in the Records NO NO
Agree with the quantity in the Stores/Pharmacy YES DOES NOT YES DOES NOT NO RECORD
(CARRY OUT A HAND COUNT IF POSSIBLE OR AGREE AGREE AGREE AGREE AVAILABLE
ASK YOUR INFORMANT TO DO SO) (1) (2) (4) (5) (7)
04 Does the Balance as recorded in the Bin Card NO NO NO BIN
Agree with the quantity in the Stores/Pharmacy YES DOES NOT YES DOES NOT CARD
(CARRY OUT A HAND COUNT IF POSSIBLE OR AGREE AGREE AGREE AGREE AVAILABLE
ASK YOUR INFORMANT TO DO SO) (1) (2) (4) (5) (7)
05 Have any of the First Line Anti-Malarials / ACT NO DATE NO DATE
passed their expiration date? YES NO VISIBLE YES NO VISIBLE
(1) (2) (3) (4) (5) (6)
06 Does this Health Facility have a plan to dispose of 
expired Drugs? YES NO
IF THE RESPONSE IS YES THEN ASK APPROPRIATE APPROPRIATE
What is that plan? PLAN EXISTS PLAN DOES DID NOT 
NOT EXIST KNOW
(1) (2) (3)
07 Please show me where or how expired drugs are APPROPRIATE NO APPROPRIATE COULD NOT 
destroyed? PLAN IN USE PLAN IN USE OBSERVE
(1) (2) (3)
  
 
Facility Code: Interviewer Code:
 
SPEAK TO THE MOST EXPERIENCED HEALTH WORKER INVOLVED IN MANAGEMENT OF CURATIVE CHILD HEALTH SERVICES. 
IT IS BEST TO APPLY THIS FORM AFTER PATIENT SESSIONS HAVE FINISHED.
OBTAIN INFORMED CONSENT, IF YOU HAVE NOT ALREADY DONE SO.
NO. QUESTIONS CODING CLASSIFICATION GO TO
401  For each of the following services, please tell me whether the service is offered by your facility, and if so,
how many days per month the service is provided at the facility, or as outreach services.
FOR THE PURPOSES OF THIS QUESTION, A MONTH IS EQUIVALENT TO FOUR WORK WEEKS.
01 Consultation or curative services for sick children A. # OF DAYS PER MONTH IN FACILITY
IF NONE, WRITE "00"
IF ALL WEEKDAYS, WRITE "20" B. # DAYS PER MONTH IN OUTREACH LOCATIONS
IF ALL DAYS including weekends, WRITE "30"
IF ONE TIME PER WEEK, WRITE "4"
02 Routine immunizations for children A. # OF DAYS PER MONTH IN FACILITY
IF NONE, WRITE "00"
IF ALL WEEKDAYS, WRITE "20" B. # DAYS PER MONTH IN OUTREACH LOCATIONS
IF ALL DAYS including weekends, WRITE "30"
IF ONE TIME PER WEEK, WRITE "4"
03 Growth monitoring & promotion -    where a healthy child is routinely A. # OF DAYS PER MONTH IN FACILITY
                   weighed, has weight charted on growth chart, feeding advice given
IF NONE, WRITE "00"
IF ALL WEEKDAYS, WRITE "20" B. # DAYS PER MONTH IN OUTREACH LOCATIONS
IF ALL DAYS including weekends, WRITE "30"
IF ONE TIME PER WEEK, WRITE "4"
402 Now I would like to ask you about the health personnel that work in this facility. I will read the type of health worker and for each one
I would like you to tell me the number sanctioned by the Ministry of Health to work in this facility and the ones who are here today.
JOB OF HEALTH WORKER A. # WORKERS SANCTIONED B. # WORKERS WHO ARE
TO WORK IN THIS FACILITY PRESENT TODAY
(FULL OR PART-TIME)
01 DOCTOR
 
02 CLINICAL OFFICER
03 REGISTERED  NURSE
04 REGISTERED MIDWIFE
05 ENROLLED  NURSE
06 ENROLLED MIDWIFE
07 LABORATORY TECHNICIAN
08 LABORATORY ASSISTANT
09 PHARMACIST
 
10 OTHER CLINICAL CARE STAFF (NURSING ASSIATNTS, ETC.)
11 ALL OTHER ASSIGNED STAFF
(for instance, clerical staff, cleaning staff, etc.)
403 During the past three years have you received any 
pre-service or in-service training on subjects YES ……………………………………………………………………………………………………………………. 1
related to maternal, child, or newborn health or illness? NO …………………………………………………………………………………………………………………. 2 405
404 Did you receive the training in any topic related to YES, IN YES, IN NO TRAINING
the following topics that I will read? PAST PAST 2-3 WITHIN PAST
IF YES, THEN ASK: 12 MONTHS YEARS 3 YEARS
When was your most recent training? READ THE LIST
01 Management of fever in children  1 2 3
01b IF YES, ASK: Did this training cover the following topics
a) How to evaluate patients with fever  1 2 3
b) How to select patients for RDT testing  1 2 3
c) Performing and reading an RDT  1 2 3
d) Management of a patient with fever and a positive RDT  1 2 3
e) Management of a patient with fever and a negative RDT  1 2 3
f) Recognition and referral of patients with severe illness  1 2 3
g) Patient education  1 2 3
h) RDT storage and monitoring  1 2 3
i) Treatment with ACT 1 2 3
01c Did the training also cover the following topics?
a) Treatment of pneumonia or Acute Respiratory Infections  1 2 3
b) Diarrhea treatment  1 2 3
c) Diarrhea treatment  1 2 3
d) Integrated Management of Childhood Illness (IMCI)  1 2 3
e) Nutrition/breastfeeding  (for instance, complementary feeding, micronutrients)  1 2 3
(for instance, complementary feeding, micronutrients)
f) Breastfeeding  1 2 3
MODULE 4: HEALTH WORKER INTERVIEW & RECORD REVIEW
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405 Now I would like to ask you some questions about YES, IN THE PAST 3 MONTHS ……………………………………………………..1
supervision from a supervisor outside the facility. YES, IN THE PAST 4-6 MONTHS ………………………………………………………….2  
a. Do you receive technical support or supervision YES, IN THE PAST 7-12 MONTHS …………………………………………………………3  407
in your work? YES, MORE THAN 12 MONTHS AGO …………………………………………………………4  407
b. IF YES, ASK:  When was the most recent time? NO SUPERVISION …………………………………………………………5 407
406 The last time you were personally supervised, did DON'T
your supervisor do any of the following? READ THE LIST: YES NO KNOW
01 Deliver supplies DELIVERED SUPPLIES 1 2 9
02 Check your records or reports CHECKED RECORD 1 2 9
03 Observe your work OBSERVED 1 2 9
04 Provide any feedback (either positive or negative) GAVE FEEDBACK 1 2 9
on your performance
05 Provide any comment that you were GAVE PRAISE 1 2 9
doing your work well
06 Provide updates on administrative or technical GAVE UPDATES 1 2 9
issues related to your work
07 Discuss problems you have encountered DISCUSSED PROBLEMS 1 2 9
08 Checked drug supply CHECKED DRUG SUPPLY 1 2 9
When was the last time that this health facility referred a child with fever to IN LAST MONTH ……………………………………………………………………………………….1
407 a higher level facility? 1 - 3 MONTHS AGO ……………………………………………………………………………………….2
4 - 12 MONTHS AGO …………………………………………………………………………………….3
OVER A YEAR AGO ………………………………………………………………………………………4
NEVER ………………………………………………………………………………………5
ASK THE HEALTH WORKER TO IDENTIFY THE OUTPATIENT PATIENT CONSULTATION REGISTER FOR THE HEALTH FACILITY. DO NOT INCLUDE
INPATIENT RECORDS. USE THE REGISTER (AND OTHER HEALTH RECORDS SUCH AS PATIENT CARD) TO ANSWER THE QUESTIONS BELOW.
408 Is there a sick child consultation register? OBSERVED REGISTER ……………………………………….1
IF YES, ASK TO SEE THE REGISTER REPORTED, NOT SEEN 2 412
NO REGISTER ………………………………………………………………………………3 412
REVIEW ENTRIES IN THE SICK CHILD REGISTER (ONLY THE ENTRIES FOR CHILDREN U5 IF ADULT AND U5 REGISTERS COMBINED).
IDENTIFY THE LAST 20 NEW CASES  OF <5YR. YEAR SICK CHILDREN SEEN AT THE HEALTH FACILITY WITH ANY OF THE FOLLOWING DIAGNOSES:
FEVER/MALARIA, PNEUMONIA/FAST OR DIFFICULT BREATHING, DIARRHEA (without blood), OR SEVERE DISEASE.  USE THE INFORMATION AVAILABLE 
ABOUT THESE CASES TO ANSWER THE QUESTIONS BELOW.
409 DOES THE REGISTER (AND OTHER HEALTH RECORDS, IF NEEDED)
CONTAIN COMPLETE INFORMATION ON AGE, DIAGNOSIS, 01 NO. OF CASES WITH AGE DOCUMENTED …………………….
& TREATMENT FOR THE LAST 20 NEW CASES OF <5YR. SICK 
CHILDREN WITH EITHER MALARIA, PNEUMONIA, OR DIARRHEA? 02 NO. OF CASES WITH DIAGNOSIS/CLASSIFICATION  DOCUMENTED
 03 NO. OF CASES WITH TREATMENT DOCUMENTED …………..
RECORD THE NUMBER OF TIMES OUT OF 20 CASES 04 NO. OF CASES WITH ALL OF ABOVE DOCUMENTED …………..
THAT THE INFORMATION WAS DOCUMENTED FOR EACH CASE
05 NO. OF CASES WITH NONE OF ABOVE DOCUMENTED …………..
410 HOW RECENT IS THE DATE OF THE MOST RECENT ENTRY? WITHIN THE PAST 7 DAYS ………………………………………………………………………..1
MORE THAN 7 DAYS OLD ………………………………………………………………………..2
411 BREAKDOWN OF LAST 20 NEW SICK CHILD CASES……
01 MALARIA OR FEVER (UNCOMPLICATED) A1. NO. OF NEW MALARIA A2 NO. MALARIA
CASES IN REGISTER OF U5 CHILDREN CASES TREATED
AMONG THE 20 WITH ACT
02 PNEUMONIA OR ACUTE RESPIRATORY INFECTION (ARI) B1 NO. OF PNEUMONIA/ARI B2 NO. PNEUMONIA
CASES IN REGISTER OF U5 CHILDREN CASES TREATED
AMONG THE 20 WITH COTRIMOXAZOLE
03 DIARRHEA WITHOUT BLOOD C1. NO. OF DIARRHEA C2 NO. DIARRHEA
CASES IN REGISTER OF U5 CHILDREN CASES TREATED
AMONG THE 20 WITH ORS & NO ANTIBIOTIC
04 SEVERE DISEASE (SEVERE MALARIA, SEVERE PNEUMONIA, D1. NO. OF SEVERE D2 NO. SEVERE
SEVERE FEBRILE ILLNESS) DISEASE CASES DISEASE
OF CHILDREN U5 CASES REFERRED
AMONG THE 20 TO NEXT HIGHER LEVEL FACILITY
412 Can you please show me a copy of the latest monthly service LATEST REPORT SEEN AND LESS THAN 3 MONTHS OLD …… 1
report that you sent to the District Health Office? LATEST REPORT SEEN AND OLDER THAN 3 MONTHS OLD ….. 2
EXAMINE THE REPORT REPORT SAID TO BE LESS THAN 3 MONTHS, NOT OBSERVED ….. 3
REPORT SAID TO BE MORE THAN 3 MONTHS, NOT OBSERVED ….. 4
NO REPORT …………………………………………………………… 5
413 LOOK FOR EVIDENCE OF USE OF SERVICE DATA
Can you tell me if you have a wall chart or graphs or have WALL CHART SUMMARIZING MSR DATA ………………. A
had a meeting among the health facility staff to discuss the GRAPH SUMMARIZING MSR DATA ………………. B
monthly service report (MSR) data within the last 3 months? MEETING TO DISCUSS MSR DATA IN  IN LAST 3 MO. ……………… C
OTHER: SPECIFY ………………. D
CIRCLE ALL THAT APPLY NONE OF THE ABOVE …………….. E
414 For each of the following diagnostic tests, please tell me if this facility can conduct the test and has all items so it can be done today, 
or if the facility has a system for having the test conducted elsewhere but getting results returned for follow up by this facility.
YES, CAN BE YES, OBSERVED TEST NOT
CONDUCTED SYSTEM FOR AVAIL-
DIAGNOSTIC TEST ONSITE TODAY TEST OUTSIDE ABLE
01 Complete blood count 1 2 3
02 Anemia (hemoglobinhematocrit, or litmus paper) 1 2 3
03 Malaria (rapid test or microscopy) 1 2 3
04 Urine glucose (dipstix or benedicts test) 1 2 3
05 Urine protein (dipstix or acetic acid) 1 2 3
06 HIV (rapid, ELISA, or Western Blott) 1 2 3
07 AFB for TB 1 2 3
08 Syphilis (VDRL or RPR) 1 2 3
NOTE ANY QUALITATIVE OBSERVATIONS HERE:
  
Appendix 19 Adherence scores for specific tasks by facilities 
 
LQAS Numbers (A1 to D in Gulu, and KA to KI in Kisoro) are codes assigned to specific HCs that were enrolled into the survey 
MEDICAL HISTORY CLINICAL EXAMINATION PERFORMING RAPID DIAGNOSTIC TEST TREATMENT COUNSELLING
DR = 6:5 DR = 6:5
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GULU A1 P P F F F F F F F F F F F F F F F F F F F F F P P
(n = 10) A2 P P F F F F F F F F F F P F P F P F P P P F P P P
A3 P P F P F F F F F F F F P P P F P P P P P P P F F
B1 P F F F F F F F F F F F P P F P P F P P P P F P F
B2 P P F F F F F F F F F F P F P F P F P P P F P P P
B3 P P F F F F F F F F F F P P P P P P P P P P P P F
C1 P F F F F F F F F F F F P F P P P F P P P F P P P
C2 P P P F F F F F F F F F P P P F P F P P P F P F P
C3 P P F F P F F F F F F F P P P P P P P P P P P P F
D P P P F F F F F F F F F P P P P P F P P P F P F P
Classification Number of successes 10 8 2 1 1 0 0 0 0 0 0 0 9 6 8 5 9 3 9 9 9 4 8 7 6
of district
Deceision rule: 7 H H L L L L L L L L L L H L H L H L H H H L H H L
KISORO KA P F P F F F F F F F F F F F F F F F F F F F F F P
(n = 8) KB P P P F F F F F F F F F F F F F F F F F F F F P P
KC P F F F F F F F F F F F P F P P P F P P P F P F P
KE P F F F F F F F F F F F F F F F F F F F F F F P P
KF P F F F F F F F F F F F F F F F F F F F F F F P F
KG P P F F F F F F F F F F F F F F F F F F F F F F P
KH P P P F F F F F F F F F F F F F F F F F F F F F F
KI P P F F F F F F F F F F F F F F F F F F F F F P P
Classification Number of successes 8 4 3 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 1 1 1 0 1 4 6
of district
Decision rule: 6 H L L L L L L L L L L F L L L L L L L L L L F L H
Success rate for using RDT (DR = 6:5)
Success rate for History taking 
(DR = 6:5)
Success rate for Physical 
examination (DR = 6:5)
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Appendix 20 Procedure-specific and cumulative adherence scores by successive 
steps  
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